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Background
Cardiovascular disease is a major health problem in the adult general population. Epi-
demiological studies strongly suggest that early life events have an important role for 
the susceptibility to develop cardiovascular disease in later life. In the 1980’s, Barker and 
Osmond showed that areas of Britain with the highest neonatal mortality rates early 
in the 20th century also had the highest incidence of cardiovascular disease in adults, 
many decades later1-2. Birth weight is an important predictor of neonatal mortality. After 
these observations, many epidemiological studies consistently showed that low birth 
weight is associated with adult health outcomes such as cardiovascular disease3, type 2 
diabetes4 and kidney disease5. It was also noted that the risk of cardiovascular disease 
was highest in subjects who show a postnatal catch-up growth after being born with 
a low birth weight6-7. These observations resulted in the “fetal origins of adult disease” 
hypothesis, also currently known as the “Developmental Origins of Health and Disease “ 
Hypothesis (DOHaD-hypothesis). This hypothesis states that a suboptimal fetal environ-
ment leads to developmental adaptations that permanently alter growth, physiology 
and metabolism, with long-term consequences for adult health.  More recently, this 
hypothesis has been adapted to a more general “developmental plasticity hypothesis”, 
which proposes that an organism may develop in different ways, depending on the 
environment it is exposed to8. Investigating specific adverse fetal exposures and early 
growth may provide new insights in mechanisms underlying the associations of low 
birth weight with adult disease. Different aspects of early development might be impor-
tant in determining future risk of adult cardiovascular and renal diseases. 
Early growth
Early postnatal growth, especially growth acceleration in infancy, has been suggested 
to partly explain the increased risk for adult diseases in later life among children with 
a low birth weight9. Children tend to grow according to their genetically determined 
growth potential. If fetal growth is restricted relative to the fetal growth potential, infant 
growth acceleration is likely to occur9. Many epidemiological studies have indeed shown 
that growth acceleration in the first months of life is associated with adverse outcomes 
in adolescence and adulthood, such as obesity and cardiovascular disease10-12. Other 
studies have shown that accelerated growth later in childhood also is important in de-
termining the risk for coronary events, impaired glucose tolerance and type 2 diabetes 
in adulthood13-14. These different findings could be explained by differences between the 
studies. However, it might also indicate that growth in different periods of life, can affect 
the risk of adult disease.
Chapter 1
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Genetics of early growth
Genetic variants associated with early growth might partly explain the association of 
early growth with adult diseases15-17. The ‘fetal insulin hypothesis’ states that common 
genetic variants related to type 2 diabetes might partly explain the associations of low 
birth weight with metabolic diseases in adulthood15. Large scale genome-wide asso-
ciation studies have identified many genetic variants associated with adult body mass 
index18, blood pressure19, type 2 diabetes20 and many other diseases. Genome-wide as-
sociation studies in children are less abundant, but provide a good opportunity for gene 
discovery as environmental factors have been present for a relatively short time period. 
Recently, two genetic loci have been identified to be associated with birth weight, of 
which one affects insulin secretion and was previously shown to be associated with type 
2 diabetes in adults17. These results are consistent with the ‘fetal insulin hypothesis’. Fur-
thermore, interactions between genetic susceptibility and the (fetal) environment and 
epigenetic changes are likely to contribute to early origins of adult health and disease8.
Cardiovascular developmental adaptations
Also, the development of the heart and blood vessels could be affected by adverse fetal 
exposures or genetic variants. Low birth weight and infant growth are associated with 
the risks of coronary artery disease, hypertension and other cardiovascular diseases6-7. 
Fetal growth restriction might lead to impaired elastin synthesis in the vessel walls, lead-
ing to changes in the mechanical properties of these vessels21-22. Also, since the number 
of cardiomyocytes is established largely in fetal life, early developmental adaptations 
might lead to remodeling of the heart. Subsequently these cardiovascular adaptations 
might predispose an individual to higher blood pressure, left ventricular adaptations 
and increased risk for cardiovascular disease.
Renal developmental adaptations
Developmental adaptations in response to adverse fetal exposures may also lead to 
smaller kidneys with a reduced number of nephrons, which in turn leads to glomerular 
hyperfiltration and sclerosis, predisposing the individual to renal damage and subse-
quent development of higher blood pressure, impaired kidney function and end stage 
kidney disease in adulthood23. Many studies showed that low birth weight is associated 
with cardiovascular disease and chronic renal failure5, 24. Low birth weight is also associ-
ated with impaired renal growth, raised blood pressure, and impaired renal function5, 
25-28.
We designed a prospective cohort study from early fetal life until the age of 6 years 
to identify specific adverse fetal exposures and genetic determinants underlying the 
17
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1associations of early growth with obesity, blood pressure and cardiovascular and renal 
structures and function (figure 1). 
Aims
The specific aims of this thesis were:
1. To examine which fetal and infant growth patterns and genetic factors are associ-
ated with childhood growth and obesity. Outcomes of interest were birth weight, 
infant head circumference and obesity in childhood.
2. To identify early environmental and genetic determinants related to development of 
the cardiovascular system in childhood. Outcomes of interest were cardiac structures 
and function, blood pressure, and arterial stiffness.
3. To identify early environmental and genetic determinants of kidney growth and 
function. Outcomes of interest were kidney volume, kidney function and blood pres-
sure.
General design
Studies focused on environmental exposures were embedded in the Generation R Study. 
This is a population based prospective cohort study from fetal life until young adulthood 
in Rotterdam, the Netherlands29-30. The Generation R Study is designed to identify early 
environmental and genetic causes of normal and abnormal growth, development and 
health in fetal life, childhood and in later life. Mothers with a delivery date between April 
2002 and January 2006 were eligible for enrolment in this study. Enrolment was aimed at 
early pregnancy, but was possible until the birth of the child. During pregnancy, assess-
Figure 1. Associations studied in this thesis.Figure 1. Associations stu ied in t is thesis. 
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ments were planned in early pregnancy (< 18 weeks of gestational age), mid-pregnancy 
(18-25 weeks of gestational age) and late pregnancy (>25 weeks of gestational age). In 
total, 9,778 mothers were enrolled in the study. Of these mothers, 91% (n=8,880) was 
enrolled during pregnancy. In the preschool period, from birth to 4 years of age, data 
collection was performed by questionnaires and visits to the routine child health care 
centers at the age of 2, 3, 4, 6, 11, 18, 24, 30, 36 and 48 months. At the age of 5 to 6 years, 
all participating children were invited to a well-equipped and dedicated research center 
in the Erasmus Medical Center-Sophia Children’s Hospital. The measurements included 
were focused on several health outcomes including body composition, heart and vas-
cular development, renal growth and obesity. Additionally, detailed assessments of fetal 
growth and organ development until the age of 2 years were conducted in a randomly 
selected subgroup of Dutch pregnancy women and their children, the Generation R 
Figure 2. Design and data collection in the Generation R Study.Figure 2. Design and data collection in the Generation R Study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enrolment  
Enrolment was aimed at early pregnancy but was allowed 
until birth 
 
Fetal phase 
Physical examinations: multiple ultrasounds fetal growth, 
parental anthropometrics 
Questionnaires: parental health, life style habits and diet 
Biological samples in mothers 
 
Birth  
Information regarding birth was obtained from midwives and 
hospital records 
Cord blood collection for DNA extraction and genotyping 
 
Pre-school age (0-4 years) 
Visits to child health care centers (median number of visits – 
9): height, weight, head circumference, neurological and 
motor development 
Questionnaires: parental health, life style habits, child health 
 
School age of 5 to 6 years 
Hands on assessments in total cohort: body composition, 
blood pressure, heart and vascular development, kidney 
growth and function  
Biological samples in children 
 
Total cohort 
 
Focus cohort 
 
Fetal phase 
Additional ultrasound assessments: 
cardiac and renal growth 
 
Pre-school age 
Additional hands on assessments:  
Ultrasound cardiac and kidney 
growth 
Body composition 
 
19
Introduction
1Focus Cohort (n=1,232). These assessments included renal and cardiac ultrasounds in 
fetal life and early childhood (Figure 2). 
GWA studies require large sample sizes in order to increase the statistical power need-
ed to identify common genetic variants associated with a particular trait. Therefore, we 
performed GWAS in collaboration with other birth cohorts, as part of the Early Growth 
Genetics (EGG) Consortium and Early Genetics and Longitudinal Epidemiology (EAGLE) 
Consortium. The aim of these consortia is to identify genetic variants related to early 
growth, head circumference, childhood obesity and blood pressure. Furthermore, we 
also performed on study in the Rotterdam Study31 and collaborated with the Cohorts for 
Heart and Ageing Research in Genetic Epidemiology (CHARGE) Consortium, which aims 
to identify genetic variants related to adult cardiovascular disease and aging-related 
phenotypes32.
Outline of thesis 
We performed studies to identify early environmental and genetic determinants of 
childhood growth, and cardiovascular and renal development. We focused on parental 
exposures during pregnancy and genetic determinants of childhood growth and blood 
pressure. 
In chapter 2, we focus on environmental and genetic determinants of childhood 
growth. We examined whether size at birth and subsequent infant growth affected the 
risk of adverse body composition and childhood overweight (chapter 2.1). Using GWAS 
we aimed to identify common genetic variants associated with birth weight (chapter 
2.2) and infant head circumference (chapter 2.3). We also investigated whether a 
common variant in the nicotine receptor cluster modifies the association of maternal 
smoking during pregnancy and fetal growth (chapter 2.4). Finally, we identified genetic 
determinants of childhood obesity (chapter 2.5).
Chapter 3 focuses on parental exposures during pregnancy, genetic determinants and 
fetal and infant growth patterns and their association with childhood cardiovascular de-
velopment. Specifically, we investigated the association of fetal and infant growth with 
childhood cardiovascular development (chapter 3.1). Furthermore, we investigated the 
effect of parental smoking during pregnancy (chapter 3.2), parental distress during 
pregnancy (chapter 3.3) and maternal diet in first trimester in pregnancy (chapter 3.4) 
on childhood blood pressure, carotid-femoral pulse wave velocity and cardiac structures 
and function. In chapter 3.5 we investigated whether genetic risk scores incorporating 
many common genetic variants can better explain variance in blood pressure in both 
children and adults, as compared to the known genetic variants associated with blood 
pressure.
Chapter 4.1 presents a study in which we describe normal kidney growth from fetal 
life until the age of two years. Furthermore, we assessed whether maternal smoking 
Chapter 1
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during pregnancy is associated with fetal and infant kidney volume (chapter 4.2). We 
aimed to identify early life environmental factors associated with kidney volume, kidney 
function and blood pressure at age of 6 years (chapter 4.3). Also, we examined whether 
common genetic variants previously associated with adult blood pressure and kidney 
function might affect kidney volume in fetal life (chapter 4.4).
Finally, chapter 5 provides a general discussion of the finding presented in this thesis. 
We will discuss previous literature, possible underlying mechanisms, new insights from 
our studies, directions for future studies and possible implications for clinical practice.
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Abstract 
Aims: We examined the associations of size at birth, with infant growth of head circum-
ference, length and weight, and fat mass and body mass index in preschool children. 
Methods: In a population-based prospective cohort study among 3,941 children, we 
repeatedly measured head circumference, length and weight until the age of 4 years. 
Catch-up and catch-down growth were defined as a change in standard deviation scores 
of >0.67 from birth to two years of age. 
Results: Although most children born small and large size for gestational age showed 
infant catch-up and catch-down growth, respectively, their mean head circumference, 
length and weight remained smaller and larger respectively, until the age of 4 years. 
Catch-up growth in children with a small and appropriate weight for gestational age 
and lack of catch-down growth in children born with a large weight for gestational age 
were associated with higher body mass index in preschool children. Children born with 
an appropriate weight for gestational age with catch-up growth and children born with 
a large weight for gestational without catch-down growth had increased risks of child-
hood overweight (odds ratios: 3.11 (95% CI: 2.37, 4.08) and 12.46 (95% CI: 6.07, 25.58) 
respectively).
Conclusions: Children born small, appropriate and large size for gestational age have 
different growth patterns in early childhood and persistent differences in their head 
circumference, length and weight until the age of 4 years. Children born with an appro-
priate weight for gestational age with catch-up growth and large weight for gestational 
children without catch-down growth have an increased risk of overweight. 
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Introduction
Both a small and large size for gestational age at birth, referred to as SGA and LGA re-
spectively, are associated with increased risks of neonatal morbidity and mortality1-2. In 
infancy, children born SGA and LGA, show growth realignment to their genetic growth 
potential. Approximately 80% of all SGA children show catch-up growth during the first 
2 years of life3-5. The proportion and timing of catch-down growth in children born LGA 
has been studied less extensively. Also, not much is known about specific growth pat-
terns and the time windows for growth realignment in infants born SGA and LGA for 
different growth parameters such as head circumference, length and weight. It has been 
suggested that both SGA and LGA are associated with the risk of obesity in later life6-9. 
This association may partly depend on higher growth rates in early childhood10-15. The 
interaction between size at birth and infant catch-up or catch-down growth in relation 
to body composition and the risk of overweight in early life is not well known.
We examined in a population-based prospective cohort study among 3,941 Duch 
children of whom 191 were SGA and 199 were LGA for birth weight, growth of the 
head circumference, length and weight during the preschool period. We also examined 
whether infant catch-up and catch-down growth in these children are associated with 
body fat mass and the risk of overweight.
Methods 
Study population and cohort
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from fetal life until young adulthood in Rotterdam, The Netherlands16. 
Enrolment in the study was aimed at early pregnancy but was possible until birth of the 
child. All children were born between April 2002 and January 200616. Written informed 
consent was obtained from all participants. The Medical Ethics Committee of the Eras-
mus Medical Center Rotterdam has approved the study. The analyses were restricted to 
4,153 Dutch children (Figure 1), defined as having both parents born in the Netherlands. 
Twins (n=124) were excluded from the analysis. Of the remaining 4,029 children, data on 
gestational age was available in 4,016 (99.7%). Data on weight, head circumference and 
length at birth was available in 4,016 (100%), 2,115 (52.7%) and 2,590 (64.5%) of these 
children, respectively. Data on postnatal growth (0-4 years) was available in 3,941 chil-
dren (98.2%). In total, 1,171 of the 4,016 children participated in a sub cohort study for 
additional assessments of body composition16. At two years of age, 835 (71.3%) of these 
children and their parents visited our research center for additional measurements. 
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Birth characteristics and definition of small and large size for gestational age
Information about sex, gestational age, head circumference, length and weight at birth 
was available from midwife and obstetrics registries. We created sex-and gestational 
age-adjusted birth head circumference, length and weight standard deviation scores 
(SD scores) within our study population using Growth Analyser 3.5 (http://www.growth-
analyser.org; Dutch Growth Research Foundation, Rotterdam, the Netherlands). The 
reference was a North European cohort17. We defined SGA as being <5th sex specific 
percentile and LGA >95th sex specific percentile for head circumference, length and 
weight at birth.
Figure 1. Study population – Flowchart
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N = 4,153 
Eligble children  
N = 3,941 
Chilren with required data available 
Excluded: twin pregnancies (n=124), missing 
data on gestational age (n=13) and postnatal 
growth (n=75) 
Birth  
Head Circumference  n=2,085 
Length    n=2,551 
Weight    n=3,941 
 
Postnatal measurements* 
Head Circumference  n=3,743 
Length    n=3,904 
Weight    n=3,915 
 
Outcome measurements 
Age 2 
Skin fold thickness    n=749 
#
 
 
Age 4 
BMI (last available measurement) n=3,531 
Overweight or obesity  n=315 
 
 
 
* At least one measurement available until the four years of age
# Skin fold thickness was measured in a subgroup of children at 24 months of age
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Growth characteristics 0-4 years
Anthropometrics were measured by well-trained staff in community health centers using 
standardized procedures at the ages of 2, 3, 4, 6, 11, 14, 18, 24, 30, 36 and 48 months16. 
The median number of visits to the health care centers was 9 (90% range: 3 – 12). Head 
circumference was measured to the nearest millimeter with a standardized tape (SECA, 
Hamburg, Germany) until the age of 12 months. Length was measured in a supine posi-
tion to the nearest millimeter until the age of 12 months with a neonatometer, after 
which height was measured in standing position with a Harpenden stadiometer (Holtain 
Ltd, Dyfed, United Kingdom). Weight was measured with a mechanical personal scale 
and body mass index (BMI) was calculated (kg/m2). Sex- and age-adjusted SD scores 
were constructed using Growth Analyser 3.5. We used the reference curve for height, 
weight, head circumference and BMI in the Netherlands to establish SD scores18. Catch-
up and catch-down growth for weight, were defined as an increase or decrease of >0.67 
SD of weight from birth to two years of age, respectively9. If weight at 24 months of age 
was not available (18.9% of study population), we used weight at 11 months, and if also 
not available (7.6%), weight at 6 months to assess catch-up or catch-down growth. This 
change represents the width of each percentile band on standard growth charts. 
Subcutaneous fat mass
Subcutaneous fat mass was measured as skin fold thicknesses (SFT), at the age of 24 
months on the left side of the body at four different sites (biceps, triceps, suprailiacal 
and subscapular) according to standard procedures by using a skinfold caliper (Slim 
Guide, Creative Health Products). Measurements of skin fold thickness were available 
in 749 (89.7%) children participating in the subgroup study. Missing skin fold thickness 
measurements were mostly due to crying and oppositional behaviour. Four well-trained 
medical assistants performed all measurements and measured SFT to the closest 0.5 
mm19. Total subcutaneous fat mass was calculated from the sum of biceps SFT + triceps 
SFT + suprailliacal SFT + subscapular SFT. Central subcutaneous fat mass was calculated 
from the sum of suprailliacal SFT + subscapular SFT. Peripheral subcutaneous fat mass 
was calculated from the sum of triceps SFT + biceps SFT. 
Overweight and obesity
We calculated the BMI using weight and length measured at the last visit available after 
the age of two years (median age 45.3 (90% range: 25.3-47.7) months). We constructed 
sex and age specific SD scores of the BMI measurements using Growth Analyser 3.5. 
Based on these SD scores prevalence of overweight and obesity was determined. Over-
weight and obesity were defined as described by Cole et al. as recommended by The 
International Obesity Taskforce20, which created centile curves from different popula-
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tions to create age and sex specific cut off points from 2 to 18 years, which correspond 
to overweight (> 25kg/m2) and obesity (>30 kg/m2) at 18 years of age.
Covariates
Maternal height was measured at enrolment. Information on parity, maternal pre-preg-
nancy weight, educational level and smoking during pregnancy (non/stopped when 
pregnancy was known/continued during pregnancy) was assessed using self-reported 
questionnaires. Child age at the visits to the child health care centers was collected from 
the staff of these centers.
Data analysis
Differences in maternal and offspring characteristics between SGA, appropriate for 
gestational age (AGA) and LGA groups were assessed using t-tests and c2-tests for 
independent samples. We used linear regression analysis to assess the associations of 
being SGA or LGA for birth weight with growth realignment (change in weight SD scores 
in specific time windows). AGA individuals were used as reference. The models were 
adjusted for the individual age period between the measurements. Similar models were 
used for assessing the associations of SGA and LGA for length or head circumference 
with subsequent change in length or head circumference SD scores per time window. 
The associations of being SGA, AGA and LGA for birth weight, stratified for infant catch-
up or catch-down growth, with subcutaneous fat mass at the age of 2 years, BMI at the 
age of 4 years and the risk of overweight and/or obesity were assessed using linear 
and logistic regression analyses. In these analyses, we used children born AGA with-
out catch-up or catch-down growth as reference category. Analyses concerning body 
composition were additionally adjusted for age and height at measurement. All models 
were adjusted for child sex and maternal age, height, pre-pregnancy weight, parity, 
educational level and smoking during pregnancy. Missing values in covariates (ranging 
from 0 to 22%), were multiple-imputed, to reduce potential bias associated with missing 
data 21. We created five imputed datasets and each dataset was analyzed separately to 
obtain the effect sizes and standard errors. The results of all five imputed analyses were 
pooled and are presented in this paper. Because the main results did not differ materially 
between analyses on complete cases and imputed analyses, we only present data on 
imputed analyses. We performed sensitivity analyses excluding preterm born children 
(gestational age at birth <37 weeks). Furthermore, we performed sensitivity analyses 
excluding children without weight measurement available at the age of 24 months to 
establish the postnatal growth pattern. All measures of association are presented with 
their 95% confidence intervals (95% CI). We considered a P-value lower than 0.05 as sta-
tistically significant. All statistical analyses were performed using the Statistical Package 
for the Social Sciences version 17.0 for Windows (SPSS Inc, Chicago, IL, USA).
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Results
Subject characteristics are shown in Table 1. The percentage of boys was 50.4%. Mothers 
of children born SGA group were smaller, less heavy and younger than mothers from 
children born AGA or LGA. They also were lower educated, smoked more often during 
pregnancy and were less frequently multiparous.
Size at birth and infant growth
Table 2 shows the change in SD scores for head circumference, length and weight in 
different time periods for children born SGA, AGA, and LGA children. Children who 
were born SGA showed substantial growth realignment for all growth characteristics, 
as compared to AGA children (p-value <0.001). For head circumference and length, the 
realignment largely occurred during the first 3 months of life, while for weight realign-
ment was present until the age of 36 months. We observed similar patterns for children 
born LGA. 
Table 1. Subject characteristics
Total group
(n =3,941)
Children born 
small size for 
gestational age 
(weight)  
(n=191)
Children born 
appropriate size 
for gestational 
age (weight)  
(n=3,551)
Children born 
large size for 
gestational age 
(weight) 
(n=199)
Maternal characteristics
Age (yrs) 31.8 (22.7-38.5) 30.6 (21.2-38.6) * 31.8 (22.6-38.5) 33.0 (26.1-40.3) **
Height (cm) 170.5 (6.5) 167.1 (6.3) ** 170.5 (6.4) 174.2 (6.3) **
Pre-pregnancy weight (kg) 67.3 (11.8) 62.8 (11.9) ** 67.1 (11.4) 75.3 (14.7) **
Parity ≥ 1 (%) 40.6 23.7 ** 40.2 64.6 **
Highest education (%)                   
      Primary/Secondary school 40.0 51.1 * 40.1 29.6 *
      Higher education 60.0 48.9 * 59.9 70.4 *
Smoking during pregnancy 
(%)
14.4 34.5 ** 13.7 4.5 *
Child characteristics at 
birth
Gestational age 39.9 (37.0-42.1) 39.7 (36.9-42.0) 39.9 (37.1-42.1) 40.0 (37.0-42.0)
Male (%) 50.4 49.7 50.4 50.8
Weight (gr) 3497 (551) 2559 (365) ** 3491 (467) 4501 (382) **
Length (cm) 50.5 (2.4) 47.3 (2.3) ** 50.5 (2.2) 53.4 (2.1) **
Head circumference (cm) 34.0 (1.6) 32.3 (1.3) ** 34.0 (1.6) 35.8 (1.4) **
Preterm birth (%) 4.4 4.7 4.4 4.0
* = p<0.05 
** = p<0.001 
P-values are obtained from t-tests and c2-tests for independent samples using the appropriate for gestational age 
children as reference group. Values are means (SD) or medians (95% range)
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Figure 2a, b and c show the differences in head circumference, length and weight 
SD scores until the age of 4 years between children born SGA, AGA and LGA for birth 
weight. Head circumference showed the most rapid catch-up growth, and the difference 
with AGA children was the smallest, as compared to the length or weight. The difference 
between SGA or LGA and AGA remained significant for all growth measures until the age 
of 4 years (p-value <0.001). 
Table 2. Size at birth and growth realignment in childhood
Age window
0-3 months 3-6 months 6-12 months 12-24 
months
24-36 
months
36-48 
months
Head 
circumference 
at birth
Change in standard deviation score of head circumference per age window
Small size for 
gestational age 
(n=105)
1.86  
(1.63 , 2.09)**
0.09  
(-0.04 , 0.20)
-0.11  
(-0.23 , 0.01)
NA NA NA
Appropriate size 
for gestational 
age (n=1,905)
Reference Reference Reference Reference Reference Reference
Large for 
gestational age 
(n=105)
-1.62  
(-1.87 , 
-1.37)**
-0.02  
(-0.15 , 0.12)
-0.08  
(-0.20 , 0.04)
NA NA NA
Length at birth Change in standard deviation score in length per age window
Small size for 
gestational age 
(n=127)
1.75  
(1.53 , 1.97)**
-0.03  
(-0.18 , 0.11)
0.19  
(0.07 , 0.31)*
0.04  
(-0.11 , 0.18)
-0.03  
(-0.14 , 0.08)
0.05  
(-0.04 , 0.14)
Appropriate size 
for gestational 
age (n=2,331)
Reference Reference Reference Reference Reference Reference
Large size for 
gestational age 
 (n=132)
-1.65  
(-1.88 , 
-1.43)**
-0.11  
(-0.26 , 0.04)
-0.06  
(-0.18 , 0.06)
0.04  
(-0.10 , 0.18)
-0.04  
(-0.15 , 0.07)
-0.01  
(-0.10 , 0.08)
Weight at birth Change in standard deviation score in weight per age window
Small size for 
gestational age 
(n=191)
1.12  
(0.96 , 1.29)**
0.24  
(0.14 , 0.33)**
0.15  
(0.07 , 0.24)**
-0.09  
(-0.19, 0.01)
0.08  
(0.01 , 0.16)*
-0.01  
(-0.08 , 0.07)
Appropriate size 
for gestational 
age (n=3,551)
Reference Reference Reference Reference Reference Reference
Large size for 
gestational age 
(n=199)
-1.25  
(-1.41 , 
-1.10)**
-0.18  
(-0.27 , -0.09)**
0.04  
(-0.05 , 0.12)
0.01  
(-0.09 , 0.10)
-0.04  
(-0.12 , 0.04)
0.01  
(-0.07 , 0.08)
* P <0.05, ** P < 0.001. Values are regression coefficients (95% confidence interval) and reflect the difference in SDS 
change in specific time windows, being small or large for gestational age, compared to being appropriate for gestational 
age. All regression models are additionally adjusted for the exact age span between the measurements.
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Figure 2. Birth weight status and postnatal growth
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(dotted line, reference). Values are regression coefficients (95% CI). 
a Head circumference 
b Length 
c Weight
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Weight at birth, infant growth and subcutaneous fat mass
Table 3 shows the associations of weight at birth, and subsequent catch-up or catch-
down growth with subcutaneous fat mass at the age of 2 years. As compared to children 
born AGA without catch-up or catch-down growth, children born SGA without catch-up 
growth and children born LGA without catch-down growth had the lowest and highest 
peripheral, central and total subcutaneous fat mass (differences for total subcutaneous 
fat mass -4.91 mm (95% CI: -11.91, 2.09) and 8.95 mm (95% CI: 3.93 , 13.97) respectively). 
Among children born AGA, infant catch-up or catch-down growth was associated with 
an increased or decreased total subcutaneous fat mass respectively (differences for total 
subcutaneous fat mass -2.84 mm (95% CI: -4.15, 1.53) and 3.50 mm (95% CI: 2.02 , 4.97) 
respectively) . Results of sensitivity analyses excluding preterm born children (Supple-
mentary Table 1) and excluding children without weight measured at 24 months of age 
(Supplementary Table 2) showed similar associations.
Table 3. Weight at birth, infant growth and subcutaneous fats mass at the age of 2 years 
Birth Weight
Peripheral fat mass 
(mm) 
(Beta (95%CI))
Central fat mass 
(mm)
(Beta (95%CI))
Total fat mass (mm)
(Beta (95%CI))
Small for gestational age 
  No catch-up (n=4) -2.35 (-6.98 , 2.27) -2.58 (-5.91 , 0.76) -4.91 (-11.91 , 2.09)
  With catch-up (n=26) -0.15 (-2.11 , 1.80) -0.11 (-1.52 , 1.30) -0.26 (-3.22 , 2.70)
P-value for difference within stratum a 0.227 0.054 0.084
Appropriate for gestational age
  With catch-down (n=174) -1.51 (-2.37 , -0.65) ** -1.33 (-1.95 , -0.71) ** -2.84 (-4.15 , -1.53) **
  No catch-up/down (n=367) Reference Reference Reference
  With catch-up (n=133) 1.47 (0.51 , 2.44) * 1.95 (1.25 , 2.76) ** 3.50 (2.02 , 4.97) **
Large for gestational age
  With catch-down (n=22) 1.21 (-0.87 , 3.31) 1.03 (-0.51 , 2.57) 2.05 (-1.18 , 5.28)
   No catch-down (n=8) 4.55 (1.24 , 7.87) * 4.42 (2.02 , 6.81) ** 8.95 (3.93 , 13.97) **
P-value for difference within stratum a 0.560 0.021 0.086
* P <0.05, ** P < 0.001. Models were adjusted for child sex, age and height at measurement, maternal age, height, pre-
pregnancy weight, parity, educational level and smoking during pregnancy. Values are regression coefficients (95% CI) 
and reflect the difference in skin fold thickness (millimeters) at the age of two years for different birth weight strata and 
postnatal catch-up or catch-down growth. AGA children without catch-up or catch-down growth were used as reference 
group. Catch-up or catch-down growth was defined as have a change in SDSweight of > 0.67 or < -0.67 from birth to two 
years of age respectively.
a The p-value for difference was obtained by conducting a linear regression analysis within each stratum assessing the 
difference between the growth patterns within the stratum.
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Weight at birth, infant growth and risk of overweight
Table 4 shows that as compared to children born AGA without catch-up or down growth, 
BMI was lowest among children born SGA without catch-up growth (difference -0.95 
SD (95% CI: -1.21, -0.70)) and highest among children born LGA without catch-down 
growth (difference 1.06 SD (95% CI: 0.77, 1.36)). Within each stratum of birth weight, 
infant catch-up or catch-down growth was strongly associated with body mass index 
(P-value for difference in each stratum <0.001). As compared to children born AGA with-
out growth realignment, catch-up growth in children born AGA and lack of catch-down 
growth in children born LGA were associated with increased risks of childhood over-
weight (odds ratios: 3.11 (95% CI: 2.37, 4.08) and 12.46 (95% CI: 6.07, 25.58) respectively). 
Results of sensitivity analyses excluding preterm born children (Supplementary Table 3) 
and excluding children without weight measured at 24 months of age (Supplementary 
Table 4) showed similar associations. 
Table 4. Weight at birth, infant growth and risk of overweight and obesity
Birth Weight
Body mass index (SD score)
(Beta (95%CI))
Overweight/Obesity
(Odds Ratio (95% CI))
Small for gestational age
  No catch-up (n=45) -0.95 (-1.21 , -0.70) ** 0.28 (0.04 , 2.07)
  With catch-up (n=119) -0.23 (-0.39 , -0.07) * 0.92 (0.43 , 1.96)
P-value for difference within stratum a <0.001 0.224
Appropriate for gestational age
  With catch-down (n=840) -0.42 (-0.49 , -0.34) ** 0.31 (0.19 , 0.50) **
  No catch-up/down (n=1,624) Reference Reference
With catch-up (n=697) 0.44 (0.37 , 0.52) ** 3.11 (2.37 , 4.08) **
Large for gestational age
  With catch-down (n=135) 0.24 (0.09 , 0.40) * 1.39 (0.75 , 2.59)
  No catch-down (n=34) 1.06 (0.77 , 1.36) ** 12.46 (6.07 , 25.58) **
P-value for difference within stratum a <0.001 <0.001
* P <0.05, ** P < 0.001
Models were adjusted for maternal age, height, pre-pregnancy weight, parity, educational level and smoking during 
pregnancy. Values are regression coefficients (95% CI) and reflect the difference in body mass index SD score for 
body mass index measured at the last visit available after the age of two years, and odds ratio’s (95% CI) reflecting the 
difference in risk for overweight and/or obesity at the last measurement available after the age of two years, for different 
birth weight strata and postnatal catch-up or catch-down growth. Children with an appropriate weight for gestational 
age without catch-up or catch-down growth were used as reference group. Catch-up or catch-down growth was defined 
as have a change in weight SDS of > 0.67 or < -0.67 from birth to two years of age respectively.
a The p-value for difference was obtained by conducting a linear regression analysis within each stratum assessing the 
difference between the growth patterns within the stratum.
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Figure 3 shows the BMI around the age of four years in different birth weight groups 
stratified by infant growth patterns. The prevalence of overweight or obesity was high-
est (48.5%) in LGA children who did not show catch-down growth.
Discussion
Our results indicate that although children born SGA and LGA show infant catch-up and 
catch-down growth, respectively, their mean head circumference, length and weight are 
persistently different at the age of 4 years. Children born AGA with subsequent catch-up 
growth and children born LGA have a higher subcutaneous fat mass and body mass 
index in childhood. 
Strength and limitations
Many studies have investigated the associations of catch-up growth and overweight 
in later ages in children born SGA10, 14-15. However, studies in children born LGA are less 
abundant and mostly did not study the effect of catch-down growth. Our analyses were 
performed in a large sample and data were prospectively collected for a large number 
of covariates, limiting selection and reporting bias. The median number of available 
Figure 3. Body mass index at the age of four years in different strata of birth weight and infant growth 
patterns
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t-test or within each stratum using the group without catch-up or catch-down growth as reference.
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measurements per group of birth weight stratified by infant growth was largely the 
same and varied between 9 and 11. A limitation might be that for a small number of 
participants (1.8%) we did not have any postnatal growth measurements available. Birth 
weight of these children was lower than of children with postnatal growth measure-
ments available (-0.33 SD (95% CI -0.57, -0.10), P=0.005). Our results would be biased 
if the associations of birth weight, infant growth and risk of overweight would differ 
between subjects included and lost to follow-up. The impact of this loss to follow-up 
is difficult to evaluate, but is unlikely to materially affect our results. Another limitation 
might be that this study was conducted within children from Dutch mothers. Therefore, 
generalizability to other ethnic groups might be limited. We did not exclude preterm 
born children, to increase generalizability to the whole range of SGA and LGA children. 
Size at birth and infant growth
We observed that catch-up and catch-down growth of weight from birth to the age 
of 2 years occurred in 74.3% of all children born SGA and in 80.8% of all children born 
LGA in birth weight, respectively. Of these children, 89.9% and 86.4% showed catch-up 
or catch-down growth in the first six months of life respectively. The majority of the 
growth realignment was seen in the first three months of age for head circumference 
and length, while weight showed catch-up growth over a longer period of time. Our 
results also showed that despite catch-up or catch-down growth, children born SGA and 
LGA have a persistently smaller or larger head circumference, height and weight until 
the age of four years, compared to children born AGA. Previous studies showed similar 
persistent differences in length and weight after being born small or large for gesta-
tional age until the age of eight to eighteen years3, 22-24. Data on head circumference 
growth is limited22. The mechanism underlying these differences in growth patterns for 
head circumference, length and weight are not known. However, the smaller effects on 
head circumference at birth and faster growth realignment are in line with the relative 
brain sparing in children with a compromised fetal growth.
Weight at birth, infant weight growth and body composition
Previous studies have shown that catch-up growth is associated with an increased fat 
mass measured at different ages5, 9, 25-26. We explored whether these associations were 
present in all birth weight groups with different postnatal growth patterns. Children 
born LGA without catch-down growth had an increased fat mass at two years of age, 
while children born SGA had a lower fat mass. Hediger et al. studied 3192 children in 
the United States and showed that in children born LGA, the increase in fat mass was 
not yet observed at the age of three years, but only present at the age of six years26. 
This study did not investigate the possible modifying effect of infant growth on body 
composition. The majority of the children born LGA children show catch-down growth 
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which could be a reason that an increased fat mass is not detected when investigating 
LGA children irrespective of their infant growth. Our results also suggest that among all 
birth weight groups, infant catch-up growth is associated with higher fat mass. Longer 
follow-up studies are needed to evaluate whether these changes persist at later ages.
Weight at birth, infant weight growth and risks of overweight
The association of between birth weight, infant growth and obesity in childhood and 
adulthood is complex and has been studied extensively. Stettler et al. showed that rapid 
weight gain in the first four months after birth was associated with overweight at the 
age of seven years across the whole range of birth weight, independent of the weight 
attained at one year of age27. Several other studies have shown that catch-up growth 
in children born SGA is associated with a higher risk of obesity in adulthood10-12. In our 
study, this effect was not yet found in children born SGA, indicating that the increase risk 
of obesity develops later in life and is not yet seen at this young age. However, we did 
find that within children born SGA, BMI at four years of age is increased when they show 
catch-up growth. Catch-up and catch-down growth in children born AGA was associ-
ated with an increased or decreased risk of overweight respectively. This confirms the 
findings of by Ong et al. showing that children with catch-down growth in infancy have 
a lower BMI at the age of 5 years9. 
Children born LGA are less extensively studied. The study of Parsons et al. using data 
from the 1958 Birth Cohort found the association between birth weight and BMI in 
adulthood to be J-shaped28. Children in the lower ranges of birth weight in early life 
tended to show rapid weight gain in early life, which ultimately may lead to obesity in 
adulthood. Children in the upper ranges of birth weight also had an increased BMI in 
adulthood, showing signs of tracking28. Our study showed that children born LGA have 
an increased BMI in early childhood. Furthermore, among children born LGA, the risk of 
childhood overweight is modified by infant catch-down growth, with the highest risk of 
being overweight when not showing catch-down growth. This is in line with the study 
by Bueno et al. among 116 children born LGA, showing that catch-down growth was 
associated with a lower BMI and abdominal circumference at the age of 23-25 years29. 
Longer follow-up in this study population and other populations is needed to assess 
whether these associations persist and other associations develop in adolescence and 
adulthood.
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Conclusions
In this study, we demonstrated that although children born SGA and LGA show infant 
catch-up and catch-down growth, respectively, their mean head circumference, length 
and weight are persistently different at the age of 4 years. Children born AGA with 
catch-up growth and children born LGA without catch-down growth have a higher 
subcutaneous fat mass and body mass index in childhood, and are at increased risk for 
childhood overweight. Results from our study suggest that these groups could be a 
potential target for early prevention of childhood obesity. 
Note: Supplementary information is available on the Obesity website: www.nature.com/
oby
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Abstract
Aims and methods: In a genome-wide association study of birth weight (up to 69,308 indi-
viduals of European descent from 43 studies), we have extended the number of genome-wide 
significant loci to seven, accounting for a similar proportion of variance to maternal smoking. 
Results and conclusions: Five of the loci are known to be associated with other pheno-
types: ADCY5 and CDKAL1 with type 2 diabetes; ADRB1 with adult blood pressure; and 
HMGA2 and LCORL with adult height. Our findings highlight genetic links between fetal 
growth and postnatal growth and metabolism.
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2.2
Introduction
Birth weight within the normal range is associated with a variety of adult-onset dis-
eases   but the mechanisms behind these associations are poorly understood1. Previous 
genome-wide association studies identified a variant in the ADCY5 gene associated with 
both birth weight and type 2 diabetes, and a second variant, near CCNL1, with no obvi-
ous link to adult traits2. 
Methods and results
To understand further the genetic factors involved in fetal growth and its association 
with adult diseases, we performed an expanded genome wide association study (GWAS) 
of birth weight in up to 26,836 individuals of European ancestry from 18 studies (Stage 
1; Supplementary Table 1; Supplementary Figures 1 to 3; see Supplementary Online 
Material for a full description of the methods). After follow-up analyses of 21 of the most 
strongly associated independent single nucleotide polymorphisms (SNPs; P < 1x10-5) 
in additional European samples (Supplementary Tables 2 and 3), we identified novel 
associations with birth weight at four loci (P < 5x10-8), and confirmed three previously 
reported associations2-4 (rs900400 near CCNL1, P = 3.6x10-38; rs9883204 in ADCY5, P = 
5.5x10-20; rs6931514 in CDKAL1; P = 1.5x10-18), in a joint meta-analysis of up to 69,308 
individuals (Table 1; Supplementary Figures 4 and 5). The index SNPs at the four newly-
associated loci were rs1042725 in HMGA2 (P = 1.4x10-19), rs724577 in LCORL (P = 4.6x10-11), 
rs1801253 in ADRB1 (P = 3.6x10-9) and rs4432842 at chromosome 5q11.2 (P = 4.6x10-8). 
The effect size estimates range from 0.034 SD to 0.072 SD per allele and equate approxi-
mately to changes in birth weight of 16 to 35g (Table 1). These estimates did not change 
materially in sensitivity analyses excluding studies with self- or parentally-reported birth 
weight data and those without a measure of gestational age (Supplementary Table 4).
Through the cellular mechanisms of gametogenesis and fertilization, fetal genotype is 
correlated with maternal genotype (r ≈ 0.5). Using up to 11,307 mother-child pairs from 
a subset of studies, we found no evidence that the seven associations we observed at P 
< 5x10-8 are driven by the maternal, rather than the fetal, genotype (likelihood-ratio test 
P >0.05; Table 1). 
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Discussion
For five of the seven confirmed associations with birth weight, correspondence with 
GWAS findings for adult traits (type 2 diabetes, blood pressure or height) provide clues 
to the biological pathways involved. Two SNPs represent the same signals as known 
type 2 diabetes loci: ADCY5 (previously reported2) and CDKAL1 (previously examined in 
smaller candidate gene studies of birth weight3-4). We observed similar z score effect size 
estimates of the associations between each of these loci and ponderal index (calculated 
as weight/length3 to indicate neonatal leanness), birth length and head circumference 
(Table 1), suggesting a general effect on fetal growth. At both loci, the birth weight-
lowering allele is associated with greater type 2 diabetes risk2-4. This observation is 
consistent with the fetal insulin hypothesis5, which proposes that common genetic 
variation influencing insulin secretion or action, both in prenatal development and adult 
life, could partly explain epidemiological correlations between lower birth weight and 
type 2 diabetes. The type 2 diabetes risk allele at ADCY5 is associated with a number of 
features suggesting impaired insulin secretion: higher glucose levels after fasting and 2 
hours after an oral glucose challenge6-7; lower 2-hour insulin levels, adjusted for 2-hour 
glucose levels7; higher fasting proinsulin (relative to mature insulin) levels8; and lower 
Homeostatic Model Assessment (HOMA)-derived index of beta-cell function HOMA-B6 
(Supplementary Table 5).  The risk allele at CDKAL1 is strongly associated with reduced 
insulin secretion in studies of adults9.  Given the key role of fetal insulin in prenatal 
growth, we hypothesize that the ADCY5 and CDKAL1 risk alleles reduce fetal insulin 
levels, which mediate the associations with birth weight. 
To investigate whether type 2 diabetes susceptibility loci other than ADCY5 and CDKAL1 
influence fetal growth, we tested the associations between 47 additional, published 
type 2 diabetes loci and birth weight in our Stage 1 meta-analysis. We observed more 
Associations between birth weight and known type 2 diabetes (T2D; a and b), systolic blood pressure (SBP, c and d) or 
height (e and f ) loci from the discovery meta-analysis of N=26,836 individuals. Plots a, c and e are quantile-quantile 
plots: the black triangles (associated with lower birth weight) and circles (associated with higher birth weight) represent 
observed P-values after removing the loci that achieved P < 5x10-8 in the overall meta-analysis, and the black line 
represents expected P-values under the null. The grey area defines the approximate 95% confidence interval around 
the expected line. Plots b, d and f show, respectively, the T2D, SBP or height effect size (left-hand y-axis), taken from 
published meta-analyses13, 19-21, against the birth weight effect size (x-axis), with a superimposed frequency histogram 
showing the number of SNPs in each category of birth weight effect size (right-hand y-axis). The odds ratios for type 
2 diabetes are all obtained from the published DIAGRAM+ Consortium meta-analysis21, the largest available reference 
sample of European descent, and while they do not necessarily reach genome-wide significance in that sample, all loci 
have shown associations with type 2 diabetes at P < 5x10-8 (see Supplementary Online Material for the list of published 
studies). Effect sizes are aligned to the T2D risk allele or the SBP- or height-increasing allele. Colours indicate birth weight 
association P-values: P<5e-08 (red); P>=5e-08 and P<0.001 (orange); P>=0.001 and P<0.01 (yellow); P>0.01 (white). The 
triangles in plot f are SNPs known to be associated with age at menarche. There were more associations between height 
loci and higher birth weight than expected under the null, and a slight excess of associations between T2D or SBP loci 
and lower birth weight (binomial sign test P = 0.02, 0.09 and 3x10-10 for b, d and f, respectively).
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associations with birth weight than expected by chance (Figure 1a), with 7 associa-
tions at P < 0.05, of which 4 achieved P < 0.01 (MTNR1B-rs1387153, KCNQ1-rs231362, 
HHEX-IDE-rs5015480 and GCK-rs4607517), including GCK at P=1x10-4. Meta-analysis of 
the HHEX-IDE result with previously published data (total n = 51,583) strengthened the 
evidence of association (P = 6.9x10-7; Supplementary Table 6). The type 2 diabetes risk 
alleles at HHEX-IDE and KCNQ1 follow ADCY5 and CDKAL1 in being associated with lower 
birth weight, providing additional support for the fetal insulin hypothesis, although the 
associations can only explain a small fraction of the epidemiological association. 
In contrast, the type 2 diabetes risk alleles at GCK and MTNR1B were associated with 
higher birth weight (Figure 1b). Higher maternal glucose levels are associated with 
higher offspring birth weight10, and both the GCK and MTNR1B loci influence fasting 
glucose levels throughout the normal physiological range6. Consistent with this, and 
with previous studies of the GCK variant11, the effect size estimates we observed for GCK 
and MTNR1B were lower after adjustment for maternal genotype (Supplementary Figure 
6). Well-powered studies of mothers and offspring will be required to test formally the 
association between maternal genotype and birth weight at these loci. The lack of a fetal 
association at GCK-rs4607517 contrasts with the strong birth weight-lowering effects of 
rare, heterozygous fetal GCK mutations12, and suggests that the common GCK variant 
does not influence insulin secretion until postnatal life. 
The association with birth weight at ADRB1 rs1801253 (Arg389Gly) links prenatal 
growth with blood pressure in adulthood since the same SNP is strongly associated with 
both systolic and diastolic blood pressure (P<5x10-8)13.  Epidemiological associations 
between birth weight and systolic blood pressure (SBP) constitute some of the strongest 
evidence supporting the fetal origins of adult disease14. Most studies report a linear in-
verse association throughout the birth weight distribution, whereby lower birth weight 
is associated with higher adult SBP. There is also evidence that birth weights at the high 
end of the distribution are associated with higher SBP15. Based on the majority of stud-
ies, we might therefore expect a fetal SBP-raising allele to be associated with lower birth 
weight. However, the birth weight-lowering allele at rs1801253 (Gly389) is associated 
with lower blood pressure in later life. We observed similar effect size estimates for as-
sociations between ADRB1 and various birth measures (Table 1), suggesting a general 
effect on fetal growth. We tested for associations between birth weight and 29 additional 
blood pressure loci in our Stage 1 meta-analysis. While we did not observe strong evi-
dence of deviation from the null (Figure 1c), associations between the SBP-raising allele 
and lower birth weight achieved P < 0.01 at GUCY1A3/GUCY1B3-rs13139571 (P=0.0008) 
and CYP17A1/NT5C2-rs11191548 (P=0.009). These were little altered on adjustment for 
maternal genotype (Figure 1d; Supplementary Table 7). 
The associations with birth weight at the HMGA2 and LCORL loci link prenatal growth 
with postnatal stature. At both loci, the birth weight-lowering allele is also associated 
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with lower adult height and associations are consistent with a primary effect on birth 
length (Table 1). The HMGA2 SNP is also strongly associated with birth head circumfer-
ence and is known to associate with head circumference in infancy and intracranial vol-
ume in adulthood16-17 suggesting a general effect on growth. Variation at LCORL has also 
been associated with peak height velocity in infancy18, indicating an effect on growth 
in childhood. When testing 178 additional published height loci (see Supplementary 
Online Material for references to published height, blood pressure and type 2 diabetes 
loci), we observed more associations with birth weight than expected by chance (Figure 
1e), indicating that many adult height loci influence prenatal growth. Of all 180 loci, 
132 show the same direction of effect size estimate with birth weight as with height 
(binomial sign test P=3x10-10), although there is no strong correlation between adult 
height and birth weight effect sizes (Figure 1f ). We did not observe any evidence that 
these associations were driven by maternal genotypes (Supplementary Table 8).
The remaining two loci (near CCNL1 and on chromosome 5q11.2) are not known to 
be associated with any other traits. The previously reported association near CCNL1 
represents the strongest association with birth weight, and shows a strong association 
with ponderal index, but relatively weak associations with birth length and head cir-
cumference (Table 1), strengthening the evidence that this locus primarily acts through 
non-skeletal growth. In a subset of 7 studies with available postnatal data, the associa-
tion had disappeared by 3 months of age (0.001 SD [95% CI: -0.030, 0.032] per rs900400 
C-allele, relative to birth weight: -0.084 SD [95%CI: -0.106, -0.062]; Supplementary Table 
9; Supplementary Figure 7), suggesting that the growth effects of the CCNL1 locus are 
specifically intrauterine. Little is known about the birth weight locus at chromosome 
5q11.2: the nearest gene, ACTBL2, is approximately 400kb away and has no obvious link 
with fetal growth. Associations at this locus are similar across the different anthropo-
metric birth measures (Table 1) and there are no associations with adult metabolic or 
anthropometric traits in published studies (Supplementary Table 5). 
We were interested to explore whether the same variants have any impact on birth 
weight in other ethnic groups. Using data from a range of non-European studies, 
including those of Middle Eastern, East and Southeast Asian and African origin (total 
n = 11,848; Supplementary Table 10), we showed that the 7 SNPs together explained 
between 0.32% and 1.52% of the variance in birth weight, which was similar to that in 
Europeans (0.76%; Supplementary Table 11; Supplementary Figures 8 and 9). 
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Conclusions
To conclude, we have identified four, and confirmed three loci associated with birth 
weight, which explain a similar proportion of variance to maternal smoking exposure 
in pregnancy (Supplementary Figure 10). The associations between five of the loci and 
adult traits (i) highlight biological pathways of relevance to the fetal origins of type 2 
diabetes, (ii) reveal complexity in that type 2 diabetes risk alleles can be associated with 
either higher or lower birth weight, (iii) illuminate a novel genetic link between fetal 
growth and adult blood pressure and (iv) demonstrate substantial overlap between the 
genetics of prenatal growth and adult height. 
Note: Supplementary information and online methods are available on the Nature 
Genetics Website: www.nature.com/ng
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Abstract
Aims and Methods: To identify genetic variants associated with head circumference 
in infancy, we performed a meta-analysis of seven genome-wide association (GWA) 
studies (N=10,768 from European ancestry enrolled in pregnancy/birth cohorts) 
and followed up three lead signals in six replication studies (combined N=19,089). 
Results and Conclusion: Rs7980687 on chromosome 12q24 (P=8.1x10-9), and rs1042725 
on chromosome 12q15 (P=2.8x10-10) were robustly associated with head circumference 
in infancy. Although these loci have previously been associated with adult height, their 
effects on infant head circumference were largely independent of height (P=3.8x10-7 for 
rs7980687, P=1.3x10-7 for rs1042725 after adjustment for infant height). A third signal, 
rs11655470 on chromosome 17q21, showed suggestive evidence of association with 
head circumference (P=3.9x10-6). SNPs correlated to the 17q21 signal show genome-
wide association with adult intra cranial volume, Parkinson’s disease and other neurode-
generative diseases, indicating that a common genetic variant in this region might link 
early brain growth with neurological disease in later life. 
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Introduction
Head circumference in infancy is used as a measure for brain size and development1-2. 
Normal variation in head circumference seems to be associated with cognitive and be-
havioral development3-5. Larger head circumference in infancy is associated with higher 
IQ scores in childhood5-7. The underlying mechanisms however, are poorly understood. 
Head circumference is a complex trait with a high heritability of around 0.7-0.98. Several 
rare mutations with large effects on head circumference have been identified9-12, includ-
ing those resulting in microcephaly and intellectual disability10-12. Common genetic 
variants that influence normal variation in head circumference in early life have not yet 
been identified. 
To search for common genetic variants associated with head circumference in infancy, 
we performed a meta-analysis of GWA studies. We reasoned that finding such common 
variants might lead to enhanced understanding of molecular mechanisms important for 
variation in brain development. 
Methods
We meta-analyzed association statistics from ~2.5 million directly-genotyped and im-
puted SNPs in infants of European descent from seven discovery GWA studies (N=10,768; 
Supplementary Table 1). In all studies head circumference in infancy (age 18 months, 
range 6 to 30 months) was measured from the occipital protuberance to the forehead, 
using a flexible, non-stretching measure tape following standardized procedures. If 
multiple measurements were available for one individual in this time window, only the 
measurement performed closest to the age of 18 months was used (Supplementary 
Tables 1 and 2). Since the relationship between head circumference and age during 
infancy is non-linear and the variance increases with age, we calculated sex- and age-
adjusted SD-scores of head circumference in each study separately13. 
In the discovery phase we identified three lead signals (Manhattan plot is shown in 
Supplementary Fig. 1); two independent loci on chromosome 12 and one on chromo-
some 17, which showed suggestive evidence for association with head circumference 
in infancy. These three loci represent the first three independent loci of the discovery 
analysis and were at 12q24.31, in SBNO1 (rs7980687, Pdiscovery=3.3x10
-7; Figure 1a), at 
12q15, near HMGA2 (rs1042725, Pdiscovery=6.6x10
-7; Figure 1b) and at 17q21.1, near CRHR1/
MAPT (rs11655470, Pdiscovery=1.4x10
-6; Figure 1c). Other loci, suggesting an association 
with infant head circumference (P<1x10-5) are described in Supplementary Table 3.
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Results
 Table 1 shows the associations of these three lead SNPs in each cohort. We followed up 
these three associations in six independent replication samples of European descent 
(N=8,321; Supplementary Table 2). We genotyped the most strongly associated SNP 
from each locus (rs7980687 from 12q24.31; rs1042725 from 12q15; rs11655470 from 
17q21.1), or a closely-correlated proxy (HapMap R2). Consistent associations were 
observed for both signals on chromosome 12 in the replication samples (P=0.003 and 
P=8.1x10-5 for rs7980687 and rs1042725 respectively). Marginal evidence of association 
for rs11655470 was seen in the replication samples (P=0.093). Genomic control cor-
rection was applied during the discovery meta-analysis stage to adjust the statistics 
generated within each cohort (λ-values ranging from 1.007-1.054, Supplementary Table 
1). Results from the replication cohorts were combined with the genomic control cor-
rected discovery results to get the overall meta-analysis results. Combining discovery 
and replication samples (N=19,089; Table 1), each A allele of rs7980687 in SBNO1 was 
robustly associated with a 0.074 SD larger head circumference (95% CI: 0.049, 0.099; 
P=8.1x10-9, explained variance 0.24%) and each T allele of rs1042725 near HMGA2 with 
a 0.065 SD smaller head circumference (95% CI: -0.085, -0.045; P=2.8x10-10, explained 
variance 0.33%). This reflects a difference of around 1.2 and 1.0 mm in head circumfer-
ence respectively. The effect of each T allele of rs11655470 near CRHR1/MAPT did not 
reach genome-wide significance in the combined analysis (effect 0.048 SD larger head 
circumference; 95%CI: 0.028, 0.068; P=3.8x10-6, explained variance 0.21%). These three 
associations showed low heterogeneity (P>0.1, I2=5-33%).
Additionally, the signals in SBNO1 and near HMGA2, but not the one near CRHR1/MAPT, 
were associated with height measured at the same visit as head circumference (Supple-
mentary Table 4). When we adjusted the model for current height, the associations of 
rs7980687 and rs1042725 with head circumference were slightly attenuated (effect size 
0.057 SD; 95%CI: 0.035, 0.080; P=3.8x10-7 and -0.048 SD; 95%CI: -0.066, -0.030; P=1.3x10-7 
for rs7980687 and rs1042725 respectively, Supplementary Table 5). The association of 
the third signal near CRHR1/MAPT was unaffected. In depth mediation analysis showed 
that the effects of rs7980687 and rs1042725 on head circumference were only partly 
(12% and 24% respectively) explained by height (Supplementary Fig. 2, Supplementary 
Table 6). The effect of rs11655470 was a completely direct effect of the SNP on head 
circumference (Supplementary Table 6). To further adjust for possible population strati-
fication we added principal components to the model, in cohorts where these measures 
were available (total N = 12,763). This did not materially change the effect on head 
circumference, indicating that the utilized association tests are robust to population 
stratification (Supplementary Table 7). The three variants were not associated with other 
covariates such as breast feeding, socioeconomic status or educational level (data not 
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shown). We did not find evidence for an interaction of these variants with infant sex or 
breastfeeding after Bonferroni correction (P>0.017, Supplementary Table 8 and 9).
In order to further investigate an effect of the three lead signals on fetal head growth, 
we assessed the associations of the variants with head circumference using third 
trimester fetal ultrasound data (n=3,781) and head circumference measured at birth 
(n=13,775), in discovery and replication cohorts that had these data available (Supple-
mentary Table 2). All three signals showed evidence of association with head circumfer-
ence in third trimester of pregnancy and at birth (Table 2). The directions of the effects 
were consistent with those in infancy.
Next, we assessed the associations of the three lead signals with intra-cranial volume 
(ICV) in adulthood, measured by magnetic resonance imaging (MRI), in 8,175 individuals 
in the CHARGE-consortium14. There was evidence of association between the signals 
near HMGA2 and CRHR1/MAPT and ICV (Table 2). For the signal near CRHR1/MAPT, a 
variant further downstream (rs9915547; r2 0.22 HapMap CEU) showed a genome-wide 
significant association (P<5x10-8). All directions of the effects were consistent with the 
observed associations for head circumference in infancy (Table 2).
We also assessed if there were possibly functional common variants in LD (r2 > 0.50) 
with our three lead SNPs, being either non-synonymous SNPs or eQTLs. One variant, 
rs1060105, in high LD with our lead signal (rs7980687 with HapMap r2 0.89), was a non-
synonymous SNP located in exon 5 of SBNO1 (missense; AGT(Ser) => AAT(Asn)). The 
minor allele (A) of rs1060105 was associated with an increased head circumference in 
infancy (effect size 0.081 SD; 95%CI: 0.048, 0.115; P=2.4x10-6 (N=10,768)). The underlying 
mechanism is unknown. Considering that transcription regulation is highly cell-type 
specific, we next evaluated whether we could find eQTLs established in brain tissue15. 
We did not find eQTLs in publicly available brain expression data15. Subsequently, 
we also explored eQTL databases from other tissues and identified three SNPs in LD 
with rs7980687 (r2 > 0.7 HapMap CEU) associated with gene transcript expression of 
CDK2AP1 and MPHOSPH9 in liver tissue, monocytes and lymphoblastoid cell lines16-18. 
Little is known on these genes except that both CDK2AP1 and MPHOSPH9 are involved 
in cell-cycle regulation (Supplementary Table 10)19-20. 
Discussion
To our knowledge, this is the first genome-wide association study on head circumfer-
ence in infancy. The top two signals (rs7980687 in SBNO1 and rs1042725 near HMGA2) 
associated with infant head circumference have previously been associated with adult 
height21. Therefore, we also assessed the association between the 180 known height 
variants and head circumference during infancy21. A strong deviation from the null-line 
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was observed on the QQ-plot (Supplementary Fig. 3). Besides SBNO1 and HMGA2, 23 
other height variants were nominally associated with head circumference in infancy 
(Supplementary Table 11). After applying Bonferroni correction for multiple testing in 
this candidate gene analysis (P<2.8x10-4), markers in/near ZNFX1 (P=6.1x10-6), OR2J3 
(P=1.8x10-5) and ZBTB38 (P=1.8x10-4) remained statistically significant associated with 
head circumference in infancy.
The relative effect size of rs1042725 near HMGA2 was similar for infant head circumfer-
ence (0.065 SD) and adult height (0.060 SD). However, the effect size of rs7980687 in 
SBNO1 on infant head circumference (0.074 SD) was considerably larger than for adult 
height (0.035 SD). As head size is correlated with total body size22, it might be that the 
top two loci have a more general regulating role in skeletal growth and bone develop-
ment. It also could be that variants in SBNO1 affect brain growth and concurrent head 
circumference, or that they affect skull growth rather than skeletal growth. The SBNO1-
gene is involved in the Notch signaling pathway23. In Drosophila, a similar gene (sno) is 
required for early embryogenesis, and absence of this gene leads to maldevelopment 
of the central nervous system23. In humans SBNO1 has been implicated in oncogenic 
processes24-25. 
The variant near HMGA2 was one of the first to be associated with adult height. Dele-
tions and truncations in the HMGA2-gene in mice and humans have been associated 
with small and large stature26-27. The effect of HMGA2 is similar for head circumference 
and adult height, thus it seems likely that it has a more general role in skeletal growth.
A third variant (rs11655470), in the promoter region of CRHR1/MAPT, was also related 
to head circumference, though this signal did not reach genome-wide significance. 
Rs11655470 lies within the 17q21 inversion, but is not strongly correlated with the 
inversion (r2 0.22 HapMap CEU). This 900kb region, corresponding to the conversion, 
contains several genes. The SNP is closely related to the CRHR1-gene (r2 0.59 HapMap 
CEU with rs171440). Variants in/near CRHR1 have been associated with brain develop-
ment and bone mineral density28-29, although the underlying mechanisms are largely 
unknown. Another gene included in the 17q21 inversion is MAPT (r2 0.22 HapMap CEU). 
Both common variants and mutations in MAPT are known to be associated with Par-
kinson’s disease and other neurodegenerative diseases30-34. Other genes in this region 
are saitohin (STH) and granulin (GRN). STH has been associated with progressive supra-
nuclear palsy and increased risk of late-onset Alzheimer’s disease35-36. Mutations in GRN 
have been shown to cause fronto-temporal degeneration37. It might be that common 
genetic variants in/near CRHR1/MAPT affect early brain development, by altering the 
stability and assembly of microtubules. Ikram et al. showed that a correlated SNP in the 
same region (rs9303525, HapMap r2 0.22 with rs11655470) is associated with adult intra 
cranial volume, reaching genome-wide significance14. Since the LD between the variants 
is low, it could be that they represent separate independent effects on different pheno-
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types. When we adjusted the effect of rs11655470 on infant head circumference for the 
CHARGE ICV signal (rs9915547), the effect was attenuated but remained significant (0.059 
SD (P=1.0x10-5) and 0.037 SD (P=7.3x10-3) before and after adjustment for rs9915547 
respectively), suggesting that these signals both tag a third marker influencing both 
phenotypes (Supplementary Table 12). However, although the association attenuates 
after conditioning on the CHARGE ICV signal, the two signals might still independently 
tag different causal markers in the region and the attenuation might be due to the weak 
LD, because of proximity, between the two signals. The marker associated with head 
circumference is in low LD with the chromosome 17q21 inversion, while the CHARGE ICV 
signal is in high LD with the inversion. Therefore, it does not seem likely that the 17q21 
inversion is causally related to infant head circumference. The biological mechanisms 
underlying these associations are largely unknown.
Conclusions
Our study highlights early effect of variants in/near SBNO1 and HMGA2 on head circum-
ference in fetal life and infancy, and shows that a variant near CRHR1/MAPT is marginally 
associated with head circumference in infancy. Our findings suggest that the genetic 
variants in the CRHR1/MAPT region might link early brain growth with neurological 
disease in later life. Further research is needed to elucidate whether these variants influ-
ence brain growth and neurodevelopment in early life.
Note: Supplementary information is available on the Nature Genetics website: www.
nature.com/ng
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Online Methods 
Stage 1: GWA meta-analysis of head circumference
Discovery samples, genotyping and imputation
We selected seven population-based studies with head circumference measured  in 
infancy (study cohort specific median age range 11-18 months) and GWA data available 
by the beginning of March 2010 (combined N=10,768): the Avon Longitudinal Study 
of Parents And Children (ALSPAC; N=1,748); The Children’s Hospital of Philadelphia 
(CHOP; N=1,008); the Copenhagen Study on Asthma in Childhood (COPSAC; N=369); 
The Generation R Study (Generation R; N=2,240); the Lifestyle – Immune System – Al-
lergy Study (LISA; N=357); the Northern Finland 1966 Birth Cohort (NFBC1966; N=4,287) 
and the Western Australian Pregnancy study (RAINE; N=759). Genotypes were obtained 
using high-density SNP arrays, and then imputed for ~2.4 million HapMap SNPs (Phase 
II, release 21/22, http://hapmap.ncbi.nlm.nih.gov/). The basic characteristics, exclusions 
(e.g. samples of non-European ancestry), genotyping, quality control and imputation 
methods for each discovery sample are presented in Supplementary Table 1. 
Statistical analysis within discovery samples
Head circumference was measured in infancy (age window: 6-30 months). If multiple 
measurements were available for one individual within this age window, the measure-
ment closest to 18 months was used. Sex- and age-adjusted standard deviation scores 
(SD score) were constructed using Growth Analyser 3.0 (http://www.growthanalyser.
org; Dutch Growth Research Foundation, Rotterdam, the Netherlands) in each study 
separately13. The association between each SNP and head circumference was assessed 
in each study sample using linear regression of head circumference SD score against 
genotype, assuming an additive model. Imputed genotypes were only used where 
directly-assayed genotypes were unavailable. 
Meta-analysis of discovery samples
Data exchange was facilitated by the SIMBioMS platform (simbioms.org)38. Prior to meta-
analysis, SNPs with a minor allele frequency <1% and poorly-imputed SNPs (proper_info 
≤0.4 [SNPTEST]; r2 ≤0.3 [MACH2QTL]) were filtered. Fixed effects meta-analyses were 
independently conducted by two investigators (H.R.T., D.O.M-K.). Meta-analysis was 
performed using the software package: METAL (http://www.sph.umich.edu/csg/
abecasis/metal/index.html); Genomic control39 was applied during the meta-analysis 
stage to adjust the statistics generated within each cohort (see Supplementary Table 
1 for individual study λ-values, discovery meta-analysis λ-value: 1.043). Meta-analysis 
was done using the inverse-variance method; a fixed effects model was assumed. SNPs 
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available in less than four discovery cohorts were excluded. Final meta-analysis results 
were obtained for 2,449,806 SNPs. We considered the top three lead signals (represent-
ing 3 distinct genomic regions on chromosomes 12 and 17) in the discovery analysis 
for further follow-up in additional samples. The two loci at chromosome 12 reached the 
threshold of P<1x10-6 and were therefore selected for replication and the third locus at 
chromosome 17 was just above that threshold (P=1.4x10-6) and was selected because of 
prior knowledge of the nearby genome wide significant hit on intra cranial volume as 
described by Ikram et al.14
Stage 2: Follow-up of three lead signals in additional samples
Follow-up samples, genotyping and analysis
We used 6 independent study samples (combined N=8,321) to follow up the three lead 
signals from the GWA meta-analysis (represented by index SNPs rs7980687, rs1042725 
and rs11655470). Details of these study samples are presented in Supplementary Table 2. 
If the index SNP was unavailable, a closely correlated proxy was substituted (rs12322888 
or rs12316131 for rs7980687 [HapMap r2=0.95]; rs7970350 or rs1351394 for rs1042725 
[HapMap r2=1 and 0.91 respectively]; rs12938031 for rs11655470 [HapMap r2=0.58]). In 
3 of the replication studies, the index SNPs were imputed from genome-wide genotype 
data (see Supplementary Table 2). The head circumference analysis (as described above) 
was performed within each study sample. 
Statistical analysis
Meta-analyses of discovery and replication samples
We performed fixed effects inverse variance meta-analyses of the head circumference 
association results for the three lead signals in the seven discovery samples and six rep-
lication samples combined. Fixed effects meta-analyses were conducted independently 
by two investigators (H.R.T., D.O.M-K.), using RMeta in R [v.2.7.0]). We used the Cochran 
Q test and the I2 statistic40 to assess evidence of between-study heterogeneity of effect 
sizes. 
Informed consent (or parental consent, as appropriate) was obtained from all discovery 
and follow-up study participants and study protocols were approved by the local ethics 
committees.
Analyses of potential confounders
To verify that the investigated lead SNPs were not associated with other covariates 
which could theoretically confound the observed associations with head circumference 
69
Genetic determinants of infant head circumference
2.3
(including height, weight and age at measurement; breastfeeding; maternal educational 
level; and sex), we used linear or logistic regression models to assess the associations be-
tween each covariate and genotype, in all discovery and replication samples. For height 
and weight, we constructed sex- and age-adjusted SD scores using Growth Analyser 
3.0 (http://www.growthanalyser.org; Dutch Growth Research Foundation, Rotterdam, 
the Netherlands) in each study separately, similar to the head circumference SD score. 
To investigate possible effects of the three lead signals on head circumference through 
height, we first conducted linear regression analysis with and without adjustment for 
height SD score. Second, we conducted a mediation analysis and assessed the direct 
SNP effects and indirect SNP effects (mediated through height) on head circumference 
for each of the signals using a seemingly unrelated regression model (STATA, StataCorp 
LP, College Station, TX, USA) or a simple path analysis model (MPLUS, Muthen & Muthen, 
Los Angeles, CA, USA), which provide identical effect estimates. To investigate whether 
the associations between genotypes and infant head circumference were similar in the 
sexes, we repeated the analyses in males and females separately. Furthermore, we evalu-
ated possible effect modification by breastfeeding status for each of the SNPs. Where 
possible, we meta-analyzed results to assess overall evidence of association.
Analysis of fetal head circumference and intra cranial volume
We explored associations of rs7980687, rs1042725 and rs11655470 with third trimester 
fetal head circumference and head circumference at birth, assuming an additive model 
using linear regression. Fetal head circumference was measured by ultrasound in three 
studies (combined N=3,781 singleton pregnancies) in third trimester of pregnancy (ges-
tational age window 27-36 weeks). Only one measurement per subject was included 
in the time window. If multiple measurements were available within the time-window, 
the one closest to the median of 32 weeks of the gestation was used. We calculated 
gestational age specific SD scores using previously published growth charts41. This 
analysis was adjusted for sex. Head circumference was measured at birth, or within the 
31st day of life, in 12 studies (N=13,775; Supplementary table 2). We created SD scores for 
head circumference within each of the cohorts and assessed the association with each 
SNP, adjusted for sex and gestational age. If head circumference was measured in the 
first month, we used gestational age at birth + age (weeks) at measurement in the first 
month. Combined effect estimates were calculated using fixed effects meta-analyses. 
We used the meta-analysis on intracranial volume in adults, measured by MRI, in the 
Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) consortium42 
as a third additional phenotype. Data collection methods, phenotype definition, baseline 
characteristics, and results of the meta-analysis are described elsewhere in this issue14, 43.
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Analysis of known adult height variants with infant head circumference
We used the discovery meta-analyses to assess the associations of the previously identi-
fied 180 known adult height loci21 with head circumference in infancy, using the same 
model as described above. We also checked whether very closely related SNPs (HapMap 
r2 >0.95) showed higher significance levels than the originally reported SNPs. SNPs with 
a P-value lower than 2.8x10-4 (0.05/180) were considered significant.
Variance explained
To estimate the percentage of variation in birth weight explained by each of the associ-
ated loci, we obtained the adjusted-R2 from univariate linear regression models of head 
circumference against genotype. We then calculated a mean value from all discovery 
and replication studies, weighted by sample size. 
Non-synonymous SNPs and eQTLs
We assessed SNPs in LD with the three lead signals and checked for non-synonymous 
SNPs or eQTLs to identify possible functional variants explaining the associations with 
head circumference. First, we used the SNP Annotation and Proxy search developed by 
the Broad institute (http://www.broadinstitute.org/mpg/snap/) to select all SNPs in LD 
(r2 > 0.50) with our three lead signals. We used the 1000 Genomes Pilot 1 set as SNP da-
taset for rs7980687 and rs1042725 and the HapMap r22 as SNP dataset for rs11655470 
(r2 > 0.50) since this SNP was not available on the 1000 Genomes dataset. Next, we 
evaluated whether these SNPs were non-synonymous using dbSNP search engine 
from NCBI. To evaluate whether there were cis-eQTLs in LD with our lead signals we 
searched publicly available eQTL databases through the NCBI GTEx (Genotype-Tissue 
Expression) eQTL Browser (http://www.ncbi.nlm.nih.gov/gtex/test/GTEX2/gtex.cgi) and 
the Generic Genome Browser (http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/). In total, 
these browsers search nine databases for eQTLs. Only cis-associations (defined as genes 
within 1Mb) that reached the P-value threshold for significance, as used in the original 
papers describing the gene expression datasets, were included in Supplementary Table 
10. The statistics behind the eQTL analysis and calculation of the threshold for declar-
ing significance of the associations are described in the published and validated eQTL 
datasets16-18.
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Abstract
Aims: Maternal smoking during pregnancy is associated with fetal growth retardation. 
We examined whether a common genetic variant at chromosome 15q25 (rs1051730), 
which is known to be involved in nicotine metabolism, modifies the associations of 
maternal smoking with fetal growth characteristics. 
Methods: This study was performed in 3,563 European mothers participating in a 
population-based prospective cohort study from early pregnancy onwards. Smoking 
was assessed by postal questionnaires and fetal growth characteristics were measured 
by ultrasound examinations in each trimester of pregnancy. 
Results: Among mothers who did not smoke during pregnancy (82.9%), maternal 
rs1051730 was not consistently associated with any fetal growth characteristic. Among 
mothers who continued smoking during pregnancy (17.1%), maternal rs1051730 was 
not associated with head circumference. The T-allele of maternal rs1051730 was asso-
ciated with a smaller second and third trimester fetal femur length [differences -0.23 
mm (95%CI -0.45 to -0.00) and -0.41 mm (95%CI -0.69 to -0.13), respectively] and a 
smaller birth length [difference -2.61 mm (95%CI -5.32 to 0.11)]. The maternal T-allele of 
rs1051730 was associated with a lower third trimester estimated fetal weight [difference 
-33 grams (95%CI -55 to -10)], and tended to be associated with birth weight [difference 
-38 grams (95%CI -89 to 13)]. This association persisted after adjustment for smoking 
quantity. 
Conclusions: Our results suggest that maternal rs1051730 genotype modifies the as-
sociations of maternal smoking during pregnancy with impaired fetal growth in length 
and weight. These results should be considered as hypothesis generating and indicate 
the need for large-scale genome wide association studies focusing on gene – fetal 
smoke exposure interactions. 
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Introduction
Maternal smoking during pregnancy is strongly associated with increased risks of 
preterm birth or a small size for gestational age at birth1. As compared to children of 
mothers who did not smoke during pregnancy, those of mothers who smoked during 
pregnancy have a 100 to 200 grams lower birth weight1. It has been estimated that, 
in Western countries, 30 percent of children with low birth weight can be explained 
by exposure to tobacco smoke during pregnancy2-3. The effects of maternal smoking 
on fetal growth differ between individuals. These differences in effects might be ex-
plained by maternal genetic predisposition. A recent genome wide association study 
meta-analysis identified a common genetic variant, rs1051730, located within the 
15q25 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4), to be 
associated with smoking quantity4. Smokers with a risk allele (T-allele) of rs1051730 
seem to have higher blood levels of nicotine, compared to smokers without the T-allele5. 
Another study showed that among mothers who smoked during pregnancy, each ad-
ditional copy of the maternal T-allele of rs1051730 resulted in a 28 grams lower birth 
weight in the offspring6, though this effect was not significant. These findings suggest 
that rs1051730 might be a common genetic variant leading to an increased suscep-
tibility of the adverse effects of maternal smoking on fetal growth and development. 
Therefore, we explored in a population-based prospective cohort study among 3,563 
European mothers, whether maternal rs1051730 modifies the associations of maternal 
smoking during pregnancy with fetal growth characteristics in different trimesters.
Methods
Design
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from early fetal life onwards in Rotterdam, the Netherlands, which has 
been described previously7-8. Enrollment was aimed at early pregnancy but was allowed 
until delivery. Extensive assessments focused on fetal growth and its main determinants 
were performed in each trimester of pregnancy. All children were born between April 
2002 and January 2006. The study has been approved by the Medical Ethical Committee 
of the Erasmus Medical Center in Rotterdam (MEC 198.782/2001/31). Written informed 
consent was obtained from all participants. 
Population for analysis 
In total, 4,716 mothers of European ancestry (86% Dutch, 14% other European) were 
included during pregnancy, of whom 3,862 mothers had a singleton live birth and had 
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genotype of rs1051730 available. We had smoking status during pregnancy and fetal 
ultrasounds available in 3,563 (92.3%) of these mothers. A participant flow chart is given 
in Figure 1.
Maternal smoking status
Information about maternal smoking status during pregnancy was obtained by postal 
questionnaires sent in first, second and third trimester. Response rates for these ques-
tionnaires were 91%, 80% and 77%, respectively8. Maternal smoking at enrollment was 
assessed in the first questionnaire by asking the mother whether she smoked during 
the pregnancy (no, yes, until pregnancy was known). In the second and third trimester 
questionnaires, the mothers were asked whether they had smoked (no, yes) during 
Figure 1. Flow chart of participants included for analysis
 
79
Interaction of genetic variant with maternal smoking on fetal growth
2.4
second and third trimester, respectively. Mothers who reported to have smoked until 
pregnancy was known (first trimester only) were considered as non-smokers. Mothers 
who reported smoking in the second or third questionnaire, were considered as moth-
ers who continued smoking during pregnancy9. Among mothers who continued smok-
ing, the number of cigarettes was classified into the following categories: less than 5 
cigarettes per day, 5–10 cigarettes per day and more than 10 cigarettes per day. 
Genotyping
Maternal DNA was extracted from whole blood samples. Genotyping of the G>T sub-
stitution of rs1051730 in mothers was performed using TaqMan allelic discrimination 
assay (Applied Biosystems, Foster City, CA, USA). Child DNA was isolated from cord 
blood. Genotyping was carried out using the Illumina 610k Quad arrays. The frequency 
distribution of maternal rs1051730 genotype did not deviate from the Hardy-Weinberg 
equilibrium in subjects with European ancestry (GG: 45.4%, GT: 43.1%, TT: 11.6%, P-
value= 0.78). Distribution of fetal genotype was similar (GG: 47.3%, GT: 41.8%, TT: 10.8%, 
P-value= 0.73). 
Fetal growth and birth outcomes
Fetal ultrasound examinations were carried out in two dedicated research centers in 
each trimester of pregnancy. Reliability and reproducibility of these ultrasound exami-
nations was tested in early pregnancy and was very good (interobserver intraclass cor-
relation coefficients above 0.988 for all fetal characteristics and interobserver coefficient 
of variation all between 2.4% and 3.8%)10. Fetal ultrasound examinations were used for 
both establishing gestational age in early pregnancy and assessing second and third 
trimester fetal growth characteristics. These methods have previously been described 
in detail8. Establishing gestational age by the first day of the last menstrual period is 
not reliable for a variety of reasons, including the large number of women who do not 
know their exact date, have irregular menstrual cycles or amenorrhea, use oral contra-
ceptive pills or bleed in early pregnancy11-12. Pregnancy dating curves were constructed 
for subjects with complete data on gestational age measured by ultrasonography and 
the last menstrual period12. Crown-rump length was used for pregnancy dating up to 
until a gestational age of 12 weeks and 5 days (crown-rump length smaller than 65 
mm) and biparietal diameter thereafter (gestational age from 12 weeks and 5 days 
onwards, biparietal diameter larger than 23 mm). Second and third trimester growth 
measurements (head circumference, abdominal circumference and femur length) 
were measured to the nearest millimeter using standardized ultrasound procedures13. 
Estimated fetal weight was calculated using the formula by Hadlock14. Gestational age 
adjusted standard deviation scores were constructed for all fetal growth measurements 
based on reference growth curves from the whole study population12. Information on 
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date of birth, sex and birth anthropometrics (head circumference, length and weight) 
was obtained from community midwife and hospital registries. Gestational age and sex-
adjusted standard deviation scores for birth anthropometrics were constructed using 
growth standards from Usher and McLean15. Because head circumference and length 
were not routinely measured at birth, missing birth measures were completed with data 
from the first month visit at the routine child health center. Of all measurements, 32% 
and 19% were based on the first month visit for head circumference and birth length, 
respectively. No differences in genotype between children with measurements at birth 
and those with measurements at child health center were observed (Chi-square tests: P 
=0.67 for head circumference and P =0.51 for birth length).
Covariates
Maternal age and information about maternal educational level and parity was ob-
tained by a questionnaire at enrollment in the study. Maternal alcohol consumption 
habits were assessed by questionnaires in each trimester. Maternal anthropometrics, 
including height and weight, were measured without shoes and heavy clothing 
and body mass index (BMI) was calculated (weight/height2 [kg/m2]) at enrollment16.
Statistical analysis
Differences in basic characteristics between mothers who did not smoke and who 
smoked during pregnancy were assessed by using a Student T-test for continuous 
variables and Chi-square tests for categorical variables. We performed cross-sectional 
analyses using linear regression models to assess the associations of the maternal risk 
allele (T-allele of rs1051730) with fetal growth characteristics in second and third tri-
mester (head circumference, femur length, estimated fetal weight) and at birth (head 
circumference, body length, weight). Based on previous studies, we considered an ad-
ditive model, but performed a sensitivity analysis using a T-dominant model.  All other 
analyses were based on an additive model and the effect estimates reflect the effect for 
each additional copy of the risk allele.  Analyses were performed in the total group, and 
in strata of mothers who did not smoke during pregnancy and mothers who smoked 
during pregnancy. We tested the interaction between maternal smoking and maternal 
genotype, to assess whether the associations of maternal smoking with fetal growth 
were modified by the T-allele of rs1051730. All models were adjusted for sex and gesta-
tional age at visit. Analyses in the total population were adjusted for smoking status. To 
assess possible confounding effects, we additionally adjusted for first trimester smoking 
quantity as a covariate. Next, a fully adjusted model was explored, with further adjust-
ment for maternal age, body mass index at enrollment, parity, educational level and 
alcohol consumption. The regression models with neonatal head circumference and 
length as outcome were additionally adjusted for postconceptional age (gestational age 
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at birth for measurements at birth or gestational age at birth plus postnatal age for mea-
surement from the child health centers) and for the source of the measurement (birth 
or child health center). We repeated the analyses for fetal genotype. The associations 
of smoke status, rs1051730 genotype and longitudinally measured fetal growth were 
analyzed using unbalanced repeated measurement regression models. The repeatedly 
measured outcome data for this analysis were the gender and gestational age adjusted 
SD scores. These models take the correlation between repeated measurements of the 
same participant into account and allow for incomplete outcome data17. We have used 
a fixed effects model without higher order terms. This approach uses the exogenous 
sampling maximum likelihood to assess the best model to calculate the effect estimates. 
The genotype categories of non-smokers and smokers categories were included in these 
models as intercept and as an interaction term with gestational age. Each individual 
could have a maximum of three measurements per growth characteristic available. The 
analyses were based on 3,563 subjects with in total 9,751, 9,843 and 10,405 measure-
ments for head circumference, length, and weight, respectively. For all three growth 
characteristics, the minimum number of measurements was 1, maximum 3 and median 
was 3 (90% range 2 -3) for head circumference, length, and weight. The outcomes reflect 
the differences in growth in gender and gestational age specific standard deviation 
scores (SDS). The repeated measurement analysis was performed using the Statistical 
Analysis System version 9.2 (SAS, Cary, NC), including the Proc Mixed module for unbal-
anced repeated measurements. All other analyses were performed using the Statistical 
Package of Social Sciences for Windows (SPSS Inc, Chicago, IL, USA), version 17.0.
Results
In our population, 610 (17.1%) mothers continued smoking during pregnancy (Table 
1). Mean maternal age was 31.1 years. As compared to mothers who did not smoke 
during pregnancy, mothers who smoked during pregnancy were shorter, had higher 
weight and were lower educated. Children of mothers who smoked during pregnancy 
had a lower birth weight than children of mothers who did not smoke. Distribution of 
maternal genotype of rs1051730 was different between non-smokers and continued 
smokers. Genotype was not associated with smoking quantity. Subject characteristics 
per maternal genotype group among continued smokers are given in Table S1.
In the total population, we did not observe associations of the maternal T-allele of 
rs1051730 with fetal growth characteristics (Table 2). Among mothers who continued 
smoking, we observed non-significant tendencies toward smaller (fetal) head circum-
ference for each additional copy of the maternal T-allele of rs1051730. The T-allele of 
maternal rs1051730 was associated with a smaller second and third trimester fetal femur 
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length [differences -0.23 mm (95%CI -0.45 to -0.00) and -0.41 mm (95%CI -0.69 to -0.13), 
respectively] and tended to be associated with a smaller birth length [difference -2.61 
mm (95%CI -5.32 to 0.11)] (Table 2). For all fetal length measures, we found a significant 
interaction between maternal smoking status and maternal genotype of rs1051730 [Pin-
teraction<0.05]. Among mothers who smoked during pregnancy, the T-allele was associated 
with a lower third trimester estimated fetal weight [difference -32.7 grams (95%CI -55.4 
to -10.0)], and tended to be associated with lower birth weight [difference -38.1 grams 
(95%CI -89.2 to 12.9)]. Among the mothers who smoked during pregnancy, those who 
had a T/T genotype gave birth to children with a birth weight that was 117 grams lower 
(95% CI -229 to -4 grams), as compared to children whose mothers had a G/G genotype. 
We found a significant interaction between maternal smoking status and maternal 
genotype of rs1051730 for fetal weight at all time points [Pinteraction<0.05].
Table 1. Subject characteristics of the mothers per smoking status (n=3,563)
Total Non-smokers Continued smokers
N= 3,563 N= 2,953 (82.9%) N= 610 (17.1%)
Mother
Age (years) 31.1 (4.5) 31.4 (4.2) 29.7 (5.6)**
Gestational age at enrollment1 
(weeks)
13.6 (10.1 to 23.2) 13.6 (10.2 to 22.9) 14.1 (9.5 to 29.4)**
Height (cm) 170.3 (6.5) 170.4 (6.5) 169.3 (6.5)**
Weight (kg) 70.2 (12.6) 70.0 (12.2) 71.2 (14.0)*
Body mass index (kg/m2) 24.2 (4.1) 24.1 (4.0) 24.8 (4.5)**
Parity (% nullipara) 59.8 60.4 57.4
Highest education finished (%)
Primary school 4.4 2.6 13.3**
Secondary school 38.5 33.7 62.5**
Higher education 57.1 63.8 24.2**
Alcohol consumption during 
pregnancy (% yes)
65.3 66.2 61.3*
Number of cigarettes smoked (%)
< 5 per day NA NA 45.2
5-10 per day NA NA 32.7
>10 per day NA NA 22.0
Genotype (%)
G/G 45.4 46.3 41.0*
G/T 43.1 42.2 47.4*
T/T 11.6 11.5 11.6
Child
Gestational age at birth1 (weeks) 40.1 (35.6 to 42.3) 40.3 (35.8 to 42.3) 40.0 (34.8 to 42.3)**
Birth weight (grams) 3476 (558) 3514 (553) 3290 (546)**
Sex (% Boys) 49.6 49.1 52.5
Values are means (SD) or percentages, 1 Median (95% range) 
Differences in distributions between groups were evaluated using a Student T-test for continuous variables and Chi-
square tests for categorical variables *P-value <0.05; **P-value <0.01
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In Figure 2, the results of maternal genotype of rs1051730 per smoking status with 
longitudinal fetal growth patterns are presented as difference in standard deviation 
scores, adjusted for gestational age and sex. This gives the relative effect in different 
periods of pregnancy. All genotype categories of mothers who smoked during preg-
nancy had smaller fetal head circumference, length and weight measures, as compared 
to the mothers who did not smoke during pregnancy. Among mothers who did not 
smoke during pregnancy, the maternal T-allele of rs1051730 had a positive effect on 
head circumference growth, but was not significantly associated with length and weight 
growth. Among mothers who smoked during pregnancy, the T-allele was associated 
with the smallest head circumference, length and weight growth. The effects seem to 
be larger for length and weight than for head circumference. The specific coefficients of 
the gestational age independent and dependent differences (interaction smoke status, 
rs1051730 genotype and gestational age) for these models are given in Table S2. 
We performed several sensitivity analyses. First, results of the analyses with a domi-
nant genetic model are shown in Table S3. Second, additional analyses showed that the 
fetal genotype of rs1051730, was not associated with any fetal growth characteristic 
Table 2. Cross-sectional associations of maternal rs1051730 genotype with fetal growth characteristics in 
different trimesters (n= 3,563)
Second trimester Third trimester Birth
Head circumference Head circumference Head circumference
Difference (95% CI) (mm) Difference (95% CI) (mm) Difference (95% CI) (mm)
Total Group N= 3,546 -0.26 (-0.56 to 0.04) 0.11 (-0.33 to 0.55) 0.16 (-0.63 to 0.95)
Non-smokers N= 2,940 -0.23 (-0.55 to 0.10) 0.23 (-0.25 to 0.71) 0.31 (-0.55 to 1.17)
Smokers N= 606 -0.43 (-1.21 to 0.35) -0.44 (-1.55 to 0.66) -0.67 (-2.71 to 1.37)
Interaction1 P=0.62 P=0.24 P=0.39
Femur length Femur length Body length
Difference (95% CI) (mm) Difference (95% CI) (mm) Difference (95% CI) (mm)
Total Group N= 3,549 0.00 (-0.09 to 0.09) -0.01 (-0.12 to 0.11) 0.33 (-0.77 to 1.42)
Non-smokers N= 2,943 0.04 (-0.05 to 0.14) 0.08 (-0.04 to 0.20) 0.82 (-0.38 to 2.02)
Smokers N= 606 -0.23 (-0.45 to -0.00)* -0.41 (-0.69 to -0.13)** -2.61 (-5.32 to 0.11)
Interaction1 P=0.03 P<0.01 P=0.04
Estimated fetal weight Estimated fetal weight Weight
Difference (95% CI) (g) Difference (95% CI) (g) Difference (95% CI) (g)
Total Group N= 3,563 0.28 (-1.88 to 2.43) 3.05 (-6.23 to 12.32) 15.95 (-5.59 to 37.48)
Non-smokers N= 2,953 1.36 (-0.99 to 3.71) 10.37 (0.22 to 20.51)* 26.81 (3.05 to 50.57)*
Smokers N= 610 -5.36 (-10.73 to 0.01) -32.66 (-55.36 to -9.97)** -38.13 (-89.16 to 12.90)
Interaction1 P=0.02 P<0.01 P=0.03
Effect estimates (with 95% confidence interval) reflect the differences in each growth characteristic for each additional 
copy of the T-allele of rs1051730 (assuming an additive model) 
1Interaction term = maternal genotype x smoking status
*P-value <0.05; **P-value <0.01
All analyses were adjusted for gestational age at visit and sex. Analyses in the total group were additionally adjusted for 
smoking status (yes, no). Birth length and head circumference at birth were additionally adjusted for source of the birth 
measurements
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Figure 2. Effect of maternal genotype and smoking status on fetal growth characteristics (SD scores)
 
Values are based on repeated linear regression models and reflect the differences in growth in gender and gestational 
age specific standard deviation scores (SDS) between the number of risk alleles and smoking status compared to the 
reference group (genotype G/G, non-smokers). Estimates are given in the Supplementary Table S2.   
*P-value <0.05; **P-value <0.01
(Figure 1a= head circumference growth, Figure 1b= length growth, Figure 1c= weight growth)
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after adjustment for the maternal genotype (Table S4). Furthermore, adjustment for ma-
ternal smoking quantity did not affect our results (Table S5). Additional adjustment for 
maternal age, body mass index at enrollment, parity, educational level and alcohol con-
sumption slightly attenuated the effect of maternal rs1051730, although the directions 
of the effects remained similar (Table S6). In these fully adjusted models, the interaction 
of maternal smoking and genotype remained significant in third trimester of pregnancy.
Discussion
Main findings
Results from this prospective population-based cohort study suggest that maternal 
genotype of the common genetic variant, rs1051730, located within the 15q25 nicotinic 
acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4), influences the suscep-
tibility of impaired fetal growth by maternal smoking. Among mothers who smoked 
during pregnancy, the T-allele resulted in smaller femur length and lower estimated fetal 
weight from second trimester onwards. 
Methodological considerations
An important strength of this study was the prospective design and the large sample 
size of 3,563 participants being studied from early pregnancy onwards. To our knowl-
edge, this study is the first study that examined the associations of maternal smok-
ing during pregnancy, and rs1051730, with fetal growth characteristics in different 
trimesters of pregnancy. A potential limitation of our study is that information about 
smoking during pregnancy was collected by questionnaires. Although assessing smok-
ing during pregnancy by questionnaire seems to be a valid method, misclassification 
may occur18. To overcome these limitations, previous studies have used biomarkers 
of tobacco exposure, including cotinine -a metabolite of nicotine- in maternal urine 
samples19-20. However, it has been demonstrated that use of cotinine levels is not 
superior to the use of self-reporting questionnaires in studying the effect of maternal 
smoking in pregnancy on birth weight21. In general, confounding is not likely to be a 
major issue in gene - outcome association studies. The unadjusted and adjusted models 
focused on the associations of rs1051730 genotype with fetal growth characteristics 
did not show large differences in effect estimates. However, smoking quantity might 
be a relevant confounder in our study, since rs1051730 is known to be associated with 
smoking quantity4. We adjusted the analyses for the number of cigarettes smoked per 
day reported in first trimester, which did not change the effect estimates. Furthermore, 
in our population of mothers who smoked during pregnancy, smoking quantity was 
not associated with rs1051730 genotype in neither first, second nor third trimester. 
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We also performed a sensitivity analysis using second and third trimester smoking 
quantity instead of first trimester smoking quantity in the models, which did not alter 
our results. Therefore it seems unlikely that smoking quantity has biased our results. 
Another potential limitation could be that women who quitted smoking when preg-
nancy was known (first trimester only) were considered as non-smokers in our analyses. 
This could have resulted in biased effect estimates if fetal growth would be different 
between quitted smokers and non-smokers. However, we have previously reported that 
first trimester smoking only does not affect second and third trimester fetal growth9. We 
performed a sensitivity analysis in which we excluded women who quitted smoking in 
first trimester, which did not change our results (data not shown).
We established gestational age by ultrasound. By using this method, growth varia-
tion of the fetal characteristics used for pregnancy dating is assumed to be zero. In 
our study, first trimester crown-rump length and biparietal diameter were used for 
pregnancy dating but not for assessing fetal growth. Since pregnancy dating char-
acteristics and growth characteristics are correlated throughout pregnancy, growth 
variation in head circumference, abdominal circumference, and femur length may 
be reduced by dating the pregnancy on the other fetal characteristics. This may have 
led to underestimation of our effect estimates. However, we expect this effect to be 
small in our results. This underestimation will consequently be lowest in women in-
cluded in the first trimester (54.7% of the population for analysis). We performed a sen-
sitivity analysis using only these women, but results did not change (data not shown). 
 
Maternal rs1051730 genotype, smoking during pregnancy and fetal growth 
The effects of maternal smoking status during pregnancy on fetal growth have been 
studied previously, showing that among mothers who continued smoking during 
pregnancy, children had smaller femur length from second trimester onwards and 
smaller head circumferences from third trimester onwards, as compared to children 
from mothers who did not smoke during pregnancy9. As compared to children of 
mothers who did not smoke during pregnancy, those of mothers who smoked during 
pregnancy have a 100 to 200 grams lower birth weight1. This fetal growth restriction 
might be caused by developmental adaptations in placental vasculature and adapta-
tions in fetal arterial resistance. A study that investigated these adaptations showed 
an increased umbilical resistance artery pulsatility index (PI) in pregnant women who 
smoked, which indicates higher feto-placental resistance. Also, a higher umbilical ar-
tery PI was associated with lower estimated fetal weight and birth weight22.  
The effects of maternal smoking on fetal growth are known to differ between individuals. 
We have previously demonstrated that maternal first trimester folic acid supplementa-
tion use reduces the adverse effects of maternal smoking during pregnancy on fetal 
growth23. Differences in effects of maternal smoking on fetal growth might also be 
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explained by maternal genetic variation. We hypothesized that maternal genotype of 
rs1051730 modifies the association of maternal smoking during pregnancy with fetal 
growth. The T-allele of rs1051730 is associated with higher smoking quantity and higher 
nicotine levels in adults4-5, 24. A previous study showed that children from mothers who 
smoked during pregnancy, had a tendency towards a 28 grams lower birth weight per T-
allele. No association was found among mothers who did not smoke during pregnancy6. 
In line with this previous study, we observed that among mothers who smoked dur-
ing pregnancy, the T-allele resulted in smaller femur length and lower estimated fetal 
weight from second trimester onwards. We did not observe any effect on fetal head 
circumference. The effects of maternal smoking in fetal head circumference seem not 
to be affected by rs1051730. Our results also suggest that rs1051730 does not have a 
direct effect on birth weight, but needs environmental factors to exert its effect. Surpris-
ingly, among non-smokers, we found a positive effect on fetal weight with each copy 
of the risk allele. We can not clearly explain this finding. It might me hypothesized that 
specific gene-environmental interactions, such as DNA methylation, changes the effects 
of specific genetic variants25. In a recent meta-analysis, the risk allele of rs1051730 was 
associated with a lower body mass index among smokers, while some studies of this 
meta-analysis showed a higher body mass index among non-smokers with the risk allele. 
However, the overall effect of the meta-analysis showed no effect of genotype among 
non-smokers26. We think that further research is necessary to explore the different effects 
of risk alleles of rs1051730 on various health outcomes among both smokers and non-
smokers. The mechanism through which rs1051730 modifies the associations between 
maternal smoking and fetal growth is yet unknown. Rs1051730 is located in the nicotinic 
acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) on chromosome 15q25. 
This locus has been investigated previously and common genetic variants in high linkage 
disequilibrium with rs1051730 (HapMap r2 > 0.8) were associated with higher circulating 
cotinine levels, but not with number of cigarettes smoked per day24. A previous study 
that assessed the association of rs1051730 with the risk of lung cancer, observed that 
subjects with the T-allele had higher mean nicotine equivalents. In this study, the T-allele 
seemed to behave as a dominant model after adjustment for smoking quantity5. The 
authors therefore concluded that T-allele carriers extract a greater amount of nicotine 
per cigarette and are exposed to a higher internal dose of tobacco-specific nitrosamine, 
as compared to subjects without the T-allele5. Whether this is caused by more intense 
smoking or by a change in the nicotine metabolism, is not clear yet.  Other studies 
suggested an additive genetic model for the T-allele of rs10517306, 27, which was also 
most compliant with our data. Thus our results suggest that children of mothers who 
smoked during pregnancy are exposed to higher levels of nicotine when the mother 
has a T-allele of rs1051730. Therefore, these children might be more susceptible to the 
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adverse effects of maternal smoking during pregnancy. Further research is necessary to 
determine the exact mechanism and underlying genetic model. 
Gene-environment interaction studies are of increasing importance in modern medi-
cine. Although smoking cessation should be advised to all pregnant women, a genetic 
risk profile might help us to target more effectively those at higher risk of growth retar-
dation and adverse pregnancy outcomes. Further research is needed to identify groups 
at risk and develop new preventive strategies.
Conclusions 
Our results suggest that maternal genotype of the 15q25 variant rs1051730 influences 
the susceptibility of impaired fetal growth in length and weight by maternal smoking. 
This association of rs1051730 with fetal growth was present in mothers who continued 
smoking during pregnancy, but not in mothers who did not smoke during pregnancy. 
These results should be considered as hypothesis generating and indicate the need for 
large-scale genome wide association studies focusing on gene – fetal smoke exposure 
interactions.
Note: Supplementary information is available on the Plos One website: www.plosone.
org
References
 1 Jaddoe VW, Troe EJ, Hofman A, et al. Active and passive maternal smoking during pregnancy and 
the risks of low birthweight and preterm birth: the Generation R Study. Paediatr Perinat Epidemiol. 
2008;22:162-71.
 2 Varvarigou AA, Fouzas S, Beratis NG. Effect of prenatal tobacco smoke exposure on fetal growth 
potential. J Perinat Med. 2010;38:683-7.
 3 Freathy RM, Mook-Kanamori DO, Sovio U, et al. Variants in ADCY5 and near CCNL1 are associated 
with fetal growth and birth weight. Nat Genet. 2010;42:430-5.
 4 Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet. 
2010;42:441-7.
 5 Le Marchand L, Derby KS, Murphy SE, et al. Smokers with the CHRNA lung cancer-associated 
variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific 
nitrosamine. Cancer Res. 2008;68:9137-40.
 6 Freathy RM, Ring SM, Shields B, et al. A common genetic variant in the 15q24 nicotinic acetylcholine 
receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to 
quit smoking in pregnancy. Hum Mol Genet. 2009;18:2922-7.
 7 Jaddoe VW, Bakker R, van Duijn CM, et al. The Generation R Study Biobank: a resource for epidemio-
logical studies in children and their parents. Eur J Epidemiol. 2007;22:917-23.
89
Interaction of genetic variant with maternal smoking on fetal growth
2.4
 8 Jaddoe VW, van Duijn CM, van der Heijden AJ, et al. The Generation R Study: design and cohort 
update 2010. Eur J Epidemiol. 2010;25:823-41.
 9 Jaddoe VW, Verburg BO, de Ridder MA, et al. Maternal smoking and fetal growth characteristics in 
different periods of pregnancy: the generation R study. Am J Epidemiol. 2007;165:1207-15.
 10 Verburg BO, Mulder PG, Hofman A, Jaddoe VW, Witteman JC, Steegers EA. Intra- and interobserver 
reproducibility study of early fetal growth parameters. Prenat Diagn. 2008;28:323-31.
 11 Tunon K, Eik-Nes SH, Grottum P. A comparison between ultrasound and a reliable last menstrual 
period as predictors of the day of delivery in 15,000 examinations. Ultrasound Obstet Gynecol. 
1996;8:178-85.
 12 Verburg BO, Steegers EA, De Ridder M, et al. New charts for ultrasound dating of pregnancy and 
assessment of fetal growth: longitudinal data from a population-based cohort study. Ultrasound 
Obstet Gynecol. 2008;31:388-96.
 13 (2000) RCoOaG. Routine ultrasound screening in pregnancy: protocol. London, United Kingdom: 
RCOG Press.
 14 Hadlock FP, Harrist RB, Carpenter RJ, Deter RL, Park SK. Sonographic estimation of fetal weight. The 
value of femur length in addition to head and abdomen measurements. Radiology. 1984;150:535-
40.
 15 Niklasson A, Ericson A, Fryer JG, Karlberg J, Lawrence C, Karlberg P. An update of the Swedish 
reference standards for weight, length and head circumference at birth for given gestational age 
(1977-1981). Acta Paediatr Scand. 1991;80:756-62.
 16 Ay L, Kruithof CJ, Bakker R, et al. Maternal anthropometrics are associated with fetal size in different 
periods of pregnancy and at birth. The Generation R Study. Bjog. 2009;116:953-63.
 17 Goldstein H. Multilevel statistical methods. 2nd ed: Edward Arnold: London 1995.
 18 Klebanoff MA, Levine RJ, Morris CD, et al. Accuracy of self-reported cigarette smoking among 
pregnant women in the 1990s. Paediatr Perinat Epidemiol. 2001;15:140-3.
 19 Hebel JR, Fox NL, Sexton M. Dose-response of birth weight to various measures of maternal smok-
ing during pregnancy. J Clin Epidemiol. 1988;41:483-9.
 20 Wang X, Tager IB, Van Vunakis H, Speizer FE, Hanrahan JP. Maternal smoking during pregnancy, 
urine cotinine concentrations, and birth outcomes. A prospective cohort study. Int J Epidemiol. 
1997;26:978-88.
 21 Haddow JE, Knight GJ, Palomaki GE, Kloza EM, Wald NJ. Cigarette consumption and serum cotinine 
in relation to birthweight. Br J Obstet Gynaecol. 1987;94:678-81.
 22 Geelhoed JJ, El Marroun H, Verburg BO, et al. Maternal smoking during pregnancy, fetal arterial 
resistance adaptations and cardiovascular function in childhood. BJOG. 2011;118:755-62.
 23 Bakker R, Timmermans S, Steegers EA, Hofman A, Jaddoe VW. Folic Acid supplements modify 
the adverse effects of maternal smoking on fetal growth and neonatal complications. J Nutr. 
2011;141:2172-9.
 24 Timofeeva MN, McKay JD, Davey SG, et al. Genetic Polymorphisms in 15q25 and 19q13 Loci, Coti-
nine Levels, and Risk of Lung Cancer in EPIC. Cancer Epidemiol Biomarkers Prev. 2011;20:2250-61.
 25 Freathy RM, Kazeem GR, Morris RW, et al. Genetic variation at CHRNA5-CHRNA3-CHRNB4 interacts 
with smoking status to influence body mass index. Int J Epidemiol. 2011;40:1617-28.
 26 Breton CV, Byun HM, Wenten M, Pan F, Yang A, Gilliland FD. Prenatal tobacco smoke exposure af-
fects global and gene-specific DNA methylation. Am J Respir Crit Care Med. 2009;180:462-7.
 27 Timofeeva MN, McKay JD, Smith GD, et al. Genetic polymorphisms in 15q25 and 19q13 loci, coti-
nine levels, and risk of lung cancer in EPIC. Cancer Epidemiol Biomarkers Prev. 2011;20:2250-61.

Chapter 2.5
A genome-wide association  
meta-analysis on childhood obesity
Jonathan P Bradfield *
H Rob Taal * et al.
For the Early Growth Genetics (EGG) Consortium
*Authors contributed equally to this work 
For the complete list of authors please see list of publications 
Adapted from Nature Genetics; 2012:44:526-531.
Chapter 2.5
92
Abstract
Aims and Methods: Multiple genetic variants have been associated with adult obesity 
and a few with severe obesity in childhood; however, less progress has been made to 
establish genetic influences on common early-onset obesity. We performed a North 
American-Australian-European collaborative meta-analysis of fourteen studies consist-
ing of 5,530 cases (≥95th percentile of body mass index (BMI)) and 8,318 controls (<50th 
percentile of BMI) of European ancestry.
Results and Conclusions: Taking forward the eight novel signals yielding association 
with P < 5x10-6 in to nine independent datasets (n = 2,818 cases and 4,083 controls) we 
observed two loci that yielded a genome wide significant combined P-value, namely 
near OLFM4 on 13q14 (rs9568856; P=1.82x10-9; OR=1.22) and within HOXB5 on 17q21 
(rs9299; P=3.54x10-9; OR=1.14). Both loci continued to show association when including 
two extreme childhood obesity cohorts (n = 2,214 cases and 2,674 controls). Finally, 
these two loci yielded directionally consistent associations in the GIANT meta-analysis 
of adult BMI.
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Introduction
Obesity is the major, increasingly prevalent health problem affecting modern societies. 
The problem is particularly severe for children in developed countries, where the preva-
lence of obesity is on the increase. Obesity present in adolescence is associated with 
increased overall mortality in later life1. Whereas the change in prevalence of obesity 
is likely to be explained by environmental changes over the last 30 years, there is also 
strong evidence for a genetic component to the risk of obesity. This is reflected in familial 
occurrences of childhood obesity, where concordance for fat mass among monozygotic 
twins is reported to be higher than in dizygotic twins. 
In the past four years, many genetic loci have been implicated for body mass index 
(BMI) / obesity from the outcomes of genome-wide association studies (GWAS), primar-
ily in adults. The first locus reliably found to harbor variation associated with adiposity, 
the fat mass- and obesity-associated gene (FTO)2, has been shown subsequently to be 
associated with obesity in all sufficiently sized study groups. Subsequent larger studies 
have revealed additional BMI/obesity genes. The largest meta-analysis of adult BMI to 
date came from the GIANT consortium, which confirmed fourteen known obesity sus-
ceptibility loci and revealed eighteen new loci associated with BMI in a study involving 
a total of 249,796 individuals3. However, these loci only account for a small fraction of 
the heritability that is known to contribute to obesity. There has been some work on 
extreme obesity in childhood (>99.5th percentile of BMI) but little progress has been 
made on less marked definitions of obesity more relevant to public health.
We reasoned that distillation of the genetic component in this complex phenotype 
should be easier in children, where environmental exposure and impact has been for 
a relatively short period of their lifetime. The relationship between BMI and body fat in 
children varies widely with age and with pubertal maturation. The Center for Disease 
Control and Prevention defined overweight as at or above the 95th percentile of BMI for 
age4. By late adolescence, these percentiles approach those used for adult definitions; 
the 95th percentile is then approximately 30 kg/m2 5.
Methods
In an effort to systematically search for childhood obesity susceptibility loci, we per-
formed a large scale meta-analysis of fourteen existing GWAS datasets for childhood 
obesity, totaling 5,530 cases (≥95th percentile of BMI achieved before the age of 18 years 
old, representing 5-30% of any given cohort) and 8,318 controls (relatively conservatively 
defined as <50th percentile of BMI consistent throughout all measures during childhood) 
of European ancestry (see Supplementary Table 1 and Supplementary Note).
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Results
Following the meta-analysis of 2.7 million SNPs (directly genotyped or imputed), signals 
at seven discrete locations reached genome-wide significance at P < 5.0x10-8. All these 
loci have been previously reported within GWAS for adult BMI (FTO, TMEM18, POMC, 
MC4R, FAIM2, TNNI3K and SEC16B), and robustly reflect previous reports on individual 
pediatric cohorts6-7. FTO gave the strongest evidence for association while TNNI3K and 
POMC, which were only detected in adult studies when using hundreds of thousands 
of participants, were readily detected in our relatively small sample size (Figure 1 and 
Supplementary Tables 2 and 3). Excluding the French and German studies from the me-
ta-analysis, we did not observe association with variants previously reported as novel in 
their extreme childhood obesity cohorts8 at the loci harboring TNKS-MSRA (rs17150703; 
P = 0.22) and SDCCAG8 (rs12145833; P = 0.57).
We took forward all eight novel signals yielding association with P < 5.0x10-6 (Table 1 
and Supplementary Table 4, the latter of which includes a heterogeneity analysis show-
ing that the different distributions in each study did not affect our results; in addition 
Supplementary Table 5 shows the results after applying a second genomic control cor-
rection to the overall discovery meta-analysis results) in order to test for replication in 
multiple independent existing datasets, the majority of which were in silico analyses. In 
our replication effort, we initially tested these eight SNPs in nine study groups that had a 
 
Figure 1
Manhattan Plot of the meta-analysis of childhood obesity GWAS runs in the discovery stage (5,530 cases and 8,318 
controls), with each locus achieving genome wide significance (P < 5x10-8) indicated in black text. In addition, the novel 
loci uncovered in this study are indicated in red text.
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comparable set of affected subjects i.e. BMI distributed normally from the 95th percentile 
upwards (n = 2,818 cases and 4,083 controls). From this attempt we observed two loci 
that yielded consistent evidence of association when combined with the discovery co-
hort, namely near olfactomedin 4 (OLFM4) on 13q14 (rs9568856; Pcombined = 1.82x10
-9; OR 
= 1.22) and within the gene encoding homeobox B5 (HOXB5) on 17q21 (rs9299; Pcombined 
= 3.54x10-9; OR = 1.14) (Table 1; see also the regional plots in Supplementary Figures 1 
and 2 for the discovery meta-analysis data).
Previous GWAS reports for extreme obesity case-control samples have demonstrated 
both confirmation of signals seen in less extreme or population based samples, such as 
FTO, as well as novel signals that are distinct from those seen at the population level8. We 
reasoned therefore that further exploration in existing extreme datasets [two cohorts 
totaling 2,214 cases (exclusively individuals approximately >4 standard deviations 
above the mean, equating to BMI>99.5th percentile] and 2,674 controls) would offer 
further insight in to how these signals operate, acknowledging the phenotypic differ-
ences and limits of sample size. Indeed, both loci emerging from the main replication 
step continued to show association folding in this more extreme phenotype (OLFM4; 
rs4833407; Poverall = 5.33x10
-9; OR = 1.18 and HOXB5; rs9299; Poverall = 1.54x10
-8; OR = 1.13) 
(Supplementary Table 6). 
As the ALSPAC cohort leveraged BMI measures made before the age of two years old as 
part of defining cases and controls, we ran sensitivity analyses limiting case and control 
definitions to children over two years of age (Supplementary Tables 7-9). In addition to 
no diminishment in the odds ratios for the OLFM4 and HOXB5 loci, we observed support 
for rs4864201 at BC041448 and rs4833407 at ALPK1 (Supplementary Tables 8 and 9).
Finally, we were interested to see whether our two main signals of interest, namely 
at OLFM4 and HOXB5, were evident in the GIANT adult BMI meta-analysis results (n = 
123,864). Indeed, both loci yielded evidence of association in this quantitative setting 
Table 1: The two key novel loci established to be associated with common early-onset obesity. 
Locus SNP Allele1/2
Nearest 
Gene Direction OR [95% C.I.] P-value
Discovery 13q14 rs9568856 A/G OLFM4 ++++++++++++-+ 1.210 [1.123, 1.305] 6.58x10-7
17q21 rs9299 T/C HOXB5 ++-++-++++++++ 1.144 [1.084, 1.207] 9.12x10-7
Replication 13q14 rs9568856 A/G OLFM4 +-++++-++ 1.225 [1.089, 1.378] 7.13x10-4
17q21 rs9299 T/C HOXB5 ++-++++++ 1.145 [1.056, 1.242] 0.00104
Combined 13q14 rs9568856 A/G OLFM4 1.215 [1.140, 1.294] 1.82x10-9
17q21 rs9299 T/C HOXB5 1.144 [1.094, 1.196] 3.54x10-9
The two loci did not reach genome wide significance but yielded P < 5x10-6 in the discovery stage (5,530 cases and 8,318 
controls). The outcome of the replication effort of these loci taken forward in to nine comparable independent cohorts 
(n = 2,818 cases and 4,083 controls) is also indicated. Separate discovery and replication data plus combined data are 
shown, with the latter indicating genome wide significance in both instances.
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(P-values= 7.75x10-5 and 0.015, respectively) with the same alleles in the same direc-
tion. Overall, seven of the eight signals initially taken forward in to the replication stage 
yielded consistent directionality, albeit not all being statistically significant, with the 
exception being rs1290002 (Supplementary Table 10).
Discussion
Overall, these data indicate that the genetic architecture of BMI and obesity overlap 
to a large extent in children as well as adults. In addition to the previously reported 
loci, we have uncovered at least two new loci associated with obesity in early life. The 
adult BMI data available from GIANT3 reveals that the influence of these two loci is also 
detected in adulthood. Interestingly, in addition to OLFM4 and HOXB5, GIANT also sup-
ports an association with three more of the eight loci initially taken forward in to the 
replication effort, namely rs4864201 at BC041448, rs4833407 at ALPK1 and rs2300095 at 
MTOR-ANGPTL7 loci, despite these signals not formally replicating in the main defined 
overall pediatric setting, suggesting that these loci should be followed up further to fully 
understand their role in the pathogenesis of obesity as a whole.
The gene encoding olfactomedin 4 (OLFM4) is the nearest gene to rs9568856 but is 
still approximately 500kb from the associated signal; the gene product has never been 
directly implicated in obesity but has been extensively studied in the context of various 
cancers. OLFM4 is a secreted glycoprotein that facilitates cell adhesion via lectins and 
cadherin on the cell surface. Although the function of OLFM4 is not well understood, 
there are several intriguing observations that link it to gut microflora and to a relation-
ship between the gut microbiome and obesity risk. For example, the OLFM4 gene 
product down regulates innate immunity against infection by the stomach bacterium, 
Helicobacter pylori9, with obese subjects having a higher occurrence of Helicobacter py-
lori infection than lean counterparts10-11; indeed, weight-loss induced by obesity surgery 
eradicates Helicobacter pylori12.
rs9299 is in the 3’ untranslated region of the gene encoding homeobox B5 (HOXB5) 
within a homeobox B cluster. HOXB5 is spatially and temporarily regulated during gut 
development13, but its role in obesity has been suggested by a study observing up-reg-
ulation of homeobox transcription factors after fat loss14. Taken together, it is possible 
that OLFM4 and HOXB5 may impact BMI via different aspects of gut function.
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Conclusions
In summary, as a consequence of extensive North American-Australian-European col-
laborative genome-wide meta-analyses on children, we have uncovered two novel 
obesity loci which have their strongest evidence for association with elevated adiposity 
in the first eighteen years of life. Further functional characterization of these signals is 
required to elucidate the precise mechanism behind these observations.
Note: Supplementary information is available on the Nature Genetics website: www.
nature.com/ng 
Online Methods
Research Subjects
The descriptions of the individual cohorts are presented as a Supplementary Note. The 
discovery set for the meta-analysis consisted of 14 studies with body mass index (BMI) 
measured in childhood (age range 2-18 years, except for ALSPAC, which also leveraged 
BMI data available from the first four clinical examinations prior to 2 years old) and 
genome-wide genotype data available by the beginning of May 2010): the Avon Longi-
tudinal Study of Parents and Children (ALSPAC, n= 976 cases / 1,244 controls); Northern 
Finland 1966 Birth Cohort (NFBC1966, n= 700 cases / 521 controls); British 1958 Birth 
Cohort – Type 1 Diabetes Genetics Consortium subset (B58C-T1DGC, n= 192 cases / 367 
controls); British 1958 Birth Cohort – Wellcome Trust Case Control Consortium Subset 
(B58C-WTCCC, n= 188 cases / 428 controls); French Young study (FRENCH YOUNG, 670 
cases/ 349 controls); Lifestyle Immune System Allergy Study (LISA, n=27 cases / 250 
controls); Western Australian Pregnancy Cohort study (RAINE, n= 232 cases / 125 con-
trols); Children’s Hospital of Philadelphia (CHOP, n= 1,445 cases / 2,802 controls); Essen 
Obesity Study (ESSEN, n=397 cases / 435 controls); Helsinki Birth Cohort Study (HBCS, 
n= 261 cases/ 403 controls); Cardiovascular Risk in Young Finns Study (YF, n= 167 cases 
/ 537 controls); Copenhagen Study on Asthma in Childhood (COPSAC, n= 62 cases / 99 
controls); CM-GOYA study (CM-GOYA; n= 21 cases / 34 controls) and Generation R Study 
(GENERATIONR, n= 192 cases / 724 controls).
The phenotypically comparable cohorts used for the replication effort were Healthy 
Lifestyle in Europe by Nutrition in Adolescence study (HELENA; n= 56 cases / 563 con-
trols), Young Hearts studies (n= 44 cases / 450 controls), the Lifestyle – Immune System 
– Allergy Study plus German Infant Study on the influence of Nutrition Intervention 
(LISA+GINI, n= 40 cases / 457 controls), Children’s Health Study (CHS; n= 311 cases / 330 
controls), Avon Longitudinal Study of Parents and Children (ALSPAC; n= 1,452 cases / 
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1,042 controls), INfancia y Medio Ambiente [Environment and Childhood] Project (INMA; 
n= 55 cases / 213 controls), Project Viva (VIVA; n= 48 cases / 184 controls), Prevention 
and incidence of asthma and mite allergy birth cohort study (PIAMA; n= 68 cases / 85 
controls) and the Northern Finland 1986 Birth Cohort (NFBC1986; n= 744 cases / 759 
controls). The two extreme obesity replication cohorts consisted of 705 German trios 
and SCOOP-UK cohort (n= 1,509 cases / 2,674 controls). Selected signals were further 
investigated in the GIANT1 cohort, using the publically available dataset at http://www.
broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files.
All cases and controls were of European ancestry. Cases were defined as having a 
BMI>95th percentile at any point in childhood. Controls were defined as consistently 
having a BMI<50th percentile throughout childhood for all measurements available for 
that individual. BMI percentiles were based on national standard growth curves, except 
in the Helsinki Birth Cohort Study (HBCS) and the Northern Finland 1966 Birth Cohort 
(NFBC1966) as pediatric measurements were made two decades ago, thus contempo-
rary curves will not be appropriate. HBCS and NFBC1966 generated their own reference 
curves. In addition, the density of data available longitudinally in the ALSPAC study 
gave rise to two differences in cases/control definition. Firstly, this collection factored in 
subjects from the first four clinical examinations of childhood and thus participants less 
than 2 years old in their consideration of trait definition (sensitivity analyses consider-
ing the use of data from participants limited to being over the age of 2 years old are 
included in Supplementary Tables 7-9). Secondly, owing to the regularity of measures 
(11 measures available), controls in the ALSPAC sample were defined as those BMI<50th 
percentile on at least 5 occasions. Known syndromic cases of obesity were excluded, 
since these individuals are likely to have a different underlying genetic architecture. 
Unless otherwise noted, all discovery sample analysis followed the same protocol and 
analysis plan.
Informed consent was obtained from all discovery study participants (or parental 
consent, as appropriate), and study protocols were approved by the local ethics com-
mittees.
Statistical approaches
Stage 1: GWA meta-analysis of childhood obesity
Statistical analysis within discovery samples
Genotypes were obtained using high-density SNP arrays, and then imputed for ~2.54 
million HapMap CEU SNPs (Phase II, release 22, http://hapmap.ncbi.nlm.nih.gov). Prior 
to imputation, we excluded SNPs with a Hardy-Weinberg equilibrium P-value (HWEP) 
< 1.0x10-6, call rate < 95 percent and minor allele frequency < 1 percent. Post imputa-
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tion, SNPs imputed with IMPUTE were excluded if the proper info was < 0.40 and SNPs 
imputed with MACH were excluded if the r2hat was < 0.30. SNPs were also excluded post 
imputation if the minor allele frequency was < 1 percent. The association between each 
SNP and case-control status was assessed in each study sample using logistic regression 
of case-control against genotype, assuming an additive model and taking into account 
genotype uncertainty. Imputed genotypes were only used where directly-assayed 
genotypes were unavailable. Unless otherwise stated, all discovery analysis followed 
the former protocol.
Meta-analysis of discovery samples
Prior to meta-analysis, SNPs with a minor allele frequency <1% and poorly-imputed 
SNPs (proper_info ≤0.4 [SNPTEST]; r2 ≤0.3 [MACH2QTL]) were filtered. Fixed effects 
meta-analyses were conducted by two independent investigators (J.B., H.R.T.). Meta-
analysis was performed using the software package: METAL (http://www.sph.umich.
edu/csg/abecasis/metal/index.html); Genomic control15 was applied to each cohort 
prior to meta-analysis. Meta-analysis was carried out using the inverse-variance method, 
fixed effects model was assumed. SNPs available for less than half of the total expected 
sample were excluded. We used the Cochran Q test to assess evidence of between-study 
heterogeneity of effect sizes.
A total of 2.7 million SNPs were analyzed in the meta-analysis unfiltered for the number 
of cohorts they appear in. Seven SNPs reached genome wide significance, all of which 
were reported previously in the adult BMI GWAS1,16. Those loci that reached a P-value 
threshold of <5x10-6 in the discovery meta-analysis, and were not identified with obesity 
related traits before (n = 8), were considered for further follow-up in additional samples. 
Stage 2: Follow-up of three lead signals in additional samples
Follow-up samples, genotyping and analysis
We used nine study samples representing a comparable dataset (combined n = 2,818 
cases and 4,083 controls) and two study samples representing an extreme obesity 
dataset (combined n = 2,214 cases and 2,674 controls) to follow up the eight novel 
signals from the GWAS discovery meta-analysis (represented by index SNPs: rs2300095, 
rs4833407, rs4864201, rs28636, rs1290002, rs9568856, rs9299 and rs17697518). If the 
index SNP was unavailable, the most closely correlated proxy available was substituted. 
In four of the replication studies, the index SNPs were imputed from genome-wide 
genotype data.
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Meta-analyses
We performed fixed effects inverse variance meta-analyses of the association results 
for the eight lead signals in the fourteen discovery samples and the nine comparable 
replication samples. We subsequently did the same with the fourteen discovery samples 
combined with the two extreme cohorts. Lastly we combined all datasets for the final 
overall meta-analysis. Fixed effects meta-analyses were conducted independently by 
two investigators (J.B, H.R.T.), again using METAL. 
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Abstract
Background: Growth in early life influences the susceptibility to cardiovascular disease 
in adulthood. Early growth induced cardiovascular programming may partly explain 
this association. We aimed to evaluate the associations of different fetal and childhood 
growth patterns with cardiovascular development in children.
Methods: In a population-based prospective cohort study among 6,416 children, fetal 
femur length and estimated fetal weight were assessed by second and third trimester 
ultrasound examinations. Child length and weight were measured at birth and at the 
ages of 0.5, 2 and 6 years. Blood pressure, carotid-femoral pulse wave velocity, left atrial 
diameter, aortic root diameter, left ventricular mass, and fractional shortening were as-
sessed at the age of 6 years. 
Results: Decreased birth weight and birth weight for gestational age were associated 
with higher systolic blood pressure, and smaller left cardiac structures at the age of 6 
years (all P<0.05). Length and weight gain between second and third trimester of preg-
nancy were positively associated with aortic root diameter and left ventricular mass. As 
compared to children with normal fetal and infant weight gain, children with low fetal 
and high infant weight gain had higher systolic blood pressure, whereas those with both 
high fetal and infant weight gain had higher left ventricular mass. No consequent effect 
of early growth on arterial stiffness was observed.
Conclusion: These observations suggest that fetal and child growth patterns influence 
cardiovascular outcomes in childhood. Early programming of cardiovascular develop-
ment may partly underlie the mechanisms that link early growth and cardiovascular 
disease in later life.
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Introduction
Epidemiological studies have provided broad evidence that early environmental expo-
sures influence the risk of various health outcomes in adulthood. Low birth weight has 
been repeatedly associated with cardiovascular disease and its risk factors in later life1-2. 
Follow up studies have shown that individuals with low birth weight and high rates of 
childhood weight gain have increased risks of cardiovascular disease, suggesting that 
not birth weight per se, but both fetal and childhood growth are related to cardiovas-
cular morbidity and mortality3. The exact growth patterns and underlying biological 
mechanisms linking early growth with cardiovascular health and disease are not known.
There is accumulating evidence that early growth induces primary cardiovascular pro-
gramming, introducing a possible mechanism through which the path of early growth 
initiates future cardiovascular disease. Comprehensive studies in children and adults 
have shown that early growth variation leads to cardiovascular structural and functional 
adaptations in early life4-7. We have previously demonstrated that third trimester fetal 
growth variation within the normal range is associated with cardiac remodelling and 
cardiac output changes consistent with a gradual increase in afterload and compromised 
arterial compliance8. Higher fetal and infant length and weight gain from third trimester 
of pregnancy to the age of 2 years was associated with a higher systolic and diastolic 
blood pressure in early childhood9. Persisting cardiovascular adaptations might explain 
part of the association between early growth and cardiovascular disease in adulthood. 
Detailed studies focused on the effects of specific fetal, and child growth patterns on 
cardiovascular development in childhood might extend our knowledge on the origins 
of cardiovascular disease in the earliest phase of life, and may provide a window of op-
portunity for the early prevention of cardiovascular dysfunction.
In this population-based, prospective cohort study among 6,416 children, we 
investigated the associations of different fetal, infant and child growth patterns with 
cardiovascular structures and function at the age of 6 years. 
Methods
Design and study population
The study was embedded in the Generation R Study, a population-based, prospective 
cohort study from fetal life onwards in Rotterdam, the Netherlands10. Enrolment in the 
study was aimed at early pregnancy, but was possible until the birth of child. Fetal and 
childhood growth were repeatedly assessed by ultrasounds and physical examinations. 
Between March 2008 and January 2012, all children and their mothers were invited to a 
dedicated research center to participate in detailed growth and cardiovascular follow up 
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measurements. Written informed consent was obtained from all parents of participants. 
In total, N = 9,506 singleton live births participated in the study. Information on birth 
weight was available in 9,425 children (99%). Of these children and their parents, 6,510 
visited the research center (median 6.0 years, 95% range 5.6 – 7.9 years). Blood pressure, 
carotid-femoral pulse wave velocity, or cardiac ultrasound measurements were per-
formed in 6,455 children. Children with echocardiographic evidence of congenital heart 
disease or kidney disease were excluded from the study (N = 40), leaving 6,416 children 
for the current analyses (Figure S1). The study has been approved by the Medical Ethics 
Committee of the Erasmus Medical Center, Rotterdam.
Fetal and infant growth
In a dedicated research facility, fetal ultrasound examinations were carried out in each 
trimester of pregnancy, using an Aloka® model SSD-1700 (Tokyo, Japan) or the ATL-
Philips® Model HDI 5000 (Seattle, WA, USA). First trimester fetal measurements were 
not included as growth characteristics because these examinations were primarily per-
formed to establish gestational age11. Second trimester (median 20.5 weeks, 95% range 
18.6 – 23.4) and third trimester (median 30.4 weeks, 95% range 28.4 – 33.1) fetal head 
circumference (HC), abdominal circumference (AC), and femur length (FL) were mea-
sured to the nearest millimetre using standardized ultrasound procedures11. Estimated 
fetal weight (EFW) was calculated using the Hadlock formula12. Gestational age adjusted 
standard deviation scores (SDS) for all fetal growth characteristics were constructed on 
data from the study group11. At birth, information on weight was obtained from com-
munity midwife and hospital registries. Preterm birth was defined as birth before 37.0 
weeks of gestation. Gestational age adjusted SDS were constructed for birth weight, 
using reference growth charts13. Fetal growth rate was defined as the change in SDS 
in the intervals between the second and third trimester, and between third trimester 
and birth. We defined small size for gestational age (SGA) as being <5th sex specific 
percentile and large size for gestational age (LGA) as being >95th sex specific percentile 
for weight at birth.
Infant growth was repeatedly measured at the Community Health Centers according 
to standardized procedures by a well-trained staff at the median ages of 6.2 months 
(95% range 5.2 – 8.3), and 24.8 months (95% range 23.4 – 28.2). Length was measured in 
supine position to the nearest millimetre and weight was measured using a mechanical 
personal scale (SECA). Sex and age adjusted SDS for infant growth characteristics were 
obtained using Dutch reference growth curves (Growth Analyzer 3.0, Dutch Growth 
Research Foundation). For each infant age interval, we defined growth as the change 
in SDS between the two time-points. Catch-down and catch-up growth for weight 
was defined as a decrease or increase of >0.67 standard deviation (SD) of weight from 
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birth to 24 months of age. This change represents the width of each percentile band on 
standard growth charts14.
Childhood anthropometrics
At the age of 6 years, child height and weight were measured without shoes and heavy 
clothing, and body mass index (BMI) (kg/m2) and body surface area (BSA) (m2) were 
calculated. All anthropometric measurements were converted to SDS. Overweight and 
obesity were defined as recommended by The International Obesity Taskforce15.
Child cardiovascular structures and function
We measured blood pressure with the child in supine position quietly awake. Systolic 
and diastolic blood pressure was measured at the right brachial artery, four times with 
one minute intervals, using the validated automatic sphygmanometer Datascope Ac-
cutor PlusTM (Paramus, NJ, USA).[15] A cuff was selected with a cuff width approximately 
40% of the arm circumference and long enough to cover 90% of the arm circumference. 
More than 90% of the children who visited the research center had four successful blood 
pressure measurements available.
Carotid-femoral pulse wave velocity, the reference method to assess aortic stiff-
ness16, was assessed using the automatic Complior SP device (Complior; Artech 
Medical, Pantin, France) with participants in supine position. The distance between 
the recording sites at the carotid (proximal) and femoral (distal) artery was measured 
over the surface of the body to the nearest centimeter. Through piezoelectric sensors 
placed on the skin, the device collected signals to assess the time delay between the 
upstroke of carotid and femoral waveforms. Carotid-femoral pulse wave velocity was 
calculated as the ratio of the distance travelled by the pulse wave and the time delay 
between the waveforms, as expressed in meters per second17. To cover a complete 
respiratory cycle, the mean of at least 10 consecutive pressure waveforms was used in 
the analyses. Recently, it has been shown that pulse wave velocity can be measured 
reliably, with good reproducibility in a large pediatric population-based cohort18.
Two-dimensional M-mode echocardiographic measurements were performed using 
the ATL-Philips Model HDI 5000 (Seattle, WA, USA) or the Logiq E9 (GE Medical Systems, 
Wauwatosa, WI, USA) devices. The children were examined in a quiet room with the child 
awake in supine position. Missing echocardiograms were mainly due to restlessness of 
the child or unavailability of equipment or sonographer. Left atrial diameter, interven-
tricular end-diastolic septal thickness (IVSTD), left ventricular end-diastolic diameter 
(LVEDD), left ventricular end-diastolic posterior wall thickness (LVPWTD), interventricu-
lar end-systolic septal thickness, left ventricular end-systolic diameter, left ventricular 
end-systolic posterior wall thickness, aortic root diameter, and fractional shortening 
were measured using methods recommended by the American Society of Echocar-
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diography19. Left ventricular mass (LV mass was computed using the formula derived by 
Devereux et al20:LV mass = 0.80 × 1.04((IVSTD + LVEDD + LVPWTD)3 − (LVEDD)3)+ 0.6. To 
assess reproducibility of ultrasound measurements, the intraobserver and interobserver 
intraclass correlation coefficients were calculated previously in 28 subjects (median age 
7.5 years, inter-quartile range 3.0 – 11.0) and varied for the main outcome measures 
between 0.91 to 0.99 and 0.78 to 0.96, respectively21.
All cardiovascular outcome measurements were converted to SDS for comparison of 
effect estimates.
Covariates
Information on maternal age, pre-pregnancy weight, parity, educational level, and 
smoking status (yes/no) during pregnancy was obtained by questionnaires. Maternal 
education was defined as the highest followed education according to the classification 
of Statistics Netherlands and was categorized in primary and secondary, or higher22. 
Maternal height was measured without shoes and pre-pregnancy BMI was calculated 
(kg/m2). Date of birth and infant sex were obtained from midwife and hospital registries. 
Infant ethnicity was classified by the countries of birth of the parents, according to the 
Dutch standard classification criteria of Statistics Netherlands and was categorized as 
European or non-European22. Breastfeeding (yes/no) was assessed using questionnaires. 
Statistical analysis
First, we assessed the associations of fetal, infant and child characteristics with cardio-
vascular outcomes at the age of 6 years using linear regression models adjusted for 
sex and current age. Since we measured blood pressure four times, we applied linear 
mixed models23, that fit the four blood pressure measurements within the same child 
as repeated outcome measures. One of the advantages of this approach is that subjects 
with the maximum number of blood pressure measurements available and the least 
individual variability in their blood pressure measurements are assigned the highest 
weight in the analysis24. Second, to investigate the associations of clinical cut off levels 
of birth characteristics with cardiovascular outcomes, we performed analyses using 
categories of gestational age, birth weight and gestational age adjusted birth weight. 
Third, we explored the associations of fetal and infant growth in different age intervals 
with cardiovascular outcomes. We used the following intervals: Second to third trimes-
ter; third trimester to birth; birth to 6 months; and 6 months to 24 months. Finally, we as-
sessed the associations of infant growth until 24 months of age and BMI categories with 
blood pressure and left ventricular mass, known risk factors for cardiovascular disease in 
adulthood, within strata of gestational age adjusted birth weight (SGA, appropriate size 
for gestational age (AGA), and LGA). All models were adjusted for relevant confounders, 
including maternal pre-pregnancy BMI, parity, educational level, smoking status during 
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pregnancy, and child’s gestational age, birth weight, sex, ethnicity, breastfeeding and 
current age and BMI. The percentages of missing covariate values within the population 
for analysis were lower than 15.0%, except for maternal pre-pregnancy BMI (25.2%) and 
breastfeeding (22.1%). Missing covariate data were imputed using the multiple imputa-
tions procedure (N = 5 imputations) and the imputed datasets were analyzed together. 
All measures of association are presented with their 95% confidence intervals (CI). The 
mixed-models were fitted using the Statistical Analysis System version 9.2 (SAS, Institute 
Inc., Gary, NC, USA). All other Statistical analyses were performed using the Statistical 
Package for the Social Sciences version 17.0 for Windows (SPSS Inc, Chicago, IL, USA).
Results
Subject characteristics
Table 1 provides a comparison in characteristics of the children included in the study 
between the original dataset and after the multiple imputation procedure. Sex-specific 
descriptives of all fetal and infant growth characteristics are given in the supplementary 
material (Table S1). Table S2 shows consequent positive associations of cross-sectional 
second and third trimester estimated fetal weight and birth weight with left atrial di-
ameter, aortic root diameter and left ventricular mass at 6 years, with stronger effect 
estimates in third trimester. Child growth characteristics were all positively associated 
with blood pressure, left atrial diameter, aortic root diameter and left ventricular mass. 
The strongest effect estimates observed for weight at the age of 24 months.
Table 1. Characteristics of study participants (N = 6,416)
Maternal characteristics
Age, y, median (95% range) 31.1 (19.8 – 39.9)
Height, cm, mean (SD) 167.5 (7.4)
Weight before pregnancy, kg, mean (SD) 66.5 (12.6)
Pre-pregnancy body mass index, kg/m2, mean (SD) 23.6 (4.2)
Parity, % (n)
  0 54.6 (3,500) 
  ≥1 42.2 (2,707) 
  Missing 3.3 (209) 
Educational level mother, % (n)
  Primary or Secondary 48.5 (3,109)
  Higher 42.5 (2,729) 
  Missing 9.0 (578) 
Smoking during pregnancy, % (n)
  No 64.9 (4,161) 
  Yes 21.9 (1,408) 
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Gestational age, birth weight, and gestational age adjusted birth weight were all in-
versely associated with systolic blood pressure, and positively associated with cardiac 
structures at 6 years of age in the fully adjusted models (Table 2). Children born preterm 
had smaller left atrial diameter, aortic root diameter and left ventricular mass. Children 
born with a birth weight <2,000 grams had a higher blood pressure and decreased 
aortic root and left ventricular mass, compared to children born with a birth weight 
3,000 - 3,499 grams. We did not observe consistent associations of birth characteristics 
with carotid-femoral pulse wave velocity.
Table 3 shows that fetal length growth rate was not associated with childhood blood 
pressure. Fetal length growth rate from second to third trimester, but not from third 
trimester to birth, was positively associated with aortic root diameter and left ventricular 
Table 1. Characteristics of study participants (N = 6,416) (continued)
  Missing 13.2 (847) 
Birth characteristics
Male sex, % (n) 3,221 (50.2) 
Gestational age at birth, wks, median (95% range) 40.1 (35.9 – 42.3)
Birth weight, g, mean (SD) 3,427 (554)
Preterm birth (<37 weeks), % (n) 5.0 (318) 
Small for gestational age, % (n) 4.2 (272) 
Large for gestational age, % (n) 4.9 (317) 
Ethnicity, % (n)
  European 62.6 (4,019) 
  Non-European 34.9 (2,236) 
  Missing 2.5 (161) 
Breastfeeding during infancy, % (n)
  Ever 72.0 (4,620) 
  Never 5.9 (379) 
  Missing 22.1 (1,416) 
Child characteristics at 6 years
Age, y, median (95% range) 6.0 (5.6 – 7.9)
Height, cm, mean (SD) 119.5 (6.1)
Weight, kg, mean (SD) 23.3 (4.3)
Body mass index, m/kg2, mean (SD) 16.2 (1.9)
Systolic blood pressure, mmHg, mean (SD) 102.7 (8.1)
Diastolic blood pressure, mmHg, mean (SD) 60.7 (6.7)
Carotid-femoral pulse wave velocity, m/s, mean (SD) 5.5 (0.9)
Left atrial diameter, mm, mean (SD) 25.2 (2.7)
Aortic root diameter, mm, mean (SD) 19.3 (1.8)
Left ventricular mass, g, mean (SD) 53.4 (11.6)
Fractional shortening, %, mean (SD) 35.2 (4.5)
Missing values continuous variables: maternal height N = 612, pre-pregnancy weight N = 1,605, pre-pregnancy body 
mass index = 1,614, child gestational age at birth N = 44, current height N = 8, current weight N = 8, and current 
body mass index N = 8. Subject characteristics based on imputed values of covariates are given in the supplementary 
materials.
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Table 2. Birth characteristics and cardiovascular structures and function at the age of 6 years
Difference in cardiovascular outcomes expressed as SD (95% Confidence Interval)
Birth characteristics Systolic blood 
pressure  
(SD = 8.1 
mmHg)
Diastolic 
blood 
pressure  
(SD = 6.7 
mmHg)
Pulse wave 
velocity  
(SD = 0.9 
m/s)
Left atrial 
diameter
(SD = 2.7 
mm)
Aortic root 
diameter
(SD = 1.8 
mm)
Left 
ventricular 
mass
(SD = 11.6 g)
Fractional 
shortening
(SD = 4.5 %)
Gestational age N = 6,372
<37.0 weeks
N = 318
0.05
(-0.05, 0.14)
-0.01
(-0.09, 0.07)
-0.09
(-0.22, 0.04)
-0.11
(-0.21, 0.00)*
-0.18
(-0.28, -0.08)†
-0.10
(-0.20, -0.01)*
0.02
(-0.09, 0.13)
37.0-41.9 weeks
N = 5,622
Reference Reference Reference Reference Reference Reference Reference
>=42.0 weeks
N = 432
-0.07
(-0.15, 0.02)
-0.04
(-0.11, 0.03)
-0.05
(-0.16, 0.06)
0.03
(-0.07, 0.12)
0.03
(-0.07, 0.12)
0.01
(-0.07, 0.10)
-0.09
(-0.18, 0.01)
P for trend <0.01 0.31 0.53 <0.01 <0.01 <0.01 0.16
Birth weight N = 6,416
<2,000 grams
N = 78
0.18
(-0.01, 0.37)
0.08
(-0.09, 0.25)
-0.28
(-0.53, -0.03)*
-0.20
(-0.41, 0.01)
-0.32
(-0.53, -0.12)†
-0.21
(-0.39, -0.02)*
0.05
(-0.18, 0.27)
2,000-2,499 grams
N = 208
-0.03
(-0.15, 0.09)
-0.03
(-0.14, 0.08)
-0.04
(-0.21, 0.12)
0.04
(-0.09, 0.17)
-0.21
(-0.34, -0.08)†
-0.19
(-0.31, -0.07)†
-0.03
(-0.17, 0.11)
2,500-2,999 grams
N = 944
0.00
(-0.06, 0.07)
0.02
(-0.04, 0.08)
-0.06
(-0.15, 0.02)
0.00
(-0.07, 0.07)
-0.16
(-0.23, -0.10)†
-0.15
(-0.22, -0.09)†
-0.01
(-0.09, 0.06)
3,000-3,499 grams
N = 2,223
Reference Reference Reference Reference Reference Reference Reference
3,500-3,999 grams
N = 2,063
-0.09
(-0.14, -0.04)†
-0.07
(-0.12, -0.02)†
-0.01
(-0.08, 0.06)
0.09
(0.04, 0.15)†
0.19
(0.13, 0.24) †
0.11
(0.06, 0.16)†
-0.07
(-0.13, -0.01)*
4,000-4,499 grams
N = 751
-0.12
(-0.19, -0.05)†
-0.08
(-0.15, -0.02)*
0.02
(-0.08, 0.11)
0.18
(0.10, 0.26)†
0.26
(0.18, 0.34) †
0.25
(0.18, 0.32)†
-0.09
(-0.17, 0.00)*
≥4,500 grams
N = 149
-0.17
(-0.31, -0.03)*
-0.09
(-0.21, 0.04)
0.02
(-0.16, 0.21)
0.15
(0.00, 0.31)
0.46
(0.31, 0.61) †
0.41
(0.27, 0.55)†
-0.16
(-0.32, 0.01)
P for trend <0.01 <0.01 0.04 <0.01 <0.01 <0.01 <0.01
Birth weight for 
gestational age N = 6,367
Small for gestational age
N = 272
0.15
(0.04, 0.25)†
0.13
(0.04, 0.22)†
-0.11
(-0.25, 0.03)
-0.04
(-0.16, 0.07)
-0.31
(-0.43, -0.20)†
-0.21
(-0.32, -0.11)†
0.06
(-0.06, 0.18)
Normal for gestational age
N = 5,778
Reference Reference Reference Reference Reference Reference Reference
Large for gestational age
N = 317
-0.07
(-0.16, 0.03)
-0.08
(-0.17, 0.00)
0.00
(-0.13, 0.13)
0.08
(-0.03, 0.19)
0.24
(0.13, 0.35)†
0.34
(0.24, 0.44)†
-0.07
(-0.18, 0.05)
P for trend <0.01 <0.01 0.06 <0.01 <0.01 <0.01 <0.01
Values are regression coefficients (95% CI) based on mixed models or linear regression models and reflect the change in 
SDS of each cardiovascular outcome for each birth weight or gestational age group, compared to the reference group. 
Models are adjusted for maternal age, pre-pregnancy body mass index, parity, educational level, and smoking status 
during pregnancy, and child sex, ethnicity, breastfeeding and current age and body mass index. Models with ultrasound 
outcomes are additionally adjusted for ultrasound device and performing sonographer. *P<0.05 †P<0.01
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mass (0.06 SDS, 95% CI 0.04, 0.09, and 0.05 SDS, 95% CI 0.03, 0.07, respectively). Infants 
with increased length gain in the first 24 months of life had a higher systolic blood pres-
sure. Although fetal weight growth rate in the period from second trimester to birth 
was inversely associated with systolic blood pressure, infant weight gain in the first 24 
months of life was positively associated with blood pressure. Fetal weight growth rate 
from second to third trimester was positively associated with aortic root diameter and 
left ventricular mass. No consistent associations were found of fetal or infant growth rate 
with childhood carotid-femoral pulse wave velocity or fractional shortening.
Size at birth, infant growth and childhood obesity and cardiovascular 
outcomes
As compared to children born AGA with normal infant weight gain until 24 months of 
age, children born SGA or AGA followed by catch up weight gain had the highest systolic 
blood pressure (0.20 SDS, 95% CI 0.04, 0.36, and 0.20 SDS, 95% CI 0.13, 0.27, respec-
tively), whereas children born LGA with a normal or catch up growth had the highest left 
ventricular mass (0.61 SDS, 95% CI 0.39, 0.82) (Figure 1). Children born SGA had a smaller 
left ventricular mass compared to the reference group, with the smallest left ventricular 
mass in children without catch up growth.
Children born SGA or AGA who became overweight or obese at the age of 6 years, had 
the highest systolic and diastolic blood pressure as compared to AGA children with a 
normal weight, as presented in Figure 2. Children born LGA who were underweight had 
the lowest blood pressure. Children born LGA who became overweight or obese had the 
highest left ventricular mass (1.17 SDS, 95% CI 0.97, 1.37).
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Discussion
In this large, population based prospective cohort study, we demonstrated that fetal, 
infant and child growth characteristics are associated with cardiovascular structural and 
functional development in childhood, independent of current BMI. These results suggest 
that both fetal and childhood growth might have persisting influence on cardiovascular 
growth and development.
Early critical growth periods for cardiovascular development 
Suboptimal cardiovascular developmental adaptations in response to or associated 
with early growth variation might partly explain the previously demonstrated increased 
predisposition to cardiovascular disease in individuals born with low birth weight1-2. The 
rates of elastin synthesis in human blood vessels increase to a maximum in the perinatal 
period, followed by a rapid fall in the synthesis rates thereafter25-26, suggesting a critical 
period for the development of the vascular system in the perinatal phase. It has been 
hypothesized that impaired fetal growth is associated with a deficient synthesis of 
elastin in the walls of the aorta and large arteries, and that this deficiency would lead 
to permanent changes in the mechanical properties of these vessels26. Indeed, adapta-
tions in arterial properties have been observed in both children21, 27-29 and adults4, 30 born 
with low birth weight, although results seem inconsistent31-32. We observed an inverse 
association of birth weight and gestational age adjusted birth weight with systolic and 
diastolic blood pressure at the age of 6 years. Furthermore, length and weight growth 
rates from second to third trimester of pregnancy were consequently associated with 
aortic root diameter, supporting the hypothesis of the presence of a critical window of 
developmental programming of the vascular system26. However, we did not find consis-
tent evidence of an association of fetal or infant growth with carotid-femoral pulse wave 
velocity at the age of 6 years. Although in contrast with previous studies4, our results 
are in line with findings of Montgomery et al. in adults aged 25 years, where neither low 
size at birth nor the interaction between birth size and adult size were associated with 
pulse wave velocity31. The discrepancy in results between studies in older and younger 
individuals is suggested to be explained by the influence of atherosclerotic lesions on 
arterial compliance with advancing age31.
Detailed studies in animals and humans have shown that intrauterine growth restric-
tion can program structural and mechanical cardiac properties in the offspring7, 33-34. In 
a case-control study among young children, fetal growth restriction induced primary 
changes in cardiac morphology, including an increase in transversal diameters and more 
globular ventricles7. The authors postulated that this cardiac remodelling is most likely 
the result of the inability of the myocardium to develop adequate hypertrophic changes 
in response to an increased workload under conditions of sustained hypoxia and 
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undernutrition7. Fetal growth of the human heart mainly involves myocardial cell hy-
perplasia, while postnatal heart growth is characterized by myocardial cell hypertrophy 
and hyperplasia of nonmuscle cells35. Although cardiomyocyte proliferation is observed 
in the heart of adults, factors that influence cardiac histology established during fetal 
life through either reduced cardiomyocyte proliferation or increased apoptosis, might 
exert a lasting effect on cardiac development. In rats, intrauterine growth restriction 
led to a reduced number of cardiomyocytes per heart at birth34. In a post-mortem study 
among four human infants with severe intrauterine growth retardation, hypoplasia of 
myocardial fibers was found36. The smaller left ventricular mass we observed in children 
with restricted fetal growth from second to third trimester and born small for gestational 
age, may reflect the inability of the left ventricle to adequately adapt according to the 
increased workload that is imposed from birth onwards, due to a lower number of 
cardiomyocytes.
Longitudinal approach of fetal and child growth
It has been hypothesized that the pattern of postnatal growth may modify the associa-
tion between restricted fetal growth and the risk of cardiovascular disease. An observa-
tional study from Finland with detailed growth data described that reduced birth weight 
followed by accelerated child growth was related to a higher risk of coronary heart 
disease in later life3. In 1,258 men participating in a follow up study in South Wales, the 
risk of coronary heart disease associated with low birth weight only observed among 
individuals with a high adult BMI37. We observed that children born SGA or AGA with 
catch up growth or overweight at the age of 6 years had a higher systolic blood pres-
sure than children born AGA followed by normal growth. Children born LGA with catch 
up growth or overweight in childhood had a higher left ventricular mass. These results 
support a mechanistic pathway where the pattern of postnatal growth following fetal 
growth influences cardiovascular development.
Methodological considerations
Main strengths of this study are its population-based, prospective design starting in 
fetal life, and the large number of fetal, infant and child growth measurements available. 
The majority of studies have no access to measurements of fetal growth other than birth 
measures, which are crude summary indices of fetal growth. To move beyond birth mea-
sures, we investigated the influence of fetal and postnatal growth, in addition to birth 
size. The repeated fetal and postnatal growth measurements provided the opportunity 
to identify critical growth periods that might influence cardiovascular development. 
A limitation of the study is that of all children, 69.1% participated in the follow-up 
measurements and 68.5% underwent one or more cardiovascular measurements. No 
differences in birth weight between children with and without one of the cardiovascular 
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measurements were observed. Selection bias due to selective loss to follow-up is of 
concern if the associations of early growth characteristics with cardiovascular structures 
and function differ between those included and those not included in the analyses. 
Although this seems unlikely, it cannot be excluded. It is expected that the potential 
confounding effect of factors related to the risk of cardiovascular disease is confined in 
young children. However, the influence of residual confounding should be considered, 
as in all observational studies.
Conclusions
This study suggests that fetal, infant and child growth are associated with cardiovascular 
development in childhood and that critical periods of growth can be identified. This 
early cardiovascular programming may subsequently increase the susceptibility to 
cardiovascular disease in adulthood. However, the long-term clinical importance of the 
changes in cardiovascular development detected in childhood due to impaired early 
growth is unknown. Whether these adaptations predict a greater risk of cardiovascular 
disease in later life, is topic for further research.
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Singleton live births 
N = 9,506 
Data on birth weight 
N = 9,425 
Data on 6 year visit 
N = 6,510 
N = 2,915 Excluded, due to withdrawal of 
consent (N = 335), loss to follow-up (N = 
1,014), or not visiting the research center (N 
= 1,566) 
 
N = 81 Excluded, due to missing data on 
birth weight 
N = 55 Excluded, due to missing 
cardiovascular measurements 
 
Participation in 6 years visit: N = 6,416 
Blood pressure: N = 6,274 
Pulse wave velocity: N = 5,122 
Cardiac ultrasounds: N = 6,113 
 
Data on cardiovascular outcomes 
N = 6,455 
N = 39 Excluded, due to echocardiographic 
evidence of heart disease (N = 27), or kidney 
abnormalities (N = 12) 
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Table S1. Characteristics of study participants after multiple imputation (N = 6,416)
Imputed
Maternal characteristics
Age, y, median (95% range) 31.1 (19.8 – 39.9)
Height, cm, mean (SD) 167.5 (7.4)
Weight before pregnancy, kg, mean (SD) 66.5 (12.6)
Body mass index before pregnancy, kg/m2, mean (SD) 23.7 (4.3)
Parity, % (n)
  0 56.2 (3,607)
  ≥1 43.8 (2,808)
  Missing -
Educational level mother, % (n)
  Primary or Secondary 54.6 (3,505)
()
  Higher 45.4 (2,910)
  Missing -
Smoking during pregnancy, % (n)
  No 74.5 (4,780)
  Yes 25.5 (1,635)
  Missing -
Birth characteristics
Male sex, % (n) 50.2 (3,221)
Gestational age at birth, wks, median (95% range) 40.1 (35.9 – 42.3)
Birth weight, g, mean (SD) 3,427 (554)
Preterm birth (<37 weeks), % (n) 5.0 (318)
Small for gestational age, % (n) 4.2 (272)
Large for gestational age, % (n) 4.9 (317)
Ethnicity, % (n)
  European 63.9 (4,101)
  Non-European 36.1 (2,314)
  Missing -
Breastfeeding during infancy, % (n)
  Ever 92.2 (5,917)
  Never 7.8 (498)
  Missing -
Child characteristics at 6 years
Age, y, mean (SD) 6.0 (5.6 – 7.9)
Height, cm, mean (SD) 119.5 (6.2)
Weight, kg, mean (SD) 23.3 (4.3)
Body mass index, m/kg2, mean (SD) 16.2 (1.9)
Systolic blood pressure, mmHg, mean (SD) 102.7 (8.1)
Diastolic blood pressure, mmHg, mean (SD) 60.7 (6.7)
Carotid-femoral pulse wave velocity, m/s, mean (SD) 5.5 (0.9)
Left atrial diameter, mm, mean (SD) 25.2 (2.7)
Aortic root diameter, mm, mean (SD) 19.3 (1.8)
Left ventricular mass, g, mean (SD) 53.4 (11.6)
Fractional shortening, %, mean (SD) 35.2 (4.5)
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Values are means (SD), medians (95% range) or numbers (%)
*Gestational age <37 weeks at delivery
†Sex specific gestational age adjusted birth weight <5th percentile in study cohort
‡Sex specific gestational age adjusted birth weight >95th percentile in study cohort
Missing values for imputed continuous variables maternal height N = 612, pre-pregnancy weight N = 1,605, pre-
pregnancy body mass index = 1,614, child gestational age at birth N = 44, current height N = 8, current weight N = 8, and 
current body mass index N = 8.
Table S2. Fetal and infant growth characteristics
Growth Characteristics
Boys
N = 3,221
Girls
N = 3,195 P-value
Fetal growth
Second trimester
  Gestational age (weeks) 20.6 (18.6 – 23.5) 20.5 (18.5 – 23.3) <0.01
  Femur length (mm) 33.5 (3.6) 33.5 (3.5) 0.75
  Estimated fetal weight (g) 387 (97) 377 (91) <0.01
Third trimester
  Gestational age (weeks) 30.4 (28.5 – 33.1) 30.3 (28.3 – 33.0) <0.01
  Femur length (mm) 57.4 (3.1) 57.6 (3.1) <0.01
  Estimated fetal weight (g) 1,633 (260) 1,619 (269) 0.04
Birth
  Gestational age (weeks) 40.1 (35.9 – 42.4) 39.8 (35.7 – 42.1) 0.10
  Length (cm) 50.6 (2.4) 49.9 (2.3) <0.01
  Weight (g) 3,489 (567) 3,364 (533) <0.01
Infant growth
6 Months
  Age (months) 6.2 (5.2 – 8.2) 6.2 (5.3 – 8.4) 0.55
  Length (cm) 68.5 (2.5) 66.7 (2.4) <0.01
  Weight (g) 8,174 (902) 7.594 (832) <0.01
24 Months
  Age (months) 24.8 (23.4 – 28.3) 24.8 (23.4 – 28.1) 0.37
  Height (cm) 88.9 (3.4) 87.7 (3.4) <0.01
  Weight (kg) 13.2 (1.5) 12.7 (1.5) <0.01
Values are means (SD) or medians (95% range). Differences between boys and girls were compared using independent 
samples t test
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Table S3. Fetal and infant growth characteristics and cardiovascular structures and function at the age of 
6 year
Difference in cardiovascular outcomes expressed as SD (95% Confidence Interval)
Growth characteristics
Systolic blood 
pressure  
(SD = 8.1 
mmHg)
Diastolic 
blood 
pressure  
(SD = 6.7 
mmHg)
Pulse wave 
velocity  
(SD = 0.9 
m/s)
Left atrial 
diameter 
(SD = 2.7 
mm)
Aortic root 
diameter 
(SD = 1.8 
mm)
Left 
ventricular 
mass 
(SD = 11.6 g)
Fractional 
shortening 
(SD = 4.5 %)
Second trimester 
Length 
(SD = 3.6 mm)
0.02
(0.00, 0.05)*
0.00
(-0.02, 0.02)
0.03
(0.00, 0.06)
0.03
(0.00, 0.06)*
0.06
(0.04, 0.09)†
0.06
(0.03, 0.08)†
-0.03
(-0.05, 0.00)
Estimated fetal weight 
(SD = 94.2 g)
0.03
(0.01, 0.05)*
0.00
(-0.02, 0.02)
0.02
(-0.01, 0.05)
0.05
(0.03, 0.08)†
0.09
(0.06, 0.11)†
0.10
(0.07, 0.12)†
-0.02
(-0.04, 0.01)
Third trimester
Length
(SD = 3.1 mm)
0.00
(-0.03, 0.02)
-0.01
(-0.03, 0.01)
0.03
(0.00, 0.06)
0.06
(0.03, 0.09)†
0.12
(0.10, 0.15)†
0.11
(0.09, 0.14)†
-0.03
(-0.06, -0.01)†
Estimated fetal weight 
(SD = 264.4 g)
0.01
(-0.01, 0.03)
-0.02
(-0.04, 0.00)*
0.03
(0.00, 0.06)*
0.09
(0.06, 0.11)†
0.16
(0.14, 0.19)†
0.15
(0.13, 0.18)†
-0.02
(-0.05, 0.01)
Birth
Gestational age 
(SD = 1.8 weeks)
-0.05
(-0.07, -0.02)†
-0.02
(-0.04, 0.00)
0.00
(-0.03, 0.04)
0.05
(0.02, 0.08)†
0.08
(0.05, 0.11)†
0.07
(0.04, 0.09)†
-0.02
(-0.05, 0.01)
Birth weight 
(SD = 554 g)
-0.03
(-0.06, -0.01)†
-0.04
(-0.06, -0.02)†
0.01
(-0.02, 0.04)
0.12
(0.09, 0.15)†
0.20
(0.18, 0.23)†
0.20
(0.18, 0.23)†
-0.04
(-0.06, -0.01)†
Gestational age adjusted 
birth weight (SD = 1.0)
-0.01
(-0.04, 0.01)
-0.03
(-0.05, -0.01)†
0.01
(-0.02, 0.04)
0.11
(0.08, 0.13)†
0.19
(0.16, 0.21)†
0.19
(0.17, 0.22)†
-0.03
(-0.06, -0.01)†
24 months
Length 
(SD = 3.4 cm)
0.11
(0.08, 0.14)†
0.04
(0.01, 0.06)†
0.04
(0.01, 0.08)*
0.17
(0.14, 0.20)†
0.25
(0.22, 0.28)†
0.32
(0.29, 0.35)†
0.00
(-0.03, 0.03)
Weight 
(SD = 1.5 kg)
0.14
(0.11, 0.17)†
0.04
(0.02, 0.06)†
0.00
(-0.04, 0.04)
0.22
(0.19, 0.25)†
0.27
(0.24, 0.30)†
0.36
(0.33, 0.39)†
0.00
(-0.03, 0.03)
Values are regression coefficients (95% CI) based on multiple linear regression models and reflect the change in SDS of 
blood pressure, carotid-femoral pulse wave velocity, left cardiac structures and fractional shortening per change in SDS 
of fetal and infant growth characteristics. Models are adjusted for child sex and current age. Models with ultrasound 
outcomes are additionally adjusted for ultrasound device and performing sonographer. *P<0.05 †P<0.01
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Abstract
Background: Fetal smoke exposure might lead to fetal developmental adaptations that 
permanently affect the cardiovascular system. We assessed the associations of both ma-
ternal and paternal smoking during pregnancy with childhood cardiovascular structures 
and function.
Methods: In a prospective cohort study among 5,565 children, we examined whether 
maternal and paternal smoking during pregnancy are associated with blood pressure, 
carotid-femoral pulse wave velocity, and left cardiac structures and function in 6 year 
old children. 
Results: As compared to children from non-smoking mothers, children from mothers 
who smoked more than 10 cigarettes per day had a higher diastolic blood pressure (dif-
ference 1.43 mmHg (95%CI: 0.22, 2.63)). Maternal smoking during pregnancy was not 
associated with childhood carotid-femoral pulse wave velocity or left cardiac structures. 
Maternal smoking of 10 or more cigarettes per day was associated with a higher frac-
tional shortening in childhood (difference 1.01% (95%CI 0.018, 1.84)). Among mothers 
who did not smoke during pregnancy, paternal smoking was associated with aortic root 
diameter, but not with other cardiovascular outcomes. 
Conclusion: Maternal smoking during pregnancy might increase childhood diastolic 
blood pressure and fractional shortening. The stronger effect estimates for maternal 
smoking compared to paternal smoking might suggest that direct intra-uterine adap-
tive responses are involved as underlying mechanisms.
131
Parental smoking and cardiovascular growth and function
3.2
Introduction
Adverse fetal exposures might lead to permanent developmental adaptations in the 
structure and function of the cardiovascular system and other organ systems, and 
increase the susceptibility of cardiovascular disease and metabolic diseases in later 
life1-3.  Maternal smoking during pregnancy is one of the most important, potentially 
modifiable, adverse fetal exposures4-5, and is strongly related with an increased risks of 
low birth weight and preterm birth5-6. There is also growing evidence for changes in 
fetal and childhood cardiovascular structures and function in children born to mothers 
who smoked during pregnancy, although results seem to be inconsistent7-10. Previous 
studies showed associations of maternal smoking during pregnancy with childhood 
blood pressure7-10, but it is not clear whether this association is explained by direct intra-
uterine mechanisms or is due to other, unmeasured, confounders. One previous study 
suggested similar effect sizes for both maternal and paternal smoking on childhood 
blood pressure9, indicating that this association might be explained by unmeasured 
environmental exposures. The extent to which maternal smoking during pregnancy is 
associated with changes in arterial stiffness, and left cardiac structures and function, 
which are independent predictors of cardiovascular disease in adulthood11-12, is not 
known. 
Therefore, we assessed in a large population-based prospective cohort study among 
5,565 children, the associations of maternal and paternal smoking during pregnancy 
with blood pressure, carotid-femoral pulse wave velocity, and left cardiac structures and 
function in school age children.
Methods
Study design and population for analysis
The study was embedded in the Generation R Study, a population-based, prospective 
cohort study from fetal life onwards in Rotterdam, the Netherlands13. Enrolment in the 
study was aimed at early pregnancy, but was allowed until the birth of the child. The 
study has been approved by the Medical Ethics Committee of the Erasmus Medical Cen-
ter, Rotterdam. Written informed consent was obtained from all parents of participants. 
In total, 9,778 mothers were enrolled in the study, of whom 8,244 (84.3%) provided 
information about their smoking habits. For the present study, only singleton life births 
were included (n=8,024), of whom 5,658 (70.5%) children attended the follow-up visit 
between March 2008 and January 2012. Children with echocardiographic evidence of 
congenital heart disease or kidney abnormalities were excluded from the study (n=33). 
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Blood pressure, cardiac ultrasound or carotid-femoral pulse wave velocity measure-
ments were successfully performed in 5,565 (98.4%) children (see figure 1).
Maternal and paternal smoking during pregnancy 
At enrolment, we asked each mother whether she smoked during pregnancy (no 
smoking; smoking until pregnancy was acknowledged (first trimester only smoking); 
continued smoking during pregnancy). Mothers who were enrolled before a gestational 
age of 18 weeks and between 18 and 25 weeks of gestation, also received a second 
and third trimester questionnaire, respectively. Mothers who reported in the first ques-
tionnaire that they smoked during the first trimester only (n=921), but still reported 
Figure 1. Flowchart 
 
  
 
Data on maternal smoking during pregnancy 
available 
N = 8,244 
Enrolled mothers 
N=9,778 
N=1,534 excluded due to missing 
data on maternal smoking during 
pregnancy  
Data on cardiovascular outcomes  N=5,565 
 
 
Blood pressure   N=5,447 
  
Carotid-femoral  
pulse wave velocity   N=4,420 
 
Cardiac ultrasounds    N=5,289 
 
 
Singleton life births with maternal smoking 
data available 
N= 8,024 
Excluded N=100 due twin births, 
N=91 due to fetal death and N=29 
loss to follow-up 
Excluded N=23 due to clinical or 
congenital heart disease, N=10 due 
to kidney abnormalities, and N=60 
due to missing data on all outcome 
measurements 
Particpation in visit at the age of six years 
N= 5,658 
Excluded N=248 due to withdrawal 
of consent, N=799 due to loss to 
follow-up and N=1,319 did not visit 
research center 
Flowchart of the study population: the Generation R Study Cohort, Rotterdam, the Netherlands.
133
Parental smoking and cardiovascular growth and function
3.2
to smoke in the second or third trimester questionnaire (n=312) were reclassified into 
the ‘continued smoking during pregnancy’ category. The same strategy was used for 
women who reported no smoking in the first questionnaire, but reported smoking in 
the second or third questionnaire (n=80). Among mothers who smoked, the number 
of cigarettes smoked daily was categorized as: no maternal smoking, <5 cigarettes/
day, 5-9 cigarettes/day, and ≥10 cigarettes/day. Paternal smoking was assessed in the 
first questionnaire by asking the mother whether the father smoked during pregnancy 
(yes, no, or do not know). Similar information completed by the father was available in a 
subset of participants (n=3,558). Agreement between these assessments by the mother 
and the father was good (sensitivity: 91%; specificity: 95%). 
Cardiovascular outcomes in children
Cardiovascular measurements in children at the age of six years, were conducted in a 
dedicated research center in the Erasmus Medical Center, Rotterdam, the Netherlands. 
The child was lying quietly, while systolic and diastolic blood pressure was measured 
at the right brachial artery in supine position, four times with one minute intervals, us-
ing the validated automatic sphygmanometer Datascope Accutor Plus TM (Paramus, NJ, 
USA)14. A cuff was selected with a cuff width approximately 40% of the arm circumfer-
ence and long enough to cover 90% of the arm circumference. More than 95% of the 
children who visited the research center had 4 successful blood pressure measurements 
available.
Carotid-femoral pulse wave velocity, the reference method to assess aortic stiffness12, 
was assessed using the automatic Complior device (Complior; Artech Medical, Pantin, 
France) with participants in supine position. The distance between the recording sites 
at the carotid (proximal) and femoral (distal) artery was measured over the surface of 
the body to the nearest centimetre. Through piezoelectric sensors placed on the skin, 
the device collected signals to assess the time delay between the pressure upstrokes 
in the carotid artery and the femoral artery. Carotid-femoral pulse wave velocity was 
calculated as the ratio of the distance travelled by the pulse wave and the time delay 
between the feet of the carotid and femoral pressure waveforms, as expressed in meters 
per second15. To cover a complete respiratory cycle, the mean of at least 10 consecutive 
pressure waveforms was used in the analyses.
Two-dimensional M-mode echocardiographic measurements were performed using 
the ATL-Philips Model HDI 5000 (Seattle, WA, USA) or the Logiq E9 (GE Medical Systems, 
Wauwatosa, WI, USA) devices. The children were examined in a quiet room with the child 
awake in supine position. Missing echocardiograms were mainly due to restlessness of 
the child or unavailability of equipment or echocardiographer. Left ventricular mass (LV-
mass), aortic root diameter (AOD), left atrial diameter (LAD), and fractional shortening 
(FS), were measured using methods recommended by the American Society of Echocar-
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diography16. LVmass was computed using the formula derived by Devereux et al17: To 
assess reproducibility of ultrasound measurements, the intraobserver and interobserver 
intraclass correlation coefficient were calculated in 30 subjects and varied between 0.85 
and 0.99 for the main outcome measures18. 
Covariates
Information on maternal age, parity, educational level, pre-pregnancy body mass index 
(BMI) and maternal and paternal ethnicity was obtained from questionnaires19. Maternal 
and paternal blood pressure at intake was measured with the validated Omron 907 
automated digital oscillometric sphygmanometer (OMRON Healthcare B.V. Hoofddop, 
the Netherlands)20. Child sex, gestational age at birth and birth weight were obtained 
from midwife and hospital registries. Breastfeeding (yes/no) was assessed using ques-
tionnaires. Current height and weight were measured without shoes and heavy clothing 
at the visit at 6 years, and BMI (kg/m2) was calculated.
Statistical methods
We assessed differences in baseline characteristics between the categories of maternal 
smoking during pregnancy using independent samples t-tests and Chi Square tests. We 
used mixed models to assess the associations of maternal smoking during pregnancy 
with childhood blood pressure21. The mixed-model method fits each of the 4 blood 
pressure measurements of every child as repeated outcome measures. Next, we used 
multiple linear regression models to assess the associations of maternal smoking with 
carotid-femoral pulse wave velocity and left cardiac structures. We also investigated the 
associations of the quantity of maternal cigarettes smoked with cardiovascular outcomes 
using similar models. Tests for trend were performed using multiple linear regression 
models in which the categories of the number of cigarettes smoked were included as 
a continuous variable, using the non-smoking mothers as reference group. All models 
were adjusted for maternal age, parity, educational level, ethnicity, pre-pregnancy 
BMI and blood pressure at intake, and child sex, gestational age at birth, birth weight, 
breastfeeding status, current age and BMI. Analyses on left cardiac structure and func-
tion were additionally adjusted for the ultrasonographer and the ultrasound equipment 
used. Missing values in covariates (ranging from 0 to 30%), were multiple-imputed, to 
reduce potential bias associated with missing data22. We created five imputed datasets 
and each dataset was analyzed separately to obtain the effect sizes and standard errors. 
The results of all 5 imputed analyses were pooled and are presented in this paper. We 
used similar models to assess the associations of paternal smoking during pregnancy 
on childhood cardiovascular outcomes among mothers who did not smoke during 
pregnancy. In these analyses we adjusted for paternal ethnicity and blood pressure at 
intake. Measures of association are presented with their 95% confidence intervals (CI). 
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All P values are 2-sided. The mixed-models were fitted using the Statistical Analysis 
System version 9.2 (SAS, Institute Inc., Gary, NC, USA). All other statistical analyses were 
performed using the Statistical Package of Social Sciences version 17.0 for Windows 
(SPSS Inc, Chicago, IL, USA).
Results
Subject characteristics
Subject characteristics are presented in the online supplement (Table 1). The percent-
age of boys was 50.0%. Children of mothers who continued smoking during pregnancy 
had a lower birth weight, as compared to children of mothers who did not smoke.
Table 1. Subject Characteristics (n=5,565)
Smoking during pregnancy
Non smoking  
(n=4159, 74.7%)
Stopped smoking
(n=494, 8.9%)
Continued smoking
(n=912, 16.4%)
Maternal characteristics
Age (y) 31.4 (21.9 , 38.6) 30.7 (20.8 , 38.5) † 29.6 (19.4 , 37.7) †
Height (cm) 167.7 (7.4) 168.7 (7.0) † 167.0 (7.1) †
Weight before pregnancy (kg) 64.0 (50.0 , 90.0) 64.0 (51.0 , 90.0) 64.0 (50.0 , 95.0)
Pre-pregnancy body mass index 
(kg/m2)
22.7 (18.7 , 32.1) 22.2 (18.6 , 30.5) 22.7 (18.5 , 32.7)
Systolic blood pressure (mmHg) 115.6 (12.3) 116 (11.9) 115.8 (11.9)
Diastolic blood pressure (mmHg) 68.5 (9.5) 67.6 (9.3) 67.1 (9.6) †
Education
Primary
Secondary
Higher
8.2
40.2
51.6
7.3
46.5 *
46.2
15.4 †
61.6 †
23.0 †
Ethnicity
Dutch or European
Non-European
63.8 
36.2
67.2 *
32.8 *
57.4 †
42.6 †
Paternal characteristics
Age (y) 33.6 (24.7 , 43.5) 32.5 (23.2 , 43.1) † 32.0 (21.6 , 41.2) †
Height (cm) 182.3 (7.8) 182.9 (8.1) 180.4 (8.1) †
Weight (kg) 83.0 (65.0 , 107.0) 83.0 (64.0 , 108.0) 82.0 (62.0 , 106.0)
Body mass index (kg/m2) 24.9 (20.4 , 31.1) 24.7 (19.9 , 31.3) 25.2 (20.1 , 31.8)
Systolic blood pressure (mmHg) 130.3 (13.5) 130.1 (14.2) 130.2 (13.6)
Diastolic blood pressure (mmHg) 73.7 (10.5) 72.7 (10.3) 72.8 (11.1)
Smoking, yes (%) 35.6 65.3 † 77.3 †
Birth characteristics
Males (%) 49.2 45.1 55.2 †
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We did not observe differences in systolic and diastolic blood pressure between children 
from mothers who did not smoke or smoked in first trimester only (Table 2). Continued 
maternal smoking during pregnancy was not associated childhood systolic blood pres-
sure (difference 0.13 mmHg (95%CI: -0.43, 0.69)), but we observed a positive trend for the 
association with diastolic blood pressure (difference 0.47 mmHg (95%CI: -0.01, 0.96). We 
observed a dose-dependent association of the number of cigarettes smoked during the 
third trimester with childhood diastolic blood pressure (P value for trend <0.01), but not 
with systolic blood pressure. Compared to mothers who did not smoke, mothers who 
smoked 10 or more cigarettes per day had children with a higher diastolic blood pres-
sure (difference 1.43 mmHg (95%CI: 0.22, 2.63)). Maternal smoking during pregnancy 
was not associated with childhood carotid-femoral pulse wave velocity. Among children 
of mothers who did not smoke during pregnancy, paternal smoking was not associated 
with childhood blood pressure or carotid-femoral pulse wave velocity. Adjustment for 
the various confounders attenuated the effect sizes of the associations. The difference 
between the non-adjusted and adjusted models was mainly explained by including 
maternal educational level and childhood body mass index in the models. We did not 
observe an interaction of parental smoking with childhood BMI (P>0.05). 
Table 1. Subject Characteristics (n=5,565) (continued)
Smoking during pregnancy
Non smoking  
(n=4159, 74.7%)
Stopped smoking
(n=494, 8.9%)
Continued smoking
(n=912, 16.4%)
Gestational age (wk) 40.1 (37.0 , 42.0) 40.1 (37.0 , 42.0) 40.0 (36.4 , 42.1) †
Birth Weight (g) 3460 (543) 3451 (549) 3285 (554) †
Preterm birth (%) 4.5 4.3 6.4
Child characteristics
Age (y) 6.0 (5.7 , 7.2) 6.0 (5.7 , 7.4) 6.1 (5.7 , 7.8) †
Height (cm) 119.4 (5.9) 119.7 (6.2) 119.6 (6.4)
Weight (kg) 22.4 (18.2 , 30.9) 22.4 (18.2 , 31.7) 23.0 (18.2 , 34.2) †
Body mass index (kg/m2) 15.8 (13.9 , 19.5) 15.8 (13.8 , 19.6) 16.1 (14.1 , 21.1) †
Mean systolic blood pressure 
(mmHg)
102.6 (8.2) 102.6 (8.7) 103.7 (8.7) †
Mean diastolic blood pressure 
(mmHg)
60.5 (6.8) 60.7 (7.2) 61.5 (7.1) †
Pulse wave velocity (m/s) 5.5 (0.9) 5.5 (1.0) 5.5 (0.8)
Left ventricular mass (grams) 53.2 (11.7) 53.4 (11.7) 54.5 (12.4) †
Aortic root diameter (mm) 19.3 (1.8) 19.2 (1.9) 19.4 (1.9)
Left atrial diameter (mm) 25.2 (2.8) 25.0 (2.8) 25.4 (2.8)
Fractional shortening (%) 35.3 (4.5) 35.6 (4.8) 35.7 (4.7) *
* P<0.05, †P<0.01. Values are means (sd) or medians (90% range).
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Parental smoking during pregnancy and childhood cardiac outcomes
We did not observe consistent associations of maternal first-trimester only or continued 
smoking during pregnancy with childhood left cardiac structures (Table 3). Continued 
maternal smoking during pregnancy of 10 or more cigarettes per day was associated 
with a higher childhood fractional shortening (difference: 1.01% (95%CI: 0.18, 1.84), 
as compared to children of mothers who did not smoke during pregnancy). The effect 
on fractional shortening increased with the number of cigarettes smoked during preg-
nancy (P value for trend: 0.01). Among children of mothers who did not smoke during 
pregnancy was, paternal smoking during pregnancy was associated with a larger aortic 
root diameter (difference 0.17 mm (95%CI: 0.05, 0.28)), but not associated with fractional 
shortening. Adjustment for the various confounders attenuated the effect sizes of the 
associations. 
Table 2. Parental Smoking during Pregnancy and Blood Pressure and Pulse Wave Velocity in 6 year old 
Children
Mean systolic blood 
pressure (mmHg) 
Mean diastolic 
blood pressure 
(mmHg) 
Pulse wave velocity 
(m/s) 
Maternal smoking during pregnancy
Non smoking during pregnancy (n=4,070) Reference Reference Reference
Stopped when pregnancy was known 
(n=481)
-0.27 (-0.98 , 0.44) -0.09 (-0.51 , 0.70) -0.05 (-0.14 , 0.05)
Continued smoking during pregnancy 
(n=896)
0.13 (-0.43 , 0.69) 0.47 (-0.01 , 0.96) -0.02 (-0.09 , 0.06)
< 5 cigarettes per day (n=354) 0.01 (-0.82 , 0.85) 0.13 (-0.58 , 0.85) -0.08 (-0.20 , 0.04)
5-9 cigarettes per day (n=217) -0.50 (-1.56 , 0.57) 0.80 (-0.11 , 1.72) 0.11 (-0.04 , 0.26)
≥10 cigarettes per day (n=129) 0.93 (-0.48 , 2.33) 1.43 (0.22 , 2.63) * 0.06 (-0.14 , 0.26)
P-value for trend 0.712 0.008 0.525
Paternal smoking 
No (n=2,369) Reference Reference Reference
Yes (n=1,298) -0.18 (-0.69 , 0.33) 0.12 (-0.39 , 0.52) 0.03 (-0.05 , 0.10)
< 5 cigarettes per day (n=570) -0.39 (-1.07 , 0.30) -0.08 (-0.73 , 0.57) 0.00 (-0.09 , 0.10)
5-9 cigarettes per day (n=260) 0.20 (-0.76 , 1.16) 0.69 (-0.13 , 1.51) 0.05 (-0.09 , 0.19)
≥10 cigarettes per day (n=441) -0.15 (-0.91 , 0.61) 0.01 (-0.57 , 0.60) -0.01 (-0.11 , 0.10)
P-value for trend 0.741 0.702 0.788 
* P<0.05, ** P<0.01. All analyses were adjusted maternal age, parity, educational level, ethnicity, pre-pregnancy body 
mass index and blood pressure at intake, child sex, gestational age at birth, birth weight, breastfeeding status, current 
age and body mass index. Values are regression coefficients (95% CI) and reflect the difference in blood pressure (mmHg) 
or pulse wave velocity (m/s) at the age of 6 years for different categories of maternal smoking during pregnancy. Children 
of non smoking mothers were used as reference group. The associations of paternal smoking and blood pressure were 
assessed among children of mothers who did not smoke during pregnancy.
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Discussion
The results of this population-based cohort study suggest that continued maternal 
smoking during pregnancy is associated with higher diastolic blood pressure and frac-
tional shortening, but not with left cardiac structures and pulse wave velocity in child-
hood. Paternal smoking was associated with a larger childhood aortic root diameter.
Strengths and limitations
The main strength of our study is the prospective data collection from early fetal life 
onwards and the size of the population-based cohort. Our analyses were based on 
Table 3. Associations of Parental Smoking during Pregnancy with Cardiac Structures and Function in 6 
year old Children 
Left ventricular 
mass (grams) 
Aortic root (mm) Left atrial 
diameter (mm) 
Fractional 
shortening (%)
Maternal smoking during 
pregnancy
Non smoking during pregnancy 
(n=3986)
Reference Reference Reference Reference
Stopped when pregnancy was 
known (n=475)
0.09 (-0.86 , 1.04) -0.10 (-0.25 , 
0.05)
-0.18 (-0.42 , 
0.06)
0.18 (-0.23 , 
0.60)
Continued smoking during 
pregnancy (n=881)
0.40 (-0.33 , 1.14) -0.05 (0.17 , 0.07) -0.07 (-0.25 , 
0.12)
0.26 (-0.06 , 
0.58)
< 5 cigarettes per day (n=351) 0.51 (-0.63 , 1.64) -0.07 (-0.25 , 
0.11)
-0.04 (-0.33 , 
0.24)
0.17 (-0.32 , 
0.67)
5-9 cigarettes per day (n=214) 0.98 (-0.48 , 2.43) 0.00 (-0.23 , 0.23) -0.20 (-0.56 , 
0.17)
0.38 (-0.29 , 
1.01)
≥10 cigarettes per day (n=126) 0.13 (-1.80 , 2.07) -0.00 (-0.31 , 
0.31)
0.01 (-0.48 , 0.49) 1.01 (0.18 , 
1.84) *
P-value for trend 0.271 0.807 0.500 0.014
Paternal smoking 
No (n=2,337) Reference Reference Reference Reference
Yes (n=1,281) 0.20 (-0.49 , 0.89) 0.17 (0.05 , 
0.28) **
-0.07 (-0.24 , 
0.10)
0.07 (-0.22 , 
0.37)
< 5 cigarettes per day (n=550) 0.42 (-0.51 , 1.35) 0.18 (0.03 , 
0.33) * 
0.02 (-0.21 , 0.25) 0.06 (-0.34 , 
0.46)
5-9 cigarettes per day (n=250) -0.62 (-1.93 , 
0.70)
0.03 (-0.18 , 0.24) -0.14 (-0.47 , 
0.18)
0.18 (-0.38 , 
0.75)
≥10 cigarettes per day (n=442) 0.21 (-0.81 , 1.24) 0.19 (0.03 , 
0.35) * 
-0.22 (-0.47 , 
0.03)
-0.10 (-0.54 , 
0.35)
P-value for trend 0.823 0.015 0.098 0.991
*P<0.05, **P<0.01. All analyses were adjusted maternal age, parity, educational level, ethnicity, pre-pregnancy body mass 
index and blood pressure at intake, child sex, gestational age at birth, birth weight, breastfeeding status, current age 
and body mass index, ultrasonographer and ultrasound device. Values are regression coefficients (95% CI) and reflect 
the difference in left cardiac structures and function at the age of six years for different categories of maternal smoking 
during pregnancy. Children of non smoking mothers were used as reference group. The associations of paternal smoking 
and left cardiac structures and function were assessed among children of mothers who did not smoke during pregnancy.
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more than 5,500 children with cardiovascular outcome measurements. The detailed 
information on maternal and paternal smoking during pregnancy enabled us to assess 
both trimester specific and dose-response relationships. Blood pressure was measured 
multiple times with one-minute intervals minimizing measurement error. We used well-
described and validated measurements to assess arterial stiffness and cardiac structures 
and function. Also, we had information about a large number of potential confounders. 
We also need to address some limitations. Information about smoking during preg-
nancy was missing for 15.6% of all mothers. This non-response would lead to biased 
effect estimates if associations of maternal smoking during pregnancy with cardiovas-
cular outcomes would be different between those mothers included and not included 
in the analyses. This seems unlikely. Biased estimates in large cohort studies mainly arise 
from loss to follow-up rather than from a non-response at baseline23. Of all children 
with available data on maternal smoking during pregnancy, 70.5 % participated in the 
follow-up measurements at the age of six years; 10.0% was lost to follow-up and 3.1% 
did not provide consent for further follow-up from the age of 6 years onwards. The rest 
of the mothers and children (16.5%) did provide consent for further follow-up, but did 
not visit the research center. Overall, mothers who did not visit the research center for 
follow-up measurements did more frequently smoke during pregnancy and were less 
educated than the total sample. This selective loss to follow-up possibly might have led 
to biased effect estimates. Some studies measured cotinine in maternal urine samples to 
limit misclassification bias24-25, but this method does not seem to be superior to the use 
of self-reported smoke exposure, due to low correlations between cotinine levels and 
smoking behaviour reported by questionnaire26-27. Finally, although we have performed 
adjustment for various potential confounders, residual confounding might still be an 
issue due to the observational design of the study. We used paternal smoking as a model 
to explore the role of residual confounding due to unmeasured environmental or family 
factors.
Parental smoking during pregnancy and childhood cardiovascular outcomes
Several studies have shown an association of maternal smoking during pregnancy with 
higher blood pressure in children, but results are inconsistent7-9, 28. Only some of these 
studies assessed a dose-response relationship of maternal smoking with childhood 
blood pressure, which could explain the non-consistent findings. A recently published 
study in a cohort born in the 1960’s, showed that the effect of maternal smoking on 
childhood blood pressure at the age of 7 years was stronger in children from heavy 
smoking mothers (>20 cigarettes/day) than in those from mothers who smoked less 
intensively28. This is in line with our findings showing the stronger association with 
childhood blood pressure in mothers who smoked 10 or more cigarettes per day during 
pregnancy.
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It is not clear whether the association of maternal smoking with childhood blood pres-
sure is explained by direct intra-uterine mechanisms or is due to other, unmeasured, 
confounders. We used two approaches to explore the role of confounding. First we 
applied adjustment for multiple potential confounders and second, we assessed the as-
sociation of both maternal and paternal smoking during pregnancy with cardiovascular 
outcomes. Adjustment for potential confounders did not fully explain the associations. 
A recent study by Wen et al. suggested that the association of maternal smoking dur-
ing pregnancy with childhood blood pressure was mediated by increased postnatal 
growth28. In our study, adjustment of the associations of maternal smoking with child-
hood blood pressure for childhood BMI only slightly attenuated the effect sizes. We also 
did not observe interactions between maternal smoking and childhood BMI. Also, our 
results were independent of the effect of maternal smoking during pregnancy on fetal 
growth. Our findings of larger effect sizes for the associations for maternal smoking 
than for paternal smoking would indicate that childhood blood pressure is influenced 
directly by intra-uterine tobacco exposure. However, we should be careful with con-
cluding intrauterine causal mechanisms since the effect estimates were small, and of 
borderline significance. Brion et al. showed similar effect sizes for maternal and paternal 
smoking during pregnancy on childhood blood pressure, suggesting that the associa-
tion of maternal smoking with childhood blood pressure is explained by unmeasured 
confounders9. 
Several studies have shown an effect of maternal smoking during pregnancy on other 
specific measures of vascular function. We have previously shown that maternal smok-
ing during pregnancy is associated with increased fetal-placental arterial resistance in 
third trimester of pregnancy10. A study by Geerts et al. among 259 mothers and children 
suggested that maternal smoking during pregnancy was associated with a thicker 
carotid artery intima media and a lower arterial distensibility at the age of 5 years29. 
We did not find an association of maternal smoking during pregnancy with childhood 
carotid-femoral pulse wave velocity. Both carotid-femoral pulse wave velocity and 
arterial distensibility are markers of arterial stiffness and a risk factor for cardiovascu-
lar disease12. The difference in results might be explained by different measurements 
techniques and localizations. Further studies focused on local and general pulse wave 
velocity measurements are needed. 
Lampl et al. examined in 34 fetuses, the association of maternal smoking with  repeat-
edly measured fetal cardiac volume and showed that cardiac growth was diminished 
in fetuses of mothers who smoked during pregnancy30. In the current study, we did 
not find associations of smoking status of the mother with left ventricular mass and 
aortic root and left atrial diameter. Surprisingly, paternal smoking during pregnancy 
was associated with a larger aortic root diameter. We cannot explain these finding by 
biological plausible underlying mechanisms. This association might be explained by 
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residual confounding or by a chance finding. We did find a dose-dependent association 
of maternal smoking during pregnancy with childhood fractional shortening. We cannot 
explain this finding, but it might be due to a higher after load due to a higher blood pres-
sure. Paternal smoking during pregnancy was not associated with fractional shortening. 
Further research is needed to assess if these changes in fractional shortening persist in 
later life and have effects on cardiac development.
The biological mechanisms underlying the associations of fetal smoke exposure with 
childhood cardiovascular outcomes are not known. Various smoking related substances 
might be involved. Nicotine is an important teratogen and induces vasoconstriction 
which leads to reduced placental blood flow and lower oxygen levels in the fetus31. Fetal 
vasoconstriction and impaired blood flow may lead to suboptimal hemodynamic stimu-
lus for placental and fetal vascular development32-33. In time, these changes in develop-
ment might result in a higher blood pressure and other cardiovascular changes in later 
life. Other toxins from maternal smoking, such as carbon monoxide and cadmium might 
also lead to reduced placental and fetal perfusion and cardiovascular responses34-35. Car-
bon monoxide is rapidly absorbed in the blood where it binds to hemoglobin and forms 
carboxyhaemoglobin which results in fetal hypoxia and animal studies have shown a 
negative effect on cardiac maturation34. Cadmium is known to accumulate in the pla-
centa is suggested to inhibit the activity of 11-B-hydroxysteroid dehydrogenase type 
2. Reduced activity of this enzyme might lead to fetal growth restriction and vascular 
adaptations35. Further research is needed to assess possible mechanisms underlying the 
associations between maternal smoking during pregnancy and cardiovascular function 
in later life.
Conclusions
In conclusion, we found that maternal smoking during pregnancy might increase child-
hood diastolic blood pressure and fractional shortening. The stronger effect estimates 
for maternal smoking compared to paternal smoking might suggest that direct intra-
uterine adaptive responses are involved as underlying mechanisms. This study adds to 
the increasing body of evidence that maternal smoking during pregnancy has adverse 
effects on childhood and adult cardiovascular health. Maternal smoking during preg-
nancy is potentially modifiable and presents a possible opportunity for prevention of 
cardiovascular disease in later life. Further research is needed to assess the fetal effects 
of smoking on postnatal cardiovascular development and to establish whether reduc-
tion of maternal smoking during pregnancy also leads to a better cardiovascular health 
in during the life course.
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Abstract
Background: Maternal psychological distress during pregnancy might lead to higher 
fetal cortisol exposure, which subsequently leads to fetal cardiovascular developmental 
adaptations and cardiovascular dysfunction in later life. We examined whether maternal 
and paternal psychological distress were associated with the cardiovascular outcome 
measurements in school age children.
Methods: In a population-based prospective cohort study among 4,831 children, we 
assessed maternal and paternal psychological distress during pregnancy by question-
naire, using the Brief Symptom Inventory. At the child age of six years, we performed 
blood pressure and carotid- femoral pulse wave velocity measurements, and M-mode 
measurements of left cardiac structures and fractional shortening.
Results: We did not observe associations of high maternal and paternal psychological 
symptom scores with childhood blood pressure and carotid-femoral pulse wave velocity 
after adjustment for potential confounders. Maternal overall psychological symptoms 
were associated with a lower childhood left ventricular mass (difference -1.10 grams 
(95% confidence interval -2.13 to -0.07) between mothers with high scores and normal 
scores), but not with other cardiac structures and fractional shortening. Paternal overall 
psychological symptoms showed a similar association with childhood left ventricular 
mass (difference -1.34 grams (95% confidence interval -3.69 to 1.02) between fathers 
with high scores and normal scores). 
Conclusion: Our results do not support the hypothesis that maternal psychological 
distress affects cardiovascular development in early life. Similar associations of maternal 
and paternal psychological distress with left ventricular mass suggest that these as-
sociations could be due to unmeasured social and environmental factors, rather than 
direct intra-uterine effects. 
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Introduction
Adverse fetal exposures may lead to permanent developmental adaptations in the 
structure and function of the cardiovascular system and other organ systems1. These 
adaptations may be beneficial on short-term, but increase the susceptibility of car-
diovascular disease and metabolic diseases in later life1. This hypothesis is largely 
based on studies showing associations of low birth weight with high blood pressure, 
cardiovascular disease and its risk factors2-4. Maternal psychological distress during 
pregnancy might be one of the adverse fetal exposures leading to fetal developmental 
adaptations5, possibly by dysregulation of the maternal hypothalamic-pituitary-adrenal 
(HPA) axis6, and higher fetal cortisol exposure6. Previous animal and human studies have 
shown that excessive exposure to exogenous glucocorticoids is associated with higher 
blood pressure in the offspring7-8. Mild endogenous elevations in cortisol levels, e.g. due 
to maternal psychological distress during pregnancy, might also lead to developmental 
adaptations9 and affect cardiovascular function in the offspring, but the number of stud-
ies is limited10. Any association of maternal pscyhological distress with childhoodblood 
pressure could be explained by direct intra-uterine mechanisms of high fetal cortisol 
levels, or by other environmental factors. Similar effect sizes for maternal and paternal 
psychological distress on childhood outcomes would indicate that associations are due 
to unmeasured shared social and envrionmental factors11.
Therefore, we assessed in a large population-based prospective cohort study among 
4,831 children, the associations of maternal and paternal psychological distress with 
blood pressure, carotid-femoral pulse wave velocity and left cardiac structures and 
function in children at the age of six years.
Methods
Study design and population
The study was embedded in the Generation R Study, a population-based, prospective 
cohort study from fetal life onwards in Rotterdam, the Netherlands12.  Enrolment in the 
study was aimed at early pregnancy, but was possible until birth of the child. Informa-
tion about maternal psychological distress during pregnancy was collected in the 
second trimester of pregnancy. Between March 2008 and January 2012, all participating 
children and their mothers were invited to a dedicated research center, to participate 
in detailed follow-up measurements at the median age of 6 years (95% range 5.6 to 7.4 
years). The study has been approved by the Medical Ethics Committee of the Erasmus 
Medical Center, Rotterdam. Written informed consent was obtained from all parents of 
participants.
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In total, 8,880 mothers were enrolled in the study during pregnancy, of whom 6,809 
(75.5%) provided information about psychological symptoms during pregnancy. For 
the present study, only singleton life births were included (n=6,708), of whom 4,872 
(72.5%) children attended the follow-up visit between January 2009 and January 2012. 
Children with clinical or echocardiographic evidence of congenital heart disease or kid-
ney abnormalities were excluded from the study (n=22). Blood pressure, carotid-femoral 
pulse wave velocity or cardiac ultrasound measurements were successfully performed 
in 4,831 children (see Figure 1).
Figure 1. Flowchart
 
 
 
Childhood cardiovascular measurements 
available 
N=4,831 
 
 
Singleton life births with maternal 
psychological distress data available 
N= 6,708 
Data on maternal psychological distress 
available 
N = 6,809 
Mothers enrolled during pregnancy 
N=8,880 
N=2,071 excluded due to missing 
data on parental distress assessed 
during pregnancy 
Excluded N=73 due twin births, N=12 
due to fetal death and N=16 loss to 
follow-up 
Excluded N=16 due to clinical or 
congenital heart disease, N=6 due to 
kidney abnormalities, and N=19 due 
to missing data on all outcome 
measurements 
Participation in visit at the age of six years 
N= 4,872 
Excluded N=183 due to withdrawal 
of consent, N=622 due to loss to 
follow-up and N=1,031 did not visit 
research center 
Flowchart of the study population: the Generation R Study Cohort, Rotterdam, the Netherlands.
149
Parental distress and cardiovascular development
3.3
Parental psychological distress
Information on maternal and paternal psychological distress was obtained by postal 
questionnaires that were returned at around 20 weeks of gestation using the Brief 
Symptom Inventory and the subscale General Functioning of the Family Assessment 
Device13. Mother and father each completed the questionnaires. The Brief Symptom 
Inventory is a validated self-report questionnaire with 53 items13. These items define 
a broad spectrum of psychological symptoms in the preceding 7 days. A global index 
(Global Severity Index) and 3 symptom scales (Depression, Anxiety, and Hostility) 
were defined13. The Global Severity Index is a measure of current level or depth of the 
symptoms, and denotes overall psychological symptoms. Each item was rated on 
five-point uni-dimensional scales ranging from ‘0’ (not at all) to ‘4’ (extremely). A score 
is provided for each symptom scale by summing the item scores of each scale and 
dividing the results by the number of endorsed symptoms. This resulted in a range of 
scores from 0 to 4. Higher scores on these scales represented an increased occurrence 
of overall psychological symptoms, symptoms of depression, anxiety, or hostility. Ac-
cording to previous studies, mothers were categorized as being sensitive for ‘clinically’ 
significant psychological symptoms (yes/no) when having a score above 0.71 on the 
overall psychological symptoms scale, above 0.80 on the depression scale, and above 
0.71 on the anxiety scale14. Fathers were categorized as being sensitive for ‘clinically’ 
significant psychological symptoms (yes/no) when having a score above 0.66 on the 
overall psychological symptoms scale, above 0.71 on the depression scale, and above 
0.65 on the anxiety scale14. In the current study, internal consistencies (Cronbach’s alpha) 
for the different scales of the mother and the father ranged from 0.72 to 0.95 and from 
0.61 to 0.93 respectively. Family stress was assessed by the subscale General Functioning 
of the Family Assessment Device. General Functioning is a validated overall self-report 
measure of health and pathology of a family and consists of a 12 items measure15. Half 
of the items describe health functioning, e.g. ‘In times of crisis, we can turn to each other 
for support’. The other half describes unhealthy items, e.g. ‘There are a lot of unpleasant 
and painful feelings in our family’. Both the mother and the father were asked to rate 
how well each item described their family by selecting from four different responses: 
strongly agree, agree, disagree, or strongly disagree. The item scores were summed 
and divided by 12, yielding a total score from 1 to 4. A general functioning score >2.17 
(cut-off) denotes high family stress15. The internal consistency of maternal and paternal 
general functioning was α=0.89 and α=0.85 respectively.
Childhood cardiovascular measurements 
All cardiovascular measurements in childhood were performed in a dedicated research 
center in the Erasmus Medical Center, Rotterdam, the Netherlands. The child was lying 
quietly, while systolic and diastolic blood pressure was measured at the right brachial 
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artery in supine position, four times with one minute intervals, using the validated au-
tomatic sphygmanometer Datascope Accutor Plus TM (Paramus, NJ, USA)16. A cuff was se-
lected with a cuff width approximately 40% of the arm circumference and long enough 
to cover 90% of the arm circumference. More than 90% of the children who visited the 
research center had four successful blood pressure measurements available.
Carotid-femoral pulse wave velocity, the reference method to assess aortic stiffness17, 
was assessed using the automatic Complior device (Complior; Artech Medical, Pantin, 
France) with participants in supine position. The distance between the recording sites 
at the carotid (proximal) and femoral (distal) artery was measured over the surface of 
the body to the nearest centimeter. Through piezoelectric sensors placed on the skin, 
the device collected signals to assess the time delay between the pressure upstrokes 
in the carotid artery and the femoral artery. Carotid-femoral pulse wave velocity was 
calculated as the ratio of the distance travelled by the pulse wave and the time delay 
between the feet of the carotid and femoral pressure waveforms, as expressed in meters 
per second18. To cover a complete respiratory cycle, the mean of at least 10 consecutive 
pressure waveforms was used in the analyses. Recently, it has been shown that a similar 
measure, carotid-radial pulse wave velocity, can be measured reliably measured with 
good reproducibility in a large pediatric population based cohort19.
Two-dimensional M-mode echocardiographic measurements were performed using 
the ATL-Philips Model HDI 5000 (Seattle, WA, USA) or the Logiq E9 (GE Medical Systems, 
Wauwatosa, WI, USA) devices. The majority (77%) of all echocardiographic measure-
ments were measured by three sonographers, and were supervised by a paediatric 
cardiologist (L.v.O.-G.). The children were examined in a quiet room with the child awake 
in supine position. Missing echocardiograms were mainly due to restlessness of the 
child or unavailability of equipment or sonographer. Left atrial diameter (LAD), inter-
ventricular end-diastolic septal thickness (IVSTD), left ventricular end-diastolic diameter 
(LVEDD), left ventricular end-diastolic posterior wall thickness (LVPWTD), interventricu-
lar end-systolic septal thickness (IVSS), left ventricular end-systolic diameter (LVESD), 
left ventricular end-systolic posterior wall thickness (LVPWTS), aortic root diameter 
(AOD) and fractional shortening (FS) as a quantification of global left ventricular systolic 
function, were measured using methods recommended by the American Society of 
Echocardiography20. Left ventricular mass (LV mass) was computed using the formula 
derived by Devereux et al21: 
LV mass = 0.80 × 1.04((IVSTD + LVEDD + LVPWTD)3 − (LVEDD)3)+ 0.6. To assess repro-
ducibility of ultrasound measurements, the intraobserver and interobserver intraclass 
correlation coefficient were calculated in 30 subjects and varied between 0.85 and 0.99 
for the main outcome measures22. 
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Covariates
Information on maternal age, parity, educational level, smoking habits during preg-
nancy, ethnicity, pre-pregnancy body mass index (BMI) and paternal ethnicity was 
obtained from questionnaires. Maternal education was defined as highest followed 
education according to the classification of Statistics Netherlands and categorized in 
primary, secondary and higher23. Maternal and paternal blood pressure at intake were 
measured with the validated Omron 907 automated digital oscillometric sphygmanom-
eter (OMRON Healthcare B.V. Hoofddop, the Netherlands)24. Date of birth, child sex, 
gestational age at birth and birth weight were obtained from midwife and hospital 
registries. Breastfeeding (yes/no) was assessed using questionnaires. Current height and 
weight were measured without shoes and heavy clothing at the visit at six years, and 
BMI (kg/m2) was calculated.
Statistics
We used mixed models to assess associations maternal psychological distress scales 
(dichotomized based on the clinical cut-offs and as continuous) during pregnancy and 
blood pressure25. The mixed-model method fits each of the as many as four blood pres-
sure measurements of every child as repeated outcome measures. One of the advantages 
of this approach, compared to using the average measure for each child as an outcome, 
is that subjects with the maximum number of blood pressure measurements available 
and the least individual variability in their blood pressure measurements are assigned 
the highest weight in the analysis26-27. We used multiple linear regression models to 
assess the association of maternal psychological distress scales (dichotomized based 
on the clinical cut-offs and as continuous) and carotid-femoral pulse wave velocity and 
left cardiac structures. All analyses were adjusted for maternal age, parity, educational 
level, ethnicity and pre-pregnancy BMI, and child sex, gestational at birth, birth weight, 
breastfeeding and age and BMI at the six year visit. Analyses on left cardiac structure were 
additionally adjusted for the performing sonographer and ultrasound device. We used 
similar models to assess the associations of paternal psychological distress scales with 
cardiovascular outcomes, adjusted for paternal ethnicity and blood pressure instead of 
the corresponding maternal variables. Missing values in covariates (ranging from 0 to 
37%), were multiple-imputed, to reduce potential bias associated with missing data28. 
We created five imputed datasets and each dataset was analyzed separately to obtain 
the effect sizes and standard errors. The results of all five imputed analyses were pooled 
and are presented in this paper. Measures of association are presented with their 95% 
confidence intervals (CI). The mixed-models were fitted using the Statistical Analysis 
System version 9.2 (SAS, Institute Inc., Gary, NC, USA). All other statistical analyses were 
performed using the Statistical Package of Social Sciences version 17.0 for Windows 
(SPSS Inc, Chicago, IL, USA).
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Results
Subject characteristics
Subject characteristics are presented in Table 1. The percentage of boys was 49.7%. The 
mean birth weight was 3441 grams (SD: 546 grams). Mean systolic blood pressure and 
diastolic blood pressure in six year old children was 102.6 mmHg (SD: 8.2 mmHg) and 
60.7 mmHg (SD: 6.9 mmHg) respectively.
Parental distress and childhood vascular outcomes
Using dichotomized symptom scales, high maternal overall psychological symptoms 
were associated with a higher childhood systolic and diastolic blood pressure in unad-
justed models (differences 0.86 mmHg (95% CI 0.11 to 1.62) and 0.72 mmHg (95% CI 0.08 
to 1.36) respectively (Table 2)). High family stress reported by the mother was positively 
associated with a higher childhood diastolic blood pressure (difference 0.75 mmHg (95% 
CI 0.20 to 1.31), but not with childhood systolic blood pressure. After adjustment for vari-
ous potential confounders, these associations attenuated towards the null and did not 
remain significant. High scores on maternal depression, anxiety or hostility symptoms 
were not associated with childhood systolic or diastolic blood pressure. We investigated 
paternal psychological distress in mothers who scored lower than the clinical cut-off 
for the respective symptom scales. High paternal overall psychological symptoms were 
associated with a higher childhood diastolic blood pressure in the unadjusted analyses, 
but these effects did not remain significant after adjustment. Neither maternal nor 
paternal psychological distress scores were associated with childhood carotid-femoral 
pulse wave velocity. 
Parental distress and childhood cardiac outcomes
Using dichotomized symptom scales, high maternal overall psychological symptom 
scores were associated with a lower childhood left ventricular mass (Table 3). After 
adjustment, the association attenuated but remained statistically significant (difference 
-1.10 grams (95% CI -2.13 to -0.07)). High scores on maternal depression and anxiety 
symptoms, but not hostility symptoms, tended to be associated with a lower childhood 
left ventricular mass (difference -0.73 grams (95% CI -1.77 to 0.30) and -0.97 (95% CI -1.94 
to -0.01) respectively) in the adjusted models. Also, high maternal hostility symptoms 
were associated with a smaller childhood left atrial diameter (difference -0.27 (95% 
CI -0.46 to -0.08)). In adjusted models, high paternal overall psychological symptoms, 
depressions symptoms and anxiety symptom scores, showed similar effect sizes with 
cardiac outcomes as compared to maternal psychological symptom scores, although 
these associations were not statistically significant. High paternal hostility symptoms 
were associated with a lower childhood left ventricular mass (difference -1.66 (95% CI 
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Table 1. Subject characteristics 
Maternal characteristics (N=4,831)
Age (y) 31.2 (21.5 – 38.2)
Height (cm) 168.0 (7.3)
Weight before pregnancy (kg) 64.0 (51.0 – 90.0)
Pre-pregnancy body mass index (kg/m2) 22.7 (18.7 – 32.0)
Systolic blood pressure (mmHg) 115.8 (12.1)
Diastolic blood pressure (mmHg) 68.2 (9.5)
Smoking during pregnancy, yes (%) 25.4 
Breastfeeding, yes (%) 92.5
Parity, multipara (%) 41.0
Education
Primary
Secondary
Higher
7.9
43.3
48.8
Ethnicity
European
Non-European
65.4
34.6
Paternal characteristics
Age (y) 33.1 (23.8 – 42.8)
Height (cm) 182 (8.0)
Weight (kg) 83.0 (65.0 – 107.0)
Body mass index (kg/m2) 22.6 (18.7 – 32.0)
Systolic blood pressure (mmHg) 130.4 (13.4)
Diastolic blood pressure (mmHg) 73.5 (10.5)
Smoking, yes (%) 45.5
Ethnicity
Dutch or European
Non-European
61.4
38.6
Birth characteristics
Males (%) 49.7
Gestational age (wk) 40.2 (37.1 – 42.1)
Birth Weight (g) 3441 (546)
Preterm birth (%) 4.6
Child characteristics
Age (y) 6.0 (5.7 – 7.2)
Height (cm) 119.5 (6.1)
Weight (kg) 23.3 (18.2 – 31.2)
Body mass index (kg/m2) 15.9 (13.9 – 19.7)
Mean systolic blood pressure (mmHg) 102.6 (8.2)
Mean diastolic blood pressure (mmHg) 60.7 (6.9)
Pulse wave velocity (m/s) 5.5 (1.0)
Left ventricular mass (g) 53.6 (11.8)
Aortic root diameter (mm) 19.3 (1.8)
Left atrial diameter (mm) 25.2 (2.7)
Fractional shortening (%) 35.3 (4.5)
Values are means (SD), medians (90% range), or percentage
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-3.18 to -0.13)). In the adjusted models, maternal and paternal psychological distress 
was not associated with childhood aortic root diameter and fractional shortening. 
Discussion
Results of this population-based cohort study suggest that maternal and paternal psy-
chological distress during pregnancy are not associated with childhood blood pressure 
and carotid-femoral pulse wave velocity. Both higher maternal and paternal psychologi-
cal distress were associated with lower childhood left ventricular mass. 
Strength and limitations
The main strength of our study is the prospective data collection from fetal life on-
wards and the size of the population-based cohort. Our analyses were based on more 
than 4,500 children with cardiovascular outcome measurements. As far as we know, 
this is the largest study, investigating the associations between parental distress and 
cardiovascular outcomes in childhood. The assessment of maternal as well as paternal 
distress, allowed us to explore whether the associations are likely due to an intra-uterine 
effects of maternal psychological distress or rather due to shared environmental fac-
tors between the mother and the father. Blood pressure was measured multiple times 
with one-minute intervals minimizing measurement error. We used well-described and 
validated measurements to assess arterial stiffness and cardiac structures and function. 
Also, we had information about a large number of potential confounders. However, some 
limitations need to be addressed. We measured maternal psychological distress at one 
time-point during pregnancy. Unfortunately, we do not have information on persistence 
and intensity of psychological symptoms throughout the pregnancy. Some studies 
have suggested that the timing of psychological distress during pregnancy might be 
important for fetal programming effects29. Information about maternal psychological 
distress was missing for 24.5% of all mothers. This non-response at baseline would lead 
to biased effect estimates if the associations of maternal psychological distress during 
pregnancy with cardiovascular outcomes would be different in mothers who were not 
included in these analyses, compared to the mothers who are included in this study. This 
seems unlikely. Furthermore, it has been described that biased estimates in large cohort 
studies mainly arise from loss to follow-up rather than non-response at baseline30. Of all 
children with available data on maternal psychological distress, 72.5% participated in 
the follow-up measurements around the age of six years; 9.3% was loss to follow-up and 
2.7% did not provide consent for further follow-up from the age of six years onwards. 
The remainder of the mothers and children without measurements available did pro-
vide consent for further follow-up but were not able to visit the research center. Overall, 
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mothers from children who did not visit the research center, had higher psychological 
distress scores, smoked more frequently and were less well educated than the total 
sample. This selective loss to follow-up might have led to biased effect estimates and 
a loss of statistical power. Assessing parental psychological distress by questionnaire 
might lead to misclassification bias, due to underreporting of psychological distress. 
In general, this misclassification most likely would lead to an underestimation of the 
effect of parental psychological distress on cardiovascular outcomes. Finally, although 
we have performed adjustment for various potential confounders, residual confounding 
might still be an issue due to the observational design of the study.
Parental distress and childhood vascular outcomes
Several studies in both animals and humans have shown that fetal exposure to high lev-
els of cortisol, e.g. due to administration of therapeutic drugs, is associated with a higher 
blood pressure in later life7-8. We hypothesized that maternal psychological distress 
would lead to an increased fetal exposure to cortisol, which could lead to a higher blood 
pressure or increased carotid-femoral pulse wave velocity. Studies of normal variation 
in endogenous cortisol levels and the effect on blood pressure in later life have been 
scarce. A small study by Rondo et al. among 130 mothers and children aged five to seven 
years, investigated the association of maternal cortisol levels in third trimester of preg-
nancy with childhood blood pressure. Although this study did not provide exact effect 
estimates, the authors mention in the discussion that maternal cortisol levels were not 
associated with childhood blood pressure10. In our study, we did not find associations of 
maternal or paternal psychological distress scales with childhood blood pressure after 
adjustment for potential confounders in the largest sample so far. Our findings suggest 
that social and environmental factors might explain the previously suggested associa-
tion. However, we have to acknowledge that maternal stress assessment was different 
in timing and instrument between the studies, which might explain the inconsistent 
results. It might also be that the maternal psychological distress does not lead to a suf-
ficient rise in fetal cortisol levels in our population. Furthermore, effects might not be 
present at this age, but might become apparent in later life. The mechanism underlying 
the association of overexposure to cortisol with a higher blood pressure in the offspring 
remains unclear, but several mechanisms have been implicated. In animal studies, 
prenatal exposure to cortisol has been associated with micro vascular dysfunction and 
affected functioning of the renin-angiotensin system and the HPA-axis in the offspring, 
with possible subsequent effects on blood pressure in later life31-32. The study by Rondo 
et al. did suggest that maternal cortisol concentrations were positively associated with 
systemic vascular resistance, as measured by analyzing the shape of arterial pressure 
wave produced by the heart beat10. In our study, we did not find any association of 
maternal psychological distress scales with carotid-femoral pulse wave velocity around 
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the same age. Further research is needed to assess the effect of maternal psychological 
distress and cortisol levels on different measures of childhood vascular function, and to 
assess whether differences arise in later life.
Parental distress and childhood cardiac outcomes
Not much is known on the effect of maternal psychological distress on cardiac de-
velopment. There have been several animal studies investigating the effect of fetal 
cortisol exposure on the developing heart33-34. In sheep fetuses it is shown that cortisol 
stimulates cell cycle activity of cardiomyocytes33. Furthermore, neonatal exposure to 
glucocorticoids has been associated with a lower heart weight in rats at the age of 4 
weeks and at older age, with depressed systolic function with compensatory dilatation 
to maintain normal cardiac output34. In line with this study, we have found that maternal 
psychological distress is associated with a lower left ventricular mass. However, we 
observed that paternal psychological distress showed similar associations, suggesting 
these associations are not due to direct intrauterine mechanisms. In contrast, Chen 
et al. found in a retrospective study among 116 children, that children, whose moth-
ers received repeated courses of antenatal corticosteroids, did not have different left 
ventricular mass and fractional shortening compared to age, sex and ethnicity matched 
control children who did not receive antenatal corticosteroids35. We also did not find 
consistent associations with other cardiac structures and fractional shortening. Residual 
confounding might be an issue; e.g. we did not take into account physical activity of the 
children. High parental psychological distress is associated with lower physical activity 
in children, which in turn is associated with a lower left ventricular mass36-37. This could 
explain (part) of the association of parental distress and left ventricular mass found in 
this study. Further research is needed to confirm these findings, identify exact underly-
ing mechanisms and to assess whether these changes persist in later life. 
Conclusions
Our study suggests that maternal psychological distress during pregnancy is not associ-
ated with childhood blood pressure and carotid-femoral pulse wave velocity. We have 
found evidence that maternal psychological distress is associated with left ventricular 
mass. However, similar effect sizes were found for paternal distress, indicating that these 
associations might be due to other shared environmental factors. Further research is 
needed to investigate the exact underlying mechanisms and the long-term effects of 
parental psychological distress on cardiovascular development.
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Abstract
Background: Suboptimal maternal dietary intake during pregnancy might lead to fetal 
cardiovascular adaptations and higher blood pressure in the offspring. The aim of this 
study was to investigate the associations of maternal first trimester dietary intake with 
blood pressure in children at the age of six years. 
Methods: We assessed first trimester maternal daily dietary intake by a food frequency 
questionnaire and measured folate, homocysteine and vitamin B12 concentrations in 
blood, in a population-based prospective cohort study among 2,863 mothers and chil-
dren. Childhood systolic and diastolic blood pressure was measured using a validated 
automatic sphygmomanometer. 
Results: Higher maternal iron intake tended to be associated with a lower childhood 
systolic blood pressure (-0.30 mmHg per standard deviation increase in iron intake (95% 
CI: -0.61 to 0.01)). Also, higher maternal vitamin B12 concentrations were associated with 
a higher diastolic blood pressure (0.31 mmHg per standard deviation increase in vitamin 
B12 (95% CI: 0.06 to 0.56)). After taking into account multiple testing, none of the as-
sociations were statistically significant. Maternal first trimester folate and homocysteine 
concentrations were not associated with childhood blood pressure.
Conclusion: Results from this study suggest that maternal iron intake and vitamin B12 
concentrations during first trimester of pregnancy might affect childhood blood pres-
sure, although the effect estimates were small and were not significant after correction 
for multiple testing. Further studies are needed to replicate these findings, to elucidate 
the underlying mechanisms and to assess whether these differences in blood pressure 
persist in later life.
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Introduction
Suboptimal maternal and fetal nutrition might lead to fetal cardiovascular develop-
mental adaptations and subsequent cardiovascular disease in later life1-3. Support for 
this hypothesis is largely based on experimental animal studies and historical cohort 
studies in humans showing associations of maternal exposure to extreme famine during 
pregnancy with development of hypertension in later life4-6. A disbalance in nutrient 
intake during pregnancy might also be an explanation for the development of hyper-
tension4. Not much is known about the associations of less extreme variations in mater-
nal dietary intake with cardiovascular disease in the offspring. Several studies focused 
on the associations of maternal micro- or macronutrient intake with childhood blood 
pressure but the results are inconclusive7-17. Two previous studies suggested that higher 
maternal fat intake during pregnancy was associated with diastolic blood pressure in 
the offspring, although the studies observed opposite effects7-8. Also, maternal intake of 
micronutrients during pregnancy, such as calcium, sodium and iron has been suggested 
to be associated with blood pressure in children, but results were not consistent9-11, 13-15. 
Other micronutrients, including folate, homocysteine and vitamin B12, might affect vas-
cular development18. High homocysteine and low folate and levels are associated with 
endothelial dysfunction19-20 and might subsequently lead to higher blood pressure in 
later life. Since vitamin B12 lower homocysteine levels, this might also influences blood 
pressure. 
We assessed in a large population-based prospective cohort study among 2,863 Dutch 
mothers and their children, the associations of maternal daily total energy intake, intake 
of macronutrients and micronutrients in first trimester of pregnancy with blood pressure 
at the age of six years. We also assessed whether first trimester folate, homocysteine and 
vitamine B12 concentrations in maternal blood were associated with childhood blood 
pressure.
Methods
Design 
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from fetal life onwards in Rotterdam, The Netherlands21-22. Enrolment in 
the study was aimed at early pregnancy, but was allowed until the birth of the child. 
Information about maternal diet and other life style related variables during pregnancy 
were collected at enrolment. At the age of six years, all participating children and their 
mothers were invited to a dedicated research center, to participate in detailed hands 
on measurements. The study has been approved by the Medical Ethics Committee of 
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the Erasmus Medical Center, Rotterdam. Written informed consent was obtained from 
all parents of participants. The present analysis was limited to Dutch mothers, since the 
food frequency questionnaire was validated for assessment of dietary intake in a Dutch 
population. We selected mothers who were enrolled in the study before a gestational 
age of 25 weeks, because we aimed to assess dietary intakes in the first trimester of 
pregnancy. In total 4,032 Dutch mothers were enrolled before a gestational age of 25 
weeks with a median of 13.6 weeks of gestation (90% range 11.5-20.2 weeks) (see Figure 
1). Data on maternal dietary intake or biomarker concentrations were available in 3,960 
(=98%) of these mothers. We excluded multiple births (n=104) and stillbirths (n=27) from 
the analyses, leaving 3,827 Dutch mothers. Of the 3,827 singleton life born children, 
2,949 (77%) children attended the follow-up visit at the age of six years. Blood pressure 
was successfully measured in 2,863 (97%) of the children who visited the research center.
Maternal daily dietary intake 
We assessed maternal dietary intake at enrolment in the study in Dutch mothers using 
a modified version of the validated semi quantitative food frequency questionnaire 
(FFQ) of Klipstein-Grobusch et al.23. The FFQ considered food intake over the prior 
three months, thereby covering the dietary intake in first trimester of pregnancy. The 
FFQ consisted of 293 items structured according to meal pattern. Questions included 
consumption frequency, portion size, preparation method, and additions. Portion sizes 
were estimated using Dutch household measures and photographs of foods showing 
different portion sizes24. We used the Dutch food composition table for calculating daily 
intake of nutritional values25. 
Folic acid supplement intake
Information on folic acid supplement use (0.4-0.5 mg) and the initiation of supplementa-
tion was obtained by questionnaires at enrolment of the study. We categorized folic acid 
supplement use into three groups: 1) periconceptional use, 2) start when pregnancy 
was known or 3) no use during pregnancy. Self-reported folic acid use was validated in 
a subgroup by serum folate levels in the first trimester, i.e. before 12 weeks of gestation. 
Within the group of mothers who reported using folic acid supplements (n=204), the 
median of serum folate was 23.5 (range 4.3-45.3) nmol/l, whereas the median serum 
folate concentrations of mothers who did not report folic acid supplement use (n=68) 
was 11.1(range 4.7-29.6) nmol/l. The difference in distribution function (Mann-Whitney 
test) was statistically significant (P<0.001)26. Information about folic acid supplement 
use was available in 2,505 subjects (87.5%).
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Folate, homocysteine and vitamine B12 concentrations
In early pregnancy (median 12.9 weeks of gestation, 90% range 10.6-16.8) venous 
samples were drawn and stored at room temperature before being transported to 
the regional laboratory for processing and storage for future studies. Processing was 
aimed to be completed within a maximum of three hours after venous puncture. The 
samples were centrifuged and thereafter stored at -80°C21. To analyze folate, homocys-
teine and vitamin B12 concentrations, EDTA plasma samples (folate, homocysteine) 
and serum samples (vitamin B12) were picked and transported to the Department of 
Clinical Chemistry at the Erasmus University Medical Center, Rotterdam in 2008. Folate, 
homocysteine and vitamin B12 concentrations were analyzed using an immunoelectro-
chemoluminence assay on the Architect System (Abbott Diagnostics B.V., Hoofddorp, 
the Netherlands). The between-run coefficients of variation for plasma folate were 8.9% 
at 5.6 nmol/L, 2.5% at 16.6 nmol/L, and 1.5% at 33.6 nmol/L, with an analytic range of 
1.8-45.3 nmol/L. The same coefficients of variation for plasma homocysteine were 3.1% 
at 7.2 μmol/L, 3.1% at 12.9 μmol/L, and 2.1% at 26.1 μmol/L, with an analytic range of 
1-50 μmol/L. This coefficient of variation for serum vitamin B12 was 3.6% at 142 pmol/L, 
7.5% at 308 pmol/L, and 3.1% at 633 pmol/L, with an analytic range of 44-1476 pmol/L. 
Plasma concentrations of maternal folate, homocysteine and serum concentrations of 
vitamin B12 in first trimester of pregnancy were available in 2,305 (80.5%) of the mothers 
of the children included in this study. Missing data were mainly due to logistical reasons. 
Blood pressure measurements
Blood pressure measurements in children were conducted around the age of six years 
in a dedicated research center in the Erasmus Medical Center, Rotterdam, the Neth-
erlands. The child was lying quietly, while systolic blood pressure and diastolic blood 
pressure were measured at the right brachial artery in supine position, four times with 
one minute intervals. A cuff was selected with a cuff width approximately 40% of the 
arm circumference and long enough to cover 90% of the arm circumference. We used 
the validated automatic sphygmomanometer Datascope Accutorr Plus™ (Paramus, NJ, 
USA)27. Of all children visiting the research center, 91.3% had four successful blood pres-
sure measurements available. 
Covariates
Information on maternal age, pre-pregnancy body mass index (BMI), parity, alcohol use 
and smoking habits during pregnancy and educational level was obtained from ques-
tionnaires. Maternal education was defined as highest followed education according to 
the classification of Statistics Netherlands and categorized in primary, secondary and 
higher28. Child sex, gestational age at birth and birth weight were obtained from midwife 
and hospital registries. Breastfeeding (ever/never) was assessed using questionnaires. 
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Current height and weight were measured without shoes and heavy clothing at the visit 
at six years, and BMI (kg/m2) was calculated.
Statistical methods
Differences in child characteristics at the age of six years between boys and girls were 
assessed using t-test and χ2-tests for independent samples. Maternal dietary intake 
variables were categorized into quintiles. This approach was used for all dietary expo-
sures (total energy, carbohydrate, fat, protein intake and the protein-carbohydrate ratio; 
calcium, iron and sodium intake; folate, homocysteine and vitamin B12 concentrations). 
We used mixed models to assess associations between predictors and blood pressure29. 
The mixed-model method fits each of the as many as 4 blood pressure measurements 
of every child as repeated outcome measures. An advantage of this modelling approach 
over using the average measure of blood pressure for each child as an outcome is that 
children with more measurements and less variability in their measurements are as-
signed more weight than those with fewer measurements, more variability, or both9, 
30. We used similar mixed-models to assess the association of folic acid supplement 
use with blood pressure at the age of six years. All analyses were adjusted for child’s 
sex, gestational age at intake and age at blood pressure measurement (crude model). 
Potential covariates were selected based on previous literature31-32. We assessed crude 
associations, adjusted for age and gender, of possible covariates with childhood blood 
pressure. Only the covariates which were significantly associated with systolic or diastolic 
blood pressure in our study population were included in our fully adjusted model. The 
fully adjusted model included maternal age, pre-pregnancy body mass index, alcohol 
use and smoking during pregnancy, educational level, gestational age at birth, birth 
weight, current body mass index and month in which blood pressure measurement was 
taken. Tests for trends were conducted by using the maternal dietary intake variables 
as continuous variable in the linear mixed-models. We provided the effect per standard 
deviation increase in the dietary intake variable. In the macronutrient analyses, we used 
the energy partition method to adjust for energy intake of the other macronutrients, 
since total energy intake and macronutrient intakes were strongly correlated33. The 
actual energy derived from the macronutrients was used in the analyses. In the micro-
nutrient analyses, we used the residual nutrient method, and additionally adjusted for 
total energy intake33. 
Missing values in covariates (ranging from 0 to 15%) were multiple-imputed to reduce 
potential bias associated with missing data34. We created five imputed datasets and 
each dataset was analyzed separately to obtain the effect sizes and standard errors. The 
results of all five imputed analyses were pooled and are presented in this paper. In this 
study we investigated maternal macronutrient intake, micronutrient intake and mater-
nal biomarker concentrations in pregnancy. Within these exposure groups, variables are 
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correlated. To take into account multiple testing, we applied a Bonferroni correction and 
considered a P-value lower than 0.017 (0.05/3 (three exposure groups)) as statistically 
significant.
The mixed-models were fitted using the Statistical Analysis System version 9.2 (SAS, 
Institute Inc., Gary, NC, USA). All other statistical analyses were performed using the Sta-
tistical Package of Social Sciences version 17.0 for Windows (SPSS Inc, Chicago, IL, USA).
Results
Table 1 presents the maternal and birth subject characteristics. The mean intake of total 
energy was 8,982.8 (SD: 2,117.3) kj/day, of calcium 1,222 (SD: 420) milligrams/day, of 
iron 12.1 (SD 3.3) milligrams/day and of sodium 3,314 (SD: 931) milligrams/day. The 
mean birth weight was 3,497 (SD: 548) grams. Child characteristics at the age of six years 
for boys and girls separately are shown in table 2. Systolic blood pressure and diastolic 
blood pressure were significantly higher in girls compared to boys (p<0.05). 
Table 1. Maternal and birth characteristics: the Generation R Study Cohort, Rotterdam, Netherlands
Not imputed Imputed
Maternal characteristics
Age 31.8 (22.2-39.6)
Height (cm) 170.8 (6.4)
Weight (kg) 68.1 (12.3) 68.1 (12.2)
Body mass index (kg/m2) 22.3 (18.2-34.3) 22.4 (18.2-34.5)
Parity  ≥1 (%)                                                                                38.4 38.4
Alcohol use (%)
 No 31.8 31.9
 First trimester only 16.7 16.5
 Continued 51.5 51.6
Smoking during pregnancy (%)
 Never 75.1 75.6
 First trimester only 9.6 9.6
 Continued 15.3 14.8
Educational level (%)
 Primary 2.5 2.5
 Secondary 36.6 36.6
 Higher 60.9 60.9
Energy intake (kj/day) 8,982.8 (2,117.3)
Carbohydrate intake (grams/day) 262.2 (74.1)
% of total energy intake 48.3 (37.2-61.3)
Fat intake (grams/day) 86.5 (24.0)
% of total energy intake 36.4 (25.3-46.4)
Protein intake (grams/day) 79.7 (18.9)
% of total energy intake 14.9 (10.7-19.9)
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Maternal total daily energy intake and daily intake of carbohydrates, fat and proteins 
were not associated with childhood systolic and diastolic blood pressure (Table 3). 
The protein-carbohydrate intake ratio was not associated with childhood blood pres-
sure (Table 3). After adjustment for confounders, maternal intake of iron tended to be 
inversely associated with childhood systolic blood pressure (-0.30 mmHg per standard 
deviation increase in iron intake (95%CI: -0.61 to 0.01),  p-value for trend 0.06), but not 
with diastolic blood pressure (Table 4). Maternal intake of calcium and sodium was not 
consequently associated with childhood systolic or diastolic blood pressure. 
We did not find an association of folic acid supplement use during pregnancy with 
childhood systolic or diastolic blood pressure (Table 5). The associations of maternal first 
trimester folate, homocysteine and vitamin B12 concentrations with childhood blood 
Table 1. Maternal and birth characteristics: the Generation R Study Cohort, Rotterdam, Netherlands 
(continued)
Not imputed Imputed
Calcium intake (milligrams/day) 1,222.3 (419.9)
Iron intake (milligrams/day) 12.1 (3.3)
Sodium intake (milligrams/day) 3,314.3 (931.3)
Folic acid use (%)
 No 9.6
 Started when pregnancy  was known 33.7
 Started periconceptional 56.7
Folate levels (nmol/l) 20.2 (8.7)
Homocystein levels (umol/l) 7.3 (2.1)
Vitamin B12 levels (pmol/l) 193.2 (87.4)
Birth characteristics
Birth weight (grams) 3,498 (548)
Gestational age at birth (weeks) 40.3 (35.9-42.3)
Sex (males %) 49.8
Breastfeeding (never) 8.7 9.2
Values are means (Standard deviation), medians (95% range) or percentages. Only
covariates with missing data were multiple-imputed.
Table 2. Child characteristics: the Generation R Study Cohort, Rotterdam, Netherlands
Boys (n= 1,427) Girls (n=1,436)
Age (years) 6.0 (5.6-7.5) 6.0 (5.6-7.1)
Height (cm) 119.9 (5.7) 119.1 (5.6)
Weight (kg) 23.0 (3.5) 22.7 (3.7)
Underweight (%) 6.4 4.0
Normal weight (%) 84.6 82.6
Overweight (%) 9.0 13.3
Body mass index (kg/m2) 15.7 (13.7-18.9) 15.6 (13.7-19.8)
Systolic blood pressure (mmHg) 102.2 (7.3) 103.3 (8.2)*
Diastolic blood pressure (mmHg) 60.2 (6.4) 61.6 (6.5)*
Values are means (standard deviation), medians (95% range) or percentages. 
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Table 3. Associations of maternal macronutrients intake during pregnancy with blood pressure at the age 
of six years in a Dutch population
Systolic blood pressure 
(mmHg)
Diastolic blood pressure 
(mmHg)
Crude model Adjusted model Crude model Adjusted model
Macronutrients  (n=2,554)
Total calorie intake (Kjoule)
First quintile Reference Reference Reference Reference
Second quintile 0.07 (-0.87 to 1.01) 0.09 (-0.83 to 1.00) 0.53 (-0.25 to 1.31) 0.55 (-0.23 to 1.32)
Third quintile  -0.15 (-1.08 to 0.79) 0.04 (-0.87 to 0.96) 0.11 (-0.67 to 0.89) 0.19 (-0.58 to 0.96)
Fourth quintile -0.44 (-1.38 to 0.50) -0.17 (-1.09 to 0.75) -0.20 (-0.99 to 0.58) -0.10 (-0.88 to 0.68)
Fifth quintile -0.14 (-1.08 to 0.80) -0.03 (-0.95 to 0.90) 0.30 (-0.48 to 1.09) 0.33 (-0.45 to 1.11)
Trend # -0.04 (-0.34 to 0.26) 0.02 (-0.27 to 0.31) 0.06 (-0.19 to 0.31) 0.07 (-0.17 to 0.32)
Carbohydrate intake (Kjoule)
First quintile Reference Reference Reference Reference
Second quintile -0.00 (-0.94 to 0.94) 0.20 (-0.75 to 1.14) 0.49 (-0.29 to 1.27) 0.52 (-0.28 to 1.31)
Third quintile  0.41 (-0.53 to 1.35) 0.61 (-0.38 to 1.60) 0.39 (-0.39 to 1.17) 0.33 (-0.50 to 1.16)
Fourth quintile -0.14 (-1.08 to 0.80) 0.06 (-0.99 to 1.11) -0.10 (-0.88 to 0.68) -0.20 (-1.09 to 0.68)
Fifth quintile 0.18 (-0.75 to 1.12) 0.37 (-0.76 to 1.50) 0.65 (-0.13 to 1.44) 0.47 (-0.48 to 1.42)
Trend # 0.07 (-0.23 to 0.36) 0.11 (-0.26 to 0.49) 0.15 (-0.10 to 0.40) 0.10 (-0.21 to 0.41)
Fat intake (Kjoule)
First quintile Reference Reference Reference Reference
Second quintile 0.09 (-0.85 to 1.02) 0.19 (-0.76 to 1.14) 0.47 (-0.31 to 1.25) 0.36 (-0.44 to 1.16)
Third quintile  -0.44 (-1.38 to 0.50) -0.24 (-1.27 to 0.79) 0.19 (-0.59 to 0.98) 0.06 (-0.81 to 0.93)
Fourth quintile -0.55 (-1.50 to 0.39) -0.27 (-1.37 to 0.82) -0.44 (-1.23 to 0.34) -0.68 (-1.61 to 0.25)
Fifth quintile -0.18 (-1.12 to 0.75) 0.19 (-1.05 to 1.43) 0.18 (-0.61 to 0.96) -0.10 (-1.15 to 0.94)
Trend # -0.12 (-0.42 to 0.17) 0.02 (-0.41 to 0.44) -0.07 (-0.32 to 0.18) -0.21 (-0.57 to 0.14)
Protein intake (Kjoule)
First quintile Reference Reference Reference Reference
Second quintile -0.75 (-1.68 to 0.19) -0.62 (-1.58 to 0.34) -0.19 (-0.97 to 0.59) -0.04 (-0.85 to 0.77)
Third quintile  -0.87 (-1.81 to 0.07) -0.68 (-1.71 to 0.36) -0.58 (-1.36 to 0.20) -0.32 (-1.19 to 0.55)
Fourth quintile -0.60 (-1.54 to 0.34) -0.34 (-1.48 to 0.80) -0.30 (-1.08 to 0.49) 0.06 (-0.91 to 1.02)
Fifth quintile -0.56 (-1.50 to 0.38) -0.45 (-1.76 to 0.84) -0.02 (-0.81 to 0.76) 0.35 (-0.75 to 1.44)
Trend # -0.15 (-0.43 to 0.17) -0.12 (-0.57 to 0.33) 0.04 (-0.21 to 0.28) 0.21 (-0.17 to 0.59)
Protein-Carbohydrate ratio
First quintile Reference Reference Reference Reference
Second quintile -1.11 (-2.05 to -0.17)* -0.90 (-1.82 to 0.02) -0.63 (-1.42 to 0.14) -0.38 (-1.16 to 0.40)
Third quintile  -0.88 (-1.81 to 0.05) -0.54 (-1.47 to 0.39) -0.80 (-1.58 to -0.02)* -0.47 (-1.25 to 0.31)
Fourth quintile -0.87 (-1.81 to 0.06) -0.50 (-1.43 to 0.43) -0.64 (1.42 to 0.14) -0.22 (-1.01 to 0.57)
Fifth quintile -0.99 (-1.93 to -0.06)* -0.65 (-1.58 to 0.29) -0.61 (-1.39 to 0.17) -0.21 (-1.00 to 0.58)
Trend # -0.21 (-0.51 to 0.08) -0.11 (-0.41 to 0.19) -0.16 (-0.41 to 0.09) -0.05 (-0.30 to 0.20)
Values are regression coefficients (95% CI) and reflect the difference in blood pressure (mmHg) at the age of six years for 
each quintile of macronutrient intake (kj derived from macronutrients). The crude model is adjusted for child sex and age 
at blood pressure measurement. The adjusted model is additionally adjusted for maternal age, pre-pregnancy body mass 
index, alcohol use and smoking during pregnancy, educational level, gestational age at birth, birth weight, current body 
mass index and month in which blood pressure measurement was taken and additionally adjusted for the energy from 
the other macronutrients following the energy partition method (1).
#Tests for trends were conducted by using the maternal dietary intake variables as continuous variable in the linear 
mixed-models. Values are regression coefficients (95% CI) and reflect the difference in blood pressure (mmHg) per 
standard deviation increase in macronutrient intake. 
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Table 4. Associations of maternal micronutrients intake during pregnancy with blood pressure at the age 
of six years in a Dutch population
Systolic blood pressure 
(mmHg)
Diastolic blood pressure 
(mmHg)
Crude model Adjusted model Crude model Adjusted model
Micronutrients  (n=2,554)
Calcium
First quintile Reference Reference Reference Reference
Second quintile 0.44 (-0.50 to 1.37) 0.47 (-0.45 to 1.40) 0.80 (0.02 to 1.58)* 0.90 (0.13 to 1.68)*
Third quintile  0.10 (-0.83 to 1.04) 0.25 (-0.68 to 1.18) 0.29 (-0.49 to 1.07) 0.52 (-0.26 to 1.30)
Fourth quintile -0.25 (-1.18 to 0.69) -0.05 (-0.98 to 0.87) -0.34 (-1.12 to 0.44) -0.10 (-0.88 to 0.68)
Fifth quintile 0.32 (-0.62 to 1.26) 0.38 (-0.54 to 1.31) 0.75 (-0.04 to 1.53) 0.92 (0.14 to 1.71)*
Trend # 0.09 (-0.21 to 0.38) 0.10 (-0.20 to 0.39) 0.15 (-0.10 to 0.40) 0.20 (-0.04 to 0.45)
Iron
First quintile Reference Reference Reference Reference
Second quintile -0.05 (-0.99 to 0.88) 0.31 (-0.63 to 1.25) 0.32 (-0.47 to 1.10) 0.63 (-0.16 to 1.43)
Third quintile  -0.57 (-1.51 to 0.37) -0.06 (-1.02 to 0.90) 0.18 (-0.60 to 0.96) 0.70 (-0.11 to 1.51)
Fourth quintile -0.94 (-1.87 to -0.00)* -0.34 (-1.31 to 0.62) -0.22 (-1.00 to 0.56) 0.32 (-0.49 to 1.13)
Fifth quintile -1.38 (-2.32 to 
-0.44)**
-0.76 (-1.73 to 0.21) -0.71 (-1.50 to 0.07) -0.14 (-0.96 to 0.68)
Trend # -0.48 (-0.78 to 
-0.18)**
-0.30 (-0.61 to 0.01) -0.23 (-0.47 to 0.02) -0.06 (-0.32 to 0.20)
Sodium
First quintile Reference Reference Reference Reference
Second quintile -0.71 (-1.65 to 0.23) -0.57 (-1.50 to 0.35) -0.41 (-1.19 to 0.38) -0.34 (-1.12 to 0.44)
Third quintile  -0.98 (-1.92 to -0.04)* -0.90 (-1.82 to 0.02) -0.49 (-1.27 to 0.30) -0.44 (-1.22 to 0.33)
Fourth quintile -0.17 (-1.10 to 0.77) -0.24 (-1.16 to 0.68) -0.11 (-0.89 to 0.67) -0.12 (-0.89 to 0.66)
Fifth quintile -0.08 (-1.02 to 0.85) -0.08 (-1.00 to 0.85) -0.30 (-1.08 to 0.48) -0.27 (-1.04 to 0.52)
Trend # 0.07 (-0.22 to 0.37) 0.06 (-0.24 to 0.35) -0.01 (-0.25 to 0.24) -0.00 (-0.25 to 0.24)
Values are regression coefficients (95% CI) and reflect the difference in blood pressure (mmHg) at the age of six years for 
each quintile of micronutrient intake. The crude model is adjusted for child sex and age at blood pressure measurement. 
The adjusted model is additionally adjusted for maternal age, pre-pregnancy body mass index, alcohol use and smoking 
during pregnancy, educational level, gestational age at birth, birth weight, current body mass index and month in which 
blood pressure measurement was taken.
Table 5. Associations of maternal folic acid supplement use during pregnancy with blood pressure at the 
age of six years in a Dutch population
Systolic blood pressure 
(mmHg)
Diastolic blood pressure 
(mmHg)
Crude model Adjusted model Crude model Adjusted model
Folic acid supplement use (n=2,379)
No (n=227) 0.64 (-0.34 to 1.61) 0.09 (-0.90 to 1.07) 0.46 (-0.35 to 1.27) -0.03 (-0.85 to 0.79)
Started when 
pregnancy was 
known (n=797)
0.04 (-0.59 to 0.66) -0.04 (-0.68 to 0.60) -0.40 (-0.92 to 0.12) -0.52 (-1.05 to 0.04)
Started 
periconceptional 
(n=1,355)
Reference Reference Reference Reference
*P<0.05
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pressure are presented in Table 6. We found no consistent associations of maternal first 
trimester folate and homocysteine concentrations with childhood systolic blood pres-
sure and diastolic blood pressure in six year old children. Lower maternal first trimester 
vitamin B12 concentrations were associated with lower childhood diastolic blood 
Table 6. Associations of maternal first trimester folate, homocysteine and vitamin B12 levels with blood 
pressure at the age of six years in a Dutch population
Systolic blood pressure 
(mmHg)
Diastolic blood pressure 
(mmHg)
Crude model Adjusted model Crude model Adjusted model
Maternal folate (n=2,266)
First quintile 0.68 (-0.26 to 1.63) 0.27 (-0.68 to 1.23) 0.46(-0.33 to 1.25) 0.14 (-0.65 to 0.94)
Second quintile 0.50 (-0.44 to 1.44) 0.41 (-0.52 to 1.35) 0.46 (-0.33 to 1.24) 0.41 (-0.38 to 1.18)
Third quintile  -0.36 (-1.29 to 0.57) -0.35 (-1.27 to 0.58) -0.22 (-1.00 to 0.56) -0.19 (-0.96 to 0.59)
Fourth quintile 0.46 (-0.47 to 1.39) 0.36 (-0.56 to 1.29) 0.60 (-0.18 to 1.38) 0.56 (-0.21 to 1.34)
Fifth quintile Reference Reference Reference Reference
Trend # 0.06 (-0.24 to 0.35) 0.11 (-0.18 to 0.40) -0.03 (-0.28 to 0.21) 0.03 (-0.21 to 0.27)
Maternal homocysteine (n=2,244)
First quintile Reference Reference Reference Reference
Second quintile 0.35 (-0.55 to 1.26) 0.23 (-0.66 to 1.12) -0.07 (-0.83 to 0.68) -0.16 (-0.90 to 0.59)
Third quintile  0.42 (-0.50 to 1.35) 0.22 (-0.69 to 1.13) -0.21 (-0.99 to 0.56) -0.33 (-1.09 to 0.43)
Fourth quintile 0.25 (-0.68 to 1.19) 0.08 (-0.83 to 0.99) -0.19 (-0.96 to 0.58) -0.28 (-1.04 to 0.48)
Fifth quintile 0.58 (-0.35 to 1.51) 0.08 (-0.84 to 1.00) -0. 23 (-1.01 to 0.54) -0.56 (-1.33 to 0.21)
Trend # -0.00 (-0.30 to 0.29) -0.00 (-0.29 to 0.28) -0.19 (-0.43 to 0.05) -0.18 (-0.42 to 0.06)
Maternal vitamin B12 (n=2,158)
First quintile -0.07 (-1.03 to 0.88) -0.50 (-1.46 to 0.45) -0.44 (-1.24 to 0.35) -0.75 (-1.54 to 0.05)
Second quintile -0.75 (-1.70 to 0.21) -0.96 (-1.91 to -0.02)* -0.70 (-1.50 to 0.09) -0.88 (-1.66 to -0.09)*
Third quintile  -0.42 (-1.37 to 0.54) -0.48 (-1.42 to 0.47) -0.38 (-1.18 to 0.41) -0.42 (-1.21 to 0.36)
Fourth quintile -0.11 (-1.06 to 0.85) -0.24 (-1.18 to 0.71) -0.15 (-0.95 to 0.64) -0.24 (-1.03 to 0.55)
Fifth quintile Reference Reference Reference Reference
Trend # 0.06 (-0.24 to 0.36) 0.18 (-0.11 to 0.48) 0.22 (-0.03 to 0.47) 0.31 (0.06 to 0.56)*
*P<0.05
Values are regression coefficients (95% CI) and reflect the difference in childhood blood pressure (mmHg) at the age of 
six years for each quintile of biomarker concentrations. The highest quintile in maternal folate and vitamin B12 levels and 
the lowest quintile in homocysteine levels were used as reference groups.
The crude model is adjusted for child sex and age at blood pressure measurement. The adjusted model is additionally 
adjusted for maternal age, pre-pregnancy body mass index, alcohol use and smoking during pregnancy, educational 
level, gestational age at birth, birth weight, current body mass index and month in which blood pressure measurement 
was taken.
#Tests for trends were conducted by using the maternal dietary intake variables as continuous variable in the linear 
mixed-models. Values are regression coefficients (95% CI) and reflect the difference in blood pressure (mmHg) per 
standard deviation increase in micronutrient intake. 
Values are regression coefficients (95% CI) and reflect the difference in blood pressure (mmHg) at the age of six years for 
each group of maternal folic acid supplement use. The crude model is adjusted for child sex and age at blood pressure 
measurement. The adjusted model is additionally adjusted for maternal age, pre-pregnancy body mass index, alcohol 
use and smoking during pregnancy, educational level, gestational age at birth, birth weight, current body mass index 
and month in which blood pressure measurement was taken
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pressure, but not systolic blood pressure (difference 0.31 mmHg per standard deviation 
increase in vitamin B12 concentration (95%CI: 0.06 to 0.56), p-value for trend 0.02), but 
not with systolic blood pressure. However, the associations between iron intake and vi-
tamin B12 concentrations with childhood blood pressure did not reach the significance 
threshold after adjustment for multiple testing.
Discussion
Results from this population-based prospective cohort study suggest that maternal 
daily macronutrient and micronutrient intake in first trimester of pregnancy is not as-
sociated with childhood blood pressure at the age of six years. We observed that  higher 
iron intake and vitamin B12 concentrations may be associated with a lower childhood 
systolic and higher diastolic blood pressure respectively, but we should also consider the 
effect of multiple testing. After multiple testing correction none of the results remained 
significant.
Strengths and limitations 
The main strength of our study is the prospective design from early life onwards and 
the large sample size of this population-based cohort. To our knowledge, this is one of 
the largest prospective studies that examined the associations between daily maternal 
intake of micronutrients and macronutrients in first trimester of pregnancy with child-
hood blood pressure. We used a food frequency questionnaire, previously validated in 
a Dutch population23, to assess dietary intake of the mothers. Although we have used a 
validated questionnaire, misclassification of dietary intake can still occur, which might 
have led to an underestimation of the effect estimates. We measured blood pressure 
in six year old children using a validated automatic sphygmanometer27 and acquired 
multiple blood pressure measurements to minimize measurement error. Furthermore, 
information about a large number of potential confounders was available. However, 
some limitations need to be addressed. Of all mothers included before a gestational 
age of 25 weeks, information on maternal dietary intake was missing for only 1.4% of 
all mothers. This non-response would lead to biased effect estimates if the associations 
of maternal dietary intake and childhood blood pressure would be different between 
mothers included and not included in the analyses. This seems unlikely because biased 
estimates in large cohort studies mainly arise from loss to follow-up rather than from a 
non-response at baseline35. Of all Dutch singleton life born children with available data 
on maternal dietary intake during first trimester of pregnancy, 74.3% participated in the 
follow-up measurements at the age of six years. Overall, mothers who did not visit the 
research center were younger, less well educated, smoked more frequently and used 
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less alcohol during pregnancy. This selective loss to follow-up might have led to biased 
effect estimates. We also have to acknowledge that our study population included in 
the analyses, is comprised of relatively healthy women with a higher proportion of 
folic acid suppelment use compared to other populations. This might have resulted 
in smaller observed differences and might limit generalizabilty to other populations. 
Also, maternal dietary intake was only assessed in first trimester of pregnancy, while 
dietary intake might change during pregnancy. Although it has been demonstrated that 
maternal nutritional intake did not change significantly during pregnancy36, second or 
third trimester maternal diet might be associated with cardiovascular development, and 
influence childhood blood pressure. Unfortunately, we were not able to assess these 
associations in the current study. Finally, although we have performed adjustment for 
various potential confounders, residual confounding might still be an issue due to the 
observational design of the study. 
Maternal macronutrient intake 
Low birth weight is associated with higher blood pressure and cardiovascular disease 
in later life37-38. It has been suggested that these associations might be explained by 
suboptimal maternal diet1-3. Historical cohort studies in the Netherlands and China 
showed that maternal exposure to famine is associated with a higher blood pressure 
in adult offspring4, 39. The effect of normal variation of maternal daily energy intake and 
macronutrient intake on childhood blood pressure has been examined in several stud-
ies, but showed inconsistent results7-8, 16. Consistent with previous studies, we did not 
observe associations of maternal total energy intake during pregnancy and childhood 
blood pressure8, 40. As suggested by Roseboom et al., it might be that an imbalance of 
maternal macronutrients, rather than total energy intake, is associated with childhood 
blood pressure4. Using the energy partition method33, we did not observe associations 
of maternal daily carbohydrate, fat or protein intake with childhood blood pressure. Two 
smaller studies from Finland and the Philippines previously showed conflicting results 
regarding the associations of maternal fat intake with childhood blood pressure7-8. Our 
results suggest there is no association of maternal fat intake with childhood blood pres-
sure. Also, a previous study showed that a higher maternal protein intake is associated 
with a lower blood pressure in boys, but these findings were not confirmed in other 
studies8, 40-41. The inconsistent results might be explained by differences in study popula-
tions. 
Maternal calcium, iron and sodium intake
Several studies, including follow-up studies of randomized clinical trials, have shown 
an association of calcium supplement use during pregnancy with lower blood pressure 
in children11, 14. However, maternal calcium intake from normal dietary intake was not 
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associated with infant and childhood blood pressure9, 14. In line with these studies, we 
did not find an association between maternal calcium intake in first trimester of preg-
nancy and offspring blood pressure. It should be noted that our population had a high 
dietary calcium intake. This could have affected our power to investigate the effects of 
low calcium intake on childhood blood pressure. Another explanation might be that 
mothers who used calcium supplements, also used other micronutrient supplements 
and the combined effect of these supplements might lead to a lower blood pressure in 
offspring14.
Animal studies have shown that maternal iron restriction during pregnancy was 
associated with a higher blood pressure in the offspring42-43. In human subjects, Brion 
et al. observed in a prospective cohort study among 7,484 subjects that maternal iron 
supplement use and iron intake from food sources, assessed in third trimester of preg-
nancy, were not associated with offspring blood pressure13. Belfort et al. showed in a 
prospective longitudinal cohort study among 1,098 American children an association 
of maternal iron supplement use with a higher systolic blood pressure in children10. 
However, maternal iron dietary intake from food sources, assessed in first and second 
trimester of pregnancy, was not associated with offspring blood pressure at both time 
points10. We observed an association of higher maternal iron intake from food with 
lower blood pressure, although the effect size was small and borderline significant. We 
assessed dietary intake in first trimester of pregnancy. It might be that part of the dif-
ferences in results between our and other studies can be explained by different timing 
of the exposure assessment. Animal studies have shown that offspring of iron restricted 
mothers have a higher blood pressure in later life, possibly mediated by cardiovascular 
adaptations in response to anaemia, which is in line with our findings42, 44. Previous 
studies in animals described the associations of maternal sodium intake with childhood 
blood pressure and suggested high sodium intake was associated with a higher blood 
pressure15, 45. In our study, maternal sodium intake was not associated with childhood 
blood pressure. However, sodium intake is poorly assessed by FFQ and, which could 
have led to an underestimation of the effect. Further experimental studies in animals 
and observational studies in humans are needed to assess the associations of maternal 
micronutrient intake with offspring blood pressure in later life, and investigate possible 
underlying mechanisms. 
Maternal folate, homocysteine and vitamin B12 concentrations
Low folate and high homocysteine concentrations during pregnancy have been as-
sociated with lower birth weight and pregnancy complications, such as spontaneous 
abortion and pre-eclampsia46-49. Low folate and vitamin B12 levels and high homocys-
teine levels might affect vascular development and subsequently lead to endothelial 
dysfunction and higher blood pressure18. One previous study described the associations 
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of supplement intake, including iron, folic acid and vitamin B12 during pregnancy with 
a lower systolic blood pressure in children at the age of two years50. However, since the 
supplement contained a combination of these nutrients they could not infer which 
nutrient contributed to the effect. 
 We did not observe associations of maternal folate and homocysteine levels during 
first trimester of pregnancy with childhood blood pressure in their offspring. Since 
higher vitamin B12 levels are associated with lower homocysteine levels, and lower 
homocysteine levels are associated with lower blood pressure in adults, we expected 
that higher maternal vitamin B12 concentrations in the blood would be associated with 
a lower childhood blood pressure. However, our results show an opposite effect; higher 
maternal vitamin B12 levels were associated with a higher childhood diastolic blood 
pressure, although the effect size was small and borderline significant. However, after 
correction for multiple testing, this association was not statistically significant. To the 
best of our knowledge, this association has not been described before and underlying 
mechanisms are not known.
Conclusions
Our study shows within a population-based cohort, that normal variation in maternal 
intake of macronutrients and micronutrients during first trimester of pregnancy is not 
associated with childhood blood pressure. We found some indications that high ma-
ternal iron intake and low maternal vitamin B12 levels seemed to be associated with 
a lower blood pressure in children at the age of six years. However, we investigated 
multiple exposures, the effect sizes are small and the associations were not significant 
after correction for multiple testing. Further studies are needed to replicate these find-
ings, to elucidate the underlying mechanisms and to assess whether these differences 
persist in later life.
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Abstract
Background: Hypertension is an important determinant of cardiovascular morbid-
ity and mortality and has a substantial heritability, which is likely of polygenic origin. 
The aim of this study was to assess to what extent multiple common genetic variants 
contribute to blood pressure regulation in both adults and children, and to assess 
overlap in variants between different age groups, using genome wide profiling. 
Methods: SNP sets were defined based on a meta-analysis of genome-wide association 
studies on systolic (SBP) and diastolic blood pressure (DBP) performed by the Cohort for 
Heart and Aging Research in Genome Epidemiology (CHARGE, n=29,136), using different 
P-value thresholds for selecting single nucleotide polymorphisms (SNPs). Subsequently, 
genetic risk scores for SBP and DBP were calculated in an independent adult population 
(n=2,072) and a child population (n=1,034). The explained variance of the genetic risk 
scores was evaluated using linear regression models, including sex, age and body mass 
index. 
Results: Genetic risk scores, including also many non-genome-wide significant SNPs 
explained more of the variance than scores based only on very significant SNPs in adults 
and children. Genetic risk scores significantly explained up to 1.2% (P=9.6*10-8) of the 
variance in adult SBP and 0.8% (P=0.004) in children. For DBP, the variance explained 
was similar in adults and children (1.7% (P=8.9*10-10) and 1.4% (P=3.3*10-5) respectively). 
Conclusion: These findings suggest the presence of many genetic loci with small effects 
on blood pressure regulation both in adults and children, indicating also a (partly) com-
mon polygenic regulation of blood pressure throughout different periods of life.
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Introduction
Elevated blood pressure is an important risk factor for stroke and ischemic heart disease, 
and is estimated to contribute to half of the global risk for cardiovascular disease1-2. Anti-
hypertensive treatment has been effective approach in reducing risks of cardiovascular 
events in people with hypertension3.
The heritability of blood pressure levels is estimated to be 30-60%4-5. Several genes 
with large effects have been identified in familial forms of hypertension, including salt-
sensitivity genes6. However, these explain a relatively small proportion of hypertension 
in the general population. Several common genetic variants associated with blood 
pressure have been identified through genome-wide association studies in adult popu-
lations, only explaining ~1% of the variance of blood pressure7-8. 
Despite the large size of the consortia used for gene discovery, many common vari-
ants with small effects on blood pressure remain unidentified. While their individual 
associations do not reach genome-wide significance, in combination these variants may 
nevertheless explain a substantial proportion of blood pressure. The extent to which 
unidentified common variants explain the missing heritability in blood pressure and 
other polygenic traits is an open and important question.
Recently, it has been shown that the presence of multiple variants affecting polygenic 
traits can be demonstrated by constructing genome wide prediction models (genetic 
risk scores) of common variants9-10. In a polygenic disease model, the more markers are 
used in the model, the better the disease is predicted. Such a model also implies that 
everybody in the population carries a substantial number of risk variants with small ef-
fects on the disease, but patients carry more of these variants than non-diseased people. 
This has been demonstrated in a recent study of schizophrenia, showing that one can 
predict disease using both genome-wide significant and non-significant SNPs, covering 
a large part of the genome9.
This approach can also be used to evaluate the evidence of overlap in genes affecting 
a continuous outcome as blood pressure, in different age groups. In metabolic diseases, 
such as diabetes and blood pressure, there is increasing interest in the role of genetic 
determinants of blood pressure and other risk factors of cardiovascular disease in order 
to improve prevention of chronic disease and identify targets for therapeutic interven-
tions.
One may argue that many genes regulating blood pressure maintenance are similar 
across age groups. We used genome wide profiling to evaluate to what extent multiple 
common genetic variants influence blood pressure in adults and secondly and to test 
whether there is overlap in genes contributing to blood pressure levels in children and 
adults, which might indicate whether there is a common polygenic regulation of blood 
pressure throughout different periods of life. 
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Methods
Genome-wide profiling
In genome-wide profiling, for a certain trait, genetic risk scores are constructed using 
data from a “discovery sample”. Sets of common variants to calculate genetic risk scores 
consist of all SNPs achieving a certain significance threshold (Pdiscovery threshold) in the 
discovery sample.  In an independent “target sample”, a subject’s genetic risk score is 
computed across all SNPs with P-value lower than the Pdiscovery threshold. The subject’s 
genotype (coded 0/1/2) is multiplied by the regression coefficient for that SNP as esti-
mated in the discovery sample, and divided by the total number of SNPs in that set. This 
risk score is calculated for all subjects in the independent target sample. Subsequently, 
an unbiased estimate of the variance explained by the genetic risk score is obtained 
by evaluating the increase in explained variance of the trait when adding the genetic 
risk score to a baseline model explaining that trait. The method has previously been 
described in detail9. In our study, we used systolic and diastolic blood pressure and hy-
pertension as traits of interest. The discovery sample was the Cohort for Heart and Aging 
Research in Genome Epidemiology (CHARGE) consortium, with a total sample size of 
29,136 participants7. We used two Dutch target samples; one adult sample (Rotterdam 
Study III) and one child sample (Generation R Study).
In the discovery sample, within each cohort of CHARGE, regression models were fitted 
for systolic blood pressure (SBP) and diastolic blood pressure (DBP) separately, and allele 
dosage, using an additive genetic model. The models were adjusted for sex, age, age 
squared and body mass index (BMI). Subsequently, the within-study associations were 
combined by prospective meta-analysis. The methods have been described in detail 
previously7.
Next, SNPs were selected using the results from the meta-analyses of GWAS on SBP in 
the discovery sample, on the basis of their nominal P-value (Pdiscovery) for association with 
SBP, using different Pdiscovery thresholds, ranging from 1.0x10
-7 to 1.0. Subsequently, these 
sets of SNPs, with different Pdiscovery thresholds, were used to calculate the genetic scores 
in the target samples. The same was done using the results from the meta-analysis of 
GWAS on DBP, creating separate genetic risk scores for DBP.
For each individual in the two independent target samples, the genetic risk scores 
were calculated by multiplying the number of risk alleles per SNP (0, 1 or 2) with the 
effect size of that SNP in the discovery meta-analysis (weighted approach), summed 
over all SNPs in the set and divided by the number of SNPs in the considered set. The 
calculations of individual scores for each set of SNPs were performed using the PLINK 
(v1.07) software, specifically by “profile scoring” option.
Subsequently, linear regression models were used to test the association between 
the individual genetic risk scores and SBP and DBP in the target samples. For subjects 
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using anti-hypertensive medication, we added 10 mmHg to the observed SBP values 
and 5 mmHg to the observed DBP values. Similarly to the discovery analysis the models 
were adjusted for sex, age BMI. For analyzing the explained variance for adult hyper-
tension (SBP>=140 mmHg, DBP >=90 mmHg or use of antihypertensive medication) 
and childhood hypertension (SBP or DBP > p95 for age, gender and height11), we used 
logistic regression. We performed sensitivity analyses in the adults excluding subjects 
meeting the criteria for hypertension in the Rotterdam Study III. We have repeated the 
main analyses after removing SNPs in high linkage disequilibrium, using the LD-pruning 
option in the Plink software12. We pruned the data considering a window of 200 SNPs, 
removing one of a pair of SNPs if the LD is greater than 0.25, and shifting the window 5 
SNPs forward to repeat the procedure.
For both the Rotterdam Study and the Generation R study, regression analyses were 
performed in SPSS 17.0 for Windows (SPSS Inc., Chicago IL, USA). The difference of the 
explained variance in the null (without genetic risk score) and alternative model (includ-
ing a genetic risk score) was considered as the variance explained by the genetic score. 
A genetic risk score with a P-value <0.05 in the model was considered as significantly as-
sociated with the trait. We also assessed the difference between two subsequent models 
both including a genetic risk score using the Akaike Information Criterion (AIC)13.
In the online supplement, we describe the discovery and target samples, their respec-
tive data collection procedures and quality control. The approaches for sensitivity 
analyses using unrelated traits as outcome and analysis using randomly selected SNP 
sets or a SNP set based on a biological pathway to calculate a genetic risk score are also 
presented in the online supplement (please see http://hyper.ahajournals.org).
Results 
Demographic data of the CHARGE consortium have been published previously7. Table 1 
shows the baseline characteristics for the Rotterdam Study III (RS-III) and the Generation 
R Study. The median age in RS-III was 56.0 years (95% range: 47.7 – 62.3), in the Genera-
tion R Study the median age was 6.0 years (95% range: 5.8 – 6.7).
Figures 1a and 1b show the increase in explained variance of SBP by the genetic risk 
scores for a range of different Pdiscovery thresholds, in the adult and child target samples, 
respectively. When considering risk scores based on sets of SNPs with low P-values in the 
discovery sample (up to Pdiscovery <1.0x10
-4), the risk scores significantly explained up to 
0.3% of variance in SBP in adults (P=0.01). These scores were non-significant in children, 
increasing the explained variance by 0.1% (P=0.305). When adding more SNPs using 
greater Pdiscovery thresholds, the variance explained by the genetic risk scores increased, 
in both adults and children. Adding genetic risk scores based on SNPs with a Pdiscovery of 
Chapter 3.5
188
<0.1, increased the explained variance of the model significantly with 1.2% in adults 
(P=9.6*10-8). In 6 year old children, the risk score based on SNPs with Pdiscovery of <0.3 sig-
nificantly increased the explained variance of the model by 0.8% (P=0.004). The increase 
in explained variance in children was less pronounced compared to adults, but showed 
a similar pattern as the adult population.
Figures 2a and 2b show the proportion of explained variance of DBP for the various 
genetic risk scores. The difference between adults and children considering genetic risk 
scores based on sets of SNPs with a low P-value in the discovery sample (up to Pdiscovery 
<1.0x10-4), was more marked. The SNP sets explained up to 0.3% (P = 0.006) of the vari-
ance of DBP in the adult population but no variance in DBP was explained in children (P = 
0.544). The genetic risk score based on SNPs with a Pdiscovery <0.3 increased the explained 
variance significantly by 1.7% (P=8.9*10-10) when the score was added to the baseline 
model. Again, in children, a similar pattern was observed. The same genetic risk score 
(Pdiscovery threshold <0.3) significantly increased the explained variance of DBP by 1.4% 
(P=5.2*10-5), almost a similar increase as in adults.
Genetic risk scores for systolic and diastolic blood pressure also were associated with 
hypertension in adults explaining up to 2.1% (P=2.0*10-9, using Pdiscovery <0.3) of the vari-
ance in hypertension in an adult population (Figure 3a and 3b). Adult based genetic risk 
scores for systolic and diastolic blood pressure did not significantly explain additional 
Table 1. Subject characteristics of the Generation R Study and the Rotterdam Study III
Characteristics Rotterdam Study III
(n = 2,078)
Generation R Study
(n = 1,034)
Age (yrs) 56.0 (47.7 – 62.3) 6.0 (5.8 – 6.7)
Female (%) 56.1 52.2
BMI (weight(kg)/length(cm)2) 26.9 (21.6 – 36.7) 15.9 (13.9 – 18.4)
Mean systolic blood pressure (mmHg) 132.7 (19.2) 102.5 (8.1)
Mean diastolic blood pressure –(mmHg) 82.6 (11.1) 60.5 (7.2)
Subjects with hypertension (%) * 47.3
Subjects using anti-hypertensive 
medication (%)
20.8
Children referred to nephrology for 
hypertension (%) †
0.5
Prevalent Type 2 Diabetes (%) 7.3
Serum total cholesterol (mmol/l) 5.6 (1.1)
HDL cholesterol (mmol/l) 1.5 (0.5)
Values are means (sd) or medians (95%-range)
* Adults: Defined as SBP>140mmHg, DBP>90 mmHg or use of anti-hypertensive medication
Children: SBP or DBP >95th percentile for gender, age and height 12
† Children were referred to pediatric nephrology department when the lowest blood pressure measurement was higher 
than the P99 for their gender, length and age 12. 
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Figure 1. Increase in explained variance in systolic blood pressure by genetic risk scores
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Bars represent the increase in explained variance (%) of systolic blood pressure, when adding the genetic risk scores for 
different p-value thresholds, to the base line model for systolic blood pressure including BMI, sex and age as covariates. 
The baseline model explained 12.8% and 5.2 % of the variance in systolic blood pressure for adults and children 
respectively. We evaluated the difference in explained variance between two subsequent models by calculating the 
Akaike Information Criterion (AIC) of each model. The difference in AIC follows ac2 distribution with one degree of 
freedom, from which the P-value was derived.
* p < 0.05 
** p < 0.001 
1a. Rotterdam Study III
1b. Generation R Study
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Figure 2. Increase in explained variance in diastolic blood pressure by genetic risk scores
Figure 2a
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Bars represent the increase in explained variance (%) of diastolic blood pressure, when adding the genetic risk scores 
for different p-value thresholds, to the base line model for diastolic blood pressure including BMI, sex and age as 
covariates. The baseline model explained 8.4% and 1.4 % of the variance in diastolic blood pressure for adults and 
children respectively. We evaluated the difference in explained variance between two subsequent models by calculating 
the Akaike Information Criterion (AIC) of each model. The difference in AIC follows ac2 distribution with one degree of 
freedom, from which the P-value was derived.
* p < 0.05
** p < 0.001
2a. Rotterdam Study III
2b. Generation R Study
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Figure 3. Increase in explained variance in hypertension by genetic risk scores
Figure 3a
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Bars represent the increase in explained variance (%) of hypertension in adults (SBP>140, DBP>90 or the use of anti 
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base line model for systolic blood pressure including BMI, sex and age as covariates. The baseline model explained 15.9% 
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3a. Systolic blood pressure scores
3b. Diastolic blood pressure scores
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variance in childhood hypertension (see Supplement figure S1a and S1b, please see 
http://hyper.ahajournals.org).
To illustrate that these results were not due to chance, we tested whether the blood 
pressure based risk scores predicted also variation in intracranial volume (in adults) and 
head circumference (in children). Figures S2a/b and S3a/b show that the genetic risk 
scores for SBP and DBP did not explain variance of these unrelated traits significantly 
(please see http://hyper.ahajournals.org). Furthermore, we created random genetic 
risk scores of sufficient size (~565k SNPs, similar to the SNP set with Pdiscovery < 0.3) and 
evaluated the additional explained variance. The random genetic risk scores showed 
a significant increase in explained variance when added to the baseline model (see 
Table 2). The additional explained variance from the random genetic risk scores was 
0.1-0.4% lower as compared to the original genetic risk scores (see Table 2). We also 
tested whether a set of SNPs from a biological pathway would lead to a higher increase 
in explained variance than SNP sets with a low P-discovery threshold. We used SNPs 
in the FGF (fibroblast growth factor) pathway as described by Tomaszewski et al14. This 
genetic risk score did not explain additional variance in all phenotypes except for adult 
hypertension based on the systolic blood pressure score (increase in explained variance 
0.3, P=0.014, see Table 3).
In a strictly normotensive population the additional explained variance of the genetic 
risk score including the most significant SNPs (Pdiscovery-threshold 1.0x10
-7) increased, 
Table 2. Additional explained variance by a random genetic risk score versus original genetic risk score 
Additional explained variance
Phenotype Random genetic risk 
score (%)
Original genetic risk 
score (%)
P-value for 
difference
Adult systolic blood pressure
(Rotterdam Study III) 
1.0 † 1.2 † 0.07
Adult diastolic blood pressure
(Rotterdam Study III)
1.3 † 1.7 † 0.01
Child systolic blood pressure
(Generation R) 
0.7 * 0.8 * 0.49
Child diastolic blood pressure
(Generation R)
1.4 † 1.6 † 0.10
Hypertension – SBP scores
(Rotterdam Study III) 
1.1 † 1.4 † 0.02
Hypertension – DBP scores
(Rotterdam Study III) 
1.7 † 2.1 † 0.01
* P value < 0.05
† P value < 0.001
Random Genetic risk score – Genetic risk score calculated on SNP set containing ~565k SNPs which were randomly 
selected out of the discovery meta-analysis, irrespective of their P-value for association. 
Original genetic risk score – Genetic risk score calculated on a SNP set with a Pdiscovery threshold of 0.3. This SNP set 
contains ~565k SNPs and showed the largest increase in explained variance.
The P-value for difference between the models was obtained by calculating the difference in Akaike Information Criterion 
between the random model and the original model. This difference follows a c2 distribution with 1 degree of freedom
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while the risk scores with more liberal Pdiscovery-thresholds had a lower additive explained 
variance compared to the original analysis. Results of sensitivity analyses are shown in 
the supplement (figure S4a and S4b). We repeated the main analyses after removing 
SNPs in high linkage disequilibrium. The pattern was similar to the original analysis, 
but the explained variance was lower. Including more SNPs in the genetic risk score 
increased the variance explained by that score. The results of these analyses are shown 
in the supplement (Figure S5a/b, S6a/b and S7a/b, please see http://hyper.ahajournals.
org).
Discussion
Our findings indicate that, in addition to the blood pressure variants now identified, 
large numbers of common genetic variants affecting blood pressure remain to be identi-
fied, and that these variants explain a significant part of the variance in blood pressure 
in adults and children. These non-significant, unidentified SNPs together explain a larger 
part of the variance than the genome wide significant SNPs only. We also showed that 
adult based genetic risk scores explained variance in blood pressure in children. This 
indicates not only that there is a polygenic effect on blood pressure in children, but 
more importantly, it indicates that there is overlap in variants involved with blood pres-
sure maintenance in adults and children and that these variants act in throughout life.
In this study, we did not remove any SNPs that are in high linkage disequilibrium 
with each other. Pruned analyses, as presented in the Supplemental Material, do not 
change our conclusion that adding more non-genome wide significant SNPs to ge-
netic risk scores increases the variance explained by these scores. However, as expected, 
removing SNPs by LD pruning results in a reduction of the variance explained. Since 
Table 3. Additional explained variance by a genetic risk score based on FGF-signaling pathway14
Phenotype Additional explained variance by signaling 
pathway genetic risk score (%)
Adult systolic blood pressure
(Rotterdam Study III) 
0.1
Adult diastolic blood pressure
(Rotterdam Study III)
0.0
Child systolic blood pressure
(Generation R) 
0.1
Child diastolic blood pressure
(Generation R)
0.1
Hypertension – SBP scores
(Rotterdam Study III) 
0.3 *
Hypertension – DBP scores
(Rotterdam Study III) 
0.1
* P value < 0.05
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SNPs in LD are removed randomly, in many cases informative SNPs are taken out of the 
analyses. Therefore a pruned analysis is expected to underestimate the true effect on the 
explained variance by the genetic risk scores.
The additive explained variance of genetic risk scores on blood pressure is maximizing 
around the Pdiscovery-threshold of 0.3 and does not increase with more liberal thresholds. 
This genetic risk score includes over 550k SNPs. This result suggests that SNPs with a 
Pdiscovery-value lower than 0.3 in the discovery sample add to the explained variance of 
blood pressure and that many common variants associated with blood pressure regula-
tion have not been identified yet. SNPs with a Pdiscovery higher than 0.3 are unlikely to 
be associated with blood pressure. Genetic risk scores of a similar size, consisting of 
randomly selected SNPs, still resulted in a significant increase in explained variance 
when added to the baseline model without a genetic risk score. The increase in ex-
plained variance based on the random genetic risk scores was lower than the increase 
based on the original genetic risk score models, although this difference was small and 
statistically significant in only half of the presented phenotypes. This result suggests 
that a sufficiently large number of SNPs tags many genes throughout the genome which 
influence blood pressure regulation. These findings are in line with our hypothesis that 
blood pressure is polygenic trait and that there are many more genes involved with 
blood pressure than are found so far in genome wide association studies. Currently, 
the advantage of using genetic risk scores based on SNPs selected on their P-value in a 
GWAS discovery sample, as compared to genetic risk scores based on a random set of 
SNPs, seems to be limited. Larger GWAS discovery samples with identification of new 
common and rare SNPs might lead to higher explained variance.
Although there have been several mutations described causing dominant, mono-
genic, forms of hypertension and more of such rare variants may still be undiscovered6, 
our results support the hypothesis that hypertension is a polygenic disease, which is 
in part explained by a large number of genes regulating blood pressure. In our adult 
population, genetic risk scores including large numbers of SNPs, explain the largest 
proportion of variance in blood pressure, indicating the involvement of multiple genes 
in blood pressure regulation.
Risk scores containing highly significant SNPs, identified in large scale genome wide 
association meta-analyses in adults7-8, were significantly associated with in blood 
pressure in adults, but not in children. There are several explanations possible for this 
finding, including a smaller number of subjects and lower power in the children cohort. 
However, this finding might also indicate that the genome wide significant SNPs found 
so far are related to late-onset pathology. It has been long hypothesized that there is a 
common polygenic regulation of blood pressure in adults and children. This is the first 
study showing evidence of such a mechanism.
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It has been shown in literature that blood pressure tracks from childhood to adult-
hood15. This study indicates that genes are explaining a part of the blood pressure 
tracking over life. We show that the same set of genes, based on an adult discovery 
sample, explain part of the variation in blood pressure in both adults and children. We 
also showed that these SNP sets explain variation in hypertension in adults, indicating 
also a polygenic origin of hypertension. It has been shown that high blood pressure in 
childhood predisposes to hypertension in adulthood16. Adult based genetic risk scores 
do not explain variance in childhood hypertension in children significantly. This fits 
with the common view that causes of juvenile hypertension are different from adult 
hypertension11.
The percentage of explained variance by genetic risk scores is still low, although the 
heritability has been shown to be substantial4, yet compared to the variance explained 
by the genome wide significant SNPs on blood pressure found so far, there is a 4-5 fold 
increase in explained variance of blood pressure in our target samples.
In the coming years the variance explained by polygenic models may be improved 
further, using technology, such as whole genome sequencing, which can be used to 
identify low frequency variants. We used common variants only (MAF >0.01) to create 
genetic risk scores. Low frequency variants may add to the variance explained by these 
genetic risk scores. Also, we assumed an additive model, similar to the discovery analysis. 
We have to recognize that the biology of the genes involved in blood pressure regulation 
and possible interactions between these genes are unknown. Another possibility would 
be to construct genetic risk scores based on SNPs included in candidate biological path-
ways. A genetic risk score including SNPs from the FGF signaling pathway14 seemed to 
explain a larger proportion explained variance in hypertension as compared to a genetic 
risk score including a similar number of SNPs, based on the previous top SNPs from the 
GWAS. This indicates that prior knowledge on biological models and underlying mecha-
nisms might improve the explained variance by genetic risk scores. Alternative methods 
of constructing genetic risk scores may be better when further research reveals more of 
the underlying genetic biology of blood pressure regulation. 
Specific common variants that are associated with blood pressure still need to be 
identified. Much research is still needed to identify more and specific genes associated 
with blood pressure regulation in adults. If these common variants overlap with blood 
pressure regulation in children, they could provide clues for early etiology of hyperten-
sion. 
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Conclusions
At this stage, individual prediction is not yet feasible. Without a doubt, the prediction of 
blood pressure will improve and might contribute to predicting high blood pressure in 
the future. Genetic profiling might be a way of identifying subgroups at genetically high 
risk for increased blood pressure at a population level17, but whether it will be enough for 
personalised medicine and early treatment of people at risk for high blood pressure (and 
possibly also other risk factors for cardiovascular disease), remains to be determined. 
Our study shows that this may require the identification of many more common variants 
with small effects on blood pressure.
References
 1 Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the 
United States 1999 to 2000: a rising tide. Hypertension. 2004;44:398-404.
 2 Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. 
Lancet. 2008;371:1513-8.
 3 Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic 
hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Coop-
erative Research Group. Jama. 1991;265:3255-64.
 4 Levy D, DeStefano AL, Larson MG, et al. Evidence for a gene influencing blood pressure on chromo-
some 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from 
the framingham heart study. Hypertension. 2000;36:477-83.
 5 Ehret GB. Genome-wide association studies: contribution of genomics to understanding blood 
pressure and essential hypertension. Curr Hypertens Rep. 2010;12:17-25.
 6 Vehaskari VM. Heritable forms of hypertension. Pediatr Nephrol. 2009;24:1929-37.
 7 Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood pressure and hypertension. 
Nat Genet. 2009;41:677-87.
 8 Newton-Cheh C, Johnson T, Gateva V, et al. Genome-wide association study identifies eight loci 
associated with blood pressure. Nat Genet. 2009;41:666-76.
 9 Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophre-
nia and bipolar disorder. Nature. 2009;460:748-52.
 10 Evans DM, Visscher PM, Wray NR. Harnessing the information contained within genome-wide 
association studies to improve individual prediction of complex disease risk. Hum Mol Genet. 
2009;18:3525-31.
 11 National High Blood Pressure Education Program Working Group on High Blood Pressure in C, 
Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure 
in children and adolescents. Pediatrics. 2004;114:555-76.
 12 Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and 
population-based linkage analyses. Am J Hum Genet. 2007;81:559-75.
 13 Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control. 
1974;19:716-23.
197
Genome-wide profiling of blood pressure in adults and children
3.5
 14 Tomaszewski M, Charchar FJ, Nelson CP, et al. Pathway analysis shows association between FGFBP1 
and hypertension. J Am Soc Nephrol. 2011;22:947-55.
 15 Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and 
meta-regression analysis. Circulation. 2008;117:3171-80.
 16 Sun SS, Grave GD, Siervogel RM, Pickoff AA, Arslanian SS, Daniels SR. Systolic blood pressure in 
childhood predicts hypertension and metabolic syndrome later in life. Pediatrics. 2007;119:237-46.
 17 Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk of complex disease. Curr 
Opin Genet Dev. 2008;18:257-63.

Chapter 4
Childhood kidney structure 
and function

Chapter 4.1
Normal kidney growth in fetal 
life and early childhood 
JJ Miranda Geelhoed
H Rob Taal 
Lidia Arends 
Eric AP Steegers
Maarten Lequin
Albert Hofman
Albert J van der Heijden
Vincent WV Jaddoe
Adapted from Pediatric Nephrology 2012;25:289-98
Chapter 4.1
202
Abstract
Background: Assessing kidney growth and development in fetal life and early child-
hood is important. However, available information about growth of kidney structures 
in early life in healthy children is limited. We constructed reference curves for kidney 
growth from third trimester of pregnancy until early childhood using data of 1,158 
healthy children. 
Methods: This study was embedded in a population-based prospective cohort study 
from fetal life onwards. Kidney size, defined as length, width, depth and volume, was 
measured in third trimester of pregnancy (gestational age 30 weeks (total range: 27.1-
35.1)) and at the postnatal ages of 6 (total range: 5.1-11.0) and 24 (total range: 21.6-31.6) 
months. Gender specific reference growth curves were constructed. Analyses were 
based on more than 5,000 kidney measurements.
Results: In third trimester of pregnancy and at the age of 6 months, all kidney measure-
ments were larger in boys than in girls. At the age of 24 months, only kidney length was 
larger in boys. Trends were seen towards smaller left kidneys compared to right kidneys 
at all ages in both genders, except for kidney length. Gender specific reference curves 
based on (postconceptional) age were constructed for left and right kidney length, 
width, depth and volume.
Conclusion: Kidney size was significantly influenced by age and gender. Left kidney 
measurements tend to be smaller than right kidney measurements, except for kidney 
length. These reference curves can be used for assessing kidney structures by ultrasound 
in fetal life and early childhood.
203
Normal kidney growth in fetal life and early childhood
4.1
Introduction
Assessing kidney size in children is important for clinical and epidemiological studies. 
Abnormal kidney development may have direct perinatal and neonatal treatment con-
sequences1. Furthermore, smaller kidney size has been suggested to be related to hy-
pertension and renal disease in adulthood. Kidney size can be measured non-invasively 
and efficiently with ultrasound. Few studies published reference ranges for kidney size 
in healthy children during fetal and neonatal life2-3. One study showed reference material 
on postnatal kidney growth from birth to 18 months of age4. These studies were based 
on data about postnatal kidney growth and mostly focused on kidney volume in relation 
to weight, height and body surface area. Recently, new reference centiles were gener-
ated to assess kidney size of children with ‘single kidneys’ to identify those patients with 
unfavourable course and relevant kidney impairment5. However, there are no studies 
available evaluating normal kidney growth from late fetal life until early childhood and 
thereby including both fetal and childhood kidney growth. This information may be of 
importance to identify abnormal kidney size and growth, with possible subsequent clini-
cal consequences6-7. Therefore, the aim of this study was to construct reference curves 
for kidney structures including, kidney length, width, depth and volume in children from 
third trimester of pregnancy until the age of 24 months in a population-based cohort.
Methods
Study design
This study was embedded in the Generation R Study, a population-based, prospective 
cohort study from fetal life until young adulthood in Rotterdam, the Netherlands8-9. 
Detailed assessments of fetal and postnatal growth and development were conducted 
in a subgroup of 1,232 mothers and their children8-9. In this subgroup, fetal kidney ul-
trasounds were performed in third trimester of pregnancy (gestational age of 30 weeks) 
and postnatal kidney ultrasounds were performed at the ages of 6 and 24 months. The 
study has been approved by the Medical Ethics Committee of the Erasmus MC, Rot-
terdam. Written informed consent was obtained from all participants. 
Population for analysis
In total, 1,232 women were enrolled in the Focus cohort. The present analysis was lim-
ited to singleton live births (n = 1,215) whose mothers participated in the third trimester 
measurements. Twin pregnancies (n = 15) and pregnancies leading to perinatal death (n 
= 2) were excluded from the analysis. Kidney ultrasounds were successfully performed 
in 95% (n = 1,158) of these subjects. Of the initial 1,215 singleton live births, 74% (n = 
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901) and 70% (n = 856) participated in the postnatal assessments at the ages of 6 and 
24 months, respectively. Kidney ultrasounds were successfully performed in 83% (n = 
747) and 80% (n = 683) of these infants, respectively. Missing values were mainly due 
to crying behaviour or unavailability of equipment or radiographer. Infants who had 
a postnatal kidney ultrasound at the ages of 6 and 24 months did not differ from the 
postnatal non-responders in fetal and birth characteristics. No kidney or ureterovesical 
anomalies other then mild pyelectasis over 10 mm (n = 3) were present in our study 
population. Analyses were based on more than 5,000 left and right kidney measure-
ments.
Ultrasound measurements
Fetal left and right kidney size was measured in third trimester of pregnancy (gestational 
age 30 weeks (total range: 27.1-35.1). In a sagittal plane, the maximum longitudinal 
kidney length was measured placing the calipers on the outer edges of the caudal and 
cranial side. Antero-posterior (kidney width) and transverse kidney diameter (kidney 
depth) were measured perpendicular to each other, outer to outer, in an axial plane10. 
The cross-sectional area in which the kidney appeared symmetrically round and at its 
maximum width was used. The images were sufficiently magnified to ensure optimal 
measurements10.
Postnatally, two-dimensional ultrasounds of the kidneys were performed using an 
ATL-Philips Model HDI 5000 (Seattle, Washington, USA) equipped with a 2.0 - 5.0 MHz 
curved array transducer in children at the ages of 6 and 24 months. The examination 
was carried out in a quiet room with the child quietly awake in a supine position. This 
position was standardised to prevent differences according to position10-11. The kidney 
was identified in the sagittal plane along its longitudinal axis. Measures of maximal bi-
polar kidney length, width and depth were obtained from both the left and right kidney. 
Kidney width and depth were measured at the level of the kidney hilum10-11. 
Mean length, width and depth were calculated as the average of three measurements 
and used for data analysis. Fetal and postnatal kidney volume were both calculated 
in cubic centimeters using the equation of an ellipsoid: volume (cm3) = 0.523 x mean 
length (cm) x mean width (cm) x mean depth (cm)11-12.
Intra and interobserver studies showed that for the fetal ultrasound measurements 
the intraclass correlation coefficient (ICC) was higher than 0.98 and the corresponding 
coefficient of variation (CV) lower than 6%. Bland and Altman plots to test agreement of 
measurements for fetal ultrasound, demonstrated 95% limits of agreement in propor-
tions to be within 10% difference from the mean of measurements, indicating good 
reproducibility13. For the postnatal ultrasound measurements, the intraobserver ICCs 
ranged from 0.93 (left and right renal width and right renal thickness) to 0.99 (left renal 
length) and interobserver ICCs ranged from 0.64 (right renal thickness) to 0.90 (right re-
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nal length). Limits of agreement in the Bland and Altman plots ranged from –8.0 to 9.2% 
(intraobserver left renal width) to the widest limit from –18.0 to 19.2% (interobserver left 
renal length)14.
Data analysis
Differences of fetal and postnatal characteristics between boys and girls were assessed 
by t-tests and one-way ANOVA for independent samples. Furthermore, we tested dif-
ferences of kidney measurements between both genders with t-tests for independent 
samples. Differences between left and right kidney were tested with paired sample 
t-tests.
Data were analyzed as recommended by Altman, Chitty and Royston15-16. For reference 
kidney growth curves, conceptional age was plotted against kidney length, width, depth 
and volume. From the original data, measurements more than two standard deviations 
(SDs) from the regression line, fitted on our data, were considered to be outliers and 
were therefore removed. The best fitting curve was determined using second-degree 
fractional polynominals17. The curve was fitted using repeated measurement analyses, 
taking into account the dependency in the data by specifying a constant covariance 
between measurements of the same subject. 
Royston and Altman have shown how to apply a particular type of statistical model to 
longitudinal data to produce growth centiles and the same model may also be used to 
calculate valid size centiles16, 18. This multilevel modeling and was used in the Generation 
R study. The best fitting fractional polynominal curves were chosen by comparing the 
deviances and by visually checking the goodness of fit. The curves were fitted using 
repeated measurement analysis. Next, regression lines were fitted for the dependency 
of the residual SD on conceptional age19. Subsequently, plotting the SD scores against 
conceptional age was used to assess correctness of the model. 
Finally centiles were derived and the curves were plotted on the data. Kidney growth 
reference curves were constructed for a conceptional age from 30 to 160 weeks. All 
statistical analyses were performed using the Statistical Package for the Social Sciences 
version 15.0 for Windows (SPSS Inc, Chicago, IL, USA) and the Statistical Analysis System 
(SAS) for Windows, version 9.1.3.
Results
The percentage of boys was 52% (Table 1). The overall median age of infants at their 
6 months visit was 6.3 months (total range: 5.1-11.0) and at their 24 months visit 25.1 
months (total range: 21.6-31.6). Growth characteristics, including third trimester head 
circumference and postnatal weight and length at the ages of 6 and 24 months of age, 
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were larger in boys than in girls (all p-values <0.001). No difference was found for ges-
tational age at birth between boys and girls. In total, 15 children in our study group ful-
filled this criterium for small for gestational age (< -2 SDS). Furthermore, only 18 children 
had a low birth weight (birth weight <2500 grams) and 23 children were born preterm 
(gestational age <37 weeks). Table 2 shows that in third trimester of pregnancy and at 
the age of 6 months all kidney measurements were larger in boys than in girls. At the 
age of 24 months, only kidney length was larger in boys than in girls. Furthermore, at all 
ages both genders showed trends towards smaller left kidney measurements compared 
to right kidney measurements, except for kidney length (Table 3). 
Available data for constructing the curves for kidney growth are shown in Table 4. 
Formulas for growth reference curves describing the mean with the corresponding 
standard deviation are given in Table 5. Standard deviation increased linearly with 
gestational age. Reference kidney growth curves of individual measurements and fit-
ted centiles are given in Figure 1. Reference values for kidney length, width, depth and 
volume are given in the Appendix.
Table 1. Subject characteristics
Boys Girls P-value
Third trimester fetal characteristics (n = 603) (n = 555)
Gestational age (weeks) 30.4 (28.7-32.8) 30.3 (28.2-32.5) 0.05
Head circumference (cm) 28.8 (1.2) 28.3 (1.1) <0.001
Abdominal circumference (cm) 26.7 (1.7) 26.5 (1.6) 0.2
Femur length (cm) 5.7 (0.3) 5.8 (0.3) 0.2
Estimated fetal weight (grams) 1632 (264) 1623 (252) 0.7
Characteristics at birth (n = 603) (n = 555)
Gestational age at birth (weeks) 40.3 (36.2-42.4) 40.3 (36.1-42.4) 0.9
Gestational age < 37 weeks (%) 12 (3.4) 11 (3.3) 0.9
Birth weight (grams) 3557 (518) 3488 (506) 0.05
Birth weight < 2500 grams (%) 8 10 0.6
Small for gestational age (%) 6 9 0.4
Characteristics at 6 months (n = 379) (n = 368)
Age at visit (months) 6.3 (5.4-8.0) 6.3 (5.4-8.2) 0.7
Weight at visit (grams) 8173 (837) 7640 (807) <0.001
Length at visit (cm) 69.4 (2.4) 67.9 (2.4) <0.001
Characteristics at 24 months (n = 333) (n = 350)
Age at visit (months) 25.1 (23.6-28.0) 25.2 (23.4-28.3) 0.3
Weight at visit (grams) 12,890 (1,395) 12,429 (1,343) <0.001
Length at visit (cm) 89.6 (3.2) 88.4 (3.3) <0.001
Values are means (standard deviation),  medians (95% range) or percentages. 
Differences between boys and girls were compared using independent samples t-tests or ANOVA
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Table 2. Differences in boys and girls stratified for left and right kidney structures
Left kidney Right kidney
Kidney 
measurement
Boys Girls P-value Boys Girls P-value
Gestational age 30 
weeks 
(n = 604) (n = 553) (n = 603) (n = 556)
 Length (mm)
39.5 (32.0-
47.0)
38.4 (32.7-
45.0)
<0.001
39.6 (32.0-
46.6)
38.5 (32.2-45.3) <0.001
 Width (mm)
21.6 (17.0-
28.0)
21.1 (16.5-
26.0)
0.001
22.4 (17.0-
28.0)
22.0 (17.0-27.6) 0.02
 Depth (mm)
22.7 (17.0-
29.0)
22.1 (17.9-
27.8)
0.001
23.2 (17.8-
30.0)
22.9 (18.0-29.0) 0.03
 Volume (cm3)
10.3 (5.4-
17.9)
9.5 (5.4-15.0) <0.001 11.0 (5.8-18.5) 10.3 (5.8-16.8) <0.001
Age 6 months (n = 375) (n = 358) (n = 379) (n = 368)
 Length (mm)
60.1 (48.6-
70.4)
58.6 (50.0-
67.4)
<0.001
58.8 (49.7-
69.3)
57.5 (49.5-67.6) <0.001
 Width (mm)
28.2 (22.3-
36.4)
27.6 (21.6-
35.7)
0.01
28.0 (21.8-
35.4)
27.5 (21.4-36.5) 0.04
 Depth (mm)
26.5 (20.1-
33.0)
25.5 (20.2-
32.2)
<0.001
27.8 (21.3-
34.9)
27.0 (20.9-34.0) 0.001
 Volume (cm3)
23.8 (14.0-
36.6)
21.9 (13.9-
33.4)
<0.001
24.0 (15.3-
35.6)
22.4 (14.2-34.6) <0.001
Age 24 months (n = 330) (n = 318) (n = 347) (n = 336)
 Length (mm)
66.8 (56.1-
80.3)
65.7 (53.7-
78.0)
0.03
65.2 (54.8-
76.6)
64.3 (53.2-76.5) 0.04
 Width (mm)
30.8 (25.6-
37.1)
30.1 (23.5-
37.8)
0.01
30.7 (25.6-
38.0)
30.6 (25.2-37.1) 0.61
 Depth (mm)
30.9 (24.8-
38.9)
30.1 (24.2-
38.1)
0.002
32.0 (25.5-
39.4)
31.9 (25.9-39.6) 0.79
 Volume (cm3)
33.6 (22.8-
51.6)
31.8 (19.3-
52.2)
0.004
33.8 (22.9-
53.3)
33.1 (22.1-49.2) 0.19
Values are means (95% range).
Differences between boys and girls were compared using independent samples t-tests.
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Table 3. Differences in left and right kidney structures stratified for gender
Boys Girls
Kidney 
measurement
Left kidney Right kidney P-value Left kidney Right kidney P-value
Gestational age 30 
weeks 
(n = 604) (n = 603) (n = 553) (n = 556)
 Length (mm)
39.5 (32.0-
47.0)
39.6 (32.0-
46.6)
0.79
38.4 (32.7-
45.0)
38.5 (32.2-45.3) 0.45
 Width (mm)
21.6 (17.0-
28.0)
22.4 (17.0-
28.0)
<0.001
21.1 (16.5-
26.0)
22.0 (17.0-27.6) <0.001
 Depth (mm)
22.7 (17.0-
29.0)
23.2 (17.8-
30.0)
<0.001
22.1 (17.9-
27.8)
22.9 (18.0-29.0) <0.001
 Volume (cm3)
10.3 (5.4-
17.9)
11.0 (5.8-18.5) <0.001 9.5 (5.4-15.0) 10.3 (5.8-16.8) <0.001
Age 6 months (n = 375) (n = 379) (n = 358) (n = 368)
 Length (mm)
60.1 (48.6-
70.4)
58.8 (49.7-
69.3)
<0.001
58.6 (50.0-
67.4)
57.5 (49.5-67.6) <0.001
 Width (mm)
28.2 (22.3-
36.4)
28.0 (21.8-
35.4)
0.50
27.6 (21.6-
35.7)
27.5 (21.4-36.5) 0.72
 Depth (mm)
26.5 (20.1-
33.0)
27.8 (21.3-
34.9)
<0.001
25.5 (20.2-
32.2)
27.0 (20.9-34.0) <0.001
 Volume (cm3)
23.8 (14.0-
36.6)
24.0 (15.3-
35.6)
0.35
21.9 (13.9-
33.4)
22.4 (14.2-34.6) 0.06
Age 24 months (n = 330) (n = 347) (n = 318) (n = 336)
 Length (mm)
66.8 (56.1-
80.3)
65.2 (54.8-
76.6)
<0.001
65.7 (53.7-
78.0)
64.3 (53.2-76.5) <0.001
 Width (mm)
30.8 (25.6-
37.1)
30.7 (25.6-
38.0)
0.68
30.1 (23.5-
37.8)
30.6 (25.2-37.1) 0.02
 Depth (mm)
30.9 (24.8-
38.9)
32.0 (25.5-
39.4)
<0.001
30.1 (24.2-
38.1)
31.9 (25.9-39.6) <0.001
 Volume (cm3)
33.6 (22.8-
51.6)
33.8 (22.9-
53.3)
0.30
31.8 (19.3-
52.2)
33.1 (22.1-49.2) <0.001
Values are means (95% range).
Differences between left and right kidney structures were compared using paired samples t-tests.
Table 4. Number of successful measurements per variable, according to age
Successful measurements (% (n))
Kidney measurement
Gestational age 30 weeks 
(n = 1,215)
Age 6 months
(n = 901)
Age 24 months
(n = 856)
Left kidney
 Length (mm) 94.9 (1153) 81.2 (732) 78.2 (669)
 Width (mm) 95.2 (1157) 77.2 (696) 72.8 (623)
 Depth (mm) 95.1 (1155) 76.8 (692) 76.9 (624)
 Volume (cm3) 94.4 (1147) 76.6 (690) 72.9 (615)
Right kidney
 Length (mm) 94.7 (1151) 82.9 (747) 81.9 (701)
 Width (mm) 95.4 (1159) 82.4 (742) 80.6 (690)
 Depth (mm) 95.4 (1159) 82.2 (741) 80.6 (690)
 Volume (cm3) 94.5 (1148) 82.1 (740) 80.4 (688)
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Table 5. Reference curves for kidney structures: equations for the mean and SD of each measurement 
based on age in exact weeks
Kidney 
measurement
Measurement Regression equation
Left kidney
Length (mm)
Mean
SD
70.7392 + 48231 × (1/Age2) - 22290 × (1/Age2)*ln(Age) -1.0112 × Gender
3.033 + 0.020 × Age
Width (mm)
Mean
SD
33.9989 + 2465.42 × (1/Age2) - 408.99 x (1/Age) - 0.6208 × Gender
2.577 + 0.004 × Age
Depth (mm)
Mean
SD
2.5301 + 5.7694 × ln(Age) - 0.6145 × Gender
2.502 + 0.0031 × Age
Volume (cm3)
Mean
SD
56.8477 + 4222.85 × (1/Age2) - 273.13 × (1/√Age) - 1.3538 × Gender
1.639 + 0.0375 × Age
Right kidney
Length (mm)
Mean
SD
69.05 + 46279 × (1/Age2) - 21206 × (1/Age2) × ln(Age) - 1.0561 × Gender
2.899 + 0.0194 × Age
Width (mm)
Mean
SD
37.4342 + 122.84 × (1/Age2) - 78.8602 * (1/√Age) - 0.2290 × Gender
2.977 - 0.00025 × Age
Depth (mm)
Mean
SD
1.2261 + 6.2168 × ln(Age) - 0.2474 × Gender
2.576 + 0.005 × Age
Volume (cm3)
Mean
SD
45.4105+22573 × (1/Age2) - 1766.41 × (1/Age) - 0.8152 × Gender
2.128 + 0.0321 × Age
Gender = 0 for boys and gender = 1 for girls. Age is defined as postconceptional age (weeks). SD, standard deviation.
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Discussion
We constructed gender-specific reference growth curves for kidney length, width, depth 
and volume using measurements from a large population-based prospective cohort 
study of healthy children followed from fetal life until early childhood. Left and right 
Figure 1. Gender-differentiated growth curves for left and right kidney length, with, depth and volume 
measurements in relation to conceptional age with 3rd and 97th fitted centiles. The straight lines represent 
boys and the dotted lines represent girls.
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kidney length was at all ages larger in boys than in girls. Left kidney measurements tend 
to be smaller than right kidney measurements, except for kidney length.
The major strength of our study is its prospective design from early fetal life and the 
size of the population-based cohort. Our reference curves were based on more than 
5,000 kidney measurements. To our knowledge, no previous studies focused on kidney 
size in early life were based on such large numbers. Of these kidney measurements, 
all fetal ultrasounds were carried out by two sonographers and 86% of all postnatal 
ultrasounds were performed by one trained sonographer20. A limitation could be that 
of all children participating in the Generation R measurements at the ages of 6 and 24 
months, kidney measurements were successfully performed in 83% and 80% of these 
infants, respectively. Missing values were mainly due to crying behavior or unavailability 
of equipment or radiographer. The effect estimates would be biased if the subject char-
acteristics differ between those included and not included in the present analyses. This 
seems unlikely. Another limitation could be that the current study was performed in a 
healthy, population based cohort study. The selection towards a healthy population in 
our cohort may lead to a limited generalizibility to preterm children or children with a 
small size for gestational age at birth children. However, these numbers were too small 
to be assessed in further detail.
In third trimester of pregnancy and at the age of 6 months, all kidney measurements 
were larger in boys than in girls. At the age of 24 months, only kidney length was larger 
in boys than in girls. Several studies in healthy neonates and adults have also shown that 
males have larger kidneys than females21-22. One explanation for this finding may be a 
growth stimulating effect of androgens or Y-chromosome related genes. Another expla-
nation could be due to the idea that testosterone levels are significantly higher during 
fetal life in males compared to females23-24. Most previous studies assessing kidney size 
beyond the neonatal period did not report a difference between boys and girls25-26. The 
differences we found were small, which may explain why they were missed in previous 
studies. 
Previously published data on kidney size showed conflicting results concerning differ-
ences between left and right side. Some studies found no difference in kidney measure-
ments between left and right side25, 27. However, others have found the left kidney to 
be the largest28-29. Concerning kidney length, there has been no disagreement about 
the left being the longest4, 21-22, 26, 28. In the present study, the left kidney was the longest 
in both genders at the postnatal ages of 6 and 24 months. In fetal life we found no 
significant difference in kidney length between left and right side.
Kidney growth is fastest during the first few weeks of life and the rate of increase 
gradually slows through the remainder of the first year of life and finally stabilizes30. To 
overcome the problem of non-linear infant kidney growth, some sonographic standards, 
including means and standard deviations, for kidney size in relation to age have been 
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published30-32. A few other studies created linear or non-linear polynominal regression 
equations for kidney size during the first year of life25-26. One study created reference 
materials for kidney size in healthy children beyond the neonatal period4. They only 
focused on kidney volume in relation to weight, height and body surface area and did 
not report data about prenatal kidney growth. To our knowledge, the present study is 
the first to provide prospective longitudinal reference material on kidney size covering 
the whole period from fetal life until infancy in a healthy population.
Conclusions
kidney size differed between boys and girls from the age of 30 weeks of pregnancy 
until 24 months of age. Left kidney measurements tend to be smaller than right kidney 
measurements. Gender-differentiated reference growth curves for both left and right 
kidneys were constructed for kidney length, width, depth and volume. These reference 
curves may be of importance to identify abnormal kidney size and growth, with possible 
subsequent clinical consequences.
Note: Supplementary information is available on the Pediatric Nephrology website: 
www.springer.com/medicine/pediatrics/journal/467
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Abstract
Background: An adverse fetal environment leads to smaller kidneys, with fewer neph-
rons, which might predispose an individual to the development of kidney disease and 
hypertension in adult life.
Methods: In a prospective cohort study among 1072 children followed from early fetal 
life onwards, we examined whether maternal smoking during pregnancy, as important 
adverse fetal exposure is associated with fetal (third trimester of pregnancy, n=1,031) 
and infant kidney volume (2 years of age, n=538) measured by ultrasound. Analyses 
were adjusted for various potential confounders. 
Results: Among continued smoking mothers, we observed dose-dependent associa-
tions between the number of cigarettes smoked during pregnancy with kidney volume 
in fetal life. Smoking  less than 5 cigarettes per day was associated with larger fetal 
combined kidney volume, while smoking more than 10 cigarettes per day tended to be 
associated with smaller fetal combined kidney volume (p for trend: 0.002). This pattern 
was not significant for kidney volume at the age of 2 years.
Conclusion: Our results suggest that smoking during pregnancy affects kidney devel-
opment in fetal life with a dose-dependent relationship. Further studies are needed to 
assess the underlying mechanisms and whether these differences in fetal kidney volume 
have postnatal consequences for kidney function and blood pressure.
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Introduction
The developmental plasticity hypothesis suggests that various adverse intra-uterine ex-
posures lead to persistent fetal developmental adaptations. These adaptations may be 
beneficial on short term but may have adverse consequences in postnatal life1. Also, they 
may lead to smaller kidneys with a reduced number of nephrons, which in turn leads to 
glomerular hyperfiltration and sclerosis, predisposing the individual to renal damage 
and subsequent development of higher blood pressure, impaired kidney function and 
end stage kidney disease in adulthood2. This hypothesis is supported by many studies 
showing associations of low birth weight with cardiovascular disease and chronic renal 
failure3-5. Low birth weight is also associated with impaired renal growth, raised blood 
pressure, and impaired renal function5-9. Thus far, the specific adverse fetal exposures 
and mechanisms underlying these associations are not known. Maternal smoking is 
a very important modifiable adverse fetal exposure in Western countries and leads to 
a decrease of 150 to 200 grams in offspring birth weight10. Maternal smoking during 
pregnancy may also have both direct and indirect adverse effects on fetal kidney de-
velopment. Several studies suggested that maternal smoking during pregnancy is also 
associated with higher blood pressure in the offspring, independent of birth weight11, 
which might be explained by an adverse kidney development12.
For the present study, we hypothesized that maternal smoking during pregnancy, 
as specific adverse fetal exposure, affects early kidney growth. In a population-based 
prospective cohort study, among 1,072 mothers and children, we evaluated the as-
sociations of maternal smoking during pregnancy with kidney volume in fetal life and 
infancy, both of those mothers who smoked during first trimester only and those who 
continued smoking throughout pregnancy.
Methods
Design
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from fetal life until young adulthood in Rotterdam, The Netherlands13-14. 
Detailed assessments were conducted in a subgroup of Dutch children and their 
parents. Mothers, who were already participating during pregnancy, were asked to 
participate in a sub cohort for additional detailed renal and cardiovascular measure-
ments. These women were all enrolled before a gestational age of 24 weeks. In total 
80% of these mothers, were willing to participate in the sub cohort. Data on smoking 
during pregnancy was available from prospectively collected questionnaires. For the 
present study, kidney measurements were performed at a gestational age of 30 weeks 
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and at the postnatal age of 24 months. Written informed consent was obtained from all 
participants. The Medical Ethics Committee of the Erasmus Medical Center Rotterdam 
has approved the study.
Population for analysis
In total 1,232 women were enrolled in the subgroup study. Twin pregnancies (n=15) and 
pregnancies leading to perinatal death (n=2) were excluded from the analysis, leading to 
1,215 singleton live births. No renal or uterovesical anomalies other then mild pyelec-
tasis over 10 mm (n=3) were present in our study. Information about smoking during 
pregnancy was not available in 110 subjects. Of the remaining 1,105 mothers, fetal 
kidney characteristics were successfully measured in 1,031 subjects (93 %). In total, 67 
% (n= 740) of the mothers and children with information about smoking during preg-
nancy participated in the follow-up study at the age of 2 years, with successful kidney 
measurements in 73% of these children (n=538). Missing data were mostly due to cry-
ing and oppositional behaviour. In total 1,072 (97%) had at least one complete kidney 
measurement.
Maternal smoking during pregnancy
Information about active smoking was obtained by postal questionnaires in the first, 
second and third trimester of pregnancy. Response rates for these questionnaires were 
90%, 93% and 92%, respectively15. Active maternal smoking at enrolment was assessed 
in the first questionnaire by asking whether mother smoked in pregnancy (no, first tri-
mester only, continued smoking during first trimester). In the second and third-trimester 
questionnaires, mothers were asked whether they smoked in the past 2 months (no, yes) 
respectively. Among the smoking mothers, the number of cigarettes was classified into 
different categories: less than five cigarettes per day; five to ten cigarettes per day; and 
more than ten cigarettes per day. Dose response analyses for first trimester only and 
continued smoking mothers were based on the first and third trimester questionnaires, 
respectively.
Kidney measurements
All ultrasound exams were performed using an ATL-Philips Model HDI 5000 (Seattle, 
WA, USA) equipped with a 5.0 MHz, high frequency curved array transducer. Ultrasound 
examinations were carried out in a dedicated and well-equipped research center in 
third trimester of pregnancy. Fetal left and right kidney biometrics were assessed. In a 
sagittal plane, the maximum longitudinal kidney length was measured placing the cal-
lipers on the outer edges of the caudal and cranial side. Antero-posterior and transverse 
kidney diameter were measured perpendicular to each other, from the one outer edge 
to the other, in an axial plane. The cross-sectional area in which the kidney appeared 
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symmetrically round at its maximum width was used. The images were sufficiently mag-
nified to ensure optimal measurements16. Postnatally, two-dimensional ultrasounds of 
the kidneys were performed in children at the age of 24 months. The examination was 
carried out in a quiet room with the child quietly awake in a supine position. This posi-
tion was standardised to prevent differences according to position16-17. The kidney was 
identified in the sagittal plane along its longitudinal axis. Measures of maximal bipolar 
kidney length, width and depth were obtained from both the left and right kidney. 
Kidney width and depth were measured at the level of the kidney hilum16-17. Both fetal 
and postnatal kidney volume were calculated using the equation of an ellipsoid: volume 
(cm3) = 0.523 x length (mm) x width (mm) x depth (mm). Left and right kidney volumes 
were added for the combined kidney volume (cm3)18.
Intra- and inter-observer reproducibility. Two well-trained, experienced sonographers 
performed all measurements. Quality checks were frequently carried out and feedback 
was provided to minimize interoperator differences. We have previously shown that kid-
ney characteristics can be reliably measured in children19. The intraobserver interclass 
correlation coefficients (ICC) ranged from 0.93 (left and right kidney width and right 
renal thickness) to 0.99 (left kidney length) and interobserver ICC ranged from 0.64 
(right kidney thickness) to 0.90 (right kidney length), indicating good reproducibility.
Covariates
Maternal height and was measured at enrolment. Information on maternal pre-
pregnancy weight and maternal educational level was assessed using self reported 
questionnaires. We defined maternal weight gain as the difference between weight at 
enrolment and weight in third trimester of pregnancy as described before20. Educational 
level of the father and family income were also assessed using questionnaires at enrol-
ment. Total daily energy intake was established using semiquantitive food frequency 
questionnaires in first trimester of pregnancy. Exact gestational age was established us-
ing fetal biometry measured in first trimester of pregnancy21. Fetal biometrics including 
head circumference (HC), abdominal circumference (AC), and femur length (FL) were 
measured using standardized ultrasound procedures in third trimester of pregnancy and 
estimated fetal weight (EFW) was calculated using the formula by Hadlock: EFW (gr) = 10 
x (1.326 – 0.00326 x AC x FL + 0.0107 x HC + 0.0438 x AC + 0.158 x FL)22. Fetal biometrics 
were measured at the same visit as the fetal kidney measurement. Date of birth, birth 
weight and sex were obtained from midwife and hospital registries. Postnatal height 
and weight were measured at the same visit as the postnatal kidney measurement.
Statistical Methods
Differences in maternal and offspring characteristics between the non-smoking, first 
trimester only and continued smokers were assessed using t-tests and nonparametric 
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tests for independent samples. Associations of maternal smoking, both first trimester 
only and continued smoking, with kidney volume were assessed using multiple linear 
regression models. We adjusted for covariates that changed the effect estimate of smok-
ing during pregnancy on kidney volume more than 10%, when added to the baseline 
model including gender, age and estimated fetal weight. All regression models were ad-
justed for fetal sex, maternal height and weight before pregnancy, maternal weight gain 
during pregnancy, total daily caloric intake, maternal and paternal educational level and 
household income. We further adjusted the analyses focused on fetal kidney volume for 
estimated fetal weight in third trimester of pregnancy (30 weeks) and gestational age 
at visit. The models focused on postnatal kidney volume were additionally adjusted for 
age, weight and height at visit. Systolic and diastolic blood pressure at intake, parity, 
maternal alcohol use during pregnancy and folic acid supplement use did not materially 
change the effect estimate. 
Subsequently, using similar models we examined the associations of the number 
of cigarettes smoked with kidney volumes. Missing values in covariates ranged from 
0 to 10%, except for paternal educational level (13.9%) and daily total energy intake 
(14.7%), and were imputed as mean for continuous variables and separate category 
for categorical variables. Since, no differences in main results were observed between 
analyses on complete and imputed analyses, we only present data on imputed analyses. 
Tests for trends were performed using multiple non-linear regression analyses, including 
a squared term of the smoking during pregnancy categories, using the non-smoking 
group as reference group. All measures of association are presented with their 95% 
confidence intervals (95% CI). We considered a P-value lower than 0.05 as statistically 
significant. All statistical analyses were performed using the Statistical Package for the 
Social Sciences version 15.0 for Windows (SPSS Inc, Chicago, IL, USA).
Results
Subject characteristics are presented in Table 1. The percentage of boys was 52.1%. The 
overall median maternal age was 31.8 (95% range: 23.5 - 37.7) years. The study group 
comprised 31 children who were born with a small size for gestational age (birth weight 
less than -2 SDS for gestational age), 37 children with a birth weight less than 2,500 
grams and 41 children who were born preterm. Table 2 shows all kidney characteristics 
measured in third trimester of pregnancy and at the postnatal age of 2 years.
Table 3 gives the adjusted associations of maternal smoking during pregnancy with 
fetal and postnatal combined volume. The results of the unadjusted model are presented 
in Table S1 in the supplement. Overall, compared to non smoking, no significant associa-
tions of first trimester only smoking or continued smoking during pregnancy with fetal 
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Table 1. Subject characteristics (n=1,072)
Smoking during pregnancy (n=1,072)
Non
(n=805)
First trimester only
(n=101)
Continued 
(n=166)
Maternal characteristics
Age (yrs) 31.7 (24.9-37.7) 30.8 (21.8-38.4) 30.4 (21.3-37.2) *
Height (cm) 171.2 (6.3) 170.7 (6.7) 169.6 (6.2) **
Pre pregnancy weight (kg) 69.5 (12.9) 66.5 (10.4) ** 67.7 (13.3)
Weight gain during pregnancy(kg) 8.0 (2.0-14.0) 9.0 (3.0-16.1) ** 8.0 (1.0-14.7)
Systolic blood pressure (mmHg) 118.7 (12.8) 118.4 (13.8) 118.0 (12.4)
Diastolic blood pressure (mmHg) 69.9 (10.1) 68.2 (9.2) 67.6 (9.3) **
Parity ≥ 1 (%) 39.4 27.7 * 44.6 
Highest education (%)                   
      Primary school 1.2 5.0 ** 6.2 **
      Secondary school 30.7 37.6 ** 56.8 **
      Higher education 68.1 57.4 ** 37.0 **
Household income (%)    
       <1200 euro 1.5 1.2 12.9 **
       1200-1600 euro 4.5 4.7 9.3 **
       >1600 euro 94.0 94.1 77.8 **
Alcohol use during pregnancy (%) 51.8 54.9 52.2
Total daily energy intake (kcal) 2109 (496) 2147 (526) 2244 (492) **
Folic acid supplement use (%) 93.1 89.0 78.2 **
Paternal characteristics
Age biological father 33.6 (26.9-42.8) 32.8 (25.5-41.1) 33.1 (23.0-41.8) *
Highest education (%)                   
      Primary school 2.7 1.2 10.4 **
      Secondary school 31.2 32.5 59.7 **
      Higher education 66.1 66.3 29.9 **
Third trimester fetal characteristics
Gestational age at assessment (weeks) 30.4 (28.8-32.2) 30.3 (28.8-31.9) 30.2 (28.6-31.7)
Head circumference (mm) 287 (266-307) 288 (267-306) 283 (263-305) **
Abdominal circumference (mm) 266 (239-293) 267 (237-299) 262 (233-295) *
Femur length (mm) 57 (53-63) 57 (52-62) 56 (51-61) **
Estimated fetal weight (g) 1619 (1264-2118) 1643 (1181-2119) 1527 (1167-2094) **
Birth characteristics
Gestational age (weeks) 40.3 (37.1-42.1) 39.9 (36.2-42.0) 40.1 (36.8-42.1)
Male (%) 51.9 44.1 57.8
Birth weight (g) 3580 (2660-4350) 3570 (2487-4643) 3412 (2342-4243) **
Low birth weight (% <2,500 g) 3.0 4.9 6.1 *
Small size for gestational age (% < -2 SD) 2.2 2.9 6.6 *
Preterm birth (%) 4.1 5.9 4.9
* = p<0.05
** = p<0.01
Values are means (sd) or medians (95% range)
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Table 2. Fetal and postnatal kidney characteristics 
30 weeks of gestation
(n = 1,031)
2 years
(n = 538)
Age at assessment (weeks) 30.2 (28.8-32.1) # 109 (103-120) ##
Left kidney structures
Length (mm) 39.0 (33.0-45.2) 66.3 (57.3-76.7)
Width (mm) 21.0 (17.0-26.0) 30.2 (25.6-36.3)
Depth (mm) 22.0 (18.0-27.0) 30.3 (25.5-36.4)
Volume (cm3) 9.6 (6.0-14.9) 31.7 (22.7-46.3)
Right kidney structures
Length (mm) 39.0 (33.0-45.0) 64.7 (55.9-75.3)
Width (mm) 22.0 (18.0-27.0) 30.6 (26.3-35.7)
Depth (mm) 23.0 (18.9-28.0) 31.7 (26.9-38.2)
Volume (cm3) 10.2 (6.4-16.4) 32.2 (23.6-47.0)
Combined kidney volume (cm3) 19.9 (12.6-30.7) 64.0 (48.5-93.6)
Values are medians (95% range)
# Gestational age during pregnancy at assessment
## Postnatal age at assessment
Table 3. Maternal smoking during pregnancy and fetal and postnatal kidney volume
Combined kidney volume
Smoking during 
pregnancy
30 weeks of gestation
(n = 1,031)
2 years
(n = 538)
Non
Reference
(n = 769)
Reference
(n = 415)
First-trimester only
(overall)
-0.06 (-1.12 , 0.99)
(n = 98)
3.92 (0.24 – 7.61) *
(n = 49)
Continued  
(overall)
0.25 (-0.65, 1.15)
(n = 164)
0.18 (-3.08 , 3.43)
(n= 74)
Number of 
cigarettes 
smoked per 
day
<5/day
1.71 (0.51 , 2.92) **
(n = 76)
0.49 (-3.81 , 4.78)
(n= 32)
5-10/day
-0.55 (-1.99 , -0.89)
(n = 55)
-0.48 (-5.66 , 4.71)
(n = 24)
>10/day
-1.95 (-3.73 , -0.16) *
(n = 32)
-2.33 (-8.65 , 4.00)
(n = 15)
P-value for trend 0.002 0.331
* p<0.05, ** p<0.01
Values are regression coefficients (95% CI) and reflect the difference in kidney volume for different categories of maternal 
smoking during pregnancy. All regression models were adjusted for fetal sex, maternal height and weight before 
pregnancy, maternal weight gain during pregnancy, total daily caloric intake, maternal and paternal educational level 
and household income. The models for fetal kidney size were also adjusted for estimated fetal weight, and gestational 
age at visit. The postnatal kidney analyses were additionally adjusted for age, weight and height at visit. 
Tests for trend were calculated using non-linear regression models including a squared term of the number of cigarettes 
smoked during pregnancy categories.
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kidney volume were observed. Smoking during first trimester only, but not continued 
smoking, was positively associated with combined kidney volume at the age of 2 years. 
Among first trimester only smokers, we did not observe consistent dose response as-
sociations between the number of cigarettes smoked and combined kidney volume in 
fetal life or at the age of 2 years (data not shown).
Among mothers who continued smoking during pregnancy, we observed a dose-de-
pendent association, between the number of cigarettes smoked during third trimester 
with fetal combined kidney volume (Table 3). Compared to non-smoking, smoking less 
than five cigarettes per day was associated with larger fetal combined kidney volume. 
Smoking more than ten cigarettes per day tended to be associated with smaller com-
bined kidney volume. We observed non-significant associations between the number of 
cigarettes smoked during pregnancy and kidney volumes at the age of 2 years. 
Figure 1 shows the regression coefficients of multiple linear regressions on com-
bined kidney volume and estimated fetal weight are affected separately by smoking 
throughout pregnancy. Estimated fetal weight proportionally decreased with the num-
ber of cigarettes smoked per day (p-value for trend: 0.01). Combined kidney volume 
however, was larger in offspring of mothers who smoked less than 5 cigarettes per day, 
Figure 1
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and became smaller with increasing numbers of cigarettes smoked per day (p-value for 
trend: 0.003). Figure 2 shows the associations of continued maternal smoking during 
pregnancy with postnatal combined kidney volume and body weight. No significant 
associations were observed.
Discussion
Results from this population-based prospective cohort study from early fetal life 
onwards suggest that first trimester only smoking is not consistently associated with 
kidney volume in fetal life and infancy, whereas continued smoking during pregnancy 
affects kidney volume in fetal life. The effect size and direction depends on the number 
of cigarettes smoked. Smoking less than five cigarettes per day was associated with 
larger fetal combined kidney volume. This association was not significant at the age of 
2 years. Smoking more than ten cigarettes per day tended to be associated with smaller 
combined kidney volume in both fetal and postnatal life. 
Maternal smoking during pregnancy is an important modifiable adverse fetal expo-
sure leading to various pregnancy complications in Western countries10, 23. The recently 
Figure 2
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demonstrated associations between maternal smoking during pregnancy with high 
blood pressure in the offspring suggest that fetal exposure to smoking has permanent 
renal and cardiovascular consequences24. We showed associations of continued smok-
ing during pregnancy with fetal kidney volume but not with postnatal kidney volume. 
The effect of continued smoking during pregnancy was dependent on the number of 
cigarettes smoked. This suggests a differential effect of maternal smoking during preg-
nancy, depending on the specific period of exposure and number of cigarettes smoked.
The main strength of our study is the prospective design from early fetal life onwards 
and the size of the population-based cohort. Our analyses were based on more than 
1,500 complete kidney ultrasounds. The size of the cohort enabled us to assess the 
associations between the number of cigarettes smoked during pregnancy and kidney 
volume. The ultrasound measurements were carried out by two sonographers with 
good reproducibility.
Of all children with available data on maternal smoking during pregnancy, 67% par-
ticipated in the follow measurements at the age of 2 years. Subjects who did not visit the 
research centre in postnatal life did not differ in fetal kidney volume from the original 
sample. However, more mothers in this group continued smoking during pregnancy and 
mothers were less well educated than the original sample. This selective loss to follow-
up, might have led to loss of power in the postnatal analyses, and possibly selection bias. 
Although we performed a meticulous adjustment, especially regarding socioeconomic 
status, residual confounding might still be an issue because of the observational design 
of the study. 
Another reason for the lacking associations in postnatal life might be that kidney mea-
surements are more difficult at the age of two years, introducing random error, which 
leads to a reduction in statistical power. One might also assume that some hypertrophy 
of nephrons is already ongoing in kidneys with lower nephron numbers (i.e. smaller fetal 
kidney volume) due to heavy smoking mothers, decreasing the difference in kidney 
volume over time. The increased kidney volume in mothers who smoked less than 5 
cigarettes per day, might have disappeared due to return to the normal kidney growth 
curve in postnatal life, while the reduced body size catches up.
Using questionnaires for collecting data on smoking behaviour might have resulted 
in underestimation of the number of cigarettes smoked per day, since some individu-
als might not report their smoking behaviour accurately. We did not measure cotinine 
levels to check smoking status in the mothers. Although assessing maternal smoking 
during pregnancy seems to be a valid method, misclassification may occur25-26. Another 
limitation might be that the present study was performed in a healthy population based 
cohort. The absolute numbers of subjects with low birth weight and preterm birth were 
small. Therefore, generalizability of our results to preterm or low birth weight children 
is limited.
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One other study among 34 subjects showed that maternal smoking during pregnancy 
leads to a different fetal kidney growth pattern compared to non-smoke exposed sub-
jects. This study suggested that reduction in kidney growth is present in third trimester 
of pregnancy resulting in relatively thinner kidneys12. This is in line with our finding that 
smoking more than 10 cigarettes in third trimester negatively affects in fetal and infant 
kidney volume. To our knowledge, no other studies examined the associations between 
maternal smoking during pregnancy and kidney size.
The mechanisms underlying the associations between smoking during pregnancy 
and fetal and infant kidney volume found in this study are not known. Animal studies 
showed that nicotine has both vasodilatatory and vasoconstrictive effect on vasculature, 
depending on the dose27-29. Higher dosage of nicotine were associated with vasoconstric-
tion and might partly explain our findings of smaller kidney size when smoking large 
numbers of cigarettes during pregnancy29. The larger kidneys among subjects exposed 
to less than five cigarettes per day could be explained by vasodilatory effects of nicotine 
on renal vasculature. Animal studies showed vasodilatory effects of low dose nicotine 
in the kidney in pre-constricted kidney vasculature30-31. Maternal smoking during preg-
nancy affects fetal growth in different trimesters of pregnancy, with the largest effect in 
the third trimester. Results suggest that smoking during pregnancy preferentially affects 
peripheral tissues25. The vasodilatory effect of nicotine on kidney vasculature might 
lead to increased kidney volume despite the negative effect on estimated fetal weight. 
However, further studies are needed to elucidate the vasoactive effects of nicotine in 
growth restricted subjects.
Another possible mechanism could be the role of the renin-angiotensin system 
(RAS). It has been shown that an intact RAS is needed for normal kidney development 
and disruption is associated with lower glomerular number, decreased renal function 
and increased adult blood pressure32-33. It also has been shown that smoking during 
pregnancy alters AT1/AT2 receptor ratio in renal tissue34. This could partly explain our 
findings that smoking more than ten cigarettes per day is associated with smaller fetal 
kidney volume. Further studies are needed to evaluate the effect of maternal smoking 
during pregnancy on RAS in humans.
The associations of low birth weight with hypertension and impaired renal function 
and end stage renal disease in adulthood are well established3, 6, 9, 35-36. Smaller kidneys 
with a reduced number of nephrons in low birth weight children might lead to hyper-
filtration resulting in glomerular sclerosis2, 37-40. This may predispose the individual to 
renal damage and development of higher blood pressure, impaired kidney function and 
end stage kidney disease in adulthood. This hypothesis is supported by animal studies, 
which have shown that various adverse intrauterine environmental exposures, such as 
low protein intake, lead to fetal growth retardation and smaller kidney size with a lower 
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nephron number41-43. Post mortem studies in humans showed that a lower nephron 
number is associated with both low birth weight and hypertension37, 39, 44-45.
Newborn kidney volume has been shown to be a surrogate of total nephron number. 
This was shown in 15 infants who died before 3 months of age, in whom an ultrasound 
was made in the first 2 days of life. There was a strong and direct relationship between 
kidney mass and nephron number46. Since nephron number varies between 250,000 and 
2,000,000 per kidney and nephron development ceases after birth44, 47, these findings 
suggest that early kidney development may be an underlying mechanism for the as-
sociations between maternal smoking during pregnancy and increased blood pressure 
in later life. Whether the differences in kidney volume due to smoking during pregnancy 
in this study also correlate with nephron number needs to be studied.
Conclusions
Our results suggest that maternal smoking during pregnancy is associated with an 
altered kidney volume in late pregnancy but not in infancy. The direction and size of the 
effect depends on the number of cigarettes smoked. These results should be considered 
as hypothesis generating. Further studies are needed to identify the underlying mecha-
nisms and to assess whether these changes in kidney size in early life are related to renal 
function and blood pressure development in later life.
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Abstract
Background: Low birth weight is associated with end-stage renal and cardiovascular 
disease. This association may be explained by persistent smaller kidneys with a reduced 
number of nephrons in children with low birth weight, and subsequent renal dysfunc-
tion and high blood pressure in later life. We examined whether kidney dimensions in 
childhood are influenced by maternal life style characteristics during pregnancy and 
birth outcomes and whether kidney dimensions are related with kidney function and 
blood pressure in school age children. 
Methods: This study was embedded in a population-based prospective cohort study 
from fetal life onwards among 6,368 children and their parents. Information about 
maternal and fetal exposures was available. At the age of 6 years, we measured kidney 
volume by ultrasound, kidney function by creatinine and cystatin C levels, and blood 
pressure. 
Results: The glomerular filtration was estimated. Maternal body mass index and calorie 
intake were positively associated with combined childhood kidney volume (p-values 
<0.05). Continued maternal smoking during pregnancy was associated with smaller 
combined kidney volume and lower glomerular filtration rate in childhood (p-values 
<0.05). As compared to term born children, preterm born children had a smaller com-
bined kidney volume at the age of 6 years (difference -6.81 mm³ (95% confidence interval 
-9.73 to -3.89)). As compared to children born with an appropriate size for gestational 
age at birth, those born with a small size for gestational age at birth had a smaller child-
hood kidney volume (difference -7.97 mm³ (95% confidence interval -10.58 to -5.36)). 
Size at birth also was associated with glomerular filtration rate and systolic and diastolic 
blood pressure (p-values < 0.05). Children with a smaller combined kidney volume had 
a lower estimated glomerular filtration rate and lower blood pressure in childhood (-4.82 
ml/min per 1.73m² per SD change in combined kidney volume, and -0.44 mmHg per SD, 
respectively). 
Conclusion: Our results suggest that childhood kidney growth and function is influ-
enced by several maternal and fetal characteristics. Smaller kidney size in childhood is 
associated with lower glomerular filtration rate and lower blood pressure.
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Introduction
Low birth weight is consistently associated with higher risks of end stage renal disease 
and hypertension in later life1-3. Brenner et al. hypothesised that the mechanisms under-
lying these associations include fetal renal developmental adaptations in response to 
various adverse early exposures4. These fetal adaptations may lead to smaller kidneys 
with a reduced number of nephrons, and subsequently to glomerular hyperfiltration 
and sclerosis, which predisposes to development of impaired kidney function and even-
tually end stage kidney disease in adulthood5-7. This hypothesis is supported by both 
animal and human studies showing that neonatal kidney volume and nephron number 
is reduced in fetal growth restricted subjects8-9. Also, a post mortem study showed that 
patients with hypertension had significantly fewer but greater glomeruli per kidney 
than nonhypertensive subjects10. Kidney size is correlated with the number of glomeruli 
and can be used in epidemiological studies as measure of kidney development11. We 
have previously shown that maternal anthropometrics, fetal growth and blood flow pat-
terns correlate with third trimester fetal kidney volume. Also, maternal smoking during 
pregnancy influences kidney volume in infancy12-13. Follow up studies suggested that 
maternal undernutrition or obesity, and fetal growth restriction affect renal function 
in adulthood, but results are inconsistent9, 14-16. Studies in children focused on early 
influences and consequences of kidney growth are important since small differences at 
young age seem to track into adulthood17, and may be associated with the risks of renal 
disease and hypertension in later life. Identification of early determinants of childhood 
kidney volume and function could be important for early prevention of renal disease in 
adulthood. 
In a population-based prospective cohort study from fetal life onwards among 6,368 
children and their parents, we examined whether kidney dimensions in childhood are 
influenced by maternal life style characteristics during pregnancy and birth outcomes 
and whether kidney dimensions are related with kidney function and blood pressure in 
school age children.
Methods
Design and study population
This study was embedded in the Generation R Study, a population-based, prospective 
cohort study from fetal life until young adulthood in Rotterdam, the Netherlands18. The 
vast majority of mothers were enrolled during pregnancy, but enrolment was allowed 
until childbirth. The study has been approved by the Medical Ethics Committee of 
the Erasmus Medical Center, Rotterdam. All participants or their parents gave written 
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consent to the study. In total 9,778 mothers were enrolled in the study, and 8,305 of 
their children participated in the follow up measurements in children aged 6 years. 
In total, 6,690 (81%) of these children visited the research center for renal follow up 
measurements. We excluded children with echocardiographic evidence of congenital 
heart disease (n=28) or kidney abnormalities (n=12). Kidney volume or blood pressure 
measurements were successfully performed in 6,368 (95%) children (Figure 1). In 4,272 
(67.1%) of those children blood samples for kidney function measurements were avail-
able. 
Main exposure variables
Maternal life style related characteristics during pregnancy 
Maternal height was measured at enrolment. Information on maternal parity, and pre-
pregnancy weight was assessed using self reported questionnaires. Pre-pregnancy body 
mass index (BMI, kg/m2) was calculated19. Maternal blood pressure was measured at 
intake with the validated Omron 907 automated digital oscillometric sphygmanometer 
(OMRON Healthcare B.V. Hoofddorp, the Netherlands)20. We assessed maternal smoking 
during pregnancy by questionnaire (no smoking; first trimester only; continued smok-
ing during pregnancy). We assessed maternal dietary intake at enrolment in the study in 
Dutch mothers using a modified version of a previously validated semi quantitative food 
frequency questionnaire (FFQ)21. The FFQ considered food intake over the prior three 
months, thereby covering the dietary intake in first trimester of pregnancy. We used the 
Dutch food composition table for calculating daily intake of nutritional values22. Total 
caloric intake was calculated. Information on folic acid supplement use (0.4-0.5 mg) and 
the initiation of supplementation was obtained by questionnaires at enrolment of the 
study. 
Birth characteristics
Gestational age in early pregnancy was established using first trimester fetal ultra-
sound23. Information on gestational age at birth and birth weight was obtained from 
community midwife and hospital registries. Preterm birth was defined as birth < 37.0 
weeks of gestation. Gestational age adjusted SDS were constructed for birth weight, 
using reference growth charts24. We defined small size for gestational age at birth (SGA) 
as being <5th sex specific percentile for weight and large size for gestational age at birth 
(LGA) as being >95th sex specific percentile for weight.
237
Early influences on kidney growth and function
4.3
Main outcome variables
Kidney dimensions 
Left and right kidney biometrics were assessed with an ATL-Philips HDI 5000 instrument 
(Seattle, WA, USA) equipped with a 2.0–5.0 MHz curved array transducer until September 
2010 or with a General Electric Logiq E9 (Milwaukee, WI, USA) equipped with a 2.0-7.0 
MHz curved array transducer after September 2010. During the examination the child 
was awake in a quiet room and calm in a standardized prone position. We identified 
the left and right kidney in the sagittal plane along its longitudinal axis. We performed 
measurements of maximal bipolar kidney length, width and depth. At the level of the 
hilum kidney width and depth were measured. The cross-sectional area in which the 
kidney appeared symmetrically round at its maximum width was used. Kidney volume 
was calculated using the equation of an ellipsoid: volume (cm3) = 0.523 x length (mm) x 
width (mm) x depth (mm)25. Combined kidney volume was calculated by summing right 
and left kidney volume. Quality checks were frequently carried out and feedback was 
provided to minimise inter-operator differences. Good reproducibility was pursued with 
intraobserver interclass correlation coefficients (ICC) ranged from 0.93 (left and right 
kidney width and right renal thickness) to 0.99 (left kidney length) and interobserver ICC 
ranged from 0.64 (right kidney thickness) to 0.90 (right kidney length)26. 
Kidney function
Serum creatinine was measured with the enzymatic method, on a Cobas c 502 analyzer 
(Roche Diagnostic, Germany). We additionally measured serum cystatin C by a particle 
enhanced immunoturbidimetric assay on Cobas c 702 analyzer (Roche Diagnostic, 
Germany). Estimated glomerular filtration rate (eGFR) was calculated according to the 
revised Schwartz formula from 200927; eGFR = 36.5 * (height (cm)/creatinine (µmol/l). 
This formula is validated in children with different characteristics28.
Blood pressure
Systolic and diastolic blood pressure was measured at the right brachial artery, four times 
with one minute intervals, using the validated automatic sphygmanometer Datascope 
Accutor Plus TM (Paramus, NJ, USA). The measurements were conducted while the child 
was quietly lying in supine position. A cuff was selected with a cuff width approximately 
40% of the arm circumference and long enough to cover 90% of the arm circumference. 
Covariates
Maternal age was registered at enrolment. Maternal ethnicity was classified by the 
countries of birth of the parents, according to the Dutch standard classification criteria 
of Statistics Netherlands18. Maternal education was defined as the highest completed 
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education according to the classification of Statistics Netherlands and was categorized 
in primary, secondary or higher18, 29. Maternal alcohol consumption during pregnancy 
was assessed using questionnaires (no alcohol pregnancy, alcohol consumption until 
pregnancy was acknowledged or continued use during pregnancy) in different trimes-
ters of pregnancy. Breastfeeding (yes/no) was assessed using questionnaires. At the age 
of 6 years, child height and weight were measured without shoes and heavy clothing, 
and body mass index (kg/m2) was calculated. 
Statistical analysis
First, we performed multiple linear regression models to explore the associations of 
maternal characteristics with childhood kidney volumes, kidney function and blood 
pressure. These models were first adjusted for sex and age (crude model), second for 
potential confounders (confounder model) and third for birth outcomes (intermediate 
model). Since we measured blood pressure four times, we applied linear mixed mod-
els30, which fit the four blood pressure measurements within the same child as repeated 
outcome measures. One of the advantages of this approach is that subjects with the 
maximum number of blood pressure measurements available and the least individual 
variability in their blood pressure measurements are assigned the highest weight in 
the analysis31. For comparison of effect estimates we present the result as difference in 
outcome per standard deviation scores for continuous variables and change per cat-
egory for categorical variables. Second, we assessed the associations of birth outcomes 
(gestational age at birth, birth weight, gestational age adjusted birth weight) with left, 
right and combined kidney volume, kidney function and blood pressure. Finally, we used 
similar multiple linear regression models to assess the associations of kidney dimensions 
with kidney function, blood pressure at age 6 years. To reduce the possibility of potential 
bias associated with missing data (ranging from 0 to 30%), missing values in maternal, 
fetal and child covariates were multiple imputed. Five imputed datasets were made and 
effect sizes and standard errors for each dataset were calculated. Finally, results from all 
five datasets were pooled and presented in this manuscript32. Regression coefficients 
for systolic and diastolic blood pressure were calculated on repeated measurements in 
a mixed model using SAS (SAS Institute Inc., Cary, NC, USA). All other statistical analyses 
were performed using the Statistical Package for the Social Sciences version 20.0 for 
Windows (SPSS, Chicago, IL, USA). 
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Results 
Subject characteristics
Maternal and child characteristics are shown in Table 1. At the age of 6 years (95 % range 
5.6 -  7.9 years), mean (SD) combined left and right kidney volume was 120.3 (23.5) 
mm³,  systolic and diastolic blood pressure were 102.7 (8.2) mmHg, and 60.7 (6.9) mmHg 
respectively. The mean glomerular filtration rate was 118.8 (16.4) ml/min per 1.73m². 
Observed data before multiple imputation is presented in Supplementary material 
(Table S1).
Table 1. Subject characteristics (n = 6,368)
Participants
Maternal characteristics
 Age, yr 30.5 (5.2)
 Height, cm 167.5 (7.4)
 Pre-pregnancy weight, kg 66.4 (12.5)
 Pre-pregnancy body mass index, kg/m2 24.0 (6.1)
 Weight gain during pregnancy, kg 7.4 (3.8)
 Systolic blood pressure, mmHg 115.6 (12.2)
 Diastolic blood pressure, mmHg 68.1 (9.5)
 Parity ≥1, % 43.9
 Ethnicity, %
  European 61.1
  Non -European 38.9
 Highest education, %
     Primary or secondary school 54.7
    Higher education 45.3
 Smoking, %
             Non-smoking 74.9
             First trimester only 8.6
             Continued smoking 16.4
Total daily energy intake, kcal 2046 (557)
Daily fat intake, % 36.2 (5.0)
Daily protein intake, % 14.9 (2.6)
Daily carbohydrate intake, % 48.6 (5.8)
Folic acid supplement use, %
 No 27.0
 Preconceptional 41.8
 Postconceptional 31.2
Infant characteristics
 Gestational age, weeks 39.8 (1.8)
 Birth weight, g 3427.7 (554.4)
 Gender, %
            Male 50.4
            Female 49.6
 Preterm birth, % 6.0
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Maternal characteristics and kidney volume, kidney function and blood 
pressure
Table 2 shows that in the fully adjusted regression model, maternal anthropometrics are 
positively associated with kidney volume and glomerular filtration rate. Each SD increase 
in maternal height was associated with an increase in combined kidney volume of 2.63 
mm³ and an increase of 0.92 ml/min per 1.73m² in glomerular filtration rate in childhood, 
respectively. Similarly maternal systolic blood pressure was positively associated with 
combined kidney volume and childhood systolic and diastolic blood pressure.
Not first trimester only, but continued maternal smoking during pregnancy was 
inversely associated with combined kidney volume (difference -1.98 mm³ (95% CI -3.80 
to –0.17)) and inversely associated with glomerular filtration rate (difference -1.82 ml/
min per 1.73m² (95% CI -3.45 to -0.19)). We did not observe a significant association of 
continued maternal smoking and blood pressure at the age of 6 years. Folic acid supple-
ment use was not associated with childhood kidney size, kidney function and childhood 
blood pressure. Results from the crude model and model adjusted for only confounders 
are shown in Supplementary material (Tables S2 and S3). 
Table 1. Subject characteristics (n = 6,368) (continued)
Participants
 Small size for gestational age, % <5th percentile 6.0
 Large size for gestational age, % >95th percentile 4.4
 Breastfeeding, %
 No 8.0
 Yes 92.0
Child characteristics
 Age, years 6.1 (0.5)
 Height, cm 119.5 (6.1)
 Weight, kg 23.3 (4.3)
 Body mass index, kg/m2 16.2 (1.9)
 Kidney volume left, mm3 61.3 (13.3)
 Kidney volume  right, mm3 59.0 (12.2)
 Kidney volume combined, mm3 120.3 (23.5)
 Systolic blood pressure, mmHg 102.7 (8.2)
 Diastolic blood pressure, mmHg 60.7 (6.9)
 Creatinine, µmol/l 37.2 (5.6)
 Cystatin C, µg/l 780 (8.0)
 GFR, ml/min per 1.73m² 118.8 (16.4)
Values are means (standard deviation) or number (%), GFR, glomerular filtration rate. 
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Birth outcomes and kidney volume, kidney function and blood pressure
Table 3 shows that as compared to term born children, preterm born children had a 
smaller combined kidney volume at the age of 6 years (difference 6.81 mm³ (95% 
confidence interval 9.73 to 3.89). The linear trend analyses showed that a 1 SD longer 
duration of gestational age was associated with a larger combined kidney volume (1.27 
mm³ (95% CI 0.60 to 1.93), higher glomerular filtration rate (0.70 ml/min per 1.73m² (95% 
CI 0.09 1.30)), and lower systolic blood pressure (0.36 mmHg (95% CI 0.60 to 0.12)). Birth 
weight was positively associated with combined kidney volume and glomerular filtra-
tion rate, but inversely associated with systolic and diastolic blood pressure in childhood 
(p-values for trend <0.05). As compared to children born with an appropriate size for 
gestational age at birth, those born with a small size for gestational age at birth had 
a smaller childhood kidney size (difference -7.97 mm³ (95% CI -10.58 to -5.36)). Size at 
birth also was associated with glomerular filtration rate and blood pressure in childhood 
(p-values < 0.05). Results from models only adjusted for sex and age are given in the 
Supplementary material (Table S4).
Kidney dimensions and kidney function and blood pressure
Overall, all kidney dimensions are inversely associated with creatinine and cystatin C 
levels and positively associated with glomerular filtration rate. Glomerular filtration rate 
increased by 4.82 ml/min per 1.73m (95%CI 4.20 to 5.44) per 1 SD increase in combined 
kidney volume. Also, combined kidney volume was positively associated with a higher 
systolic blood pressure (increase per 1 SD 0.44 mmHg (95% CI 0.17 to 0.70).
Discussion
Results from this population-based prospective cohort study from early fetal life on-
wards showed that several maternal characteristics, preterm birth and small size for 
gestational age at birth are associated with smaller kidneys, and lower glomerular filtra-
tion rate at the age of six years. Smaller kidney size is associated with lower glomerular 
filtration and lower blood pressure in childhood.
Methodological considerations
A major strength of our study is its prospective design from fetal life onwards within a 
large population-based cohort. Our analyses were based on more than 6,000 children 
with kidney growth, kidney function and blood pressure measurements available. Of 
the children who participated in the Generation R Study at age 6 years, more than 75% 
did participate in the kidney follow up studies. Overall, children and their mothers 
who did not visit the research center for follow-up measurements did more frequently 
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smoke during pregnancy and were less educated than the total sample. Of all children 
who visited the research center at age of six years, 95% provided useful blood pres-
sure or kidney measurements. Selective follow up might have led to selection bias if 
the investigated associations would be different in those included and not included in 
the analysis. This seems unlikely but cannot be excluded. In total, 67% of all children 
provided useful blood samples for measurements of creatinine and cystatin C levels, 
since not all participants in the study gave consent for collecting blood samples. There 
were no differences in maternal and birth characteristics between children with and 
without blood samples. However, children without blood samples had smaller kidney 
dimensions and higher blood pressure at the age of six years. These differences might 
have led to and underestimation of the associations between kidney dimensions and 
kidney function. Furthermore, statistical power might have been reduced due to the 
missing data. We used well described and validated measurements to measure kidney 
size and function. Currently, no precise measurement of nephron number is possible in 
vivo. We used kidney size as measure of kidney development. Kidney size seems to be 
correlated with the number of glomeruli and can be used in epidemiological studies as 
measure of kidney development.  Postmortem studies in humans showed that a lower 
nephron number is associated with low birth weight and hypertension10, 33. A recent 
study showed an association between newborn kidney volume and nephron number 
in fifteen infants, who died before three months of age, in whom an ultrasound was 
performed in the first two days of life. There was a strong relationship between kidney 
mass and nephron number11. This association is supported by study by Hinchliffe et 
al. demonstrating a strong correlation between renal volume and glomerular number 
up to 40 weeks of gestation, in eleven spontaneously aborted fetuses34. Several other 
post-mortem studies in humans, who died in the perinatal period, showed consistent 
associations between renal size and glomerular number35-36. Therefore, kidney volume 
seems to be a good surrogate for nephron number. However, it could be that glomerular 
enlargement due to glomerulosclerosis attenuates the differences in kidney volume 
and therefore might lead to an underestimation of the associations. Furthermore, differ-
ences might be smaller and therefore more difficult to detect. This could have affected 
the power of our study to establish associations. Finally, although we had information 
about a large number of potential confounders, residual confounding might still be an 
issue due to the observational design of the study.
Early life and kidney growth and function.
Several studies showed associations of low birth weight with renal disease and hyper-
tension in later life1-3. The underlying mechanisms for these associations are not exactly 
known. It has been hypothesized that early life adverse exposures impact fetal program-
ming and increases the risk of chronic disease in adult life4, 37. More specifically, adverse 
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fetal exposures in early life may lead to reduced congenital nephron number. This reduc-
tion may lead to glomerular hyperfiltration and subsequent glomerulosclerosis, which 
on long term might lead to impaired renal function and hypertension5-6. This hypothesis 
is supported by animal and human studies showing associations between low birth 
weight and nephron number36, 38-40.  Also, a post mortem study showed that patients 
with hypertension had significantly fewer but greater glomeruli per kidney than non-
hypertensive subjects10. The associations of low birth weight with kidney function and 
blood pressure are well-established but the effect estimates seem small1, 3. 
Maternal life style related characteristics might lead to adverse fetal environment 
and subsequently to renal developmental adaptations, which might have long term 
consequences. We observed that maternal height and pre-pregnancy weight, daily 
calorie intake and maternal folic acid use during pregnancy were associated with larger 
kidney size and lower glomerular filtration rate. We also observed that maternal contin-
ued smoking during pregnancy was associated with smaller kidney volume and lower 
kidney function. In the models adjusted for potential confounders, maternal smoking 
during pregnancy was not associated with diastolic blood pressure. Previous studies 
indicated an association between smoking and kidney volume and blood pressure with 
inconsistent results12, 41-43. Recently, large cohort study in young Swedish men showed a 
small significant increase in systolic and diastolic blood pressure in subjects exposed to 
maternal smoking during pregnancy44. Further research is needed to provide insight in 
the consequences of maternal smoking on blood pressure and kidney function in later 
life. 
A systematic overview in 2009 indicated that individuals born with low birth weight 
have a 70% increased risk of getting chronic kidney disease in later life1. In our study, 
birth weight was positively associated with kidney estimated glomerular filtration rate. 
Especially children with a birth weight lower than 2,000 grams had significantly lower 
kidney function compared to children with a normal weight. Rather than birth weight 
or gestational age per se, size at birth for gestational age may be a better reflection 
of intra-uterine growth restriction. A Norwegian study showed that young adults born 
with a small size for gestational age had an increased risk of low-normal creatinine clear-
ance compared with children with appropriate birth weight for gestational age15. This is 
in line with our findings showing that children born with a small size for gestational age 
children had smaller kidneys and impaired kidney function compared to children born 
appropriate size for gestational age. A Dutch study in severely growth restricted children 
did not show associations of birth weight with renal function in young adults9.
Not much is known about the associations of kidney volume with kidney function. 
A recent study, which included 257 healthy control subjects, indicated that renal mass 
was negatively associated with creatinine levels in serum45. In line with this study, we 
observed strong negative associations of kidney dimensions with creatinine, cystatin C 
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and positive associations with glomerular filtration rate, which is in line with the hyper-
filtration hypothesis. 
We hypothesized that smaller kidneys are associated with higher blood pressure, but 
observed a positive association. Di Zazzo et al found no consistent association between 
kidney size and systolic and diastolic blood pressure. It might be that our association 
might be explained by residual confounding ofchild body composition.  
The associations between adverse fetal exposures and blood pressure in later life 
might partly be explained by adaptations of kidney development. However, also other 
pathways and mechanism may underlie these associations, which may include the re-
nin-angiotensin-system, influences on arterial stiffness and fetal myocyte development. 
Future studies are needed to investigate possible underlying mechanisms and identify 
possible targets for intervention.
Conclusions
The present study suggests that maternal life style related characteristics influence 
childhood kidney volume and impaired kidney function. Also, birth weight, gestational 
age and size for gestational age at birth are associated with kidney growth, kidney func-
tion and blood pressure at the age of six years. Furthermore, kidney volume, as a marker 
of congenital nephron endowment, is associated with kidney function, which is in line 
with the hyperfiltration hypothesis. Surprisingly, we found a positive association of 
kidney volume with systolic blood pressure. Further studies focused on the underlying 
mechanisms of these associations and the influence on risk of developing hypertension 
and kidney disease are needed. The associations between kidney volume and kidney 
function in the present study, implicate that kidney volume might be a predictor of 
kidney function in later life. Future studies should focus on determinants, for example 
genetic and epigenetic influences, of development of kidney dimensions. 
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Supplements
Table S1. Subject characteristics.
Observed data Imputed data
Maternal characteristics
Age (years) 30.5 (5.2) 30.5 (5.2)
Height (cm) 167.5 (7.4) 167.5 (7.4)
Pre-pregnancy weight (kg) 66.5 (12.6) 67.4 (17.4)
Pre-pregnancy body mass index 
(kg/m2)
23.6 (4.2) 24.0 (6.1)
Weight gain during pregnancy (kg) 7.4 (3.9) 7.4 (3.8)
Systolic blood pressure (mmHg) 115.6 (12.2) 115.6 (12.2)
Diastolic blood pressure (mmHg) 68.1 (9.5) 68.1 (9.5)
Parity ≥1 (%)
             Missing
42.2
3.3
43.9
Ethnicity (%)
  European 60.0 61.1
  Non -European 37.4 38.9
             Missing 2.4
Highest education (%)
    Primary or secondary school 48.5 54.7
   Higher education 42.5 45.3
             Missing 9.1
Smoking (%)
             Non-smoking 64.8 74.9
             First trimester only 7.7 8.6
             Continued smoking 14.2 16.4
             Missing 13.3
Alcohol use during pregnancy (%)
     Non 36.6 46.4
    First trimester only 10.9 13.3
     Continued 32.1 40.3
             Missing 20.4
Total daily energy intake  (kcal) 2046.7  (557.4) 2027.3 (561.9)
Daily fat intake (%) 36.2 (5.7) 36.2 (5.0)
Daily protein intake (%) 14.9 (2.6) 14.9 (2.6) 
Daily carbohydrate intake (%) 48.7 (6.5) 48.6 (5.8)
Folic acid supplement use (%)
 No 17.4 27.0
 Preconceptional 29.7 41.8
 Postconceptional 21.9 31.2
             Missing 31.0
Infant characteristics
Gestational age (weeks) 39.8 (1.8) 39.8 (1.8)
Birth weight (g) 3427.9 (553.8) 3427.7 (554.4)
Gender (%)
            Male 50.4 50.4
            Female 49.6 49.6
            Missing 0.0
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Preterm birth (%)
            Missing
6.0
1.5
6.0
Small size for gestational age, % 
<5th percentile
6.0 6.0
Large size for gestational age, % 
>95th percentile
4.4 4.4
 No 5.9 8.0
 Yes 71.9 92.0
             Missing 21.2
Child characteristics
Age (years) 6.1 (0.5) 6.1 (0.5)
Height (cm) 119.5 (6.1) 119.5 (6.1)
Weight (kg) 23.3 (4.3) 23.3 (4.3)
Body mass index (kg/m2) 16.2 (1.9) 16.2 (1.9)
Kidney volume left (mm3) 61.3 (13.3)
Kidney volume  right (mm3) 59.0 (12.2)
Kidney volume combined (mm3) 120.3 (23.5)
Systolic blood pressure (mmHg) 102.7 (8.2)
Diastolic blood pressure (mmHg) 60.7 (6.9)
Creatinine (µmol/l) 37.5 (6.1)
Cystatin C (mg/l) 78.0 (8.0)
GFR (ml/min per 1.73m²) 118.80 (16.41)
Values are means (standard deviation)
Missing values for continuous variables are for maternal characteristics: age (n = 0), height (n = 610), pre-pregnancy 
weight (n = 1600), pre-pregnancy body mass index (n = 1609), weight gain during pregnancy (n = 834), systolic blood 
pressure (n = 644), diastolic blood pressure (n = 644), total daily energy intake (n = 1923), daily fat intake (n = 1923), daily 
carbohydrate intake (n = 1923), daily protein intake (n = 1923), for infant characteristics: gestational age (n = 46), birth 
weight (n = 12), for child characteristics: age (n = 0), height (n = 8), weight (n = 8), body mass index (n = 8) 
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Abstract
Background: Smaller kidneys with reduced number of nephrons in early life lead to 
impaired kidney function and risk for hypertension and chronic kidney disease. These 
associations might be partly explained by common genetic variation. We aimed to as-
sess the associations between common genetic variants, which have recently shown to 
be associated with blood pressure or kidney function, with fetal kidney volume.
Methods: In a prospective population based cohort study in Rotterdam, the Netherlands, 
we investigated among 855 children, followed from early fetal life onwards (born 2003 
-2005), whether common genetic variants previously associated with blood pressure or 
kidney function, were associated with combined third trimester fetal kidney volume.
Results: After taking into account multiple testing, only rs12940887 (near ZNF652) was 
significantly associated with fetal kidney volume (β: 0.88 (95%CI: 0.40; 1.37) cm3 per 
minor allele, p-value<0.001), but the effect showed the opposite direction as expected. 
The remaining common genetic variants were not associated with fetal kidney volume. 
We also did not find associations of genetic variants previously shown to affect newborn 
kidney volume, with third trimester fetal kidney volume.
Conclusions: Our results suggest that common genetic variants, associated with kidney 
function or disease and blood pressure, do not affect the third trimester fetal kidney 
volume. Further studies are needed to elucidate the mechanisms underlying the as-
sociations between small kidney size and increased risks of hypertension and impaired 
kidney function in adulthood. 
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Introduction
Many studies have shown associations of low birth weight with cardiovascular disease 
and chronic renal failure1-2. Low birth weight is also associated with impaired renal 
growth, raised blood pressure and impaired kidney function in later life1-3. The hyperfil-
tration hypothesis suggests that smaller kidneys with lower numbers of nephrons lead 
to hyperfiltration in the remnant nephrons, eventually resulting in glomerular sclero-
sis4-5. This may predispose the individual to renal damage and development of higher 
blood pressure, impaired kidney function and end stage kidney disease in adulthood4. 
A previous study showed associations of kidney size and low nephron number with 
hypertension6. Nephron number has been shown to vary widely between individuals, 
ranging from 250,000 to 2,000,000 nephrons per kidney7-8. A strong relationship be-
tween newborn kidney volume and nephron number was shown in fifteen infants who 
died before three months of age, in whom an ultrasound was performed in the first two 
days of life9. Several other post-mortem studies in humans, who died in the perinatal 
period, showed consistent associations between renal size and glomerular number8, 
10. Therefore, kidney volume seems to be a valid marker for nephron number. Kidney 
growth and development is complex and influenced by many genetic and environmen-
tal factors11-12. Multiple genes are involved in kidney development, e.g. in regulating the 
branching process of the ureteric bud. Mutations in these genes are known to cause 
agenesis or dysgenesis of the kidney11. It seems likely that also common genetic vari-
ants account for part of the normal variation in nephron endowment. Thus far, only a 
few genetic variants have been shown to affect kidney volume9, 13-14. It might be that 
common genetic variants, previously associated with blood pressure or kidney function, 
are also associated with kidney volume. These common genetic variants are identified 
in genome wide association studies conducted in thousands of individuals and explain 
~1-2% of the variation in these phenotypes15-21.
We hypothesized that common genetic variants underlie part of the associations 
of smaller kidney size in early life, as marker for a lower nephron number, with higher 
blood pressure and impaired kidney function in later life. Therefore we assessed in a 
population-based cohort study among 855 subjects, the associations of 58 common 
genetic variants, previously shown to be related to blood pressure or kidney function 
in adult life, with fetal kidney volume. We expected that a blood pressure increasing 
allele or kidney function decreasing risk allele would be associated with a smaller kidney 
volume in early life. Also, we attempted to replicate the associations of four common 
genetic variants and one haplotype with fetal kidney volume9, 13-14.
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Methods
Design
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from fetal life until young adulthood in Rotterdam, The Netherlands22-23. 
Detailed assessments of fetal and postnatal growth and development have been con-
ducted in a randomly selected subgroup of Dutch children and their parents. Mothers, 
who were already participating during pregnancy, were asked to participate in additional 
detailed renal and cardiovascular measurements. These women were all enrolled before 
a gestational age of 24 weeks. In total 80% of the approached mothers were willing to 
participate in these additional studies. Fetal kidney ultrasounds were performed in the 
third trimester of pregnancy (median age: 30.4 weeks of gestation (90% range 28.8–32.1 
weeks)). In total 1,232 women were enrolled in the subgroup cohort. Twin pregnancies 
(n=15) and pregnancies leading to perinatal death (n=2) were excluded from the analy-
sis, leading to 1,215 singleton live births. No renal or ureterovesical anomalies other 
then mild pyelectasis over 10mm (n=3) were present in our study. Kidney ultrasounds 
were successfully performed in 95% (n=1,158) of these subjects. DNA was available in 
855 (74%) of these subjects. The study was approved by the Medical Ethics Committee 
of the Erasmus MC, Rotterdam. Written informed consent was obtained from all partici-
pants22-23.
Genotyping
Cord blood for DNA isolation was available in 74% of all live-born participating children. 
Sex-mismatch rate between genome based sex and midwife-record based sex was low 
(<0.5%), indicating that possible contamination of maternal DNA was extremely low. 
Missing cord blood samples were mainly due to logistical constraints at the delivery. 
Individual genotype data were extracted from the genome-wide Illumina 610 Quad 
Array. If SNPs were not directly genotyped, we used MACH (version 1.0.15) software to 
impute genotypes using the HapMap II CEU (release 22) as reference set.
Selection of common genetic variants
The PubMed database was searched with ‘genome wide association study’, combined 
with ‘blood pressure’ or ‘kidney function’ as search criteria. We selected genome wide 
association studies, since these provide robust evidence of association, conducted in 
samples of European ancestry. Seven genome wide association studies were found; four 
on blood pressure and hypertension, three on kidney function and kidney disease15-21. If 
identical study populations were used in subsequent genome wide association studies, 
we selected common genetic variants from the genome wide association study with the 
largest sample size. Furthermore, we selected SNPs to assess in our study if the P-value 
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of the association was <5.0x10-8. If SNPs were in high linkage disequilibrium (R2 HapMap 
CEU ≥ 0.5) with each other, we selected the SNP with the strongest association reported, 
unless these SNPs were associated with different phenotypes. In total, 30 SNPs related 
to blood pressure and 28 SNPs related to kidney function or disease, were selected for 
this study. Next, the Pubmed database was searched with ‘common variant’ and ‘kidney 
size’ or ‘kidney volume’ as search criteria, to identify the studies which assessed associa-
tions between common genetic variants and kidney size or volume. We identified four 
studies investigating genes in the branching pathway; the PAX-gene, the RET-gene, the 
ALDH1A2-gene and the GDNF-gene. We selected SNPs in our study if the P-value of the 
association in previous studies was < 0.059, 13-14, 24. 
Kidney measurements
Fetal left and right kidneys were measured in the third trimester of pregnancy with 
an ATL-Philips HDI 5000 instrument (Seattle, WA, USA) equipped with a 2.0–5.0 MHz 
curved array transducer. In a sagittal plane the maximum longitudinal kidney length 
was measured, with the callipers placed on the outer edges of the caudal and cranial 
sides. Antero-posterior (kidney width) and transverse (kidney depth diameters were 
measured perpendicular to each other, from the one outer edge to the other, in an 
axial plane. Values of maximum bipolar kidney length, width and depth were obtained 
from both the left and right kidney. Kidney width and depth were measured at the level 
of the kidney hilum. Fetal kidney volume was calculated, using the equation of an el-
lipsoid: volume (cm³) = (0,523 x length (mm) x width (mm) x depth (mm))/1000. Left 
and right kidney volumes were added for the combined kidney volume (cm³)25-26. Fetal 
growth characteristics (head circumference (HC), abdomen circumference (AC) and 
femur length were measured at the same visit, and fetal weight was estimated27. Two 
well-trained, experienced sonographers performed all measurements. Quality checks 
were frequently carried out and feedback was provided to minimize interoperator differ-
ences. Fetal growth measurements were shown to be measured reliably. The intra- and 
interobserver interclass correlation coefficients were all higher than 0.98, indicating 
good reproducibility28. The estimated fetal weight (EFW) is calculated by the formula: 
EFW (grams) =10 * (1.326-0.00326 *AC* FL+0.0107 *HC+0.0438 *AC+0.158 * FL)29.
Statistical methods
Associations of common genetic variants and fetal kidney volume were assessed using 
linear regression, assuming an additive model. The model was adjusted for sex, gesta-
tional age at measurement and estimated fetal weight. We adjusted for these variables 
because of their relation with kidney volume30. The results did not differ materially 
between analyses with and without adjustment. In order to assess the combined effects 
of the common genetic variants, we calculated a risk allele score, by summing the risk 
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alleles (common genetic variants previously associated with higher adult blood pres-
sure or impaired kidney function) per individual, and analyzed the association of the 
number of risk alleles with fetal kidney volume. To take into account multiple testing, we 
applied a Bonferroni correction and considered a P-value lower than 8.6x10-4 (0.05/58) 
as statistically significant. Controlling for the false discovery rate, a less conservative ap-
proach31-32, did not change the results materially. All statistical analyses were performed 
using the Statistical Package for the Social Science version 17.0.2 for Windows (SPSS Inc, 
Chicago, IL, USA).
Results
Table 1 presents the maternal and fetal subject characteristics, including all measured 
kidney characteristics. The combined kidney volume, as well as the relative kidney vol-
ume was higher in boys than in girls (p<0.01). 
Table 1. Population characteristics
Maternal characteristics ( n=855)
Age 31.9 ( 21.9-39.4)
Height 171.1 ( 6.4)
Weight 71.4 (12.8)
Body mass index 23.4 (18.9-34.6)
Parity (%)                                                        ≥ 1 40.6
Fetal characteristics (n=855) 
sex (males %) 53.3
Gestational age at measurement 30.4 (28.5-32.7)
Estimated fetal weight (g) 1639 (268)
Right kidney structures
Length (mm) 39.0 (32.1-46.0)
Width (mm) 23.0 (18.0-29.7)
Dept (mm) 22.0 (17.0-28.0)
Volume (cm3) 10.3 (5.8-17.9)
Left kidney structures 
Length (mm) 39.0 (32.7-47.0)
Width (mm) 22.0 (17.0-28.0)
Dept (mm) 21.0 (16.9-26.9)
Volume (cm3) 9.6 (5.4-16.1)
Combined kidney volume (cm3) 20.6 (5.6)
Kidney volume/EFW (cm³/kg) 12.7 (3.1)
Values are means (sd) or medians (95% range)
Estimated fetal weight is the estimated weight at measurement
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Table 2 gives the associations of the selected common genetic variants, known to be 
associated with blood pressure or kidney function, with fetal kidney volume. Out of 30 
genetic variants known to be associated with blood pressure, only rs12940887 (near 
ZNF652) was significantly associated with fetal kidney volume (β: 0.88 (95%CI: 0.40; 1.37) 
cm3 per minor allele, P<0.001), but the effect of this variant did not show the expected 
direction. Overall, eighteen common variants (60%) previously associated with blood 
pressure, showed the expected direction of the association with fetal kidney volume, 
but these associations were not significant. Of the common variants known to be associ-
ated with kidney function or kidney disease, four (rs11959928 (in DAB2), rs10109414 (in 
STC1), rs12460876 (in SLC7A9) and rs4805834 (near SLC7A9)) out of 28 variants (14.3%) 
showed evidence of association with fetal kidney volume (P<0.05), though they did not 
reach the significance threshold after adjustment for multiple testing. The expected 
direction of the associations was found in two (rs11959928 and 4805834) of these com-
mon variants. Overall, thirteen (46.4%) common genetic variants showed the expected 
direction of the association with fetal kidney volume. A risk allele score summing all risk 
alleles of the common genetic variants associated with adult blood pressure and kidney 
function, was not associated with fetal kidney volume (β -0.04 (95% CI: -0.11 , 0.03) cm3 
per risk allele, P=0.25).
We did not find evidence of associations between common genetic variants in PAX2 
(rs4244341 and rs11592735), RET (rs1800860) and ALDH1A2 (rs7169289) and fetal kid-
ney volume (Table 3). The previously described AAA-haplotype in PAX2 (rs11190688, 
rs11190702 and 11599825)13 was not significantly associated with fetal kidney volume.
Table 3. Common genetic variants and their association with fetal kidney volume 
SNP Chr. Position Minor 
Allele
Minor 
allele 
frequency
Gene Previously 
reported effect 
on kidney 
volume
Effect estimate 
for fetal kidney 
volume (cm3)
P-value Direction as 
expected
rs11190688
rs11190702
rs11599825
10 102514460
102532515
102510165
Haplotype: 
AAA
PAX2 ↓13 0.19 (-0.52; 0.89) 0.60 No
rs4244341 10 102498567 T 0.22 PAX2 ↓13 -0.37 (-0.94; 0.20) 0.21 Yes
rs11592735 10 102518253 A 0.04 PAX2 ↓13 -0.43 (-1.73; 0.87) 0.52 Yes
rs1800860 10 42926693 A 0.30 RET ↓9 0.31 (-0.21; 0.82) 0.25 No
rs7169289 15 56030975 G 0.17 ALDH1A2 ↑14 0.30 (-0.38; 0.98) 0.39 Yes
Effect estimates are regression coefficients (95% CI) and reflect the difference in kidney volume per minor allele. All 
regression models were adjusted for fetal sex, gestational age at measurement and estimated fetal weight. We assumed 
an additive model.
Chr, chromosome
Expected direction: We expected that the common genetic variants, known to be associated with kidney volume, 
showed the same direction as described before in literature.
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Discussion
Results from this population-based prospective cohort study suggest that common 
genetic variants, which have previously shown to be associated with blood pressure or 
kidney function15-20, not explain the associations of smaller kidneys with higher blood 
pressure and impaired kidney function in later life. Also, previously found associations of 
common genetic variants involved in the branching pathway with neonatal kidney size9, 
13-14, were not confirmed in this study.
Previous studies showed the association of low birth weight with smaller kidneys and 
a lower number of nephrons7-8, 10. Smaller kidneys, with a reduced nephron number, 
may lead to hyperfiltration in the remaining nephrons, resulting in glomerular sclerosis. 
Subsequently this may predispose an individual to the development of higher blood 
pressure, impaired kidney function and chronic kidney disease4, 10, 33-35. Postmortem stud-
ies in humans showed that a lower nephron number is associated with low birth weight 
and hypertension6, 36. A recent study showed an association between newborn kidney 
volume and nephron number in fifteen infants, who died before three months of age, 
in whom an ultrasound was performed in the first two days of life. There was a strong 
relationship between kidney mass and nephron number9. This association is supported 
by study by Hinchliffe et al demonstrating a strong correlation between renal volume 
and glomerular number up to 40 weeks of gestation, in eleven spontaneously aborted 
fetuses37. Several other post-mortem studies in humans, who died in the perinatal 
period, showed consistent associations between renal size and glomerular number8, 10. 
Low birth weight has also been shown to be associated with low nephron number8, 10, 33, 
36. Ultrasound studies in fetuses and children have shown that low birth weight is associ-
ated with smaller kidney size35, 38-40. Previously we have shown that kidney characteristics 
track from third trimester of pregnancy to the postnatal age of two years30. Therefore, 
fetal kidney volume also seems to be a good surrogate for nephron number. However, 
differences in fetal kidney volume might be smaller and therefore more difficult to de-
tect. This could have affected the power of our study to establish associations. 
The nephron number varies widely between individuals ranging from 250,000 to 
2,000,000 nephrons per kidney7-8. The fetal kidney develops forms two components, 
the metanephric mesenchyme and the Wolffian duct. The ureteric bud forms as an 
outgrowth of the Wolffian duct and reciprocal induction between the metanephric 
mesenchyme and the ureteric bud results in branching of the uretiric bud. Through 
various complicated processes, metanephric tubules and glomerular components are 
formed. Kidney and nephron growth and development are influenced by genetic and 
various environmental factors11-12, 41-44. Many molecular mechanisms are required for dif-
ferent aspects of nephrogenesis, such as the ureteric bud outgrowth and branching11-12. 
Ureteric branching is a very important part of nephrogenesis and thought to be a major 
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determinant of nephron endowment11-12. Several genes, such as PAX2, RET and GDNF, 
have been suggested to be involved in these steps in nephrogenesis. Mutations in these 
genes seem to cause kidney agenesis or dysgenesis and fewer nephrons in animals and 
humans11, 45. Adverse fetal environmental exposures could also affect kidney develop-
ment, although information on specific adverse fetal exposures affecting kidney devel-
opment is limited. It has been shown that continued smoking during pregnancy of more 
than ten cigarettes per day is associated with smaller kidneys in fetal life41 and higher 
blood pressure in childhood46. Also, other environmental exposures, such as nutrition, 
folic acid supplementation, and placental dysfunction might affect kidney develop-
ment. Several animal studies have shown that low maternal protein intake and vitamin 
A deficiency during pregnancy lead to smaller kidneys and increased blood pressure in 
the offspring42-44.
It seems likely that genetic factors partly explain variation of nephron number, and 
thus kidney size, in the general population11. There have been no heritability stud-
ies performed on kidney volume in healthy populations, but a study in families with 
polycystic kidney disease showed that kidney volume has a heritability of 0.4247. The 
association between smaller kidneys and higher blood pressure, impaired kidney func-
tion and kidney disease in adulthood, might be partly explained by common genetic 
variation, resulting in lower nephron endowment in individuals. In our study, we only 
found rs12946454, near ZNF652, to be significantly associated with a larger kidney 
volume. ZNF652 has been implicated in tumor genesis48. Another gene in this region, 
PHB, is shown to be involved in angiogenesis49. It might be that this variant influences 
angiogenesis which may subsequently lead to a larger kidney volume. Further research 
is needed to identify underlying mechanisms and to evaluate whether carrying kidney 
volume increasing alleles of this variant also leads to better kidney function and lower 
blood pressure. 
We did not observe any associations in the expected direction of previously identified 
common variants affecting blood pressure and kidney function in adulthood15-21, with 
fetal kidney volume. We expected that a blood pressure increasing allele or a kidney 
function decreasing allele would be associated with a smaller kidney volume in fetal 
life. This suggests that these variants do not underlie the association between smaller 
kidneys and increased blood pressure and impaired kidney function in later life. It might 
be that we cannot identify associations, because of the small differences in kidney size 
in fetal life. It also could indicate that there might be other genes underlying this as-
sociation. Combining the information of all common genetic variants, by calculating a 
risk allele count, also did not show evidence for association of these variants with fetal 
kidney volume. Genome wide association studies including much larger sample sizes 
than published so far, might result in common genetic variants that do affect kidney 
volume. These studies might be powerful enough to detect small differences in blood 
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pressure or kidney function possibly caused by slightly smaller or larger kidneys and 
could provide evidence for a genetic basis of the hyperfiltration hypothesis.
Other interesting genes could be genes involved in the kidney branching morpho-
genesis. Mutations in genes such as PAX2 and RET lead to hypoplasia or agenesis of the 
kidney9, 11, 13. Both PAX2 and RET play a role in the outgrowth of the ureteric bud and 
are mainly involved in first phase kidney development11.To determine whether common 
genetic variants in these genes also reduce kidney volume, several studies were con-
ducted in a Canadian newborn population9, 13-14. Variants in PAX2, RET and ALDH1A2 have 
been shown to affect kidney volume9, 13-14. Subjects carrying a specific PAX2-haplotype 
or the adverse allele of rs1800860 in the RET gene had a 10% smaller kidney volume 
than subjects not carrying these variants9, 13. Also rs4244341 and rs11592735 in the PAX2 
gene were associated with a smaller kidney volume13. Homozygosity for the minor allele 
of rs7169289 in ALDH1A2 was associated with a 22% larger newborn kidney volume14. 
In our study, we did not find any association of these variants with fetal kidney volume. 
The absolute effects on fetal kidney volume might be smaller and more difficult to 
establish, as compared to a newborn population. This study (n=855) includes a larger 
number of subjects, as compared to the previous studies9, 13-14. However, it could also 
be that these variants exert their effect later in pregnancy. Also, the variants in PAX2, 
RET and ALDH1A2 have not been associated with increased blood pressure or impaired 
kidney function in adulthood as far as we know. These findings do not support the 
hypothesis that genetic factors partly underlie the association between smaller kidneys 
and increased blood pressure or impaired kidney function. 
The lack of evidence for a genetic basis of the hyperfiltration hypothesis could indicate 
that an adverse fetal environment, such as fetal nicotine exposure, is more important 
than genetic factors in explaining this hypothesis. It seems likely that genetic factors 
only cause small differences in kidney volume, which could be difficult to detect and 
might be of little clinical interest, but combined could add to the hyperfiltration hy-
pothesis. Further research is necessary to identify specific adverse fetal exposures and 
genetic factors that underlie the association of kidney volume with blood pressure and 
kidney function.
Conclusions
Our results suggest that common genetic variants, previously associated with adult 
blood pressure and kidney function, do not underlie the associations of smaller kidneys 
with a reduced nephron endowment in early life with higher blood pressure or impaired 
kidney function in later life.
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Introduction
Many epidemiological studies suggest that early life events have an important role for 
the susceptibility to develop adult diseases. Low birth weight and subsequent childhood 
growth have been associated with a wide range of adult diseases, such as metabolic, 
cardiovascular and renal diseases1-6. These observations have resulted in the “Develop-
mental Origins of Health and Disease“ Hypothesis, which proposes that an organism 
may develop in different ways, depending on the environment it is exposed to7. The aim 
of this study was to identify specific fetal exposures and genetic determinants underly-
ing the associations of early growth with obesity, and measures of cardiovascular and 
renal structures and function. In this chapter, we give an overview of the main findings 
of the studies in this thesis, what they add to the existing body of literature and possible 
clinical implications of these studies. Furthermore, we consider methodological issues 
and give suggestions for future research.
Main findings
Early growth and body composition
The relationship between birth weight and obesity is complex. Both low and high birth 
weight are associated with an increased risk of obesity in later life8. Also, early childhood 
growth seems to be an important determinant of body composition in later life. Birth 
weight and early childhood growth are not independent of each other. Catch-up growth 
in infancy has been proposed to be one of the underlying mechanisms of the associa-
tions of low birth weight with adult diseases4. Children born small size for gestational 
age (SGA) frequently show catch-up growth in early postnatal life9-10. Many studies have 
shown that catch-up growth in children born SGA is associated with metabolic diseases 
in later life11. Children born large size for gestational age (LGA), also show compensa-
tory catch-down growth in early life, but the effect of catch-down growth in children 
born LGA has less frequently been studied. In this thesis, we showed that children born 
small size and large size for gestational age display catch-up and catch-down growth 
respectively in the first months of life. Despite this compensatory growth these children 
still have persistent differences in height, weight and head circumference until the age 
of 4 years. We also demonstrated that catch-up and catch-down growth in children born 
SGA and LGA modifies the association of size at birth with subcutaneous fat mass, body 
mass index and the risk of being overweight or obese at the age of four years (this thesis). 
Furthermore, effect modification of the association of birth weight with childhood over-
weight by postnatal catch-up and catch-down growth was also noted in children born 
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appropriate size for gestational age (AGA). Children born AGA with catch-up growth and 
children born LGA without catch-down growth have a higher subcutaneous fat mass 
and body mass index in childhood, and are at increased risk for childhood overweight. 
Results from our study suggest that these groups could be potential targets for early 
prevention of childhood obesity.
Genetics of early growth
Heritability studies show that growth in early life is partly determined by genetic factors 
(D.O. Mook-Kanamori, in press 12). Therefore, common genetic variants are likely to af-
fect growth in early life and might partly explain the association between early growth 
and adult disease. In a population based cohort from the UK, common genetic variants 
known to be associated with adult BMI, also were robustly associated with a greater 
weight gain in infancy, indicating that early growth is on the pathway to adult obesity 
risk13. Novel genetic determinants of early growth might provide insight in biological 
pathways and underlying mechanisms of these associations. Genome-wide association 
studies allow researchers to study many common genetic variants for association with 
a specific outcome in a hypothesis-free manner. In one analysis, the associations of 2.5 
million common genetic variants can be explored. Common genetic variants are likely 
to have small effects, compared to rare mutations with large effects14. As a consequence, 
large sample sizes are needed to detect the small differences caused by common ge-
netic variants. International consortia have been set up to provide the infrastructure for 
collaboration, which is needed to amass the sample size needed for successful genome-
wide association study meta-analysis. The Early Growth Genetics (EGG) Consortium 
aims to identify common genetic determinants associated with various aspects of early 
growth. 
Genome-wide association studies in adults have identified many common genetic 
variants associated with body mass index15, waist circumference16, body fat distribu-
tion17 and height18. However, genome-wide association studies in children have been 
scarce. Only one genome-wide association meta-analysis was performed in children 
before the work presented in this thesis. Freathy et al. showed that common genetic 
variants in ADCY5 (rs9883204) and near CCNL1/LEKR1 (rs900400) were associated with 
birth weight. The ADCY5 (rs9883204) locus was also implicated in the regulation of 
glucose levels and susceptibility of type 2 diabetes19, providing evidence that genetic 
variation can at least partly explain the association between low birth weight and type 
2 diabetes in later life. This is in line with the ‘fetal insulin hypothesis’, which states that 
that common genetic variants related to type 2 diabetes might partly explain the as-
sociations of low birth weight with metabolic diseases in adulthood20. In this thesis, we 
present the second genome-wide association study on birth weight performed in the 
EGG-consortium, in up to 69,308 individuals. We identified seven loci, including the two 
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previously published loci, associated with birth weight. Five of the loci are known to be 
associated with other outcomes: ADCY5 (rs9883204) and CDKAL1 (rs6931514) with type 
2 diabetes; ADRB1 (rs1801253) with adult blood pressure; and HMGA2 (rs1042725)and 
LCORL (rs724577) with adult height. The results of this meta-analysis highlight biological 
pathways of relevance to the fetal origins of type 2 diabetes and blood pressure and 
demonstrate overlap between the genetics of fetal growth and adult height.
Common genetic variants are also likely to be associated with other aspects of early 
growth. Head circumference in infancy is used as a measure for brain size and develop-
ment21-22 and has a substantial heritability of 0.7-0.923. Normal variation in head circum-
ference seems to be associated with cognitive and behavioral development24-26. Larger 
head circumference in infancy is associated with higher IQ scores in childhood26-28. Sev-
eral rare mutations with large effects on head circumference have been identified29-32, 
including those resulting in microcephaly and intellectual disability30-32. In this thesis we 
present a genome-wide association study meta-analysis on infant head circumference. 
We identified two loci robustly associated with infant head circumference, one in HMGA2 
(rs1042725) and one near SBNO1 (rs7980687)33. These two loci were previously associ-
ated with adult height18, however conditional analyses showed that the effect on infant 
head circumference was largely independent of the effect on height. Another locus, in 
a region previously associated with Parkinson’s disease and other neurodegenerative 
diseases34-36, which includes the MAPT en CRHR1 genes, also showed evidence for as-
sociation with infant head circumference (rs11655470). Investigators from the CHARGE 
consortium showed that genetic variants in the same region were associated with intra 
cranial volume, which is a measure of maximum brain size37. This could indicate that 
common genetic variants in this region might link early brain growth with neurological 
disease in later life33, 37.
It is likely that the gene-environment interactions also can affect birth weight, with 
common genetic variants only having an effect in a specific environmental setting. A 
previous study has suggested an interaction of maternal smoking with genetic variants 
in the nicotine receptor cluster, affecting birth weight38. In mothers who smoked, the 
risk allele of this variant was associated with a lower birth weight, while in non-smoking 
mothers the genotype did not have an effect on birth weight. Since birth weight is a 
crude end-point of fetal growth and can be the result of different growth patterns, we 
investigated whether this variant was associated with a fetal growth. In mothers who 
smoked, each maternal risk allele was associated with a reduced fetal growth, although 
the effect on birth weight itself was not significant39. These results suggest that the nega-
tive effect of maternal smoking during pregnancy is modified by this genetic variant in 
the nicotine receptor cluster. Since the findings on birth weight are non-significant, it 
also highlights the need of a well-powered sample of mothers and offspring to study 
this specific, and other possible gene-environment interactions. 
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Childhood obesity itself is one of the most important predictors of adult obesity and 
an increasingly prevalent problem in developed countries40-41. Since environmental 
exposures, such as nutrient rich diet, are present for a relatively short period, children 
provide an excellent opportunity to investigate the genetic contribution to the devel-
opment of obesity. We performed a genome-wide association study meta-analysis on 
childhood obesity status. Many known common genetic variants associated with adult 
BMI were also associated with an increased risk of childhood obesity. More importantly, 
we identified two novel loci associated with childhood obesity, located near OLFM4 
and HOXB5. These two genes seem to be involved in different aspects of gut function42. 
Further functional characterization of these signals is needed to investigate the exact 
underlying mechanisms and function.
Cardiovascular development
Studies in children showed that left ventricular mass tracks from childhood to adult-
hood43-44, implying that left cardiac structures also track during childhood and adoles-
cence. However, a relatively smaller left ventricle and aortic root in early life may lead to 
insufficient cardiac functioning in later life. The heart may respond to this insufficiency 
by growth and adverse remodeling. Since the number of cardiomyocytes is established 
largely in fetal life, cardiac adaptations might lead to left ventricular hypertrophy and 
dysfunction45-48. Left ventricular hypertrophy is an important risk factor for cardiovas-
cular morbidity and mortality in adulthood49-50. Therefore, fetal exposures who affect 
cardiac development may have consequences in later life. It has also been hypothesized 
that fetal growth restriction leads to impaired elastin synthesis in the blood vessel walls, 
leading to changes in the mechanical properties of these blood vessels51. Specific adverse 
fetal exposures might also lead to developmental changes in function and structure of 
blood vessels, which may predispose an individual to hypertension and cardiovascular 
disease in adulthood.
Growth in fetal life and early childhood seems to influence the susceptibility to cardio-
vascular disease in later life. Detailed studies in animals and humans have shown that 
fetal and childhood growth variation is associated with cardiovascular structural and he-
modynamic adaptations in early life5, 52-67. In this thesis, we investigated the associations 
of different fetal, infant and child growth characteristics with cardiovascular structures 
and function at the age of 6 years and whether postnatal growth patterns modified 
the association of size at birth on childhood cardiovascular development. We showed 
that birth weight, and to a lesser extent gestational age, was associated with childhood 
blood pressure and fractional shortening, and positively associated with left cardiac 
structures. We also showed that postnatal catch-up and catch-down growth modified 
the associations between size at birth and childhood cardiovascular development. This 
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suggests that specific early growth patterns are associated with altered cardiovascular 
development.
One of the possible adverse fetal exposures is maternal smoking during pregnancy. 
Maternal smoking during pregnancy is one of the most important, potentially modifi-
able, adverse fetal exposures68-69, and strongly related with increased risks of low birth 
weight and preterm birth69-70. Maternal smoking may lead to developmental adapta-
tions with subsequent effects in postnatal life, such as higher blood pressure, obesity 
and type 2 diabetes71. However, it is not clear from previous studies whether these as-
sociations are due to direct intra-uterine effect of fetal smoke exposure or due to other, 
unmeasured confounders. We showed that maternal smoking during pregnancy is as-
sociated with childhood diastolic blood pressure and fractional shortening, but not with 
systolic blood pressure, carotid-femoral pulse wave velocity and left cardiac structures. 
To assess the role of confounding we also assessed whether paternal smoking during 
pregnancy was associated with the same outcome measurements72. Similar effect sizes 
for maternal and paternal smoking would suggest that these associations are explained 
by unmeasured environmental determinants72. Among mothers who did not smoke 
during pregnancy, paternal smoking was associated with aortic root diameter, but not 
with other cardiovascular outcomes. The stronger effect estimates for maternal smok-
ing affecting diastolic blood pressure and fractional shortening, compared to paternal 
smoking might suggest that direct intra-uterine mechanisms are involved, but since 
paternal smoking was associated with childhood aortic root diameter, we must be care-
ful to conclude direct intra-uterine effects.
Maternal psychological distress during pregnancy might also be one of the adverse fe-
tal exposures leading to fetal developmental adaptations73, possibly by dysregulation of 
the maternal hypothalamic-pituitary-adrenal (HPA) axis74, and subsequent higher fetal 
cortisol exposure levels74. Previous animal and human studies have shown that excessive 
exposure to exogenous glucocorticoids is associated with higher blood pressure in the 
offspring75-76. Mild endogenous elevations in cortisol levels, e.g. due to maternal psycho-
logical distress during pregnancy, might also lead to developmental adaptations and 
affect cardiovascular function in the offspring77. We did not find evidence for association 
of maternal psychological distress with childhood blood pressure and carotid-femoral 
pulse wave velocity. High maternal overall psychological symptoms were associated 
with a lower childhood left ventricular mass, however paternal psychological showed a 
similar effect size. The similar effect sizes for maternal and paternal psychological distress 
with left ventricular mass suggest that these associations could be due to unmeasured 
shared social and environmental factors, rather than direct intra-uterine effects.
Exposure to extreme famine during pregnancy has been associated with a higher risk 
of adult diseases, such as hypertension78-80. The association of less extreme variations 
in maternal nutrition during pregnancy with blood pressure in the offspring has been 
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investigated in several studies, but results are inconclusive81-91. Possible underlying 
mechanisms are unclear, but might involve an effect on endothelial function, with 
subsequent changes in blood pressure development92. In this thesis, we found marginal 
evidence that low maternal iron intake and high vitamin B12 concentrations were asso-
ciated with a higher childhood blood pressure, but the effect sizes were small and after 
taking into account multiple testing these associations were not statistically significant. 
Intake of other macronutrients and micronutrients was not associated with childhood 
blood pressure.
Apart from environmental exposures, genetic factors are also involved in blood pres-
sure regulation from childhood to adulthood. The heritability of blood pressure is esti-
mated to be 30-60%93-94. Previous genome-wide association studies identified several 
common genetic variants associated with adult blood pressure, only explaining ~1% of 
the variance of blood pressure in the investigated populations95-96. It has been shown 
that the presence of multiple variants affecting polygenic traits can be demonstrated 
by constructing genome-wide prediction models (genetic risk scores) of common vari-
ants97-98. We demonstrated that genetic risk scores incorporating many common variants 
explained more of the variance of blood pressure than genetic risk scores only based 
solely on common genetic variants reaching genome-wide significance in both adults 
and children. These results suggest that there are many more common genetic variants 
affecting blood pressure and that there are multiple genes involved in blood pressure 
regulation, which partly overlap in adults and children. Recently, the largest genome-
wide association study meta-analysis on blood pressure in adults so far, identified 30 
loci associated with blood pressure, confirming that blood pressure has a polygenic 
origin99. This indicates the need for larger genome-wide association studies, to identify 
more genetic variants involved in blood pressure regulation and improve the variance 
explained by genetic factors.
Renal development
The formation of nephrons (nephrogenesis) starts from 30 days of gestation onwards 
and continues until 36 weeks of gestational age. The number of nephrons is determined 
in fetal life as nephrogenesis ceases in postnatal life. On average about 750,000 neph-
rons per kidney are formed, but the nephron number can vary between 250,000 and 
2,000,000 per kidney100-101. Adverse fetal environment might have negative effects on 
nephrogenesis, resulting in a lower number of nephrons. Animal studies have shown 
that various adverse intra-uterine environmental exposures, such as low protein intake 
and vitamin A deficiency, lead to fetal growth retardation and smaller kidneys with a 
lower nephron number102-104. Post mortem studies in humans showed that a lower 
nephron number is associated with both low birth weight and hypertension101, 105-108. It 
has been hypothesized that smaller kidneys with a reduced number of nephrons in low 
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birth weight children might lead to hyperfiltration of the remaining nephrons, even-
tually resulting in glomerular sclerosis (‘the hyperfiltration hypothesis’)109-110. This may 
predispose the individual to renal damage and development of higher blood pressure, 
impaired kidney function and end stage kidney disease in adulthood. Indeed, epidemio-
logical studies clearly showed that low birth weight was associated with hypertension, 
impaired renal function and end stage renal disease in adulthood3, 56, 111-113.The best 
surrogate marker for assessing nephron number in epidemiological studies seems to 
be kidney weight or kidney size measured by ultrasound101, 105-106, 108, 114-119. In this thesis 
we described normal kidney growth from fetal life until the age of two years, to enable 
identification of abnormal kidney size and growth120. Abnormal size or growth may have 
subsequent short and long-term consequences.
According to the hyperfiltration hypothesis, adverse fetal exposures, might lead to 
smaller kidneys with lower nephron numbers, with possible effects in later life. We have 
demonstrated that maternal smoking during pregnancy, as specific fetal exposure, is 
associated with an altered kidney volume in third trimester of pregnancy, but not in 
infancy. The direction and size of the effect depended on the timing and number of 
cigarettes smoked during pregnancy121. Children of mothers who smoked intensively 
(>10 sigarettes per day) during pregnancy, had smaller kidneys compared to children 
of mothers who did not smoke during pregnancy. This effect was independent of the 
effect of maternal smoking on fetal growth. These findings suggest that early kidney 
development may be an underlying mechanism for the associations between maternal 
smoking during pregnancy and increased blood pressure in later life121-122.
Identification of maternal, fetal and infant determinants of childhood kidney volume 
and function may be important for early prevention of renal disease in adulthood. 
Impaired renal function in children, possibly as a consequence of smaller kidney with 
a lower number of nephrons, could be an early sign of developing renal disease. At 
the age of 5 to 6 years we examined which maternal, fetal and infant characteristics 
were important determinants of kidney volume and function. We showed that maternal 
anthropometrics, smoking during pregnancy, birth weight and gestational age were the 
main determinants of total kidney volume and function. This was in line with previous 
studies in a subsample of the Generation R Study which showed that maternal weight 
before pregnancy and maternal height were associated with kidney volume in fetal life 
and at the age of 2 years119, 123. Some of these factors are potentially modifiable and 
might provide targets for intervention to improve renal health on a population level. 
Furthermore, we also showed that smaller kidneys with reduced total kidney volume 
were associated with a decreased kidney function. This is in line with the hyperfiltration 
hypothesis and might indicate that kidney volume, which is easily measured, could be a 
tool to identify children at risk for developing impaired renal function and hypertension 
in later life.
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The associations of smaller kidneys holding lower number of nephrons with high 
blood pressure and impaired kidney function might partly be explained by genetic 
factors. It seems likely that common genetic variants account for part of the normal 
variation in nephron endowment. It has been shown that common genetic variants in 
PAX2, RET and ALDH1A2, genes involved in kidney branching morphogenesis, are as-
sociated with newborn kidney volume114, 124-125. We did not find associations of common 
genetic variants in these genes with fetal kidney volume. We also showed that com-
mon genetic variants, previously associated with blood pressure or kidney function in 
adults99, 126, were not associated with fetal kidney volume127. These findings suggest that 
these variants do not underlie the association of lower nephron number with higher 
blood pressure and impaired kidney function. However, it might be that our study was 
not adequately powered, or that other genetic factors might explain this association.
Methodological considerations 
Specific methodological considerations of the studies have been discussed in the 
separate chapters of this thesis. Here, general methodological issues regarding selection 
bias, information bias and confounding are discussed. We also address methodological 
issues regarding genetic association studies.
Selection bias 
Selection bias can occur if the association between the determinant and outcome of 
interest is different in subjects who participate in the study and those who did not par-
ticipate in the study, but were eligible for the study. Selection bias may also occur when 
there is a selective loss to follow-up128. Of all children eligible at birth, the overall response 
to participate in the Generation R Study was 61%. The mothers of non-participating chil-
dren more frequently belonged to an ethnic minority and had a lower socio-economic 
status, compared to mothers who were participating in the study. Participating mothers 
and children had less medical complications, such as preterm birth and low birth weight, 
suggesting a selection toward a relative more healthy study population129. This selection 
at baseline may reduce statistical power, due to lower prevalence rates, and possibly 
limit generalizability of our findings to other, less healthy, populations. 
It has been described that biased estimates in large cohort studies mainly arise from 
loss to follow-up rather than non-response at baseline130. Selection bias due to selec-
tive loss to follow-up may occur if the associations studied differ between those lost to 
follow-up and those still included in the population for analysis. In the studies presented 
in this thesis, the response in at follow-up generally was around 70%. Approximately 
10% of the children who were not included were loss to follow-up, the remainder either 
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withdrew consent for the study or was not able to visit the research center. Overall, 
mothers from children who did not visit the research center more frequently engaged in 
unhealthy life style habits and were less well educated than the total sample. This selec-
tive loss to follow-up towards a more healthy population may have biased our effect 
estimates, but is difficult to quantify. 
Information bias
Information on the determinants and outcomes in the non-genetic studies described in 
this thesis are obtained by physical examinations and questionnaires. Random misclas-
sification of the determinant or outcome can lead to bias towards the null. Differential 
misclassification, which occurs for instance when misclassification of the determinant 
is related to the outcome, could lead to biased effect estimates. Exposure data used in 
our studies were collected before assessment of the outcome, which makes differential 
misclassification of the exposure unlikely. However, underreporting of specific adverse 
exposures, such as maternal smoking during pregnancy and psychological distress, 
may still occur, although the mothers were not aware of specific research questions. 
Depending on the research question, this might lead to an overestimation (e.g. selective 
underreporting of heavy smokers when investigating a dose-response relationship) or 
underestimation (e.g. underreporting of smoking when investigating effect of smoking 
yes/no) of the effect. To overcome this limitation, studies have tried to use biomarkers of 
exposures superior to the use of questionnaires, but this has proven to be difficult131-132. 
In most of our studies, the outcome was assessed using standardized hands-on assess-
ments of body composition and cardiovascular and renal development. Furthermore, 
the observers were blinded to the exposure status, which makes differential misclas-
sification of the outcome less likely.
Confounding
A confounding factor is a factor associated with both the determinant and the outcome 
and if not taken into account, this may lead to a biased effect estimate of the associa-
tion between the determinant and the outcome. In the non-genetic studies presented 
in this thesis we used multiple approaches to explore the role of confounding in the 
investigated association. First, we adjusted for multiple potential confounders in our 
analyses. In some of the studies, adjustment for potential confounders attenuated 
significant associations to non-significance indicating that the unadjusted association 
is confounded. In other studies, the association did not attenuate or only slightly, indi-
cating the association is possibly a true association between the determinant and the 
outcome. Although there are many potential confounders available in the Generation R 
Study, it still may be that we did not measure all potential confounders. Also, measure-
ment error of the confounding variables can occur, thus residual confounding might 
Chapter 5
288
still be an issue. Second, where possible, we assessed the associations of both maternal 
and paternal exposures during pregnancy. Similar effect sizes for maternal and paternal 
factors would suggest that an association of the maternal factor is likely to explained by 
unmeasured environmental factors, rather than direct intra-uterine mechanisms72.
Genetic association studies
Different strategies have been used to identify genetic determinants of disease or other 
outcomes. In the past decades, many candidate gene studies investigated the associa-
tion of one or several common genetic variants with a specific outcome. These studies 
used an ‘a priori’ hypothesis to select the genes and variants to investigate. In more recent 
years, genome-wide association studies have been the main approach to identify new 
common genetic variants associated with an outcome. Using genome-wide association 
studies one can test the association of a large number (~2.5 million) genetic variants in 
a hypothesis-free manner. Because of this large number of associations tested, false-
positive findings are likely to occur when using a conventional statistical significance 
threshold. It has been shown that a genome-wide association analysis reflects approxi-
mately 1 million independent hypothesis tests133. Therefore the statistical significance 
threshold of genome-wide association studies has been set to 5x10-8, reflecting a 
Bonferroni correction of testing one million variants (0.05/1,000,000)133. Since common 
genetic variants are likely to have small effects, false-negative findings are likely to occur 
due to insufficient statistical power in a single study. It is therefore necessary to combine 
many subjects from different studies with genotypic data available, to generate suffi-
cient power for identification of new common genetic variants. For this goal, consortia 
of collaborating studies, such as the Early Growth Genetics Consortium, have been set 
up to increase the sample size of the genome-wide association meta-analyses.
Although the selection of children with or without genetic data usually is not related 
to the outcome under investigation, population stratification may arise when genotype 
and outcome distribution is different between subgroups of the population in your study, 
and can give rise to false positive findings134. Several strategies have been proposed 
to correct for possible population stratification. Genomic control was applied in all of 
the genome-wide association studies presented in this thesis, to correct for population 
stratification. Misclassification or information bias can occur in the determination of the 
genetic determinants and the outcome, in each of the participating studies. Stringent 
quality control is applied when genotyping and imputing genotypic data of the partici-
pants in each study, which have been described in the genome-wide association studies 
in this thesis. General guidelines for sharing genome-wide association data and correct 
meta-analysis of this data have been described previously135. Outcome assessment can 
differ between the participating studies in a genome-wide association meta-analysis. 
This might lead to random misclassification, as it is not likely to be related to the geno-
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type of the individuals, and therefore reduce statistical power to detect associations 
of genetic variants with the outcome. Outcome definition is important and should be 
assessed as similar as possible in the different studies participating. 
Clinical implications and future perspectives
Early growth
Many studies have shown that catch-up growth in children born small for gestational 
age is associated with adverse metabolic effects in later life. However, children born ap-
propriate size for gestational age and large size for gestational age, also exhibit postnatal 
growth patterns, which might affect their risk of being overweight. In comparison with 
catch-up growth in small for gestational age children, catch-down growth in large for 
gestational age children, has not been investigated often. We have shown that catch-up 
and catch-down growth in the first two years of life after being born small, appropriate 
or large size for gestational age modifies the risk for overweight and obesity at the age 
of four years. This study showed that children born large size for gestational age who do 
not show catch-down growth are at a high risk for developing childhood overweight. 
Also children born appropriate size for gestational age exhibiting postnatal catch-up 
growth, have an increased risk for overweight. These groups might be potential targets 
for early prevention of overweight in children, although evidence for interventions to 
prevent overweight in pre-school children is scarce. The effectiveness of such interven-
tions should be determined first.
Genetics of early growth
In this thesis we describe several common genetic variants associated with different 
aspects of early growth; birth weight, infant head circumference and childhood obe-
sity. The last few years, many common genetic variants have been identified with adult 
cardiovascular and metabolic disease by means of large scale genome-wide association 
studies. Early growth is an important determinant of the risk of adult disease. We identi-
fied several variants that are related both to early growth and adult disease (blood pres-
sure, obesity and type 2 diabetes). This indicates that common genetic variants partly 
underlie the association between low birth weight and diseases in later life, and that the 
genetic variants act throughout the life course. Furthermore, it highlights that the fetal 
and early postnatal period provides a possible window of opportunity to improve adult 
health. Although the clinical implications of these findings are limited for know, future 
research might provide further insight and understanding of underlying pathogenic 
mechanisms. In turn, these findings might give rise to useful clinical applications or new 
drug targets.
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Genetic risk prediction
At this stage, individual risk prediction is not feasible and personal genetic profiles that 
can be purchased on the internet are of little use so far136. The common genetic vari-
ants that have been identified usually have small effects and are not comparable to the 
risk of traditional risk factors, e.g. smoking or overweight for the risk of cardiovascular 
disease. The main reason for this is that these genetic variants explain a very small part 
of the variance in the investigated phenotypes, even when considering multiple genetic 
variants. Using information of multiple common genetic variants might improve genetic 
risk prediction, but several studies have shown that the additive value of these genetic 
risk profiles is limited so far, e.g. in type 2 diabets137. 
The genetic prediction of complex diseases will probably improve in the future by 
identifying more variants associated with the disease and the identification of rarer 
variants with larger effects. Genetic profiling might be a way of identifying subgroups at 
genetically high risk for increased blood pressure at a population level138, but whether it 
will be enough for personalised medicine and early treatment of people at risk for adult 
diseases, remains to be determined. Work in this thesis indicates that this may require 
the identification of many more common variants with small effects on blood pressure.
Next steps after genetic findings
It is important to emphasize that the genetic variants associated with a specific out-
come, are not necessarily the functional variants that cause the change in disease risk 
or phenotype. It is more likely that the variant, for which the association is observed, 
is in linkage disequilibrium with the causal variant. In order to find the causal variant, 
dense genotyping of all the genetic variants in this region is needed. Furthermore, 
studies in other ethnic groups might provide refinements of the associated signal. Also, 
sequencing in large sample sizes can help to investigate if rare variants are causing the 
association that was identified.
Identifying the causal gene or variant is also an important step to make findings of 
genome-wide association studies clinically relevant. The genome-wide association 
study approach does not identify the causal gene directly. To investigate which gene is 
causal for the association found, the effect on gene expression can be assessed. If the 
associated genetic variant also affects gene expression, this could point to the causal 
gene. It is important where expression of the gene is investigated since gene expression 
is tissue specific. Furthermore, animal knockout models could be used if available, and if 
these animals show the disease of interest, this could point to a causal effect of the gene. 
If there are genes known to be involved in Mendelian forms of the studied outcome this 
might provide clues for a possible causal gene and could be used to prioritize further 
research.
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Future of genome-wide association studies 
Increasing sample size is a key factor for the identification of novel genetic variants of 
complex polygenic phenotypes such as body mass index and blood pressure. In adults, 
large meta-analyses in up to 200,000 individuals have identified many genetic variants 
associated with several phenotypes. Some of these phenotypes are particularly interest-
ing to study in children since environmental influences have been present for a relatively 
limited period of their life-time. In adults, the environmental influence on e.g. body mass 
index may be more important than genetic factors, which makes identification of vari-
ants associated with body mass index more difficult. However, although the number of 
subjects with genome-wide association studies and childhood data is likely to increase, 
other options to further increase the power to identify common genetic variants con-
tributing to a complex disease or trait, can be considered.
It could be that within one locus, multiple common genetic variants are independently 
associated with the phenotype. These secondary signals can be found by conditioning 
on the identified variants as has been proposed recently139. Also, gene-environment 
interactions might add to explain the variance in complex phenotypes. Genome-wide 
approaches testing gene-environment interactions might be hampered by the different 
assessments and definitions of the environmental factor under study and the different 
periods of enrolment in the studies which can be decades apart. This heterogeneity 
reduces the power to find statistically significant gene-environment interactions. Ide-
ally, future studies should aim to adopt similar assessment strategies in have the most 
fruitful meta-analysis. Another option might be to combine related traits in a multivari-
ate genome-wide association study. This way, common genetic variants affecting both 
traits, i.e. having a pleiotropic effect, can be identified, beyond those already identified 
in ‘regular’ genome-wide association studies. These approaches can be used indepen-
dently of each other, in an attempt to increase the number of identified genetic variants, 
which increases the possibility of findings that might be translated to relevant clinical 
applications.
Environmental exposures 
In this thesis we describe associations of environmental exposures during pregnancy 
and postnatal development of the cardiovascular and renal system. Due to the obser-
vational design of our study we cannot establish whether this association is causal or 
not, due to possible residual confounding. A randomized controlled trial is the preferred 
study design to establish causation. However, with adverse environmental exposures, 
such as maternal smoking and maternal psychological distress, this is not possible. For 
other exposures, such as maternal nutrition, this might be feasible and randomized con-
trolled trials could overcome this issue, possibly identifying mechanisms that underlie 
the associations. 
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Role of confounding
An approach that we have used for adverse fetal exposures in thesis is to asses the as-
sociations of paternal lifestyle habits. Comparing maternal and paternal effects might 
provide a way to separate intra-uterine effects from associations explained by social, 
familial and environmental factors72. Future research should aim to also involve and 
include fathers in the study with similar exposure assessment, to compare the associa-
tions of both maternal and paternal exposures during pregnancy with offspring health 
where possible.
Also, it might be hard to disentangle pre- and postnatal environmental exposures as 
these are likely to be highly correlated. For instance, mothers who smoke throughout 
pregnancy are likely to continue smoking in postnatal life. Exposure assessment should 
be similar in prenatal and postnatal life. Ideally, biomarkers of exposure could be deter-
mined in pre and postnatal life.
Cardiovascular development
Early markers of cardiovascular adaptations might provide insight in the underlying 
mechanism of the association between low birth weight with cardiovascular disease in 
later life. Subtle changes in cardiovascular development can be identified already in early 
life and follow-up studies should determine how these changes relate to cardiovascular 
disease in later life. New imaging techniques such as magnetic resonance imaging of 
the heart and three dimensional ultrasounds, can provide more detail in cardiovascular 
development at young ages and possibly identify other mechanisms important in the 
development of cardiovascular disease in adult life.
Also, endothelial dysfunction and structural vascular changes might underlie part of 
the association between low birth weight and cardiovascular disease in later life. In this 
thesis, we have measured pulse wave velocity as marker of arterial stiffness. We did not 
find associations of environmental exposures and pulse wave velocity. At this age, dif-
ferences in arterial stiffness might be too small to detect. Future studies should focus on 
other markers of vascular adaptations such as flow-mediated arterial dilatation, intima 
media thickness and retinal arteriolar narrowing. 
Renal development
Early renal development is important in determining the number of nephrons avail-
able for the remainder of the life time of the individual. Kidney volume, especially in 
children, seems to be a reliable surrogate for nephron endowment140. Future research 
should focus on more reliable ways of determing nephron number in population based 
studies. There is some promising evidence that magnetic resonance imaging techniques 
can provide individual counts of glomerular number in rats, which is equivalent to the 
nephron number141. If these methods could be extrapolated to humans it could provide 
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the means for large scale epidemiological studies, to directly assess determinants of 
nephron number and how this affects the development of hypertension and chronic 
kidney disease. Other earlier markers of kidney disease, such as mildly impaired kidney 
function, might also be subject to fetal programming. Identifying possible modifiable 
exposures associated with an impaired kidney function early in life, might give new 
biological insights in the development of hypertension and kidney disease. 
Not only nephron endowment can be affected by adverse fetal exposures. Other 
important pathways, such as endocrine pathways, can be ‘programmed’ as well. The 
renin-angiotensin-aldosteron (RAS) system is important for blood pressure and organ 
development, and its activity can be altered by adverse fetal environment142-143. Other 
possible systems include the glucocorticoid metabolism and the renal tubular function 
(sodium reabsorption)144. Future studies should focus on identifying the underlying 
pathogenic mechanisms, including these pathways, as they may help to prevent the 
development of hypertension and kidney disease in an individual at risk. Subsequently, 
there is need for randomized clinical trials in humans if applicable, timed in pregnancy 
and aimed to prevent cardiovascular disease in later life, investigating if findings from 
epidemiological studies truly can add to the prevention or treatment of adult diseases.
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In chapter 1 the background and rationale of the studies presented in this thesis are 
given. Many epidemiological studies suggested that early life events have an important 
role for the susceptibility to develop diseases in adult life, such as cardiovascular and 
metabolic diseases. These observations resulted in the “Developmental Origins of Health 
and Disease“, recently adapted to a more general “developmental plasticity hypothesis”, 
which proposes that an organism may develop in different ways, depending on the 
environment it is exposed to in fetal and early postnatal life. Numerous observational 
studies have shown that low birth weight and growth acceleration in the first months of 
life is associated with adverse outcomes in adolescence and adulthood, such as obesity, 
cardiovascular, renal and metabolic disease. We reasoned that investigating specific 
adverse fetal exposures and early growth may provide new insights in mechanisms un-
derlying the associations of low birth weight with adult disease. Genetic factors associ-
ated with early growth might also partly explain the association of early growth with 
adult diseases. In this thesis, we performed studies to identify early environmental and 
genetic determinants of childhood growth, and cardiovascular and renal development. 
We focused on parental exposures during pregnancy and genetic determinants of early 
growth, cardiovascular and renal development. 
In chapter 2 we studied environmental and genetic determinants of different aspects 
of early growth. In chapter 2.1, we examined the postnatal growth of children born 
small (SGA), appropriate (AGA) and large size for gestational age (LGA). We showed 
that children born SGA and LGA display catch-up and catch-down growth respectively 
in the first months of life. Despite the compensatory growth these children still have 
persistent differences in head circumference, height and weight until the age of 4 years. 
In the same study, we also assessed whether postnatal growth patterns could modify 
the risk of childhood overweight and adverse body composition. We demonstrated that 
catch-up and catch-down growth in children born SGA and LGA modifies the associa-
tion of size at birth with subcutaneous fat mass, body mass index (BMI) and the risk of 
being overweight or obese at the age of 4 years. Furthermore, effect modification of the 
association of birth weight with childhood overweight by postnatal catch-up and catch-
down growth was also noted in children born AGA. Children born AGA with catch-up 
growth and children born LGA without catch-down growth have a higher subcutane-
ous fat mass and BMI in childhood, and are at increased risk for childhood overweight. 
Results from our study suggest that these groups could be potential targets for early 
prevention of childhood obesity.
In chapter 2.2 we investigated which common genetic variants are associated with 
birth weight, using a genome wide association study approach. For this, we meta-
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analyzed 18 genome-wide association studies and followed up 21 lead signals in 24 in-
dependent replication samples, including up to 69,308 individuals of European descent. 
We identified seven common genetic variants robustly associated with birth weight. Five 
of the loci were previously associated with other outcomes. Variants in or near ADCY5 
and CDKAL1 were associated with type 2 diabetes. The variant in ADRB1 was previously 
associated with blood pressure and HMGA2 and LCORL with adult height. These results 
demonstrate that the well described association between low birth weight and type 2 
diabetes and blood pressure has a genetic component, next to possible programming 
effects by the fetal environment.
Chapter 2.3 describes a genome-wide association meta-analysis on infant head cir-
cumference. We meta-analyzed GWAS from 7 different studies, and selected 3 variants 
for replication in an additional 6 studies. In total, we included more than 19 thousand 
individuals in this study. We identified two variants in or near HMGA2 and SBNO1 robustly 
associated with infant head circumference. Although these loci have previously been 
associated with adult height, their effects on infant head circumference were largely 
independent of their effect on infant height. We also found suggestive evidence that 
another variant, in a region previously associated with neurodegenerative diseases 
(17q21 including MAPT and CRHR1), was associated with infant head circumference. 
Other investigators found the same region to be associated with intra cranial volume. 
This could indicate that genetic variation in this region might link early brain growth 
with neurological disease in later life.
In chapter 2.4 we studied whether genes and environment interact with each other 
to affect a specific outcome. We investigated whether maternal smoking during preg-
nancy modified the effect of a genetic variant in the nicotine receptor cluster on birth 
weight. We showed that in mothers who smoked during pregnancy, each maternal risk 
allele was associated with a reduced fetal growth. In mothers who did not smoke dur-
ing pregnancy, we did not find an association of the genotype with birth weight. This 
indicates that the environment (smoking) and the genotype (nicotine receptor cluster) 
interact with each other to affect fetal growth.
Chapter 2.5 again uses a genome-wide association approach to identify common 
genetic variants associated with childhood obesity. We performed a collaborative 
meta-analysis of 14 studies consisting of 5,530 cases (≥95th percentile of BMI) and 
8,318 controls (<50th percentile of BMI) of European ancestry. We followed up 8 novel 
signals for replication in 9 independent replication samples of European ancestry. We 
observed two loci robustly associated with childhood obesity, namely near OLFM4 and 
within HOXB5 located on chromosome 13 and 17 respectively. Both genes have been 
implicated in different aspects of gut function, but further functional characterization is 
needed to elucidate the precise underlying mechanisms.
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In chapter 3 we focused on fetal and infant growth patterns, parental exposures during 
pregnancy and genetic determinants and their association with childhood cardiovascu-
lar development.
In chapter 3.1 we aimed to identify patterns of fetal and infant growth associated with 
childhood blood pressure, carotid-femoral pulse wave velocity and cardiac structures 
and function. We found that birth weight was inversely associated with cardiovascular 
function and positively associated with cardiac structures. These associations were 
modified by postnatal growth patterns. Children born SGA with catch-up growth had a 
higher systolic blood pressure, and LGA without catch-down growth had the largest left 
ventricular mass, compared to children born AGA without postnatal catch-up or catch-
down growth. This suggests that specific fetal and infant growth patterns are associated 
with cardiovascular development.
In chapter 3.2 we assessed the associations of both maternal and paternal smoking 
during pregnancy with childhood cardiovascular structures and function. We observed a 
dose-dependent association of the number of cigarettes smoked by the mother during 
pregnancy with diastolic blood pressure, but not with systolic blood pressure. Maternal 
smoking during pregnancy was not associated with childhood carotid-femoral pulse 
wave velocity or left cardiac structures. Maternal smoking of ten or more cigarettes per 
day was associated with a higher fractional shortening in childhood. Among mothers 
who did not smoke during pregnancy, paternal smoking was associated with aortic root 
diameter, but not with the other cardiovascular outcomes. The stronger effect estimates 
for maternal smoking compared to paternal smoking might suggest that direct intra-
uterine adaptive responses are involved as underlying mechanisms.
In chapter 3.3 we examined whether maternal and paternal psychological distress 
were associated with the cardiovascular outcome measurements in school age chil-
dren. We assessed maternal and paternal psychological distress during pregnancy by 
questionnaire, using the Brief Symptom Inventory. At the child age of six years, we 
performed blood pressure and carotid- femoral pulse wave velocity measurements, and 
M-mode measurements of left cardiac structures and fractional shortening. We did not 
observe associations of high maternal and paternal psychological symptom scores with 
childhood blood pressure and carotid-femoral pulse wave velocity after adjustment for 
potential confounders. Maternal overall psychological symptoms were associated with 
a lower childhood left ventricular mass. The association of paternal overall psychological 
symptoms with childhood left ventricular mass showed a similar effect size. This may 
suggest that these associations could be due to unmeasured social and environmental 
factors, rather than direct intra-uterine effects.
In chapter 3.4 we investigated the associations of maternal first trimester dietary 
intake with blood pressure in children at the age of six years. We assessed first trimester 
maternal daily dietary intake by a food frequency questionnaire and measured folate, 
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homocysteine and vitamin B12 concentrations in blood. Childhood systolic and diastolic 
blood pressure was measured using a validated automatic sphygmomanometer. Ma-
ternal intake of macronutrients was not associated with childhood blood pressure. We 
found associations of higher maternal iron intake with a lower childhood systolic blood 
pressure and higher maternal vitamin B12 concentrations with a higher diastolic blood 
pressure, although the effect sizes were small and borderline significant. Concentra-
tions of folate and homocysteine in first trimester pregnancy were not associated with 
childhood blood pressure. The results of this study do not provide clear evidence for 
nutritional programming of childhood blood pressure at this age. 
In chapter 3.5 we aimed to assess to what extent multiple common genetic variants 
contribute to blood pressure regulation in both adults and children, and to assess 
overlap in variants between different age groups, using a technique called genome-
wide profiling. We created sets of common genetic variants based on genome-wide 
association study meta-analyses on systolic and diastolic blood pressure performed 
by the Cohort for Heart and Aging Research in Genome Epidemiology consortium. 
Subsequently, genetic risk scores for systolic and diastolic blood pressure were calcu-
lated in an independent adult population and a child population. Genetic risk scores, 
including also many non-genome-wide significant genetic variants explained more of 
the variance than scores based only on very significant genetic variants in adults and 
children. These findings suggest the presence of many genetic loci with small effects on 
blood pressure regulation both in adults and children, indicating also a (partly) common 
polygenic regulation of blood pressure throughout different periods of life.
Studies focused on early environmental and genetic determinants of renal growth, 
function and development are presented in chapter 4. We constructed gender specific 
reference growth curves for kidney growth (left and right kidney length, width, depth 
and volume) from third trimester of pregnancy until the age of two years (chapter 4.1). 
Kidney size was significantly influenced by age and gender. These reference curves can 
be used for assessing kidney structures by ultrasound in fetal life and early childhood.
In chapter 4.2, we examined whether maternal smoking during pregnancy, as im-
portant adverse fetal exposure is associated with fetal (third trimester of pregnancy) 
and infant kidney volume (2 years of age) measured by ultrasound. Among continued 
smoking mothers, we observed dose-dependent associations between the number of 
cigarettes smoked during pregnancy with kidney volume in fetal life. Smoking less than 
5 cigarettes per day was associated with larger fetal combined kidney volume, while 
smoking more than 10 cigarettes per day tended to be associated with smaller fetal 
combined kidney volume. These associations were not seen at the age of 2 years. Our 
results suggest that smoking during pregnancy affects kidney development in fetal life 
with a time-specific and dose-dependent relationship. 
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In chapter 4.3 we aimed to identify early life environmental factors associated with 
kidney volume, kidney function and blood pressure at age of six years. We identified that 
maternal anthropometrics, smoking during pregnancy and birth weight for gestational 
age were the main determinants of total kidney volume and function (creatinine and 
cystatin C levels in serum). Furthermore, we showed that kidney volume at the age of 
six years is positively associated with kidney function in childhood. These results are 
in line with the ‘hyperfiltration hypothesis’ and indicate that the developing kidney is 
important for future adult health. Modifiable exposures that affect kidney development 
can be potential targets for future intervention studies.
In chapter 4.4 we examined whether common genetic variants previously associated 
with adult blood pressure and kidney function might affect kidney volume in fetal life. 
After taking into account multiple testing, one variant near ZNF652 was significantly 
associated with fetal kidney volume, but the effect showed the opposite direction 
as expected. The remaining common genetic variants were not associated with fetal 
kidney volume. We also did not find associations of genetic variants previously shown 
to affect newborn kidney volume, with third trimester fetal kidney volume. Our results 
suggest that common genetic variants, previously associated with adult blood pressure 
and kidney function, do not underlie the associations of smaller kidneys with a reduced 
nephron endowment in early life with higher blood pressure or impaired kidney func-
tion in later life.
In chapter 5 we discussed the results of the aforementioned chapters in a broader 
perspective and discussed methodological considerations, important for this line of 
epidemiological research. Furthermore, we describe possible clinical implications of the 
results of these studies and make suggestions for future research possibilities.
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Epidemiologische studies hebben laten zien dat de eerste levensfase na de geboorte 
een belangrijke rol kan hebben in het ontwikkelen van ziekten op volwassen leeftijd, 
zoals hart- en vaatziekten en type 2 diabetes. Deze studies hebben geleid tot het 
formuleren van de “Developmental Origins of Health and Disease Hypothese”, die stelt 
dat een organisme zich op verschillende manieren kan ontwikkelen, afhankelijke van 
de omgeving waarin het zich bevind tijdens het foetale en vroege postnatale leven. 
Adaptaties die gemaakt worden in deze fase, zijn gunstig op korte termijn, maar kunnen 
nadelige effecten hebben op lange termijn. Vele observationele studies hebben laten 
zien dat laag geboorte geweest en snelle postnatale groei in de eerste maanden van het 
leven zijn geassocieerd met veelvoorkomende ziekten bij volwassenen zoals obesitas, 
hart-, vaat- en nierziekten. Wij redeneerden dat het onderzoeken van specifieke nadelige 
omgevingsfactoren en vroege groei, en hun associatie met hart-, vaat- en nierontwikke-
ling op de kinderleeftijd tot nieuwe inzichten zou kunnen leiden, in de onderliggende 
mechanismes van de associatie van laag geboorte gewicht met ziekten bij volwassenen. 
Genetische factoren die geassocieerd zijn met vroege groei zouden ook een deel van 
deze associatie kunnen verklaren. In dit proefschrift hebben we studies uitgevoerd om 
vroege omgevings- en genetische factoren van vroege groei en hart-, vaat- en nieront-
wikkeling te identificeren. In hoofdstuk 1 geven we de achtergrond en redenen voor de 
verschillende studies in dit proefschrift gegeven.
In hoofdstuk 2 bestuderen we omgevingsfactoren en genetische determinanten die 
verschillende aspecten van vroege groei beïnvloeden. In hoofdstuk 2.1 hebben we de 
posnatale groei beschreven van kinderen die met een te laag, normaal of te hoog ge-
wicht voor de zwangerschapsduur zijn geboren. Een groot deel van de kinderen met een 
te laag of te hoog gewicht voor de zwangerschapsduur lieten ‘catch-up’ en ‘catch-down’ 
groei zien in de eerste maanden na de geboorte. Ondanks deze compensatoire groei 
hadden deze kinderen persisterende verschillen in hoofdomtrek, lengte en gewicht op 
de leeftijd van 4 jaar. In deze studie hebben we ook onderzocht welke postnatale groei 
patronen in deze groepen kinderen, het risico op nadelige lichaamssamenstelling en 
overgewicht bij kinderen verhogen of verlagen. ‘Catch-up’ of ‘catch-down’ groei modi-
ficeerde de associatie van het gewicht voor de zwangerschapsduur en subcutane vet 
massa, body mass index (BMI), en het risico op overgewicht of obesitas op de leeftijd 
van 4 jaar. Dit effect was ook zichtbaar in kinderen met een normaal gewicht voor de 
zwangerschapsduur. Kinderen met een normaal gewicht voor de zwangerschapsduur 
die ‘catch-up’ groei laten zien, en kinderen met een te hoog gewicht voor de zwanger-
schapsduur zonder ‘catch-down’ groei hadden een hoger subcutane vetmassa en BMI 
op de kinderleeftijd, en een hoger risico op overgewicht. Deze resultaten laten zien dat 
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deze twee groepen kinderen mogelijke risico groepen zijn waarin vroege preventie van 
overgewicht bij kinderen toegepast zou kunnen worden.
In hoofdstuk 2.2 hebben we onderzocht welke genetische varianten geassocieerd zijn 
met geboorte gewicht. Dit hebben we gedaan door gebruik te maken van genoomwijde 
associatie studies. Met deze aanpak kunnen onderzoekers de relatie testen tussen 2,5 
miljoen genetische varianten en een uitkomst van interesse, in een analyse. Deze vorm 
van onderzoek maakt geen gebruik van een voorafgestelde hypothese die onderzocht 
word maar is een hypothesevrije onderzoeksvorm. In deze studie hebben we een meta-
analyse uitgevoerd van 18 genoomwijde associatie studies en hebben de 21 sterkst 
geassocieerde, onafhankelijke en nieuwe signalen (P-waarde < 1x10-5) opgevolgd in 24 
onafhankelijke studie populaties. In totaal hebben we 69,308 individuen geïncludeerd 
in deze studie. We toonden zeven genetische varianten aan die geassocieerd waren met 
geboorte gewicht. Vijf van deze varianten zijn eerder geassocieerd met andere uitkom-
sten op volwassen leeftijd. Genetische varianten in of nabij de genen ADCY5 en CDKAL1 
zijn eerder geassocieerd met type 2 diabetes. Een genetische variant in ADRB1 is eerder 
geassocieerd met bloeddruk en varianten in HMGA2 en LCORL zijn eerder in relatie 
gebracht met volwassen eindlengte. Deze resultaten laten zien dat de veel beschreven 
associatie tussen laag geboorte gewicht en ziekten op latere leeftijd een waarschijnlijk 
ook een genetische component heeft. 
Hoofdstuk 2.3 beschrijft een genoomwijde associatie studie van hoofdomtrek op de 
peuterleeftijd; rond de leeftijd van 1,5 jaar. We hebben hiervoor een meta-analyse uit-
gevoerd van 7 verschillende studies en de 3 sterkste signalen van deze analyse geselec-
teerd voor replicatie in 6 onafhankelijke studie populaties (totaal aantal geïncludeerde 
kinderen = 19,089). We hebben aangetoond dat twee genetische varianten in of nabij 
HMGA2 en SBNO1 zijn geassocieerd met hoofdomtrek op de peuterleeftijd. We vonden 
ook sterke aanwijzingen dat een genetische variant in een regio op chromosoom 17 ook 
geassocieerd is met hoofdomtrek op de peuterleeftijd. Deze regio bevat onder andere 
het MAPT en CRHR1 gen en is voorheen geassocieerd met neurondegeneratieve ziekten 
zoals de ziekte van Alzheimer en Parkinson. Genetische varianten in dezelfde regio zijn 
geassocieerd met intra cranieel volume, een maat voor maximaal bereikt breinvolume. 
Dit betekent mogelijk dat genetische variatie in deze regio vroege breingroei in verband 
zou kunnen brengen met neurologische ziekten op later leeftijd.
In hoofdstuk 2.4 hebben we bestudeerd of genen en omgeving met elkaar kunnen 
interacteren en een effect kunnen hebben op foetale groei. We hebben onderzocht of het 
wel of niet roken van de moeder tijdens de zwangerschap, het effect van een genetische 
variant in de nicotine receptor op geboorte gewicht kan modificeren. In moeders die 
rookten tijdens de gehele zwangerschap, was elk risico allel van de genetische variant 
in de nicotine receptor geassocieerd met een verminderde foetale groei. In moeders die 
niet rookten tijdens de zwangerschap, vonden we geen associatie tussen het genotype 
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en foetale groei. Dit geeft aan dat de omgeving (roken van de moeder) en het genotype 
(nicotine receptor) samen interacteren en foetale groei vertragen.
Hoofdstuk 2.5 maakt opnieuw gebruik van een genoomwijde associatie studie 
aanpak, met het doel genetische varianten te identificeren die geassocieerd zijn met 
overgewicht bij kinderen. We hebben een meta-analyse uitgevoerd van 14 genoom-
wijde associatie studies, bestaande uit 5,530 gevallen van obesitas (>95ste percentiel van 
BMI) en 8,138 controles (<50ste percentiel voor BMI) van Europese afkomst. Vervolgens 
hebben we de 8 sterkst geassocieerde, niet eerder beschreven, genetische varianten 
geselecteerd voor replicatie in 9 onafhankelijke studies. In deze studie toonden we aan 
dat twee genetische varianten, nabij OLFM4 en in HOXB5 (liggend op respectievelijk 
chromosoom 13 en 17), geassocieerd zijn met overgewicht bij kinderen. Beide genen 
zijn eerder in verband gebracht met verschillende aspecten van de functie van de dar-
men, echter vervolgonderzoek is nodig om precies te achterhalen hoe deze genetische 
varianten leiden overgewicht op de kinderleeftijd.
In hoofdstuk 3 hebben we de focus gelegd op patronen van foetale en vroege post-
natale groei, blootstellingen tijdens de zwangerschap, genetische varianten en hun 
associatie met cardiovasculaire ontwikkeling van kinderen. In hoofdstuk 3.1 hadden 
we als doel groeipatronen van foetale en vroeg postnatale groei te identificeren die 
geassocieerd waren met bloeddruk, carotis-femoralis pulse wave velocity en structuren 
en functie van het hart op zesjarige leeftijd. We vonden dat geboorte gewicht negatief 
geassocieerd was met cardiovasculaire functie en positief geassocieerd met cardiale 
structuren. Deze associaties werden gemodificeerd door postnatale groeipatronen. Kin-
deren met een klein gewicht voor de zwangerschapsduur met ‘catch-up’ groei hadden 
een hogere bloeddruk op de leeftijd van zes jaar, kinderen met een te hoog gewicht 
voor de zwangerschapsduur zonder ‘catch-down’ groei, hadden de grootste cardiale 
structuren, vergeleken met kinderen geboren met een normaal gewicht voor de zwan-
gerschapsduur zonder ‘catch-up’ of ‘catch-down’ groei. Dit suggereert dat specifieke 
groeipatronen in het vroege leven geassocieerd zijn met cardiovasculaire ontwikkeling.
In hoofdstuk 3.2 hebben we de associatie tussen roken van zowel moeder als vader 
tijdens de zwangerschap en cardiovasculaire structuren en functie onderzocht. Op de 
leeftijd van zes jaar hebben we bloeddruk metingen verricht, carotis-femoralis pulse 
wave velocity bepaald en middels M-mode echografie hebben we metingen verricht 
van de cardiale structuren en fractionele verkorting van de linker kamer. We vonden een 
dosisafhankelijke associatie tussen het aantal sigaretten gerookt door de moeder en een 
hogere diastolische bloeddruk bij de kinderen, maar niet met de systolische bloeddruk. 
Het roken tijdens de zwangerschap van de moeder was niet geassocieerd met carotis-
femoralis pulse wave velocity of hartstructuren. Kinderen van moeders die meer dan 
tien sigaretten per dag rookten, hadden een hogere fractionele verkorting dan kinderen 
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van moeders die niet rookte tijdens de zwangerschap. In kinderen van moeders die niet 
rookte tijdens de zwangerschap, was roken van de vader geassocieerd met de diameter 
van de wortel van de aorta, maar niet met andere structuren van het hart. Het grotere 
effect grootte van roken van de moeder tijdens de zwangerschap op diastolische bloed-
druk en fractionele verkorting, in vergelijking met de het roken van vader, suggereert 
dat er intra-uteriene adaptaties betrokken zijn als onderliggend mechanisme. 
In hoofdstuk 3.3 hebben we onderzocht of psychologische distress bij moeder en 
vader is geassocieerd met de cardiovasculaire uitkomstmaten bij kinderen rond de 
schoolleeftijd. We hebben psychologische distress gemeten met de ‘Brief Symptom 
Inventory’-vragenlijst. We hebben geen associaties aangetoond van hoge psychologi-
sche symptoom scores van moeder of vader met bloeddruk en carotis-femoralis pulse 
wave velocity in de kinderen, na correctie voor potentieel verstorende factoren. Hoge 
scores van moeder op overall psychologische symptomen was geassocieerd met lagere 
linker ventrikel massa. De associatie van dezelfde scores van vader met linker ventrikel 
massa liet een zelfde effect grootte zien, wat suggereert dat de associaties verklaard 
kunnen worden door ongemeten sociale en omgevingsfactoren, in plaats van direct 
intra-uteriene mechanismes. 
Hoofdstuk 3.4 beschrijft de associaties van het dieet van de moeder tijdens het 
eerste trimester van de zwangerschap en bloeddruk van 6 jarige kinderen. We heb-
ben het dieet gemeten met behulp van een voedingsvragenlijst en hebben folaat, 
homocysteine en vitamine B12 concentraties gemeten in het bloed van de moeder. 
Systolische en diastolische bloeddruk bij de kinderen werd gemeten met een gevali-
deerde automatische sphygmanometer. De maternale intake van macronutriënten was 
niet geassocieerd met bloeddruk bij kinderen. Een hoge intake van ijzer in het eerste 
trimester van de zwangerschap was geassocieerd met een lagere systolische bloeddruk 
van de kinderen. Hogere concentraties van vitamine B12 waren geassocieerd met een 
hogere diastolische bloeddruk. Deze associaties hadden echter een klein effect grootte 
en waren marginaal significant. Concentraties van folaat en homocysteine in het eerste 
trimester van de zwangerschap waren niet geassocieerd met bloeddruk bij kinderen 
van zes jaar. De resultaten van deze studie geven geen duidelijk bewijs voor het pro-
grammeren van bloeddruk door bij kinderen van deze leeftijd door maternale voeding 
tijdens de zwangerschap.
In hoofdstuk 3.5 hebben we bepaald of meerdere genetische varianten bijdragen 
tot de regulatie van bloeddruk in volwassenen en kinderen, en of er overlap in gene-
tische varianten belangrijk voor bloeddruk, tussen deze leeftijdsgroepen. We hebben 
gebruik gemaakt van een techniek genaamd ‘genome-wide profiling’. We hebben sets 
van genetische varianten gecreëerd op basis van een genoomwijde associatie studie 
op systolische en diastolische bloeddruk bij volwassenen, uitgevoerd door het CHARGE 
consortium. Vervolgens hebben we voor elk van deze sets, genetische risico scores 
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berekend voor individuen in twee onafhankelijke studies in volwassenen en kinderen. 
Genetische risico scores die informatie van veel genetische varianten bevatten, waren 
beter in het verklaren van de variatie in bloeddruk dan scores berekend op basis van 
alleen de sterkst geassocieerde genetische varianten, zowel in volwassenen als in kin-
deren. Deze bevindingen suggereren dat er veel genen/genetische varianten die een 
rol spelen bij de regulatie van bloeddruk in volwassenen en kinderen, en dat er een ge-
deeld gemeenschappelijke genetische regulatie van bloeddruk aanwezig is gedurende 
de beide levensfasen. 
De studies die zich focussen op omgevingsinvloeden en genetische determinanten 
van niergroei, nierfunctie en nierontwikkeling worden gepresenteerd in hoofdstuk 4. 
We hebben geslachtsspecifieke referentie curven gecreëerd voor niergroei (linker en 
rechter nier lengte, wijdte, transverse diameter en volume) van het derde trimester van 
de zwangerschap to de leeftijd van 2 jaar (hoofdstuk 4.1). Leeftijd en geslacht hadden 
een significante invloed op de grootte van de nieren. Deze referentie curven kunnen ge-
bruikt om de normale en abnormale groei van nieren in het foetale en vroeg postnatale 
leven te bestuderen. 
In hoofdstuk 4.2 hebben we bestudeerd of maternaal roken tijdens de zwanger-
schap, als een belangrijke potentieel veranderbare nadelige omgevingsfactor voor de 
foetus, is geassocieerd met niervolume in het derde trimester van de zwangerschap en 
op de leeftijd van twee jaar. In moeders die rookte tijdens de gehele zwangerschap, 
observeerden we een dosisafhankelijke associatie tussen het aantal sigaretten dat de 
moeder rookte en foetaal niervolume. Moeders die minder dan 5 sigaretten per dag 
rookten, hadden foetussen met een groter niervolume, terwijl bij moeders die meer 
dan 10 sigaretten per dag rookten de foetussen juist kleinere nieren leken te hebben. 
Deze associaties konden we niet aantonen op de leeftijd van 2 jaar. Deze resultaten 
suggereren dat roken tijdens de zwangerschap de foetale nierontwikkeling zou kunnen 
verstoren, maar dat dit afhangt van het moment en de hoeveelheid van het roken.
In hoofdstuk 4.3 hadden we als doel vroege determinanten van nier volume, 
nierfunctie en bloeddruk op de leeftijd van zes jaar te onderzoeken. We vonden dat 
anthropometrie van de moeder, roken van de moeder tijdens de zwangerschap en ge-
boortegewicht voor de zwangerschapsduur, de belangrijkste determinanten waren van 
niervolume en nierfunctie (serum creatinine en cystatine C). We vonden eveneens dat 
een groter niervolume sterk geassocieerd was met een betere nierfunctie op de leeftijd 
van zes jaar. Deze resultaten zijn in overeenstemming met de hyperfiltratie hypothese. 
Dit suggereert dat een goede nierontwikkeling belangrijk is voor de gezondheid op 
latere leeftijd. Beïnvloedbare omgevingsfactoren die de nierontwikkeling beïnvloeden, 
kunnen mogelijke ‘targets’ voor toekomstige interventie studies.
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In hoofdstuk 4.4 hebben we onderzocht of genetische varianten die eerder gerela-
teerd waren aan bloeddruk of nierfunctie in volwassenen, ook geassocieerd waren aan 
foetaal niervolume gemeten in het derde trimester van de zwangerschap. Nadat we heb-
ben gecorrigeerd voor de meerdere geteste hypotheses, bleef een genetische variant 
nabij ZNF652 significant geassocieerd met foetaal niervolume. Het effect liet echter de 
omgekeerde richting zien dan we verwachtten. De andere genetische varianten waren 
niet geassocieerd met foetaal niervolume. We vonden ook geen associatie met foetaal 
niervolume van genetische varianten die eerder geassocieerd waren met niervolume bij 
pasgeborenen. Deze resultaten laten zien dat genetische varianten, eerder geassocieerd 
met bloeddruk of nierfunctie bij volwassenen, de associatie tussen kleinere nieren met 
verminderd aantal nefronen en hoge bloeddruk en verminderde nierfunctie op latere 
leeftijd niet kunnen verklaren.
In hoofdstuk 5 worden de resultaten van de studies in dit proefschrift in een breder per-
spectief besproken en bespreken we methodologische aspecten, belangrijk voor deze 
lijn van epidemiologisch onderzoek. Vervolgens beschrijven we mogelijke klinische 
implicaties van de resultaten uit dit proefschrift en doen suggesties voor toekomstige 
gebieden van onderzoek. 
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Dankwoord
Voordat ik begin aan het deel van dit proefschrift met de grootste (sociale) impact fac-
tor, wil ik allereerst graag alle deelnemers aan het Generation R onderzoek bedanken. 
Zonder jullie geen data, geen succes en geen promotie – kortom: onmisbaar. Ik hoop dat 
alle deelnemers nog lang betrokken blijven bij het onderzoek om de gezondheid voor 
de komende generaties te bevorderen. 
Ik wil op deze plaats graag mijn beide promotoren bedanken. Professor van der 
Heijden, beste Bert, als promotor hebt u mij in discussies over manuscripten zeer scherp 
gehouden en hield altijd oog voor de eventuele klinische implicaties van de resultaten. 
U hebt me laten zien hoe je de wetenschap met de kindergeneeskunde kan combineren 
en ik kijk ernaar uit ook op klinisch vlak veel van u te leren. Professor Hofman, beste 
Bert, bedankt voor de begeleiding. Als geen ander kunt u promovendi en studenten 
motiveren tot het doen van onderzoek. Dank voor uw enthousiasme en begeleiding 
tijdens dit project. 
Dr. Jaddoe, beste Vincent. Nadat ik vier en een half jaar geleden teleurgesteld in de 
arts-assistenten kamer binnen kwam en vertelde over mijn gefrustreerde pogingen 
een promotieplek te bemachtigen, heb je mij als promovendus binnen gehaald bij 
Generation R. Dat wij elkaar kenden maakte de start makkelijker en onze samenwerking 
is altijd recht door zee geweest. Ik wil je heel erg bedanken voor alle begeleiding op 
wetenschappelijk gebied, interesse op persoonlijk vlak en je hulp bij de voortzetting van 
mijn loopbaan en toekomst als kinderarts!
Professor van Duijn, beste Cock, dank voor het aandachtig lezen van mijn proefschrift 
en uw commentaar. Eveneens bedankt voor alle aanstekelijke colleges waar mijn ge-
netische interesses versterkt zijn en onze prettige samenwerking de afgelopen jaren. 
Professor Hokken-Koelega en professor Reiss, dank u voor het plaatsnemen in de kleine 
commissie en het aandachtig lezen van mijn proefschrift. Professor Helbing en professor 
Gansevoort; hartelijk dank voor het plaatsnemen in de grote commissie. 
Dr. Timpson, dear Nic, thank you for joining my PhD-defense on your anniversary! I 
would like to thank you for your persisting enthusiasm and criticism in our combined 
and other GWAS efforts. Always seek for the most optimal and scientific solution, that’s 
one thing I have learned from you. I wish you the best of luck for the future and hope we 
will work together again in future projects. Thanks!
Drie en een half jaar heb ik mijn werkplek gehad in het Ae-gebouw, kamer Ae-026, 
als een van de weinigen zonder kamerswitch. Ik wil graag al mijn kamergenoten be-
danken voor de fijne en gezellige tijd met jullie. Hanan, jij hebt me opgevangen toen 
ik als wetenschappelijk groentje arriveerde uit de kliniek. Ik kon altijd met vragen bij 
je terecht, dank nogmaals voor alle hulp. Buiten je hulp, was het bovenal natuurlijk erg 
gezellig om af en toe even te kletsen over andere zaken in het leven (en ik hoop dat er 
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nog vele kamerlunches zullen volgen!). Layla, ruim 3 jaar zijn wij elkaars kamergenoten 
geweest. Een superleuke tijd, die ik voor geen goud had willen missen. We gingen al 
snel met elkaar op congres naar Hamburg en Chili en later volgden ook London en 
Cyprus. Je bent altijd vrolijk, vooral ’s ochtends vroeg als ik nog maar net wakker ben. 
Dank voor je interesse in alles wat ik wel en niet deed. Ik ben ervan overtuigd dat je 
een uitstekende radioloog zult worden! Nina en Ank, jullie verblijf in Ae-026 was relatief 
kort, maar ook jullie bedankt voor alle gezelligheid! Ik ben ervan overtuigd dat jullie 
goede onderzoekers zijn en een uitdagend project als dat van jullie tot een uitstekend 
einde zullen brengen. Selma, de laatste anderhalf jaar ben jij Ae-026 komen versterken. 
Na Hanan en Ank, beide rustig, was het een kleine cultuurshock en moest ik wel even 
wennen aan de snelheid van onze gesprekken. Samen met Layla hebben we het Ae-026 
diner ingevoerd, ik hoop dat er nog vele volgen! 
Natuurlijk zat ik niet gekluisterd in een kamer en wil ik graag ook alle andere collega 
promovendi en studenten bedanken met wie ik samen heb gewerkt. Met het risico een 
paar namen te missen (bij voorbaat: excuses) wil ik hier graag noemen; Agnes (buur-
vrouw!), Ankie (goed voorbeeld doet volgen), Claudia (lunch buddy), Denise (mijn mede 
kindergeneeskunde geïnteresseerde), Dennis (genetisch expert), Edith (1 van de 5 ;)), 
Fleur (London altijd gezellig!), Hanneke (stress, stress, maar onze paper is er uiteindelijk 
toch bij! Dank!!), Jolien de G-S (superuitje), Leontine (keigezellig), Lisan (ook keigezellig), 
Marieke en Nienke (gillend door de muren heen te horen), Miranda (organisatietalent), 
Monica (si!), Ralf (ja dit is goed genoeg voor NG!) en Romy (GWAS is echt leuk hoor).
Uiteraard wil ik hier ook mijn paranimfen eren. Arjan en Layla, ik kan mij geen beter 
duo voorstellen om me bij te staan tijdens de verdediging. Arjan, dank voor al je be-
langstelling de afgelopen jaren. Onze discussies over de politiek, economie, financiën 
en andere gewichtige zaken (uiteraard onder genot van), en onze stapavonden waren 
zeer welkome intermezzo’s in het onderzoekersleven. Ik hoop dat er nog vele van deze 
avonden volgen in het leven als arts in opleiding! Lieve Layla, we hebben al zoveel 
gedeeld de afgelopen jaren dat je uiteraard ook mijn paranimf moet zijn. Dank voor alle 
steun de afgelopen tijd!
A word of thanks to my international fellow-EGGs; together we have survived many 
frustrations and celebrated many successes in the end. I would like to thank the EGG 
consortium for the great work the past years. I am sure the success will continue.
Uiteraard functioneert een afdeling niet zonder goede ondersteuning. Mw. Prettig, 
beste Patricia, bij jou kan iedereen altijd terecht, kan iedereen (ik in ieder geval) altijd 
lachen en je zegt waar de dingen op staan. Bedankt voor al je hulp de afgelopen vier 
jaar en ik wens je alle goeds! Claudia, zonder jou zou niemand deadlines halen. Mijn 
dank gaat uit naar jou vanwege alle supersnel aangeleverde datasets, kritische vragen 
over opschoning en de data die ‘van jou’ is en waar je heel erg goed over waakt. Ook 
wil ik alle onderzoeksmedewerkers, in het speciaal alle ‘prikkers’ en allen die echo’s 
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hebben gemaakt, erg bedanken voor het mede verzamelen van de data gebruikt in dit 
proefschrift. Yvonne, bedankt voor alle gezelligheid achter de balie! Op deze plaats wil ik 
ook graag de Nierstichting bedanken voor het mogelijk maken van dit promotie onder-
zoek; zonder wetenschappelijk onderzoek geen vooruitgang en subsidies zijn daarvoor 
belangrijk. Allemaal doneren dus!
Lieve familie en vrienden. Jullie hebben de afgelopen jaren veel interesse getoond in 
wat ik heb onderzocht. Lieve Opa en Oma Obbink, ik heb bewondering voor jullie door-
zettingsvermogen en levensvisie. Mijn elfde stelling had ik niet zonder jullie kunnen 
schrijven. Lieve pa en ma, ook jullie wil ik graag bedanken voor alle interesse en support 
die ik de laatste jaren van jullie heb gekregen. Onbetaalbaar! Ries en Lia, eveneens dank 
voor jullie belangstelling. Bart, Bert en Jaap (en de vrouwen!); bedankt voor alle spe-
lavonden de afgelopen jaren. Ook voor jullie vragen over mijn saaie onderzoekswerk, 
die al snel over gingen in grappen en grollen. Roos en Almar, heel erg bedankt voor het 
ontwerpen van de oh zo belangrijke voorkant van dit proefschrift. Wat de rest er ook 
van vindt, ik vind de voorkant in ieder geval erg mooi! Flap en Mo, dank voor de ‘lekkere’ 
hardloopontspanning en sportexperimenten; veel geluk de komende jaren. Aan alle 
leden van de kampcommissie; bedankt voor jullie lol, gekkigheid, afleiding, nog meer 
lol en gekkigheid de afgelopen jaren. De inhoud van dit boekje zal jullie misschien niet 
allemaal interesseren, maar als alternatief kun je het altijd gebruiken als aanmaakpapier 
voor het kampvuur! 
Lieve Marjolein, als geen ander ken jij nu de ins en outs van het onderzoekersleven. 
Gelukkig wist jij me ook eraan te herinneren dat het goed was om af en toe te ontspan-
nen, te verhuizen, te reizen, lekker te lunchen en te shoppen. Zo fijn samen … ‘La Pura 
Vida’!!
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